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Abstract 
 
The complex process of wound repair becomes disrupted in the elderly with a 
profound effect on patient morbidity and huge financial implications for the NHS. 
While age itself is a risk factor for delayed healing recent work implicates 
estrogen decline, rather than intrinsic ageing per se, as the critical regulator of 
delayed healing in elderly subjects. In women estrogen levels fall dramatically 
post-menopause and with increasing life expectancy most women in the 
developed now world spend at least a third of their lives in a state of estrogen 
deprivation. Estrogen replacement can reverse this delay, but unfortunately long 
term estrogen treatment (HRT) increases breast cancer risk such that steroidal 
estrogen is now listed as a carcinogen. The aim of this study has been to 
functionally dissect the role of estrogen signalling during repair at the molecular, 
cellular and physiological levels. New data presented within this thesis reveal 
estrogen to be a global regulator of healing with pleiotropic effects on multiple 
wound cell types. By combining pharmacological manipulation and genetic 
ablation my data reveals novel diametrically opposed roles for the two estrogen 
receptor isoforms, ERα and ERβ, during healing. I have further exploited this to 
demonstrate the in vivo therapeutic potential of compounds with receptor 
selective agonistic/antagonistic activity. Additionally, I have further investigated 
the mechanism of action of estrogen and these selective compounds, 
implicating the pro-inflammatory cytokine macrophage migration inhibitory factor 
(MIF) in beneficial effects on healing. This research leads the way toward 
translation into human studies with the ultimate aim of developing targeted 
therapeutics for the treatment of delayed acute and chronic wounds, particularly 
in the elderly.  
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1 INTRODUCTION 
 
1.1 Human Skin Structure 
 
The skin is the outermost organ of the human body and serves as the 
primary defence system against the external environment. It provides ongoing 
protection against infection from micro-organisms (reviewed in Lee et al., 2006) 
and is the primary barrier against dehydration, and mechanical, chemical, 
osmotic, thermal and photic damage, primarily UV exposure (reviewed in 
Forslind et al., 1997; Rees, 1999). The skin also plays a role in sensation, 
thermoregulation and biochemical, metabolic, and immune functions and is the 
largest multi-functional organ of the human body (reviewed in Wysocki, 1999).  
Human skin accounts for about 15% of an adult human’s body weight 
(Farabee, 2000) and has a surface area of 16,000 to 18,000 square cm 
(Bender, 1995). In different areas of the body the skin has varying thicknesses, 
depending on location, ranging from 40µm on the upper eyelids, to 1mm on the 
plantar (sole of the foot) and palmar (palm of the hand) regions (Ha et al., 2005; 
Morganti et al., 2001). An average square inch of skin contains 650 sweat 
glands, 20 blood vessels, 60,000 melanocytes and more than 1000 nerve 
endings (Gallala, 2006).  
Human skin consists of four distinctly recognisable layers: the epidermis, 
the basement membrane, the dermis and the subcutaneous layer, and houses 
nerve endings, vasculature, hair follicles, sweat glands, sebaceous glands and 
nails (Gould, 1996) (Figure 1.1) 
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1.1.1 The Epidermis 
 
The epidermis, the most superficial human skin layer, protects the body 
against physical trauma, chemical damage and UV radiation. It is derived from 
embryonic ectoderm (Cunningham and Robinson, 1918) and is composed of 
four histologically distinct layers;  the stratum basale, the stratum spinosum, the 
stratum granulosum and the stratum corneum (Elias, 2005; Hardman et al., 
1999; Madison, 2003) (Figure 1.2). The lowest layer, the stratum basale, is 
joined to the basement membrane, the junction between the epidermis and the 
dermis, by hemidesmosomes, and comprises a single layer of columnar cells 
with elongated nuclei. The stratum spinosum lies immediately over the stratum 
basale and consists of a number of rows of spinous cells, named so because of 
their histological spiny appearance under a light microscope, due to 
desmosomes between the cells. Above the stratum spinosum lies the stratum 
granulosum, which consists of one to three layers of angular shaped and 
flattened keratinocytes, with darkly stained nuclei and containing basophilic 
artery vein 
Figure 1.1. Representation of the structure of normal human skin (figure modified from 
Gould, 1996). Broadly speaking the skin is divided into three principal layers: the epidermis; 
the dermis; and the subcutaneous layer. The epidermis is further divided into the basale, 
spinosum, granulosum and corneum and is connected to the dermis by the basement 
membrane. The dermis is composed of fibroblast-derived collagen, elastin fibres and 
polysaccharides. 
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granules called keratohyaline granules, which contain filaggrin. The stratum 
corneum makes up the outermost layer of the epidermis and is made up of 
annucleate, cornified dead keratinocytes, rich in keratin (Cunningham and 
Robinson, 1918). The stratum corneum acts as the primary barrier to stop 
percutaneous water loss and entry of micro-organisms (Elias, 2005). The 
epidermis contains a specific set of stem cells, which are thought to reside in 
the basal layer. These cells rely on mesenchymal and basement membrane 
stimuli to remain proliferative (reviewed in Fuchs, 2009). The cells produced in 
the stratum basale terminally differentiate and move outwards, and are finally 
shed as dead cells  (reviewed in Blanpain and Fuchs, 2009). There are four 
different cell types that comprise the majority of the epidermis; stratified 
keratinocytes, the primary cell of the epidermis; melanocytes, which are the 
pigment producing cells and contribute to UV protection (Wickett and Visscher, 
2006); Langerhans cells which have a role in immune surveillance and; Merkel 
cells which are involved in sensation (Clark, 1996). The epidermis expresses 
various keratin proteins, including, but not exclusively, K1, K2e, K5, K9, K10 
and K14 (reviewed in Lane and McLean, 2004).  
  
 
Stratum corneum 
Stratum granulosum 
Stratum spinosum 
Stratum basale 
Figure 1.2. Structure of the human epidermis. Haematoxylin & Eosin stained section of 
human upper arm skin. Scale bar = 50µm (figure drawn by the author [EE]). 
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Epidermal thickness varies depending on location, with the thickest being on the 
palms of the hands and soles of the feet and thinnest being on the eyelids and 
penis (Cunningham and Robinson, 1918). 
 
1.1.2 The Basement Membrane 
 
The basement membrane is the separating structure between the 
epidermis and the dermis. It contains proliferative granular cells and mediates 
the passage of chemical signals between the dermis and the epidermis (Clark, 
1996) while acting as a mechanical barrier (Liotta et al., 1980). The basement 
membrane can also be further subdivided into three sub-layers: the lamina 
lucida, lamina densa and sublamina densa (Wysocki, 1999). It tightly anchors 
the epidermis and dermis together, by interactions between hemidesmosomes 
and anchoring filaments and fibrils, while also providing support for the 
epidermis, resistance to shearing forces and determines the polarity of skin 
growth (Bruckner-Tuderman, 1999). Hemidesmosomes are specialised protein 
complexes that adhere to basal keratinocytes (Borradori and Sonnenberg, 
1999) and can be divided into 2 classes: type I, found in stratified epithelium, 
including skin, and type II, found in intestine (Litjens et al., 2006). The basement 
membrane is mainly composed of α6β4 integrin, laminin 5, collagens IV and VII 
and elastic fibres that stretch across the basement membrane, directly linking 
the epidermis to the dermis (Leigh et al., 1988; Weber et al., 1982). 
 Mutations in the genes for basement membrane complexes, including 
the intermediate filament proteins, keratins 5 and 14 (K5 and K14) (Coulombe 
et al., 1991; Lane et al., 1992), lead to the down-regulation of cell junction 
proteins, including laminins (Liovic et al., 2009), and subsequent reduced 
adhesion between the epidermis and the dermis leading to blistering diseases, 
such as Epidermolysis Bullosa (EB). Minor trauma or force can disrupt cellular 
junctions and cause muco-cutaneous blistering (Aumailley et al., 2006). 
 
1.1.3 The Dermis 
 
The dermis, derived from the embryonic mesoderm (Cunningham and 
Robinson, 1918), forms the majority of the skin. It is tough and resilient and 
contains a network of mechanically strong fibres, comprised of collagens I and II 
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(Epstein and Munderloh, 1978), elastin, polysaccharides and very few cells. Of 
these few most are fibroblasts, but mast cells, macrophages, lymphocytes, and 
melanocytes are also present. Fibroblasts are the primary cellular source of 
collagens and elastins (Wood, 1985). The dermis extends from the lamina 
densa of the basement membrane to the subcutaneous layer and contains 
various skin appendages including sweat glands, apocrine glands, sebaceous 
glands, hair follicles and nails and supports the epidermis (Marieb and Hoehn, 
2007) (Figure 1.3). 
The dermis is composed of two layers: papillary and reticular (James et al., 
2005). The outer papillary layer is thin and contains loosely woven elastin and 
collagen fibres and a large number of blood vessels. The superior surface 
contains projections into the epidermis, called dermal papillae. The papillae may 
contain nerve endings and Meissner’s Corpuscles, or touch receptors. In areas 
such as the plantar and palmar regions the papillary dermis contains rete 
ridges, undulations of the dermo-epidermal junction (Murphy et al., 2007). The 
reticular layer comprises the lower 80% of the dermis and is composed of 
dense, disorganised connective tissue, mainly collagen fibres, primarily 
arranged in planes parallel to the skin surface. Glycosaminoglycans (GAGs) in 
the dermis are able to bind up to a thousand times their volume in water, which 
keeps the skin hydrated. The majority of GAGs in the skin are hyaluronic acid or 
a member of the chondroitin sulphate family (Waller and Maibach, 2006). The 
cutaneous plexus, the blood vessels that supply the reticular are housed below 
the layer, and above the hypodermis (Braverman, 2000). 
Collagen makes up the majority of the structural protein of the dermis, 
giving it strength and toughness. Collagen I accounts for approximately 80% of 
dermal collagen, with the remainder being type III (Epstein and Munderloh, 
1978). Elastin fibres, which comprise the other major component of the dermis, 
extending from the lamina densa  to the subcutaneous layer, provide the skin 
with elastic qualities and the ability to return to a normal configuration after 
stretching (Wood, 1985; Wysocki, 1999). Additional elastic fibres are located in 
the dermis and are organised into two different location-specific types: 
superficial oxytalan fibres that extend from the dermal-epidermal junction and 
elaunin fibres which morphologically resemble elastin, are comprised of bundles 
of fibrotubules and are connected to the elastic fibres of the reticular dermis 
(Cotta-Pereira et al., 1976).  
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1.1.4 The Hypodermis 
 
The hypodermis or subcutaneous layer is the deepest layer of the skin, 
composed mostly of mesenchymally derived adipose tissue. The hypodermis 
comprises two layers: the panniculus adiposus and the panniculus carnosus 
(Rook and Burns, 2004) and is derived from the ectoderm. The panniculus 
adiposus is comprised of adipose tissue while the panniculus carnosus is 
composed of striated muscle fibres (Spence and Mason, 1992). The 
hypodermis provides a cushioning effect for the underlying muscles, tendons, 
bones and joints. It contains hair roots, nerves and blood vessels and the depth 
of the layer varies according to the site on the body (Wood, 1985). 
Subcutaneous adipose cells also play a role in signalling and produce leptin 
(Klein et al., 1996) which regulates cutaneous wound repair (Murad et al., 
2003). 
 
1.1.5 Skin Appendages 
 
Human skin contains a many appendages, including nails, hairs, sweat 
glands and sebaceous glands. The nails are located superficially with the root 
Reticular 
dermis 
Papillary 
dermis 
Figure 1.3. Structure of the human dermis. Haematoxylin & Eosin stained section of 
human upper arm skin. Scale bar = 50µm (figure drawn by the author [EE]). 
Epidermis 
Dermis 
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lying just above the dermis (Baran et al., 2005), while the hairs are anchored 
deeper in the skin with the follicles located in the dermis or lower, depending on 
the stage of the hair follicle cycle, with the hair shaft extending up through the 
other layers of the skin (Baran et al., 2005). Hair follicles go through three 
stages: growth, termed anagen; involution, termed catagen; and rest, termed 
telogen (reviewed in Paus and Cotsarelis, 1999). In humans each follicle 
undergoes its own hair cycle, termed asynchronous (Chase, 1954). Human hair 
undergoes life-long follicle cycles with anagen often lasting for years depending 
on the site of the body, followed by a rapid catagen phase, preceding telogen. 
These phases are regularly interspersed with hair shaft shedding, termed 
exogen (reviewed in Paus, 2007). Hairs play a role in homeostasis, immune 
defence, via the secretion of sebum from sebaceous glands, sensation, 
attractiveness, social signalling, protection and wound healing (reviewed in Ito 
and Cotsarelis, 2008; Stenn and Paus, 2001). The hair follicles house a specific 
set of stem cells which have the ability to become multiple cell types when 
stimulated (Cotsarelis, 2006; Roh and Lyle, 2006). With erector pilli muscles in 
the dermis which attach to the dermal sheath of the follicle the hairs are able to 
become erect to insulate the skin from heat loss. Sebaceous glands are located 
next to the hair follicle in the dermis and secrete sebum on to the hair shaft. 
Sweat glands are located in the deep dermis and their primary function is for 
excretion and to cool the body (Cunningham and Robinson, 1918). The skin is 
highly innervated and contains neurones that sense touch, heat and pain  
(reviewed in Lumpkin and Caterina, 2007) 
 
1.1.6 Skin Vasculature 
 
 Human skin is supplied by a vast network of blood vessels, which 
transport oxygen and nutrients to the dermis, avascular epidermis and skin 
appendages, while removing waste products. Blood vessels also act to control 
temperature, by dilating or contracting to mediate skin surface heat loss 
(Wysocki, 1999). Skin microcirculation is composed of nutritive capillaries and 
thermoregulatory arteriovenous vessels (Flynn et al., 1988). Blood supply to the 
skin is organised in two regions: the upper subpapillary perplexus and the lower 
cutaneous plexus (Chao and Cheing, 2009). Lymphatic vessels draining from 
the dermis to lymph nodes provide a 2-way transport system for inflammatory 
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cells, absorb and transport fats around the body and remove interstitial fluid 
from tissues (Gawkrodger, 2002). 
 
1.1.7 Cell Adhesion 
  
Cell adhesion is particularly important in the skin, an organ under great 
mechanical stress, and cells adhere to each other or to the extracellular matrix 
(ECM). Hemidesmosomes, specialised cell junctions, attach basal epidermal 
keratinocytes to the underlying basement membrane, providing anchorage. 
Together with intermediate filaments and anchoring fibrils they make up the 
hemidesmosomal adhesion complex (reviewed in Borradori and Sonnenberg, 
1999). Hemidesmosomes are comprised of three classes of proteins: 
cytoplasmic plaque proteins, transmembrane proteins and basement 
membrane-associated proteins (Hopkinson and Jones, 2000). Desmosomes 
are cell-cell junctions found in epithelia and in adopting a hyperadhesive state 
provide the tissue with tensile strength (reviewed in Garrod and Chidgey, 2008). 
They are composed of several linking proteins: desmosomal cadherins 
(desmoglein and desmocollin), the armadillo proteins (plakoglobin and 
plakophillin) and desmoplakin  (Getsios et al., 2004).  
 
1.2 Murine skin structure 
 
Murine skin is composed of the same layers as human skin, however, with a far 
thinner epidermis (Sougrat et al., 2002; Trainer and Alexander, 1997) and a 
dermis populated with hair follicles (Trainer and Alexander, 1997; Yan et al., 
1993) (Figure 1.4). In mice and rats large numbers of follicles cycle together, in 
a synchronous manner and this often occurs in a wave travelling from anterior 
to posterior. With increasing age the wave becomes asynchronous and 
synchronicity is localised to patches (Durward and Rudall, 1949). Murine hair 
follicle transition occurs much faster than in humans: anagen lasts between one 
and three weeks, followed by catagen, lasting a matter of days, and 
subsequently telogen, which lasts for approximately 2 weeks (Muller-Rover et 
al., 2001). In telogen the hair follicle is housed in the dermis, while during 
anagen the hair follicle extends through the dermis to the panniculus carnosus. 
As the follicle transitions from anagen to catagen to telogen the follicle returns 
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to the upper dermis (Muller-Rover et al., 2001).  In human and mouse skin the 
subcutaneous layer lies directly above a striated muscle layer, the panniculus 
carnosus. A crucial species difference is that rodents have loose skin, as do 
many other mammals, whereas humans, most primates and pigs do not 
(reviewed in Davidson, 1998; Dorsett-Martin, 2004). Additionally, a population of 
T cells present in skin varies between human and mouse. Mammalian T cells 
express a heterodimeric T cell receptor (TCR), which recognises foreign bodies 
by either an MHC I or II mechanism. In human epithelial tissue, such as the 
skin, the TCR is most commonly composed of an αβ chain, while a small subset 
of T cells express γδ chains instead. Interestingly, in murine epidermis γδ-type 
TCRs predominate on T cells while there is a scarcity of αβ-type TCRs (Payer 
et al., 1992). 
  
 
 
 
 
 
 
 
 
Figure 1.4. Structure of murine skin. Haematoxylin & Eosin stained section of murine 
dorsal skin. Black arrows indicate hair follicles. Scale bar = 50µm (figure drawn by the 
author [EE]). 
Dermis 
Epidermis 
Reticular 
dermis 
Papillary 
dermis 
Hypodermis 
(subcutaneous 
layer) 
 36
1.3 Skin Ageing 
 
As with many tissues in the human body skin undergoes structural 
changes with increasing age (Balin, 1988). Skin ageing manifests as wrinkling, 
sagging, increased laxity (Jenkins, 2002) and solar lentigines or “liver spots” 
(Bolognia, 1995). There are two reasons for skin ageing: true biological ageing 
and environmental factors, and skin changes result from a combination of the 
two. Biological cutaneous ageing is primarily determined by genes and is 
clinically considered as an increase in fragility, a loss of elasticity and a change 
in skin appearance to give a transparent quality. The skin is also more 
vulnerable to trauma and injury which is associated with the increase in fragility 
(McColloch et al., 1995). Environmental ageing occurs through exposure to 
external influences, primarily a cumulative exposure to sunlight. Sun damaged 
skin, often termed photoaged skin, is course, rough and has deep lines and 
wrinkles, and exhibits irregular pigmentation (Figure 1.5) and disorganised 
dermal fibres (Figure 1.6) (Jenkins, 2002; Tsoureli-Nikita et al., 2006). Indeed, 
solar lentigines are considered a good indication of cumulative sun exposure 
(Bolognia, 1995).  
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Whilst the etiology between intrinsic and environmental ageing is quite 
different some of the deleterious changes look quite similar in both, for example, 
increased matrix metalloproteinase (MMP) activity and decreased collagen I 
expression (Ashcroft et al., 1997e; Pillai et al., 2005; Tsoureli-Nikita et al., 
2006). 
Intrinsic skin ageing involves slow deterioration of tissue function, and is 
similar in most internal organs. Specifically, the epidermis and dermis thins at 
the dermo-epidermal junctions (Jenkins, 2002) and as a result the overall 
thickness of the skin decreases steadily. There is a decrease in dermal cell 
density and vascularisation with age (Thomas, 2001). The number and 
Figure 1.5. Macroscopic differences in intrinsic and extrinsic cutaneous ageing in 
humans. Sun-protected skin (a) exhibits fine wrinkling with age. Sun-exposed skin (b) 
exhibits deep wrinkles, rough texture and often uneven pigmentation (figure taken from 
Tsoureli-Nikita et al., 2006). 
Figure 1.6. Histological differences in intrinsic and extrinsic cutaneous ageing in 
humans. Weigert’s resorcin fuschin staining of human sun-protected and sun-exposed 
skin. Sun-protected skin (a) is comprised of dense oxytalan fibres, extending from the 
dermal-epidermal junction, connecting to the underlying elastic fibres. Sun-exposed skin (b) 
has significantly reduced and disorganised oxytalan fibres (figure taken from Tsoureli-Nikita 
et al., 2006). 
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biosynthetic capacity of fibroblasts is reduced, as is tissue elasticity, while skin 
collagen content decreases and collagen fibres become tightly packed in a 
randomly orientated manner (Jenkins, 2002). Intrinsic skin ageing is thought to 
be the result of at least three events: decreased cellular proliferation, eg. 
epidermal keratinocytes (McCulloch, 1995), dermal fibroblasts and 
melanocytes; decreased dermal matrix synthesis; and concomitant increased 
expression of collagen matrix degrading enzymes, eg. MMPs (Farage et al., 
2008). The decreased cellular proliferation is primarily due to cellular 
senescence. Senescent cells enter a stage of irreversible growth arrest, acquire 
resistance to apoptosis and show altered differential functions. It is thought that 
accumulation of senescent cells that are not dividing and exhibit altered gene 
expression and phenotype, will eventually lead to decline in tissue function and 
integrity (Jenkins, 2002). 
In normal skin collagen is organised into bundles, with a basket-weave-
like pattern (van Zuijlen et al., 2003). Collagen content decreases with age and 
the rate is the same in both males and females, about 1% per year throughout 
the adult life. However, female skin starts with a slightly lower proportion of 
collagen than that of males (Shuster et al., 1975). The physical properties of 
collagen, the bundle size and density, also change with age (Richard et al., 
1993) and collagen fibres become thicker and less soluble as collagen 
synthesis declines (Oikarinen, 2004). The features of ageing in adult skin are 
very closely associated with the total collagen content of the skin (Shuster et al., 
1975).  
  
1.4 Cutaneous Wound Repair 
 
At the most basic level wound repair is an extremely complex sequence of 
events and the innate skin repair response comprises of broad overlapping 
phases. Repair initiates with haemostasis, or arrest of haemorrhage, which 
occurs within minutes of injury, clotting damaged vessels and preventing blood 
loss while forming a temporary cutaneous barrier. Within minutes or hours of 
injury the inflammatory response is initiated, with initial recruitment of 
neutrophils and later an influx of monocytes and macrophages. The proliferative 
phase begins within days of injury and involves proliferation of fibroblasts in the 
dermis, proliferation of epidermal keratinocytes, thus facilitating re-
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epithelialisation, or the restoration of the epidermal barrier, and angiogenesis. 
During this period myofibroblasts in the wound contract, bringing the edges of 
the wound closer together. The final stage is matrix formation and remodelling 
with the production of a mature scar, which, in humans, can take up to a year, 
post-injury (Hunt et al., 2000; Shaw and Martin, 2009) (Figure 1.7). Under 
normal circumstances the processes follow a very specific time sequence, but 
the phases are not mutually exclusive and overlap in time (reviewed in Guo and 
Dipietro, 2010; Gurtner et al., 2008; Shaw and Martin, 2009). 
 
 
There are many different cell types involved in the healing process, and they 
are sourced from the epidermis, dermis, hair follicles and blood vessels. Table 
1.1 outlines the major cells involved in repair and their source, timing and 
function. 
 
 
 
 
 
 
 
 
Figure 1.7. Diagramatic representation of a timeline of the phases of wound healing. 
0 = time of wounding, H = haemostasis (figure drawn by the author [EE]). 
0 21 Days post-wounding 
Inflammation 
H 
Re-epithelialisation 
Wound contraction 
Matrix deposition 
Angiogenesis 
Proliferation Scar 
1 year 
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Table 1.1 The roles and sources of the major cell types involved in wound 
repair 
 
Cell Type Source of cell Timing and role References 
Platelets Damaged blood 
vessels 
Arrive immediately at the site of injury 
and contribute to haemostasis, by 
adhering and aggregating to form a 
clot. Release PDGF and TGFβ. 
(Lynch et 
al., 1987; 
Nurden et 
al., 2008) 
Neutrophils Arrive from blood 
vessels 
Early stages of inflammatory 
response. Destroy invading microbes. 
(Dovi et al., 
2004; Kim 
et al., 2008) 
Mast cells 
Some already in 
tissue, others arrive 
from blood vessels 
Early role in regulating inflammatory 
response, angiogenesis and ECM 
reabsorption 
(Trabucchi 
et al., 1988) 
Macrophages 
Some already in 
tissue, most from 
blood-borne 
monocytes 
Secondary influx from blood after 
neutrophils have destroyed any 
immediate microbes in the wound. 
Phagocytose foreign bodies and 
damaged tissue, release cytokines 
and proteases. 
(DiPietro, 
1995; 
Leibovich 
and Ross, 
1975) 
Keratinocytes 
Peri-wound 
epidermis and 
appendages (hair 
follicles, sweat 
glands) 
Brief lag (hours) after injury then 
horizontal migration initiates from 
wound edges to restore epidermal 
barrier 
(Santoro 
and 
Gaudino, 
2005) 
Fibroblasts/ 
Myofibroblasts 
Peri-wound dermis, 
fibrocytes from 
circulation 
Early migration into wound area to 
form granulation tissue. 
Transformation into myofibroblasts 
occurs later in process and causes 
contraction of the wound bed 
(Darby and 
Hewitson, 
2007) 
Endothelial 
cells 
Endothelial 
Progenitor Cells 
(EPCs) from blood 
vessels, originally 
from bone marrow 
Involved in angiogenesis. Endothelial 
cells migrate and proliferate to form 
new blood vessels in the wound site 
during hypoxia 
(Lamalice et 
al., 2007; 
Mace et al., 
2005) 
Dendritic cells 
Epidermally-derived 
Langerhans cells 
and dermally-derived 
dendritic cells 
Involved in re-epithelialisation in first 2 
days post-wounding and immune 
response 
(Erdag et 
al., 2008; 
Juhasz et 
al., 1996) 
 
Early stages of repair represents hours to days post-wounding. Late stages of repair represents 
days to weeks post-wounding. 
 
 
1.4.1 Haemostasis 
 
Haemostasis is the arrest of bleeding by the natural process of blood 
clotting, or by medical intervention. Insult to the skin causes surface activation 
of Hageman factor, or Factor XII, the release of tissue procoagulant from the 
damaged cells and expression of surface membrane coagulation factors and 
phospholipids on activated platelets and endothelial cells (reviewed in Adams et 
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al., 2007). Following injury platelets form a haemostatic plug to stop bleeding 
(McCulloch, 1995). The regulatory protein platelet-derived growth factor (PDGF) 
is released from platelets and has been found to be chemotactic for fibroblasts 
and smooth muscle cells, in vitro (Grotendorst et al., 1982; Grotendorst et al., 
1981). The blood coagulation ceases when the clot initiation stimulus stops. 
Several intrinsic blood vessel activities limit the extent of platelet aggregation 
clotting, including the production of Prostacyclin, which inhibits platelet 
aggregation; antithrombin III binding to thrombin, which inhibits its activity; 
generation of protein C, which is an enzyme that degrades coagulation factors 
V and VIII; and the release of plasminogen activator, which initiates clot lysis via 
conversion of plasminogen to plasmin. Thrombin catalyses the conversion of 
fibrinogen to fibrin at the end of damaged blood vessels, and fibrin cross-links 
with platelets to prevent blood loss (Weisel, 2005). 
Haemostasis is the main player in blood clotting, but also provides a 
matrix scaffold for cells once recruited to the site of injury, specifically fibrin in 
connection with fibronectin, where it acts as a scaffold for monocytes and 
fibroblasts (Tonnesen et al., 2000). Fibrin strands form a mesh between 
aggregated platelets, trapping red blood cells and forming an impermeable clot. 
The clot seals the injury site and prevents further bleeding and infection (Cohen, 
1992) (Figure 1.8). The clotting process is also part of the inflammatory 
response in wound healing, and Hageman factor activation leads to the 
generation of its fragments, bradykinin and vasoactive agents, and to the 
induction of classical and alternative complement cascades (Clark, 2001). In 
turn this results in the generation of anaphylatoxins C3a and C5a which directly 
increase blood vessel permeability and attract neutrophils and monocytes to the 
site of injury (Fernandez et al., 1978). 
Ultimately the success of haemostasis is dependant on platelet adhesion 
and aggregation. When platelets aggregate they express several clotting factors 
and release adenosine diphosphatase (ADP). These products promote 
coagulation and further platelet activation (Clark, 1996). 
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1.4.2 Inflammatory Response 
 
 The immune response, the host defence against infection, can be divided 
into two: innate immunity and acquired immunity. Innate immunity is determined 
by genetics, and recognition proteins are coded for in germline cells, while 
acquired immunity is attained by exposure to an antigen during the organisms 
life, either through infection (active immunity), or by transfer of an antibody 
(passive immunity) (Fearon, 1999). The majority of the cells involved in the 
healing response are innate inflammatory cells, and include neutrophils, 
macrophages, mast cells, dendritic cells, eosinophils and basophils (Noble and 
Jiang, 2006). However, a role for T cells and B cells in the wound healing 
process has been demonstrated. In the absence of dendritic cell-derived T cells 
healing is delayed (Jameson et al., 2002), and epidermally-derived T cells 
locally secrete growth factors in the skin during the healing process (Toulon et 
al., 2009). Mice that are deficient in B-1 cells exhibit increased inflammatory cell 
infiltration, particularly neutrophils, and have a delayed healing response 
(Oliveira et al., 2010). 
Neutrophils arrive in the wound in large numbers, within a few minutes of 
injury, attracted by a variety of chemotactic factors, and remove foreign 
particles, including bacteria (Singer and Clark, 1999). They kill bacteria by 
Platelets and fibrin clot the wound 
Clot forms to protect from blood 
loss and/or foreign bodies 
entering wound 
Fibroblast 
Platelet 
Fibrin 
Figure 1.8. Representation of haemostasis in wound healing. Tissue injury causes 
disruption of blood vessels resulting in activation of the coagulation cascade. Platelets 
aggregate and a provisional fibrin matrix fills the wound space to provide a temporary barrier. 
The clot seals the wound site preventing further bleeding and infection (figure drawn by the 
author [EE]). 
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means of phagolysosomes (Lee et al., 2003) and release enzymes and reactive 
oxygen species, which act to kill invading microbes (James et al., 2003; Martin 
and Feng, 2009; Roy et al., 2006).  
As well as providing the stimulus for directed migration of inflammatory 
cells chemotactic factors increase CD11 and CD18 expression on the neutrophil 
surface, and in conjunction with Factor X, mediate the adherence of neutrophils 
to the blood vessel endothelium and facilitate the migration of leukocytes 
through the endothelium. At sites of infection or injury cytokines released in the 
tissue signal to leukocytes in the neighbouring blood vessels. Endothelial 
surface proteins, namely selectins, are expressed on the inner wall of the blood 
vessel which causes leukocyte attachment. Leukocytes “roll” along blood vessel 
walls until they find a point to exit, either between two endothelial cells 
(paracellular extravasation) or through one cell (transcellular extravasation) 
(Figure 1.9)  (Ley et al., 2007). 
 
 
 
This activation also stimulates the release of elastase and collagenase 
molecules, which facilitates cell migration through blood vessel basement 
membranes (Tonnesen, 1989). Neutrophil phagocytosis involves recognition 
and attachment of C3b coated antigen to Fc receptors on the cell (Hakansson 
and Venge, 1982). Neutrophils are also able to target microbes by trapping 
Leukocyte 
Endothelial 
cell 
Rolling 
Slow rolling 
Attachment 
Transmigration 
Crawling 
Figure 1.9. The multi-stage process of leukocyte migration from blood vessel to 
tissue. The passing leukocyte attaches to the endothelial cells via E- and P-selectin. 
Leukocytes roll along the endothelial wall, ultimately resulting in firm attachment. The 
leukocyte crawls until a cell-cell junction and transmigration of the cell into the tissue occurs 
between two cells (paracellular extravasation) (figure adapted from Ley et al., 2007, drawn 
by the author [EE]). 
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them in extruded nets of fibres that bind to Gram-positive and -negative bacteria 
(Brinkmann et al., 2004). 
Unless extensive wound contamination has occurred the infiltration of 
neutrophils into the wound ceases within a few days. Most of the neutrophils are 
trapped within the wound clot and desiccated tissue and are then either 
extruded with the eschar or destroyed by macrophage phagocytosis (Newman 
et al., 1982).  
Monocytes continue to enter the wound site in response to 
chemoattractants [eg. Macrophage Chemoattractant Protein (MCP) -1, 
Macrophage Inflammatory Protein (MIP) -1 and Growth-Related Oncogene α 
(MIP-2 in mouse) (reviewed in Werner and Grose, 2003)]. Fragments of ECM, 
including collagen, elastin, fibronectin, thrombin, and Transforming Growth 
Factor β (TGF-β) stimulate circulating monocytes to attach to the endothelium 
of blood vessels and migrate through the blood vessel wall into the tissue 
(Werner and Grose, 2003).  
Blood borne monocytes are recruited into tissue, in response to a 
number of stimuli, including integrins, and can be activated in one of two 
manners: classically or alternatively, which are often considered as 
inflammatory or reparative macrophages, respectively. This activation occurs in 
response to specific cytokines, including IFNγ (classical) and IL-4 and IL-13 
(alternative) (reviewed in Gordon, 2003). Stein et al. (1992) described 
alternatively activated macrophages and how they had a specifically different 
phenotype to what are now known as classically activated macrophages. 
Classically activated macrophages are associated with a Th1 response, 
promoting chronic inflammation, matrix destruction and tissue injury while 
alternatively activated macrophages are associated with a Th2 response and 
act to resolve inflammation, promoting matrix generation, angiogenesis and cell 
proliferation (Duffield, 2003; Gordon, 2003). 
Monocyte adherence also induces expression of colony-stimulating 
factor-1, which is a cytokine necessary for monocyte-macrophage survival; 
tumour necrosis factor-α (TNF-α), an inflammatory cytokine; platelet derived 
growth factor (PDGF), a chemoattractant and mitogen for fibroblasts; as well as 
the transactivating factors c-fos and c-jun. Other macrophage cytokines, such 
as TGF-β and interleukin-1 (IL-1) are adherence independent. When 
macrophages are activated by bacterial endotoxin they stimulate further release 
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of cytokines, which recruit other inflammatory cells. Macrophages release 
growth factors that initiate granulation tissue formation and are continually 
synthesising and secreting growth factors and cytokines (Chen et al., 2004) and 
macrophage-derived growth factors, such as fibroblast growth factor (FGF) are 
almost certainly required for initiation and propagation of new tissue formation in 
wounds (Shaw et al., 1990).  Macrophages play a major role in the transition 
period between inflammation and repair in the wound healing process (Figure 
1.10). 
 
 
 
The importance of inflammatory cells in wound healing is a contentious 
issue. The PU.1 null mouse, which is unable to produce functioning 
macrophages and neutrophils, heals normally (Martin et al., 2003), while 
neutropenic mice exhibit accelerated wound closure (Dovi et al., 2003). More 
recently it has been demonstrated that when macrophages are depleted in the 
early and mid stages of healing, using a transgenic mouse which expresses the 
human diphtheria toxin (DT) receptor under the control of the myeloid specific 
LysM-Cre promoter, there is a significantly detrimental effect on healing (Goren 
et al., 2009; Lucas et al., 2010), while selective ablation of macrophages using 
a transgenic mouse which expresses DT receptor under the control of the 
CD11b promoter, causes a delay in re-epithelialisation, reduced angiogenesis 
Neutrophils arrive in the wound 
within minutes of injury 
Monocytes enter later and are 
differentiated into macrophages 
Figure 1.10. Representation of the inflammatory phase in wound healing. Platelets and 
macrophages trapped in the fibrin matrix release cytokines which initially recruit neutrophils 
and later monocytes to the injury site. Fibronectin filaments provide a scaffold for the 
migration of inflammatory cells into the wound bed (figure drawn by the author [EE]). 
Blood vessel 
Fibroblast 
Neutrophil 
Macrophage 
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and collagen deposition in the wounds and up-regulation of TNF-α and TGFβ1 
(Mirza et al., 2009). 
 
1.4.3 Granulation tissue formation and the proliferative phase 
 
Granulation tissue starts to form about 4 days post-injury (Halloran and 
Slavin, 2002). It is so called because of the granular appearance of the tissue 
when it is incised and examined visually. The granulation tissue consists of 
macrophages, fibroblasts, loose connective tissue, blood vessels and cytokines 
and growth factors, in particular TGFβ, which is required for granulation tissue 
induction (Werner et al., 2007) (Figure 1.11). While low levels of cytokines 
circulate in the plasma activated platelets release large amounts of growth 
factors, particularly TGFβ-1, into the wound area. TGFβ-1 initiates its own gene 
transcription creating a positive feedback loop, while also recruiting further 
inflammatory cells (Klass et al., 2009). 
The fibrin clot, in addition to providing support to the wound, promotes 
granulation tissue formation by acting as a scaffold for the contact guidance of 
fibroblasts and inflammatory cells and as a reservoir for cytokines, such as 
TGFβ and TNF-α. Macrophages in the wound provide a continuous source of 
cytokines, which are necessary to stimulate angiogenesis and the formation of 
fibrous tissue (Nathan, 1991).  
 Fibroblasts are the predominant cell type involved in the proliferative 
tissue phase (Beanes et al., 2003). The migration of fibroblasts into the wound 
is controlled by TGFβ and PDGF, using fibrin and fibronectin as a scaffold 
(Figure 1.11) (Hsieh and Chen, 1983). Cell migration is facilitated by the 
expression of β1 integrins in response to Epidermal Growth Factor (EGF) and 
TGFβ (Bellas et al., 1991). Fibroblast proliferation in response to PDGF and 
FGF also synthesises fibronectin (Wegrowski et al., 1989), which ultimately 
replaces the fibrin clot. Fibroblasts in the wound deposit collagen in the 
granulation tissue, gradually replacing fibronectin, a process that is regulated by 
TGFβ (Sporn and Roberts, 1992), PDGF (Pierce et al., 1989) and FGF 
(Broadley et al., 1989). Extracellular matrix (ECM) is primarily deposited at the 
wound margin, while granulation tissue is developing, but is deposited more 
centrally in the wound as the granulation tissue grows into the wound space 
(Clark, 1996). During the proliferative phase granulation tissue maturation 
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occurs and fibroblasts cease to produce ECM and begin differentiating into 
myofibroblasts (Gabbiani et al., 1971). 
 
1.4.4 Re-epithelialisation 
 
In order for a wound to heal epidermal keratinocytes are required to 
proliferate and migrate to re-establish the cutaneous barrier (Kirfel and Herzog, 
2004). Re-epithelialisation is initiated by 18 hours post-wounding by cell-to-cell 
contact signalling that indicates the absence of neighbouring cells at the wound 
edge, termed “free edge effect” (Matsuzaki et al., 2004). Basal epidermal 
keratinocytes at the wound edge change morphologically: they become 
flattened and intracellular desmosomes, the structures that link epithelial cells, 
are altered (Matsuzaki et al., 2004). Desmosomes are cell-cell junctions that link 
cells together, and provide the tensile strength the tissue requires. 
Desmosomes exist in two states: calcium- (Ca2+) dependent and Ca2+-
independent. In normal tissue desmosomes exist in a hyper-adhesive, Ca2+-
independent state; however, during times of cell migration and proliferation, for 
example, growth, development and wound healing, desmosomes revert to a 
Ca2+-dependent state, a switch that is thought to be controlled by Protein 
Kinase C α (PKCα) (Garrod et al., 2005). Hemidesmosomes, the junctions 
between the epidermis and basement membrane, become altered to allow cells 
Re-epithelialisation under clot 
restores cutaneous barrier 
Granulation tissue, containing 
macrophages, fibroblasts, 
connective tissue and blood 
vessels, forms 4 days post injury 
Blood vessel 
Fibroblast 
Keratinocyte 
Macrophage 
Fibronectin/collagen 
Figure 1.11. Representation of the proliferative phase in wound healing. Granulation 
tissue consisting of macrophages, fibroblasts, loose connective tissue and blood vessels 
forms once the inflammatory phase subsides, while growth factors and cytokines circulate in 
the blood plasma (figure drawn by the author [EE]). 
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to migrate (Matsuzaki et al., 2004). EGF, KGF and TGFβ-1 and -2 stimulate 
keratinocyte proliferation and migration (Matsuzaki et al., 2004) while MMPs 
produced by the damaged keratinocytes at the wound edge cleave collagen in 
the basal lamina, allowing cell migration (Salo et al., 1994). MMP1 expression is 
a critical signal for the initiation of keratinocyte migration after cutaneous injury 
(Pilcher et al., 1997) and is expressed by wound edge keratinocytes during re-
epithelialisation but ceases immediately upon restoration of the epidermis 
(Saarialho-Kere et al., 1992; Saarialho-Kere et al., 1993). 
Keratinocytes extend pseudopodia from the basolateral side into the 
wound and increased actinomysin filaments cause contraction and cell 
movement (Mitchison and Cramer, 1996). As a result of the morphological 
changes epidermal cells at the edge of a wound have lateral mobility and the 
ability to migrate. Prior to epidermal migration base fibronectin is laid down over 
the wound to allow keratinocyte migration and attachment (Matsuzaki et al., 
2004). Keratinocytes from the stratified epidermal sheet or the hair follicle start 
to move across each other in a “leap frog” fashion. Cells at the migrating front 
are successively overtaken and replaced by cells from behind them. These cells 
stretch over the adhered basal layer (fibronectin) and attach at the wound edge 
and become the leading cells (Krawczyk, 1971) (Figure 1.12) 
There are several keratinocyte subtypes involved in the wound healing 
process, and the expression of keratinocyte intermediate filaments can possibly 
be used to ascertain the different phenotypic subtypes and maturation of 
keratinocytes. Basal keratinocytes and cells leading the wound edge express 
keratins K5 and K14 and reduced expression of K15, whereas suprabasal cells 
show a more elaborate pattern of expression, dependant of their situation in the 
healing wound and their location in the suprabasal area of the epidermis. It has 
been noted that suprabasal keratinocytes at the wound edge express K10 
whereas some keratinocytes in the wound centre do not express K10, but 
instead express K6, K16 and K17 (Bernot et al., 2004; Patel et al., 2006; Porter 
et al., 2000; Wong and Coulombe, 2003). 
Epidermal keratinocytes will normally cease proliferation and migration 
once the wound is fully closed (Gipson et al., 1988), a phenomenon that is 
thought to be via cell-cell contact inhibition and a loss of integrin expression 
(Martin, 1997). Once epithelialisation is achieved keratinocytes resume a 
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normal phenotype and become firmly attached to the newly developed 
basement membrane by hemidesmosomes (Matsuzaki et al., 2004). 
 
 
Epithelialisation is crucial for efficient wound healing to restore the 
cutaneous barrier of the skin, so one would assume that defects in the process 
of re-epithelialisation would have a detrimental effect on wound repair. The 
effect of the growth factor KGF on re-epithelialisation and wound healing is a 
contentious issue. KGF mRNA is highly expressed during wound healing 
(Werner et al., 1992) and KGF stimulates keratinocyte proliferation and 
migration (Finch et al., 1989; Tsuboi et al., 1993). Werner et al. (1994) reported 
that in mice where FGF function had been blocked in the epidermis using a 
truncated FGFR2-IIIb healing of incisional dorsal wounds was delayed. 
However, Guo et al. (1996) reported that mice null for the KGF gene showed no 
delay in healing dorsal incisional wounds and tail wounds. Staiano-Coico et al. 
(1993) found that the application of KGF to porcine skin wounds accelerates re-
epithelialisation, while Sanz Garcia et al. (2000) identify that EGF, KGF and 
basic FGF (bFGF) all promote wound re-epithelialisation. 
 
1.4.5 Angiogenesis 
 
Angiogenesis is the formation of new blood vessels in tissue, during 
development or in response to injury or tumour angiogenic factors. The 
microvascular cell, the major cell involved in the process of angiogenesis in a 
wound, is quite different to the cells lining the endothelial of larger vessels of the 
Figure 1.12. Illustration of keratinocyte migration in the leading edge of the epidermal 
tongue, in a “leap-frog” fashion. Keratinocytes at the wound edge migrate on to 
provisional wound matrix (FN), sucessively overtaking each other by “leap-frogging”. BM = 
basement membrane, FN = fibronectin (figure adapted from Matsuzaki et al., 2004, drawn 
by the author [EE]). 
BM FN 
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circulatory system. With normal growth dermal microvascular endothelial cells 
(DMECs) retain an epithelialoid morphology. However, cells at the wound edge 
in vivo and those in vitro that are artificially scratched change morphology to 
spindle-shaped myofibroblast-like cells (Chaudhuri and Karasek, 2006). 
There are different mechanisms of angiogenesis; physiological and 
pathological. Physiological angiogenesis occurs in a developing foetus and 
continues into adulthood; the vessels formed are highly organized and arranged 
in a regularly spaced manner. Pathological angiogenesis occurs in 
tumorigenesis, myocardial infarction, wounding or inflammation, and the new 
vessels formed are highly abnormal, irregularly arranged and branched, and 
often hyperpermeable to plasma and plasma proteins (Dvorak, 2005). 
Within a couple of days of wounding, angiogenic capillary sprouts invade 
the wound clot and the granulation tissue. As collagen accumulates in the 
wound area the density of vessels in the granulation tissue decreases. 
Endothelial cell ECM receptors and angiogenic cytokines, including vascular 
endothelial growth factor (VEGF), TGF-β and FGF, are crucial for 
morphogenetic changes in blood vessels during healing and further stimulation 
of other growth factors (Tonnesen et al., 2000). It is thought that EGF, TGFβ, 
KGF and TNF-α all stimulate the production of VEGF (Frank et al., 1995). 
VEGF-A mediates vascular hyperpermeability, angiogenesis and inflammation, 
all of which are critically involved in tissue repair.  It has been shown that there 
is a significantly increased level of the VEGF-A inhibitor, the soluble form of the 
VEGF receptor VEGFR-1 (sVEGFR-1) in non-healing wounds compared to 
healing wounds (Eming and Krieg, 2006). FGF and FGF2 are released at the 
wound site by damaged endothelial cells (Clark, 1996) and promote 
angiogenesis (Cao et al., 2003). Peroxiredoxin 6 (Prdx6), a signal transduction 
enzyme, is upregulated in wounded skin and in Prdx6 knockout mice wounding 
causes severe haemorrhage in the granulation tissue (Kumin et al., 2007). 
Angiogenesis is crucial for wound repair, however, some aspects appear 
more important than others. For example, endostatin, a cleavage product of 
collagen XVIII, strongly inhibits angiogenesis in one type of carcinoma 
metastases in mice (O'Reilly et al., 1997). Interestingly, wounded mice treated 
with recombinant murine endostatin show no macroscopic differences in 
wounds compared to untreated mice. However, upon ultrastructural 
investigation severe abnormalities were noted, with narrower blood vessels 
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exhibiting irregular luminal surfaces, but with no change in VEGF and 
angiopoieitin-1 and -2 expression. Together this data suggests that endostatin 
also has a significant effect on angiogenesis in wound repair, but not to an 
extent that substantially effects overall healing (Bloch et al., 2000). In mice 
treated with neutralising FGF antibodies the early stages of wound healing were 
significantly affected, with reduced protein and collagen content in the wounds 
(Broadley et al., 1989) but no discernable differences in angiogenesis. VEGF is 
strongly upregulated in wounds of healthy mice during the period of granulation 
tissue formation and angiogenesis. However, in diabetic (db/db) mice that heal 
poorly, VEGF expression is reduced, suggesting a potential role for VEGF and 
angiogenesis in delayed healing (Eming and Krieg, 2006; Frank et al., 1995).  
 
1.4.6 Wound Contraction 
 
Wound contraction assists in the overall healing process with the 
centripetal movement of the wound edges, which ultimately results in a reduced 
wound size. Dermal fibroblasts at the wound edges start to proliferate after 
injury and 3-4 days post-wounding they begin to migrate into the wound 
provisional matrix (Martin, 1997). This lag phase between the time of wounding 
and fibroblast migration is thought to be due to quiescent fibroblast activation 
(McClain et al., 1996). PDGF and TGFβ act as fibroblast mitogens and/or 
chemotactic factors (Eriksson et al., 1992; Frank et al., 1996) while activin, a 
TGFβ-related growth factor, is identified in wound edge fibroblasts (Hubner et 
al., 1996). TGFβ-1 has the greatest effect on late stage fibroblasts, those 
present at 21-28 days post-wounding, indicating a role in contraction (Reed et 
al., 1994). 
During intermediate stages of healing, 7-14 days post-wounding, a 
proportion of the recently invaded fibroblasts take on a myofibroblast 
phenotype, characterised by large bundles of microfilaments, which contain  F-
actin, along the plasma membrane and at cell-cell and cell-matrix linkages 
(Gabbiani et al., 1971; Welch et al., 1990) and the ability to express α smooth 
muscle actin (αSMA) (Desmouliere et al., 2005). The transition of fibroblast to 
myofibroblast involves an intermediate precursor cell, the protomyofibroblast. 
The protomyofibroblast contains stress fibres with β and γ cytoplasmic actins. 
The protomyofibroblast most commonly evolves into a myofibroblast containing 
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αSMA fibres (Figure 1.13) (Desmouliere et al., 2005; Tomasek et al., 2002). 
This switch is thought to be primarily controlled by TGFβ1 (Desmouliere et al., 
1993). The αSMA fibres become aligned with the extracellular fibronectin fibrils 
across the radial wound axis. As the edges of the wound are drawn closer 
together the granulation bed contracts (Desmouliere et al., 2005). 
 
 
 Once the wound has sufficiently contracted a series of signalling events 
occur: initially fibroblasts activate an adenosine 3’5’-monophosphate (cAMP) 
pathway which in turn desensitises PDGF and EGF receptors on the 
myofibroblast surface (Lin and Grinnell, 1993). This causes the cells to return to 
a quiescent state and apoptosis occurs (Desmouliere et al., 1995).  
 In wounds that were splinted to remain open the expression of 
contraction-associated genes, such as αSMA, appeared earlier than in normal 
wounds, confirming that wound tension is required for myofibroblast 
differentiation and contraction (Hinz et al., 2001). 
 
 
 
Figure 1.13. Fibroblast differentiation in a wound. A proportion of wound fibroblasts 
evolve firstly into an intermediary proto-myofibroblast and then to a contractile 
myofibroblast, a process driven by TGFβ stimulation by keratinocytes (figure adapted from 
Werner et al., 2007, drawn by the author [EE]). 
ECM 
Keratinocytes 
Fibroblast Proto-myofibroblast Myofibroblast 
TGFβ. ET-1 TGFβ 
TGFβ. 
IL-1, 
activin 
KGF, TGFβ. 
IL-6, activin 
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1.4.7 Remodelling and maturation 
 
Tissue remodelling involves the transition from the provisional matrix, 
including the fibrin clot, to a collagenous scar. Alteration of the provisional 
matrix of fibrin and collagen involves lysis of the clot, deposition of fibronectin 
and proteoglycans and collagen remodelling, and can take up to a year to 
complete (Hanna and Giacopelli, 1997; Quinn et al., 1998).  Once the wound is 
closed there is very little risk of infection, but the scar is cellular and highly 
vascularised, appears pigmented and is elevated (Clark, 1996) (Figure 1.4). 
As granulation tissue invades the clot it is lysed at the leading edge of 
the granulation tissue by matrix metalloproteinases (MMPs) and tissue 
plasminogen activator (tPA) (Lund et al., 2006; Saarialho-Kere et al., 1992) and 
eventually the clot will lift off (Figure 1.14). 
Hyaluronan, or hyaluronic acid (HA), is a major component of early 
granulation tissue, but content falls after day 5 day post-wounding, when it 
remains at a fairly constant level from day 10 onwards (West et al., 1997). As 
HA levels decrease in the second week post-wounding the extracellular matrix 
proteoglycans, produced by the mature scar fibroblasts, increase. 
Proteoglycans also play a role in regulating cell function and versican, a 
component of proteoglycans that contributes to tissue resilience in the wound 
scar (Schonherr et al., 1991; Wight et al., 1989), promotes cell migration by 
decreasing cell adhesion (Yamagata et al., 1993). If HA levels remain high 
during the remodelling phase the amount of collagen deposition is affected 
(Mast et al., 1993; Mast et al., 1992). 
Collagen I is the stable and mature form in skin while collagen III is less 
stable and usually seen in the early phases of healing (Schaffer and Becker, 
1999). A balance between the degradation and synthesis of collagen exists 
during remodelling, with the ratio between type III and type I collagen 
decreasing throughout the process (Bailey et al., 1975). The ECM degradation 
is controlled by MMPs that are secreted by fibroblasts, epidermal cells and 
endothelial cells (Madlener et al., 1998). MMPs are able to cleave collagen, with 
MMP2 (gelatinase/type IV collagenase) able to cleave type VI collagen, 
denatured collagens and reconstituted type I collagen fibrils. However, the 
closely related MMP9 (gelatinase/type IV collagenase) is unable to cleave 
soluble or fibrillar collagen. MMP2 is unable to degrade native interstitial 
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collagens, which is thought to be susceptible only to the interstitial collagenases 
MMP1 and MMP8 (Aimes and Quigley, 1995). TGFβ-1 up-regulates collagen 
synthesis by fibroblasts and in doing so enhances collagen deposition and the 
synthesis of tissue inhibitors of metalloproteinases-1 (TIMP-1). TIMPs act by 
inhibiting MMPs (Edwards et al., 1992a). 
Despite the extensive remodelling phase of wound healing, scar tissue 
only regains about 80% of its original strength and its function is never 
completely restored (Levenson et al., 1965). A keloid or hypertrophic scar may 
be formed when the phases of wound healing are disrupted, particularly 
granulation tissue formation and resolution (Ogawa, 2010). The distinguishing 
histological feature between keloid scars and hypertrophic scars is the presence 
of thick collagen bundles in keloid scars that are absent in hypertrophic scars 
(Ogawa et al., 2009). 
The balance between production of TGFβ-1, -2 and -3 has a major 
impact on fibrosis and scarring (Bock et al., 2005). TGFβ-1 is required for 
efficient wound healing and TGFβ-1 treatment enhances healing of chronic 
wounds (Bernstein et al., 1991). However, TGFβ1 in a mouse model of healing 
causes fibrosis (Mori et al., 1999). Interestingly, TGFβ-3 treatment accelerates 
healing while preventing scarring (Ferguson et al., 2009; Shah et al., 1995; Wu 
et al., 1997). Smad3 and Smad2 are intracellular mediators of TGFβ function 
and act as transcriptional activators (Derynck et al., 1998; Massague, 1998) and 
both mediate intracellular signalling of TGFβs 1, 2 and 3, which have all been 
shown to be essential in cutaneous wound healing (reviewed in O'Kane and 
Ferguson, 1997; Roberts, 1995).  Smad3 null mice exhibit accelerated 
cutaneous wound healing compared to wild-type mice, characterised by 
accelerated re-epithelialisation and reduced infiltration of monocytes (Ashcroft 
et al., 1999b). Smad3 plays a role in androgen-mediated inhibition of healing 
but its role in estrogen-mediated healing has not been fully determined 
(Ashcroft et al., 2003a). 
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1.5 Aberrant Wound Healing 
 
Wound healing is a complex series of events and is crucial in restoring 
the cutaneous barrier and preventing blood loss and infection by invading 
foreign bodies after injury. The rate and quality of wound healing are influenced 
by a number of factors, including the depth and surface size of the wound and 
many other contributing morbidity factors. Age is an important factor and acute 
wound healing is markedly delayed in the elderly (Holt et al., 1992). The delay 
in healing of wounds often leads to local infection and the transition to a non-
healing wound. Pathological conditions such as venous insufficiency and 
diabetes mellitus also contribute directly to the formation of chronic, non-healing 
ulcers, and will be discussed in more detail in the following sections. The 
treatment of wounds such as these put significant financial burden on the 
world’s health services. Foot ulceration is the most common cause of 
hospitalisation for diabetics (Reiber, 1992) and in 1998 24,000 hospital 
admissions in the UK were diabetic patients suffering from foot ulceration, 
costing the NHS an estimated £17 million (Currie et al., 1998). Treatment of 
venous ulcers cost the NHS £400 million in 1997 and the majority of this was for 
dressings and community nursing costs (Ruckley, 1997) while treatment of 
pressure ulcers was estimated at £300 million in 1988 (Waterlow, 1988). 
Fibroblasts and 
myofibroblasts 
secrete MMPs 
Connective tissue 
deposited in the 
wound 
Fully restored 
cutaneous barrier 
Clot is lysed and 
comes off 
Figure 1.14. Representation of the remodelling phase of wound healing. Remodelling 
involves the replacement of the provisional matrix of fibronectin and fibrin with connective 
tissue, including collagen, and the formation of a mature scar. The extracellular matrix 
(ECM) degradation is controlled by MMPs, secreted by fibroblasts, endothelial cells and 
epidermal keratinocytes (figure drawn by the author [EE]). 
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1.5.1 Chronic Wounds 
 
Chronic wounds are particularly prevalent in the elderly and occur when 
the normal healing process is disrupted and does not progress in a timely 
manner (reviewed in Taylor et al., 2005), remaining in a sustained inflammatory 
state (Ashcroft et al., 1997e). Diabetes, malnutrition, and renal disease all 
contribute to chronic wound progression leading to hypoxia, infection, tissue 
necrosis and ischemia (reviewed Stadelmann et al., 1998). Granulocyte and 
macrophage numbers decline early in the healing process in acute wounds, 
while populations of these cells remain elevated in chronic wounds (Loots et al., 
1998) due to impaired efferocytosis, or dead cell clearance, and excessive pro-
inflammatory cytokine production (Khanna et al., 2010).  
There are a number of causes of chronic wounds, with many etiological 
classes but the three most common types are diabetic ulcers, venous ulcers 
and pressure sores (Nwomeh et al., 1998).  
 
1.5.2 Diabetic Ulcers 
 
Those suffering from diabetes (both types I and II) are at risk of 
developing non-healing foot ulcers, an estimated lifetime risk of 25% (Singh et 
al., 2005) and it is estimated that the incidence of lower leg amputation in 
diabetics over the age of 45 is 8 times more than in non-diabetics (Johannesson 
et al., 2009). Diabetes leads to two major conditions affecting the foot: 
neuropathy and vasculopathy. At least 28% of diabetics suffer from peripheral 
neuropathy (Young et al., 1993) while motor neuropathy results in abnormal foot 
shape and weight bearing, predisposing the foot to injury (reviewed in Cheer et 
al., 2009). Diabetic ulcers most often occur in patients who are suffering from 
neuropathy and are therefore unable to sense and relieve cutaneous pressure. 
Additionally, arteriosclerosis is more common and more aggressive in diabetics 
than in non-diabetics (Robinson et al., 2009). Wound ischemia develops 
because of microvascular occlusion and poor oxygen and nutrient delivery, and 
ultimately tissue necrosis occurs (reviewed King, 2001). Like many chronic 
wounds diabetic wounds exhibit impaired macrophage and neutrophil function, 
in turn increasing the risk of infection and prolonging healing time (Loots et al., 
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1998). The size, duration and grade (see Table 1.2) of the wound has a direct 
impact on healing potential (Margolis et al., 2002a). 
 
Table 1.2 The Curative Health Services (CHS) wound grade scale (modified 
from Margolis et al., 2002a) 
 
 
Wound Grade Wound Description 
1 Partial thickness, only dermis and epidermis 
2 Full thickness and subcutaneous tissues 
3 Grade 2 plus exposed tendons, ligaments and/or joints 
4 Grade 3 plus abscess and/or osteomyelitis 
5 Grade 3 plus necrotic tissue in the wound 
6 Grade 3 plus gangrene in the wound and surrounding tissue 
 
 
1.5.3 Venous Ulcers 
 
The initiating factor for venous leg ulceration is prolonged venous 
hypertension, resulting from either valve dysfunction with venous reflux, venous 
thrombosis causing outflow obstruction, or a combination of both (Raffetto, 
2009), ultimately causing major capillary damage. The mechanism by which 
hypertension causes ulcers is largely unknown, although there are several 
theories, including the peri-capillary fibrin cuff theory (Browse and Burnand, 
1982; Burnand et al., 1982), a decreased pressure gradient leading to reduction 
in capillary bed perfusion pressure and capillary flux (Coleridge Smith et al., 
1988) and the growth factor trap hypothesis (Falanga and Eaglstein, 1993). 
Leukocyte activation and the release of proteases and oxygen free radicals 
results in endothelial cell dysfunction and capillary occlusion causes hypoxia, 
leading to bacterial infection and ultimately impaired healing (Olivencia, 1999). 
Fibroblasts derived from the edges of venous ulcers also have impaired ability 
to synthesise collagen in vitro (Herrick et al., 1996). 
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1.5.4 Pressure Sores 
 
 Pressure sores primarily affect those who remain stationary for large 
periods of time, for example, the elderly, disabled, debilitated, babies and young 
children. Pressure, underlying bones, moisture of the skin, increasing age and 
co-morbidity are the main factors affecting the development of a pressure ulcer 
(Allman et al., 1995; Thomas et al., 1996; Torrance, 1983). Pressure ulcers 
usually develop on the lower half of the body, most commonly in the pelvic area 
(Grey et al., 2006). In the UK pressure ulcers affect 10% of hospitalised patients 
and 5% of community-living patients (Kaltenthaler et al., 2001) and in 2004 the 
cost of treatment of pressure ulcers was approximately £2 billion, 4% of the total 
NHS expenditure (Bennett et al., 2004). However, much of these costs could 
have been avoided with appropriate preventative measures, including 
repositioning and pressure relief mattresses (Catz et al., 2005). Development of 
a pressure ulcer increases mortality rate by 7.23% (Zhan and Miller, 2003). 
 
1.5.5 Multiple causation 
 
It is estimated that between 30% and 40% of ulcers have more than one 
contributory aetiological factor, which can influence the treatment a patient 
requires (reviewed Baker et al., 1991; Bergqvist et al., 1999). There are several 
factors influencing the occurrence of an ulcer, including diabetes, a history of 
thrombosis, age at which the first ulcer occurs, the duration of ulcer and the 
percentage recurrence of ulcers (reviewed Bergqvist et al., 1999; Margolis et 
al., 2004). For example, approximately 25% of those with a venous ulcer also 
have a history of deep vein thrombosis (Nelzen et al., 1991). 
Pain is a problem in all ulcer sufferers except those suffering from 
neuropathy as a result of diabetes. Current treatments are particularly poor, 
ranging from silver and honey impregnated dressings, to maggot debridement 
therapy. At present basic treatments termed “good wound management” 
including wound cleansing, regular surgical debridement and sterile dressings 
are widely used, while compression bandage therapy and mechanical offloading 
are used for the treatment of venous ulcers and diabetic ulcers, respectively 
(Gibbs et al., 2007; Sackheim et al., 2006). However, these treatments treat 
only the secondary causes of the wound, and do not address the underlying 
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molecular and cellular processes that contribute to and ultimately determine 
how a wound heals. 
 
1.6 Age-related delayed healing 
  
While the elderly are more at risk of developing a chronic wound they 
also suffer from a delay in healing of acute wounds (Holt et al., 1992). An 
increase in fragility of aged skin together with impaired immune response and 
cellular ageing contribute to impaired wound healing in the elderly, associated 
with disruption of the normal phases of repair leading to an increase in healing 
time following injury (reviewed Thomas, 2001). As the average age of the 
population has increased the proportion of elderly people in the population has 
also increased and with it the incidence of delayed healing. Archival studies 
highlight several events which contribute to age-related delayed healing: 
delayed haemostasis (Banerjee and Etherington, 1974; Boldt et al., 2001; 
Fukaya et al., 2000), a prolonged and excessive inflammatory response with 
increased pro-inflammatory cytokine production (Ashcroft et al., 1998), reduced 
fibroblast proliferation (Reed et al., 2001), up-regulated protease activity 
(Ashcroft et al., 1997e), reduced matrix deposition (Ashcroft et al., 1997c; 
Ashcroft et al., 1997f; Ashcroft et al., 2002) and reduced re-epithelialisation 
(Gilchrest, 1983) (Figure 1.15). 
 
 
 60
 
1.6.1 Effect of age on haemostasis 
 
 With increasing age the body’s ability to arrest bleeding is impaired. 
During abdominal surgery it was recorded that blood loss after one day post-
operation was not significantly different between a group of patients under the 
age of 60 and those over the age of 70, and von Willebrand Factor (vWF), an 
endothelial marker of coagulation, remained unchanged between the groups 
Prolonged and excessive 
inflammatory response Reduced angiogenesis 
Reduced re-epithelialisation and 
impaired platelet function 
Reduced matrix 
deposition and 
tensile strength 
Increased wound area 
and delay in healing 
Reduced 
fibroblast 
proliferation 
Young 
Old 
Accelerated re-
epithelialisation 
Increased fibroblast 
proliferation and 
matrix deposition 
Figure 1.15. Representation of changes in healing with age. A delay in haemostasis, 
impaired platelet function and reduced re-epithelialisation lead to a delay in the arrest of 
bleeding in the elderly. Age-related delayed healing is associated with a prolonged and 
excessive inflammatory response and increased pro-inflammatory cytokine production, in 
addition to reduced fibroblast production and matrix deposition (figure drawn by the author 
[EE]). 
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over the course of the study. However, platelet function was found to be 
impaired in the elderly patients, indicated by a significantly longer “closure time”, 
assessed by measuring the time taken for platelets to occlude a Platelet 
Function Analyser-PFA 100™ (Boldt et al., 2001).  Elderly patients having 
undergone coronary bypass surgery have more pronounced fibrinolysis and 
platelet activation than young patients (Pleym et al., 2006). Fukaya et al. (2000) 
determined platelet aggregation is increased with age, while an archival study 
found the speed of platelet aggregation to be considerably slower in the elderly, 
although total platelets were increased compared to young subjects (Banerjee 
and Etherington, 1974).  
 
1.6.2 Effect of age on inflammation 
 
The impaired healing in wounds of the elderly has been strongly linked to 
excessive inflammation, especially neutrophil recruitment and resolution and 
protease production. Monocytes and macrophages also express increased 
levels of pro-inflammatory cytokines such as TNF-α, which subsequently 
stimulates further leukocyte recruitment (reviewed in Ashcroft and Ashworth, 
2003). 
A study where cutaneous punch biopsies were taken from healthy 
volunteers ranging in age from 19 to 96 years old recorded an early and 
excessive increase in the neutrophil response in aged volunteers compared 
with young volunteers, with significantly greater neutrophils in the wounds of 
older patients at days 1, 3, 7 and 14 post-wounding. The authors identified an 
excessive number of late stage macrophages, stained by the marker 25F9, in 
wounds from both male and female aged subjects, at all time points studied 
(days 1, 3, 7, 14, 21 and 84 post-wounding). Of interest the aged subjects 
exhibited a reduction of CD3 positive T cells at days 14 and 21 post-wounding 
(Ashcroft et al., 1998).  
It has been postulated that some populations of T cells are lost with 
increasing age due to telomere shortening (Akbar et al., 2004), which would 
presumably translate into a reduced or retarded cutaneous inflammatory 
response. Antigen recall is significantly retarded in the elderly, due to defective 
activation of dermal blood vessels preventing memory T cells entering the skin 
(Agius et al., 2009) while a reduction in CD28+ T cells occurs with increasing 
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age (Weng et al., 2009), ultimately contributing to a defective inflammatory 
response. 
An overall delay in wound healing in the elderly has also been linked to 
an altered endothelial cell adhesion molecule (CAM) profile having an influence 
on extravasation of leukocytes from the vasculature to a wound (Ashcroft et al., 
1998). The expression of ICAM-1, a protein present on endothelial and 
epithelial cells, monocytes and eosinophils between 0 and 4 days post-
wounding (Dressler et al., 1997), was delayed in wounds from aged subjects 
and exhibited a lower intensity of staining compared to young subjects (Ashcroft 
et al., 1998). 
 
1.6.3 Effect of age on matrix deposition 
 
With increasing age dermal fibroblast proliferation and migration is 
impaired and lipid composition and mitochondrial membrane of fibroblasts are 
altered (Reed et al., 2001; Schroeder et al., 1984). The synthesis of fibronectin, 
an early component of the healing wound matrix, produced by fibroblasts prior 
to collagen production, is upregulated in late passage human fibroblasts 
(Shevitz et al., 1986). In contrast Takeda et al., (1992) have reported a decline 
in fibronectin mRNA in ageing human fibroblasts in vitro. In vivo studies suggest 
that protein levels of collagen and fibronectin in normal skin, acute wounds and 
chronic wounds are reduced with age, despite increased or similar expression 
levels (Ashcroft et al., 1997c; Herrick et al., 1997; Vitellaro-Zuccarello et al., 
1994).  
The elevated number of neutrophils in the wounds of elderly patients 
causes over-production of elastase, which is associated with an excessive 
breakdown of fibronectin (Herrick et al., 1996). MMP2 and -9, which are known 
to degrade tissue collagen (Aimes and Quigley, 1995), are up-regulated in 
acute and chronic wounds from elderly patients (Ashcroft et al., 1997e; Ashcroft 
et al., 1997f). Ageing also affects the injury-induced expression of tissue 
inhibitors of metalloproteinases (TIMPs), including TIMP-1 and TIMP-2 
(Ashcroft et al., 1997b). 
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1.6.4 Effect of age on re-epithelialisation 
 
The proliferation and migration of epithelial cells that occurs in a healing 
wound is delayed with intrinsic ageing in both healthy human subjects and 
animal models. Human keratinocytes, the primary cell type involved in re-
epithelialisation, show an age-related reduction in migration and proliferation in 
vitro and are less sensitive to EGF and KGF (Gilchrest, 1983). Ageing is 
associated with an increased response to interferon, a negative growth factor, 
which inhibits the growth of human keratinocytes (Peacocke et al., 1989). A 
delay in the production of epidermal growth factor (EGF) has been identified in 
wounds of mice of increasing age (Ashcroft et al., 1997d). 
In vivo studies in old and young human subjects and murine models 
have shown that there are differences in the rate of re-epithelialisation with 
increasing age. Holt et al. (1992) found that re-epithelialisation, assessed 
visually, was significantly increased in young individuals (18-55 year olds) 
compared to old individuals (over 65 years). Ashcroft et al. (1997a) found that 
the percentage re-epithelialisation of human wounds was significantly delayed 
at day 7 post-wounding in aged subjects (55 to 65 years old) compared to 
young subjects (20 to 39 years old). In vitro studies support these results, 
whereby keratinocyte cultures from upper arm biopsies of young volunteers 
proliferate at a faster rate than those cultured from old volunteers (Stanulis-
Praeger and Gilchrest, 1986). 
 
1.6.5 Effect of age on angiogenesis 
 
The majority of studies have associated ageing with a decrease in 
angiogenesis (Rivard et al., 1999; Swift et al., 1999). Studies in vivo have linked 
increasing age with a reduction in capillary growth (Yamaura and Matsuzawa, 
1980), a delay in angiogenesis and a defect in the production of VEGF (Swift et 
al., 1999) and TGF-β (Rivard et al., 1999). Ashcroft et al. (1997c) reported an 
increase in angiogenesis in aged mice (30 months old) compared to young mice 
(6 months old), but that this response was delayed. In a simple dermal model 
Sadoun and Reed (2003) found that the area invaded by newly formed 
microvessels was significantly lower in aged mice (23 to 25 months old) than 
young mice (6 to 8 months old) and that capillary density was substantially 
reduced. These changes in angiogenesis with age are attributed to a number of 
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processes: impaired vasodilation, defects in growth factor expression and signal 
transduction, retarded endothelial cell migration, alterations in matrix synthesis 
and reduced proliferation of progenitor endothelial cells (Reed and Edelberg, 
2004). 
 
1.6.6 Effect of age on remodelling 
 
Ashcroft et al. (1997f) found expression of elastin and fibrillin at the 
mRNA level did not change with age, but there was a significant increase in 
both elastin and fibrillin in acute wounds taken from aged individuals, a result 
that was particularly pronounced in females. The gelatinase MMP2 is 
upregulated in ageing human skin and this may intrinsically predispose skin to 
tissue breakdown, disrupting remodelling and ultimately impairing healing  
(Ashcroft et al., 1997e). Lenhardt et al. (2000) report that hydroxyproline 
concentration (a measure of collagen deposition) was significantly reduced in 
elderly men compared to young men  and in aged male mice, the deposition of 
type I and III collagen is reduced in wounds, although collagen bundle 
architecture appears normal (Ashcroft et al., 1997c).  
The tensile strength of scar tissue is reduced compared to normal skin 
(Levenson et al., 1965). The effect of age on the strength of scar tissue is a 
contentious issue. Animal models have shown increased, decreased or similar 
wound strength in aged animals versus young animals (Beck et al., 1993; 
Ershler et al., 1984; Holm-Pedersen and Zederfeldt, 1971; Sandblom et al., 
1953). However, in humans, the rate of wound dehiscence, the separation of 
the wound edges during healing, is reported to be two to three times higher in 
patients over the age of 60 (Mendoza et al., 1970) and with increasing age the 
tensile strength of wounds is decreased and less force is required to disrupt 
wounds in patients over the age of 80 (Lindstedt and Sandblom, 1975). 
Interestingly scarring is markedly improved in aged mice compared with 
normal adult mice (Ashcroft et al., 1997c) and scarring is reduced in aged 
human skin (Ashcroft et al., 1999a). It is hypothesised that while the rate of 
healing in the elderly is prolonged, healing in the young is accelerated, but at 
the expense of scar quality (Ashcroft et al., 1997c). In addition, differing levels 
of TGFβ3 in wounds from elderly and aged animals may contribute to this 
difference in remodelling: TGFβ3 reduces scarring when applied topically to 
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rodent wounds (Ashcroft et al., 1997d; Shah et al., 1995) and has now been 
extensively tested in humans as an anti-scarring therapy (reviewed in Occleston 
et al., 2008). 
 
1.7 The Menopause 
 
 The menopause is a significant event in a woman’s life that occurs with 
age and marks the end of a woman’s fertile period. In the UK the average age 
of onset is 51 years, usually occurring between the ages of 45 and 56, however, 
in rare cases, does occur in women in their 20s and 30s, known as premature 
menopause (Baramki and Jones, 1966). The term menopause is strictly defined 
as the permanent cessation of menstruation resulting from the loss of ovarian 
follicular activity. The phase of time either side of this is known as the peri-
menopause, or climacteric, which can last as long as ten years and represents 
the peak of physical and psychological symptoms (reviewed in Sulak, 1996).  
 During normal menstruation in humans estrogens and progesterone, 
produced by the ovaries, are released into the bloodstream causing the 
subsequent release of luteinising hormone (LH) and follicle stimulating hormone 
(FSH), in turn stimulating the production of estradiol from the ovaries which 
causes endometrial proliferation. LH is then involved in ovulation and in the 
absence of fertilisation estrogen and progesterone levels decrease, the 
endometrium is shed and menstruation occurs. The human estrus cycle lasts 
approximately 28 days (Lawn, 1973). Estrogen levels in the reproductive cycle 
begin to fall from the age of approximately 35 years and FSH production is 
increased in an effort to stimulate ovarian function. Estrogen levels eventually 
fall too low to stimulate endometrial growth and bleeding stops completely 
(Abernethy, 1997). However, hormonal decline is not confined to women: 
estrogen levels decrease with age in both female and male humans (Labrie et 
al., 1997).  
 Mice have an estrus cycle of approximately 4 days and are polyestrus 
(have more than one estrus cycle during a year). The cycle is divided into 4 
phases which can be distinguished by behaviour, and changes in cell 
morphology and physiology: it is possible to determine what stage of the cycle 
mice are in with the use of vaginal smears (Champlin et al., 1973). Mice also go 
through a phase similar to the menopause, between 12 and 14 months of age 
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(Silver, 1995), and this is characterised by a decline in fertility, uterine changes 
(Danilovich and Ram Sairam, 2006) and variability in cycle length (Wise et al., 
1999). 
 Due to the menopause and increasing life expectancy over the last 100 
years the majority of women in the developed world now live for about one third 
of their lives in a state of systemic estrogen deprivation (Figure 1.16) (Barrett-
Connor, 1995). 
 
 
 
 
The peri-menopause and menopause periods are associated with 
serious pathology and unpleasant symptoms, including hot flushes (affecting 
approximately 70% of menopausal women (reviewed in Bachmann, 1999)), 
irregular menstrual cycle, insomnia, depression and anxiety, mood swings and 
weight gain during the peri-menopause period and a long term decrease in 
bone density, increased incidence of osteoporosis and risk of fractures 
(estimated to be as prevalent as 45% in Caucasian women over the age of 50 
(Melton et al., 1992) and increased risk of heart disease (Colditz et al., 1987), 
breast cancer (Rinaldi et al., 2006), delayed wound repair (Ashcroft et al., 
1997a) and incontinence (Waetjen et al., 2009). Historically women were 
prescribed Hormone Replacement Therapy (HRT) during the peri-menopause 
Age of menopause 
Life expectancy 
Figure 1.16. The period of systemic estrogen deprivation increases with elongated 
female life expectancy. With advances in medical science an average woman in the UK 
now survives to a mean age of 81 (Matheson, 2009), living at least a third of her life in a 
state of estrogen deprivation (black arrow). This has serious implications on health and 
quality of life. 
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and into the menopause period to alleviate symptoms and to reduce the long 
term risk of severe pathology (Upton, 1984). HRT is provided as combined 
estrogen-progesterone therapy (to prevent uterine cancer) or estrogen-only 
therapy (for women who have had a hysterectomy), can be cyclical or 
continuous and is administered by tablet, patch or implant (reviewed in Upton, 
1984). HRT is also used as a method of treating osteoporosis, has favourable 
effects on serum cholesterol levels and dramatically reduces the incidence of 
cardiovascular disease in post-menopausal women (Nabel, 2006). 
 
1.7.1 Animal model of post-menopause 
 
 In post-menopausal women reduced estrogen is associated with 
osteoporosis and osteoarthritis (Melton et al., 1992; Roman-Blas et al., 2009), 
neurological conditions including stroke and Alzheimer’s disease (Jorm et al., 
1987; Lisabeth et al., 2009), cardiovascular conditions including myocardial 
infarction and heart failure (Barrett-Connor, 1995; Isles et al., 1992), delayed 
wound repair (Ashcroft et al., 1997a), hot flushes (Bachmann, 1999) and 
depression (McIntyre et al., 2005). With the replacement of hormones by HRT 
many of these symptoms are eradicated or alleviated. Female rodents with 
ovaries surgically removed (ovariectomised, Ovx) are often used as an animal 
model of post-menopausal women as they exhibit a similar phenotype. In Ovx 
rodents the replacement of estrogen reverses menopausal symptoms, as in 
humans (Ashcroft et al., 1997a; Edwards et al., 1992b; Liu et al., 2002; Most et 
al., 1995; Patten et al., 2004). Table 1.3 outlines examples of Ovx animals used 
as models of post-menopause. 
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Table 1.3 Ovariectomised (Ovx) rodents are used as models of post-
menopause in studies investigating bone, brain, vasculature, musculature 
and motor neurone changes 
 
Condition Model 
Estrogens effects on skeleton of Ovx mice (Edwards et al., 1992b) 
17β-estradiol and osteoclastic resorption in Ovx mice (Most et al., 1995)  Osteoporosis 
17β-estradiol and calcium malabsorption in Ovx mice (Kalu and Chen, 
1999)  
Neuroprotective action of estradiol in Ovx mice (Dubal et al., 2001) 
Neuroprotective effects of estrogen analogues in Ovx rats (Liu et al., 2002) Brain injury 
Effect of estrogen in an Ovx rat model of stroke (Ardelt et al., 2005) 
Effects of 17β-estradiol on experimental myocardial infarction in Ovx mice 
(van Eickels et al., 2003) 
17β-estradiol and cardiomyocyte survival in Ovx mice (Patten et al., 2004) Cardiac injury 
ERβ selective agonists as a protective agent in cardiovascular system in 
Ovx mice (Nikolic et al., 2007) 
Ovx as model of estrogen deprivation (Gilliver and Ashcroft, 2007; Gilliver et 
al., 2008; Hardman et al., 2005) Delayed 
wound repair Effect of estrogen replacement on wound repair in Ovx mice (Ashcroft et al., 
1997a; Ashcroft et al., 2003b) 
Effect of Ovx on nifedipine-induced hot flushes in mice (Kai et al., 2003) 
Hot flushes 
Effect of exercise on hot flushes in Ovx mice (Shuto et al., 2005) 
Depression Immobility as a sign of depression in Ovx mice (Bekku and Yoshimura, 2005)  
 
 
1.8 Steroid Sex Hormones  
 
 Estrogens and progestagens are primarily female sex steroids and are 
produced by the ovaries. Testosterone, an androgen, is the most abundant 
male sex steroid and is produced by the testes.  However, small amounts of 
estrogens are produced in men while small amounts of testosterone are 
produced in women. 
 
1.8.1 Estrogens 
 
Estrogen was first discovered by Allen and Doisy (1923), and is now known 
to play a major role in embryonic and foetal development to regulate sexual 
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characteristics, fertility and the reproductive cycle (Korach, 1994). Estrogens 
are a group of steroid compounds and function as the primary female sex 
hormone. The three major naturally occurring estrogens in women are estriol, 
estradiol (alpha and beta isomers) and estrone (Figure 1.17). 17α-estradiol is 
considered as the hormonally inactive isomer of 17β-estradiol (Vargas et al., 
1989). 
 
  
Estriol is produced almost exclusively during pregnancy, in the 
developing foetus and placenta (Buster, 1983). Estradiol is the most potent 
estrogen of the human body and is found in both males and females, but at 
particularly high concentrations in pre-menopausal women (Miller, 1999). 
Estrone is the least abundant of the three in pre-menopausal women, but 
becomes the most abundant estrogen in post-menopausal women (Cauley et 
al., 1994), almost entirely formed from the peripheral conversion of 4-
androstone-3,17-dione (Longcope, 1971). Both estradiol and estrone are 
secreted by the ovaries, while small amounts of estrone, particularly in post-
menopausal women, are produced by the conversion of androstenedione, 
secreted by the adrenal glands, in fatty tissue of the female body, the liver and 
the breasts (Figure 1.19). Estrogens are active in several target tissue sites of 
the human body, with the most noticeable in the reproductive tract, the breast 
Estriol 
17β-Estradiol 
Estrone 
Figure 1.17. Structures of the female sex hormones estriol, estradiol and estrone. 
Estradiol is the primary female sex hormone but estriol and estrone are secreted by the ovaries 
in pre-menopausal women. All contain a phenolic A-ring and at least one hydroxyl D-ring, which 
enables binding to specific receptors (figure drawn by the author [EE]). 
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and the neuroendocrine tissues, while the significant drop in estrogen during 
menopause has been linked to osteoporosis and cardiovascular disease, 
indicating a role for estrogen in bone and cardiovascular systems (reviewed in 
Korach, 1994). Table 1.4 outlines the target tissues of estrogen in human and 
mouse. 
 
 
Table 1.4 Target tissues of the effects of estrogens 
 
Target Organ Human Mouse 
Reproductive tract  (Parl et al., 1987) (Lemmen et al., 1999) 
Breast  (Seth et al., 2002) (Haslam and Levely, 1985) 
Bone  (Grandien et al., 1995) (Hughes et al., 1996) 
Liver  (Rossini et al., 1989) (Takada et al., 1997) 
Heart  (Mahmoodzadeh et al., 2006) (Liu et al., 2008) 
Brain  (van Amelsvoort et al., 2001) (Mitra et al., 2003) 
Skin  (Haczynski et al., 2002) (Stumpf et al., 1974) 
Bladder  (Shen et al., 2006) (Elicevik et al., 2006) 
Skeletal muscle  (Lemoine et al., 2003) (Baltgalvis et al., 2010) 
 
 
Estrogens primarily signal through two nuclear hormone receptors, ERα and 
ERβ (Kuiper et al., 1996; Kumar et al., 1986; Walter et al., 1985), which will be 
discussed in more detail in Chapter 3.  
 
1.8.2 Progestagens 
 
Progestagens are primarily involved in the maintenance of pregnancy. 
Progesterone (Figure 1.18), the primary progestagen is produced by the corpus 
luteum in most mammals, including humans (Purves, 2001). It is the precursor 
of aldosterone, and, after conversion to 17-hydroxyprogesterone, of cortisol and 
androstenedione. Androstenedione can then be converted to testosterone, 
estrone and estradiol (Figure 1.19). Progesterone exerts its action primarily 
through a distinct, membrane bound progesterone receptor (PR) and also acts 
as an anti-inflammatory agent  (Nakagawa et al., 1981; Rae et al., 2004). 
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1.8.3 Androgens 
 
Androgens are steroid sex hormones that control the development of 
characteristics and fertility in males. The testes produce testosterone, the 
primary male hormone and androstenedione, while the adrenal gland produces 
Dehydroepiandrosterone (DHEA), a precursor to estrogen, DHEA-Sulphate 
(DHEA-S) and Dihydrotestosterone (DHT), a more potent metabolite of 
testosterone. DHEA is converted from 17α-hydroxypregnenolone, while 
testosterone is converted from androstenedione (Figure 1.19). Testosterone is 
secreted into the bloodstream in response to LH, a hormone secreted by the 
pituitary gland (Ewing et al., 1983). 
 
1.8.4 Systemic steroid hormone biosynthesis 
 
Estrogen, progesterone and testosterone are primarily derived from 
pregnenolone, which in turn is formed from cholesterol. Primarily pregnenolone 
is converted to 17α-hydroxypregnenolone and DHEA, and progesterone is 
converted to 17α-hydroxyprogesterone and androstenedione. Testosterone and 
androstendione are formed from 17α-hydroxypregnenolone (Olson et al., 2006). 
Aromatase controls the rate limiting step in the production of estrogen, from 
androstendione and testosterone, while also converting testosterone to estradiol 
in ovarian granulosa cells and androstendione to estrone in adipose tissue 
(Figure 1.19). The 17β-hydroxysteroid dehydrogenases are responsible for the 
reduction and oxidation of estrogens to a more or less active form, for example, 
the reduction of estrone to estradiol and the oxidation of estradiol to estrone. 
The action of these enzymes function in an intracrine fashion, acting through an 
Figure 1.18. Structure of the female sex steroid progesterone. Progesterone is involved 
in reproduction and pregnancy and is produced by the ovaries, adrenal glands, and during 
pregnancy, the placenta (figure drawn by the author [EE]).  
O 
O 
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intracellular receptor, and therefore the action of the enzyme occurs within the 
cell and is not visible in the general circulation (Olson et al., 2006). 
 
 
 
 
Estrogens and androgens are also locally synthesised in peripheral tissues from 
the precursors DHEA, DHEA-S and androstenedione by aromatase (reviewed 
in Bulun et al., 1999). In fact, in post-menopausal women sex steroids are 
produced almost entirely in peripheral tissues from DHEA and DHEA-s of 
adrenal origin (reviewed in Labrie et al., 2000). The local formation of sex 
steroids allows target tissues to adjust levels and metabolism to meet local 
needs (Labrie, 1991). The components of the skin contain all the enzymes 
required to convert DHEA and DHEA-S to steroid sex hormones, including 17β- 
hydroxysteroid dehydrogenase (17β-HSD) (Hughes et al., 1997; Thiboutot et 
al., 1998) and 3β-hydroxysteroid dehydrogenase (3β-HSD) (Dumont et al., 
1992; Sawaya and Penneys, 1992), aromatase (Hughes et al., 1997; Lachgar et 
al., 1999; Sawaya and Penneys, 1992) and 5α-reductase (Eicheler et al., 1995; 
Thiboutot et al., 2000). Human skin expresses one isoform of 3β-HSD, the 
enzyme that catalyses the conversion of DHEA to androstenedione and 
androstenediol to testosterone, in sebaceous glands (Dumont et al., 1992; 
Sawaya and Penneys, 1992) and 17β-HSD, the enzyme that catalyses the 
direct conversion of DHEA to testosterone, estrone and 17β-estradiol (Thiboutot 
Aromatase 
Cholesterol Pregnenolone 17α-Hydroxypregenolone DHEA 5-Androstenenediol 
Progesterone 17α-Hydroxyprogesterone Androstenedione Testosterone 
17β-estradiol Estrone 
Aromatase Aromatase 17β-HSD 
17β-HSD Aromatase Aromatase 
3β-HSD 
Aromatase Aromatase 
17β-HSD 
3β-HSD 
3β-HSD 3β-HSD 
DHEAs 
Figure 1.19. Steps in the synthesis of systemic steroid hormones including estrogen, 
progesterone and testosterone (figure modified from Olson et al., 2006, drawn by the 
author [EE]). Progesterone, testosterone and the estrogens are all produced from the 
precursor pregnelone, which in turn is derived from cholesterol. Estradiol is derived from both 
testosterone and estrone. DHEA = dehydroepiandrosterone; DHEAs = 
dehydroepiandrosterone sulphate; 17β-HSD = 17β- hydroxysteriod dehydrogenase, 3β-HSD 
= 3β- hydroxysteriod dehydrogenase. 
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et al., 1998). As both 3β-HSD and 17β-HSD are present in keratinocytes the 
epidermis may play a key role in local sex steroid synthesis in the skin (Labrie 
et al., 2000).  
 
1.8.5 Women’s Health Initiative 
 
The Women’s Health Initiative (WHI), established in 1991 in the United 
States (and conducted in 40 US Clinical Centres) was the first large scale study 
of the causes of morbidity and mortality among post-menopausal women 
(Anderson et al., 2004; Nabel, 2006). More than 160,000 volunteers between 
the ages of 50 and 79 were recruited to this clinical trial of hormone therapy. 
The study objective was to determine the effect of hormone therapy, diet and 
vitamin supplementation on coronary heart disease, osteoporotic fractures, 
breast and colorectal cancers and coronary heart disease. The hormone arm of 
the study was set up as two parallel randomised, double-blind, placebo 
controlled clinical trials. Peri- or post-menopausal female volunteers were given 
either conjugated equine estrogen (CEE) alone (0.625mg/day), for those who 
have previously had a hysterectomy, or in combination with progestin 
(2.5mg/day) or placebo (Anderson et al., 2004). The estrogen plus progestin 
trial was prematurely terminated in July 2002 when it was identified that the 
incidence of breast cancer, stroke and coronary heart disease in the HRT group 
had exceeded the acceptable limits set at the start of the study (Nabel, 2006). 
Despite this early termination of the estrogen plus progestin trial the WHI 
estrogen-only trial continued with substantial scrutiny from an independent data 
and safety monitoring board. In February 2004 the estrogen-only trial was also 
terminated slightly ahead of the planned completion date (of October 2004 to 
March 2005) (Anderson et al., 2004).  
However, more recently Rossouw et al. (2007) published controversial 
re-analysis stating that women who initiated HRT close to menopause tended to 
have a reduced risk of coronary heart disease (CHD) compared to the 
previously stated increased risk in women of varying distance from the 
menopause. However, the trend was found to be statistically non-significant for 
the criteria set up before the study. The risk of stroke was found to be elevated 
regardless of years since menopause, but the risk of mortality followed a similar 
non-significant trend to that of CHD. These results highlighted the potential 
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difference of HRT use during the peri-menopause and post-menopause 
periods, and the reasons for these variations are still unclear and are the 
subject of much investigation. 
 
1.8.6 Million Women Study 
 
 The Million Women Study (MWS) was initiated in the UK in 1996 
investigating the use of HRT in more than one million post-menopausal women 
aged 50 and over. The study confirmed findings from the WHI of an increased 
risk of stroke, breast cancer and coronary heart disease in women prescribed 
HRT compared to those who were taking placebo, and additionally highlighted a 
slight increase in the risk of ovarian cancer with HRT use. The study highlighted 
that the risk of developing breast cancer is substantially greater for women 
taking combined (estrogen-progesterone) HRT than for estrogen-only HRT, 
while also confirming an increased risk of endometrial cancer in women 
prescribed estrogen-only HRT (Banks et al., 2004; Beral et al., 2007; Beral et 
al., 2005a; Beral et al., 2005b). 
After the publication of the Women’s Health Initiative and The Million 
Women Study and extensive media coverage the rate of HRT prescription has 
declined substantially (Lagro-Janssen et al., 2010; Menes et al., 2009; Udell et 
al., 2006). 
 
1.9 Effect of estrogens on skin 
 
During the menopause, skin undergoes major changes, which include 
reduced epidermal and dermal thickness and a decrease in collagen (Brincat et 
al., 1987). Many post-menopausal women also complain of dry, flaky skin that 
bruises easily (Brincat et al., 1985). Archival research identified that follicular 
hormone, now known to be estrogen, could be absorbed through the skin and 
have estrogenic effects. In addition, application had local effects which included 
improving acne and eczema (Loeser, 1937). Topical estrogen increases skin 
moisture content and enhances stratum corneum barrier function (Pierard-
Franchimont et al., 1995; Schmidt et al., 1996b), increases collagen I and III in 
the dermis of post-menopausal women, maintaining skin thickness (Shah and 
Maibach, 2001; Son et al., 2005; Varila et al., 1995) and generally improves the 
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external appearance of facial skin (Brincat et al., 1985; Schmidt et al., 1996a). 
Aertgeerts (1974) discovered that topical application of estriol succinate 
resulted in increased epidermal thickness, fewer wrinkles and increased blood 
flow in the skin, while topical estriol or estradiol treatment also improves cell 
proliferation resulting in increased epidermal thickness (Punnonen, 1971). 
Topical treatment of estradiol reverses skin atrophy by stimulating keratinocyte 
production, reducing apoptosis and reducing tissue breakdown by inhibiting 
MMP production and activity in the skin (Brincat, 2000). Estrogens also have a 
mitogenic effect in the skin (Son et al., 2005; Verdier-Sevrain et al., 2004), in 
line with hyper-proliferative and neoplastic effects in mammary and endometrial 
epithelium (Fishman et al., 1995; Quarmby and Korach, 1984). In addition, 
topical estrogen treatment increases the number, thickness and improves the 
orientation of dermal elastin fibres, which effectively reverses skin wrinkles 
(Punnonen et al., 1987). However, it is thought that topical estrogen therapy 
only has effects on skin in hormonally deprived women as there is little effect in 
those with normal ovarian function and no effect in the skin of elderly males 
(Goldzieher, 1949), although androgen treatment did cause skin differences 
(Goldzieher et al., 1952). 
Estrogen is thought to be protective against photoageing and skin cancer 
as the rate of mortality from non-melanoma skin cancer (Weinstock, 1994) and 
melanoma (Miller and Mac Neil, 1997) is lower in women. Some women 
experience improvements in the skin disorder psoriasis during pregnancy, 
attributed to increased systemic estrogen levels (Boyd et al., 1996; Dunna and 
Finlay, 1989) while the combined (estrogen plus progesterone) contraceptive 
pill is often prescribed for severe acne (Arowojolu et al., 2009). 
Topical estrogen increases collagen content in the skin of rats and 
guinea pigs (Henneman, 1968; Smith and Allison, 1966a), increases hyaluronic 
acid synthesis in animal models (Sobel et al., 1965) and promotes epidermal 
thickening in mice (Bullough, 1947). Estrogen deprivation in rats, through 
ovariectomy (Ovx), enhances sensitivity to UV skin damage and accelerates 
photoageing, measured as wrinkling, a loss of elasticity and damage to elastic 
fibres (Tsukahara et al., 2001).  
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1.10 Effect of estrogens on wound repair 
 
Both age and gender are risk factors for poor or delayed healing, 
however, a recent study identified estrogen deprivation as the major factor 
controlling delayed healing in elderly male and female humans. Many genes, 
that are known to be associated with delayed healing, such as the pro-healing 
growth factor transforming growth factor alpha (TGFα) and those associated 
with chronic wounds such as arginase 1 (ARG1), that have been found to be 
altered in elderly male subjects, are also known to be estrogen regulated. 
Hardman and Ashcroft (2008) described that, using a microarray study, 78% of 
genes that were differentially expressed between wounds from young and 
elderly men were regulated by estrogen while only 3% were regulated by age 
alone. A number of studies have found that post-menopausal women on HRT 
are less likely to develop a venous leg ulcer or pressure ulcer than those 
women who are not (Berard et al., 2001; Margolis et al., 2002b). However, 
estrogen, in pre-menopausal women taking the contraceptive pill, has been 
linked to an increase in deep vein thrombosis (DVT) (Kierkegaard, 1985). 
Systemic estrogen replacement (HRT) improves healing in post-menopausal 
women (Ashcroft et al., 1997a) while topical estrogen replacement, in the form 
of a cream, accelerates healing in both male and female aged human subjects, 
especially females (Ashcroft et al., 1999a).   
Estrogen receptors (ERs) are present on fibroblasts (Haczynski et al., 
2004), macrophages (Harkonen and Vaananen, 2006), neutrophils (Molero et 
al., 2002) and epidermal keratinocytes (Mosselman et al., 1996; Thornton et al., 
2003a, b), cells important in skin homeostasis and the repair process. Based on 
in vivo and in vitro studies, estrogen treatment is thought to accelerate healing 
by stimulating epithelialisation, reducing inflammation, modulating cytokine 
expression and enhancing matrix deposition (Figure 1.20) (Ashcroft et al., 
1997a; Ashcroft et al., 1999a). 
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Estrogen replacement accelerates cutaneous healing in hormonally deprived 
female mice and rats (Ashcroft et al., 1997a; Ashcroft et al., 2003b) while 
estrogen treatment in male rats improves healing (Rajabi and Rajabi, 2007). 
Systemic treatment with the sex steroid precursor DHEA accelerates wound 
healing in young Ovx female mice and old (30-32 month) male mice, a result 
attributed to the local conversion of DHEA to estrogen via the estrogen 
receptors (Mills et al., 2005). Of interest, androgens are detrimental to healing 
and castration of male mice and rats or treatment with the androgen receptor 
antagonist flutamide improves healing (Ashcroft and Mills, 2002; Gilliver et al., 
2006; Gilliver et al., 2003), while DHT, a metabolite of testosterone, retards re-
epithelialisation and ultimately affects wound closure (Gilliver et al., 2009).  
 Although important information regarding the effects of estrogen in 
wound healing in hormonally deprived animals exists it is unclear by what 
mechanisms estrogen is affecting wound repair, at the molecular level, and the 
effects of estrogen on independent cell types. 
 
1.10.1  Effect of estrogens on inflammation and cytokine production 
 
One accepted reason for the delay in healing in the elderly is an 
excessive and prolonged inflammatory phase and increased pro-inflammatory 
cytokines (reviewed in Ashcroft and Ashworth, 2003). In vivo estrogen treatment  
in humans is associated with a reduction in inflammatory cell influx to the wound 
Untreated Estrogen treated Decreased 
epithelialisation Increased 
epithelialisation 
Neutrophil 
Macrophage 
Increased 
inflammation 
Reduced 
matrix 
Increased protease 
activity 
Decreased 
inflammation 
Increased 
matrix 
Large wound area 
Reduced wound 
area 
Decreased 
protease 
activity 
Figure 1.20.  Proposed differences between estrogen treated and untreated acute 
wounds. Estrogen treated wounds exhibit reduced inflammation, pro-inflammatory 
cytokines and protease activity, increased re-epithelialisation and matrix deposition and an 
overall smaller wound area and accelerated healing than untreated wounds from estrogen-
deprived subjects (figure drawn by the author [EE]). 
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site (Ashcroft et al., 1999a). Estrogen treatment in ovariectomised sows 
reduces the total number of lymphocytes in blood and improves the phagocytic 
ability of neutrophils by enhancing the oxidative metabolism (Magnusson and 
Einarsson, 1990). In vitro estrogen treatment down-regulates the expression of 
the cell adhesion molecule L-selectin on neutrophils, preventing the ability of 
excessive neutrophil accumulation at sites of inflammation (Ashcroft et al., 
1999a).  
The increase in numbers of neutrophils in the wound results in an 
increase in the levels of neutrophil-derived elastase, which is linked to 
excessive tissue breakdown (Herrick et al., 1996) and in humans the reduction 
in the accumulation of neutrophils as a result of estrogen treatment leads to 
reduced tissue breakdown due to elastase activity (Ashcroft et al., 1999a). 
Estrogen has long since been believed to have direct effects on 
monocytes and macrophages, due to the presence of estrogen receptors 
(Gulshan et al., 1990), a result that has more recently been supported 
(Harkonen and Vaananen, 2006; Murphy et al., 2009). In vivo Ovx mice have 
increased macrophage infiltration to wounds, indicating a role for estrogen in 
the control of excessive inflammation (Ashcroft et al., 2003b). Estrogen is also 
potently anti-inflammatory in other tissues: estradiol reduces the inflammatory 
response to cholera toxin injection, measured by a reduction in footpad 
swelling, a reaction attributed to the effect of estrogen on bone marrow-derived 
leukocytes (Josefsson et al., 1992) and estradiol is anti-inflammatory in the 
brain, protecting against neurodegeneration (Vegeto et al., 2003). 
Estrogen down-regulates the expression of pro-inflammatory cytokines, 
including TNF-α, Monocyte Chemotactic Factor (MCP-1), Interleukin (IL) -1β 
and -6, and, of particular importance, Macrophage Migration Inhibitory Factor 
(MIF), a cytokine that plays a major role in the beneficial effects estrogen has 
on wound repair. TNF-α and IL-1β expression is reduced after estradiol 
treatment in an animal model of stroke (Zhang et al., 2010), while in post-
menopausal women estrogen deficiency increases T cell secretion of IL-1, IL-6 
and TNF-α (Pfeilschifter et al., 2002). In vitro estrogen treatment reduces the 
expression of MCP-1 by murine fibroblasts (Kovacs et al., 1996), regulates the 
synthesis of IL-1 by macrophages (Hu et al., 1988) and directly down-regulates 
the production of MIF by human monocytes, in turn down-regulating the 
production of other pro-inflammatory mediators, such as the Th1 cytokines 
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Tap1 and interferon-γ (IFN-γ) (Hardman et al., 2005). MIF plasma levels are 
negatively correlated with estrogen in female humans (Aloisi et al., 2005) and 
MIF levels are increased in post-menopausal women, a change that can be 
reversed with HRT (Hardman et al., 2005).  
 
1.10.2  Effect of estrogens on re-epithelialisation 
 
Estrogen has a mitogenic effect on keratinocytes which in turn improves 
the re-epithelialisation of the wound (Son et al., 2005; Verdier-Sevrain et al., 
2004). Ashcroft et al. (1997a) described that post-menopausal women who 
have never taken HRT exhibited impaired re-epithelialisation of wounds 
compared to pre-menopausal women. Just 3 months of HRT was sufficient to 
reverse this delay and individuals showed similar re-epithelialisation to pre-
menopausal women. 
  
1.10.3  Effect of estrogens on remodelling and tissue proliferation 
 
Estrogen affects matrix deposition by mesenchymal cells and this is 
reduced after only 1 month of estrogen deficiency (Calvin et al., 1998). In 
addition estrogen affects the expression of platelet derived growth factor 
(PDGF) by monocytes and macrophages (Shanker et al., 1995). The up-
regulation of PDGF-A by estrogen has a positive effect on wound remodelling 
as PDGF stimulates angiogenesis and wound contraction by acting as a 
mitogenic and chemotactic factor for fibroblasts (Battegay et al., 1994). 
However, the role of estrogen in angiogenesis is complicated. It has been 
suggested that estrogen affects angiogenesis by influencing endothelial cells, 
by increasing in vitro attachment of endothelial cells to laminin, collagen I and IV 
and fibronectin. Estradiol appears to aid angiogenesis by increasing the ability 
of endothelial cells to form capillary-like structures when placed on reconstituted 
basement membrane (Morales et al., 1995). However, some animal studies 
describe how estrogen treatment results in no increase or a decrease in 
angiogenesis (Lundgren, 1973; Nyman, 1971) giving conflicting results. 
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1.11 Conclusions 
 
Human skin has evolved the ability to rapidly and effectively repair itself 
after trauma, protecting the body from blood loss, infection and further damage. 
This essential innate response is impaired in the elderly leading to excessive 
inflammation, retarded re-epithelialisation, impaired wound contraction and 
reduced deposition of matrix components. The tensile strength of wounds in the 
elderly is reduced, however, wounds heal with less scarring and improved 
dermal architecture. 
While intrinsic ageing is likely to play a role in delayed healing in the 
elderly, observed gender differences in specific repair phases suggest that 
systemic hormone levels could in fact play a more important role than age 
alone. Indeed data to date suggests estrogens can and do accelerate healing in 
both animal and human models. The replacement of systemic estrogen to 
hormonally-deprived subjects reduces local inflammation, accelerates wound 
closure and promotes matrix deposition. However, with the publication of 
findings from the Women’s Health Initiative and The Million Women Study 
concerning the risks associated with the use of HRT and extensive media 
publicity that followed there is urgent need for an alternative. 
Estrogenic compounds such as Selective Estrogen Receptors (SERMs) 
appear to be potential candidates for therapeutics, having estrogenic properties 
in the skin, whilst lacking the carcinogenic potential of estrogens in the breast 
and uterus (Chapter 4) (Howell et al., 2004). Additionally, evidence suggests 
that the two estrogen receptor isoforms play very different roles in terms of 
wound repair, the manipulation of which could be crucial in the way we treat 
chronic wounds in the elderly (Chapter 3). In particular, a single nucleotide 
polymorphism in the ON exon of the ERβ gene of the Caucasian population is 
associated with venous ulceration in the elderly (Ashworth et al., 2005, 2008). 
 The discovery of the importance of the pro-inflammatory cytokine 
macrophage migration inhibitory factor (MIF) in estrogen regulated wound repair 
has lead to much investigation of the specific role of MIF in terms of skin and 
healing. MIF is directly responsive to estrogen and is elevated in chronic non-
healing wounds, while neutralisation improves healing (Ashcroft et al., 2003b; 
Hardman et al., 2005). Estrogen down-regulates MIF expression, which 
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dampens inflammation and in turn accelerates healing (Chapter 5). However, 
the role of MIF in individual cell types involved in healing is unknown. 
 
1.12 Aims of the study 
 
Impaired wound healing in the aged costs the NHS over £2 billion a year 
(Bennett et al., 2004), in addition to substantially increasing patient morbidity 
and mortality. It has been demonstrated that estrogen is of fundamental 
importance in reversing age-related delayed healing in vivo, reducing local 
inflammation (Ashcroft et al., 1997a; Ashcroft et al., 1999a) and inhibiting MIF 
expression (Ashcroft et al., 2003b), however the mechanisms of this action are 
largely unknown.  
Aim 1: Recent data has suggested a link between ERβ and venous 
ulceration (Ashworth et al., 2005, 2008). The initial aim of the study was to 
identify the roles of the estrogen receptor isoforms, ERα and ERβ in each 
phase of wound healing using a combination of in vivo and in vitro experiments 
in global ER knockout mice and ovariectomised mice treated with the ERα and 
β agonists PPT and DPN.  
Aim 2: In the post-Women’s Health Initiative era (with the publicised 
detrimental effects of prolonged estrogen treatment) there is an urgent need for 
alternative therapies to classical HRT. Thus, the second aim of the study was to 
investigate the potential of a specific class of compounds [Selective Estrogen 
Receptor Modulators (SERMs)] to restore healing in estrogen deprived female 
mice. In addition to quantitative planimetric analysis of wound healing and the 
local inflammatory response this study utilised a novel reporter mouse, the 
ERE-luc mouse, allowing real time visualisation of estrogen receptor activation 
after treatment with estrogenic compounds. 
Aim 3: The importance of MIF in modulating estrogen’s beneficial effects 
on the skin repair process has recently been shown. MIF acts as a downstream 
mediator of estrogen and indeed appears to be involved in all phases of wound 
healing from inflammation and pro-inflammatory cytokine production to re-
epithelialisation and matrix remodelling (Ashcroft et al., 2003b; Hardman et al., 
2005). The third aim of this study was to dissect cell-type specific MIF and 
estrogen interactions in relevance to wound healing, using a well-characterised 
in vivo animal model of tissue repair and in vitro cell assays.  
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 The ultimate aim of this work is to inform the future development of 
therapeutic strategies to accelerate healing and reduce local inflammation in 
hormonally-deprived elderly patients with delayed healing. Data generated will 
be of relevance to ageing and repair in other body systems. 
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2 MATERIALS AND METHODS 
 
2.1 Animal Experiments 
 
All animal studies were performed in accordance with the UK Home 
Office regulations and with licence approval. 
 
2.1.1 Breeding of Estrogen Receptor knockout mice 
 
Estrogen receptor alpha and beta knockout mice (ERαSTKO and 
ERβSTKO) mice were kindly donated by Pierre Chambon, Institute for Genetics 
and Cellular and Molecular Biology, Strasbourg, France. ERαSTKO and 
ERβSTKO mice were bred from heterozygous mating pairs or triplets, 
earpunched at 5-6 weeks old and genotyped using the following protocol. 
 
2.1.2 Preparation of Genomic DNA from Tissue 
 
300 µl of cell lysis solution and 30 µl of Proteinase K solution (Promega) 
was added to the eppendorf tube containing the tissue and incubated for 16 
hours at 55˚C. 1 µl of RNase solution A (10mg/ml) was added to each tube and 
a further 2 µl of Proteinase K added if any solid tissue remained in the tube. The 
samples were incubated at 37 ˚C for 30 minutes and spun in a centrifuge (MSE 
Microcentaur) at 9,500 G for 5 minutes to separate the hair. The supernatant 
was transferred into a clean eppendorf tube using a pipette and 100µl of Protein 
Precipitation solution added to each tube. The samples were vortexed 
vigorously for 20 seconds and spun in a centrifuge at 9,500 G for 5 minutes. 
The supernatant was transferred to a clean eppendorf tube containing 
300 µl of isopropanol and inverted several times to allow the DNA to precipitate. 
To allow maximum DNA precipitation the tubes were incubated at 4 ˚C for 30 
minutes. The samples were centrifuged at 9,500 G for 3 minutes and the 
isopropanol poured away and tubes inverted on absorbent tissue for several 
minutes and stood upright to allow the pellet to air dry. 50 µl of sterile water was 
added to each tube and the DNA allowed to re-dissolve overnight at room 
temperature. 
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2.1.3 Genotyping 
 
12.5 µl of Mastermix (Hot Star, Qiagen), 1 µl of genomic DNA and 12.5 µl 
of the appropriate primer sets (see Appendix), were added to a 0.5 ml 
eppendorf tube. The tubes were gently flicked to mix and the solution collected 
at the bottom of the tubes. Tubes were run at the desired program in a PCR 
machine (as described in Dupont et al., 2000). 
A 2% 1x agarose gel was prepared by mixing 2 ml of 50x TAE buffer 
(see Appendix), 2 g of agarose and 100 ml dH2O and heating to boiling point. 
Once the gel had cooled slightly 5 µl of Safeview nucleic acid stain (NBS 
Biologicals, Cambridgeshire, UK) was added and the flask swirled to mix. The 
gel was poured into a mould with the desired comb and allowed to set at room 
temperature. Running buffer was prepared by mixing 10 ml of 50x TAE and 500 
ml of dH2O. Once the gel had set it was placed in a gel tank and the running 
buffer added. 4 µl of loading buffer (Sigma Aldrich, UK) was added to each 
sample and 16 µl of the solution pipetted into each well and the gel run at 60 V 
for 1 hour. Once sufficiently run the gel was visualised on a UV transilluminator 
and photographs taken on a digital camera (UVP BioImaging Systems). 
 
2.1.4 Bilateral ovariectomy 
 
The mice were initially anaesthetised using a mixture of isoflurane and 
nitrous oxide with pure oxygen, in an anaesthetic box, and once sedated 
transferred to the operating table where anaesthetic administration was 
continued via a mask. The lower ventral side of the mouse was shaved using 
electric clippers (Wella, Hampshire, UK), the area cleaned using a pre-injection 
alcohol-impregnated swab (Seton Healthcare, Liverpool, UK) and a small 
incision made in the skin using sharp sterile scissors. Using forceps the body 
wall was gripped and an incision made at 90˚ to the initial incision. This was 
done to decrease the chance of tearing and rupturing the sutures post-
operatively.  The uterus was identified by fat pads and the ovaries were found 
by following the length of the uterine horns. The fallopian tubes were held in 
place with the forceps and the ovaries removed using sharp sterile scissors. 
The body wall was closed with absorbable polyglycolic acid suture (Dexon II, 
Johnson & Johnson). The incision in the skin was sutured using silk braided 
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non-absorbable sutures (Ethicon Mersilk, Johnson & Johnson) and 0.1 mg/kg of 
buprenorphine was given intraperitoneally (IP) as analgesia. The mice were left 
for a month prior to any further intervention to allow any circulating steroid 
hormones to deplete to a basal level. 
All mice were fed on a casein based diet (unless otherwise stated), 
without α-α or soy derivatives, which are known to be estrogenic (Mucedola Srl 
4RF21TC, Batch 208201, Milan, Italy) to limit the levels of circulating estrogen. 
It should be noted that the diet is not an estrogen free diet but is a commercially 
available normal mouse diet. However its estrogenic activity has been tested by 
Ciana et al. in ERE-luciferase mice and in this diet, the percentage of 
phytoestrogens is certified to be less than 4 ppb (parts per billion) according to 
international standards. This particular diet did not transcriptionally activate the 
estrogen receptors (ERs) and stimulate luciferase expression in ERE-luciferase 
mice, while other diets did activate the ERs (Ciana et al., 2005). 
Sham-Ovx mice were not used in this investigation as previous studies 
have shown that the procedure of sham-Ovx has no effect on wound healing 
when compared to intact animals (Ashcroft et al., 1997a). 
Intact female mice were housed together prior to wounding to allow 
synchronicity of hormone cycling. Previous studies have shown that the change 
in hormone levels observed during the female reproductive cycle of rats had no 
significant effect on the healing response (Roth et al., 1981) and similar effects 
have been shown by the Ashcroft laboratory in both murine and human models 
(unpublished data). 
 
2.1.5  Wounding  
 
2.1.5.1 Incisional wounds 
 
The mice were anaesthetised with isoflurane, oxygen and nitrous oxide 
inhalation. The dorsal area was shaved and cleaned using a pre-injection 
alcohol-impregnated swab (Seton Healthcare, Liverpool, UK). Two full-thickness 
1 cm dorsal incisions were made through the dorsal skin and panniculus 
carnosus muscle with a scalpel blade (Swann-Morton, Sheffield, UK). The 
wounds were made 2 cm from the base of the skull and 0.5 cm either side of 
the midline, as shown in Figure 2.1. The animals were given buprenorphine (0.1 
mg/kg) (sc) as analgesia, which does not influence wound healing or 
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inflammation (Ashcroft et al., unpublished data). Buprenorphine is a semi-
synthetic opiate, which has powerful analgesic properties. 
 
 
 
Figure 2.1. The positioning of dorsal wounds in the murine incisional model. Under 
anaesthetic two full-thickness 1 cm incisional wounds were made 2 cm from the base of the 
skull and 0.5 cm either side of the midline, through the dorsal skin and panniculus carnosus 
muscle, with a scalpel blade (figure drawn by the author [EE]). 
 
 
2.1.5.2 Excisional wounds 
 
As with the incisional wounding, the mice were anaesthetised with 
isoflurane, oxygen and nitrous oxide inhalation and the dorsal area was shaved 
and cleaned. Two full-thickness 6 mm diameter excisions were made through 
the dorsal skin and panniculus carnosus muscle with a punch biopsy (Stiefel 
Laboratories, Florida, USA). The wounds were made 2 cm from the base of the 
skull and 0.5 cm either side of the midline, as shown in Figure 2.2. As with 
incisional wounding the animals were given buprenorphine (0.1 mg/kg) as 
analgesia. 
 
 
 
2cm 
1cm 
1cm 
 87
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.2. The positioning of dorsal wounds in the murine excisional model. Under 
anaesthetic two full-thickness 6 mm excisional wounds were made 2 cm from the base of the 
skull and 0.5 cm either side of the midline, through the dorsal skin and panniculus carnosus 
muscle, with a punch biopsy (figure drawn by the author [EE]). 
 
 
The animals were housed in separate cages post-operatively and the 
wounds left uncovered and allowed to heal by secondary intention. On the 
required day post-operatively the mice were sacrificed. Euthanasia of animals 
was carried out by carbon dioxide overdose. 
 
2.1.6 Tissue harvest 
 
Blood was extracted via a cardiac puncture, using a 1 ml U-100 syringe 
(0.33 mm, 29 G x 12.7 mm, BD Microfine, Becton Dickinson, SA, Madrid). The 
blood was placed in eppendorf tubes at room temperature for 30 minutes, to 
allow it to clot. The serum was collected by centrifugation at 8,000 G for 10 
minutes and pipetted off and stored at -80 ˚C to be used for the future 
measurement of 17β-estradiol by Enzyme ImmunoAssay (EIA).  
Wounds were photographed for macroscopic analysis using a FujiFilm 
FinePix S5700 camera (Fuji, Tokoyo, Japan). The wounds were excised down 
to the underlying muscle and immediately bisected. One half of each wound 
2cm 
1cm 
6mm 
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was placed in formalin fixative solution (see Appendix), before embedding in 
paraffin wax (see 2.1.8). The other half of each wound was ‘snap frozen’ in 
liquid nitrogen and stored at -80 ˚C for biochemical analysis. Peritoneal 
macrophages were extracted by peritoneal gavage. A small incision was made 
in the skin and body wall on the ventral surface. 8 ml of ice-cold, sterile 
Phosphate Buffered Saline (PBS) (Gibco, Paisley, UK) was injected into the 
peritoneal cavity using a 10 ml syringe and a 19 gauge needle (Becton-
Dickinson, Devon, UK). The PBS was then extracted and kept on ice for 
isolation of macrophages. 
The hair on the ventral side was removed using warm wax (Veet, Reckitt 
Benckiser, Clevedon, UK) and a section of skin was removed using sharp 
scissors and transferred to a 15 ml Falcon tube containing DMEM without 
phenol red (Lonza, Wokingham, UK) and kept on ice for subsequent 
keratinocyte and fibroblast isolation. 
The uterus was removed and inspected for evidence of estrogen 
deprivation: a shrunken uterus indicates a lack of systemic estrogen (Garcia-
Perez et al., 2006). A piece of liver was collected for subsequent genotyping (for 
transgenic mice) or as positive control tissue (for ERE-luc mice) and stored at -
80 °C. 
 
2.1.7 Isolation of peritoneal macrophages 
 
20 ml of Ficoll-Paque Premium solution (Amersham, GE Healthcare, 
Chalfont St. Giles, UK) was measured into a 50 ml Falcon tube. 20 ml of PBS 
containing isolated peritoneal macrophages was carefully pipetted on top of the 
Ficoll-Paque, avoiding mixing the two solutions. The tube was centrifuged at 
9,000 G for 30 minutes. The cloudy layer formed within the gradient, containing 
the macrophages, was carefully pipetted off and placed in 1.5 ml eppendorf 
tubes. The remaining solution was discarded. 
The macrophages were pelleted by centrifugation at 12,500 G at 4 ˚C for 
10 minutes. The supernatant was discarded, the pellet re-suspended in 1 ml 
PBS and cells washed again by centrifugation at 12,500 G at 4 ˚C for 10 
minutes. 
The washed cells were re-suspended in 1 ml of RPMI 1640 medium 
(Lonza) and counted using a Hausser Bright-Line haemocytometer. Cells were 
plated out in 12 well culture plates at a concentration of 1,000,000 cells per well 
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and incubated at 37 ˚C and 5% CO2 for 6 hours (for RNA analysis) or used for 
macrophage migration assays (2.2.10). For RNA analysis supernatant was 
removed and transferred to 1.5 ml eppendorfs and stored at -20 ˚C. 0.5 ml 
TRIzol® solution (Invitrogen) was added to each well and cells removed using a 
cell scraper (Boyum, 1976). Plates were stored at -20 ˚C for further analysis. 
 
2.1.8 Wound processing 
 
 After the wounds had been bisected, one half of each wound was placed 
in a formalin fixative solution (see Appendix). After 24 hours the wounds were 
transferred to a 70 % ethanol: 30 % dH2O solution until tissue processing was 
carried out using Tissue-TEK Vacuum Infiltration Processor (Miles Scientific, 
Illinois, USA), as described in Table 2.1. 
 
Table 2.1 The protocol for embedding tissue in wax 
 
Step Stage Time (minutes) Temperature (˚C) 
1 70% IMS 45 Room Temperature 
2 90% IMS 60 Room Temperature 
3 100% IMS 30 Room Temperature 
4 100% IMS 30 Room Temperature 
5 100% IMS 60 Room Temperature 
6 50% IMS/50% Toluene 30 Room Temperature 
7 Toluene 30 Room Temperature 
8 Toluene 30 Room Temperature 
19 Toluene 60 Room Temperature 
10 Wax 15 60 
11 Wax 15 60 
12 Wax 30 60 
13 Wax 60 60 
 
IMS = Industrial Methylated Spirit. (IMS used was supplied by Genta Medical, New York, and 
the Tolulene was supplied by Fisher Scientific, Loughborough, UK). The conditions used for 
embedding were recommended and supplied by Miles Scientific (Illinois, USA).  
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Tissue was embedded into blocks using Paraffin “Lambwax” (RA Lamb), 
with the cut edge of the bisected wound downwards in the block. 6 µm thick 
sections were cut through the block at 90˚ to the wound edge using a 
microtome (Leica). The sections were placed onto twinfrost microscope slides 
(Scientific Laboratory Supplies Ltd, Nottingham, UK) coated with Vectabond 
Reagent (Vector Laboratories, Peterborough, UK) (see Appendix) and allowed 
to completely dry for histological analysis. The slides were coated to prevent 
disruption of the sections when staining. 
 
2.1.9 Histological Analysis 
 
Before staining, slides were placed in Xylene (Genta Environmental, 
York, UK) for 15 minutes to de-wax and remove excess wax. The slides were 
then sequentially passed through five decreasing alcohol concentrations of 
100%, 100%, 90%, 70% and 50% for a period of 60 seconds in each, to 
rehydrate the sections. The slides were then placed in ddH2O for 30 seconds to 
remove excess alcohol. 
 
2.1.9.1 Haematoxylin and Eosin Staining 
 
The slides were fully immersed in Gill’s Haematoxylin (Vector, UK) for 60 
seconds and then rinsed in running tap water for 5 minutes to destain. The 
slides were then fully immersed in Eosin (Sigma Aldrich, UK) for 10 seconds 
and then rinsed in running tap water for 5 minutes to destain. 
Slides were passed sequentially through increasing alcohol 
concentrations, 60 seconds in each, to dehydrate the sections (50%, 70%, 90%, 
100%, 100%) and placed in Xylene until mounting.  
Slides were mounted with coverslips (Scientific Laboratory Supplies Ltd) 
and Pertex mounting medium (CellPath, Newtown Powys, UK). 
 
2.1.9.2 Peroxidise Immunohistochemical Staining 
 
After the removal of wax and rehydration, the slides were placed in 
citrate buffer, pH 6.0 (see Appendix), and boiled in a microwave for 150 
seconds for antigen retrieval. The slides were then fully submerged in 
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Phosphate Buffered Saline (PBS) solution (see Appendix) for 60 seconds. Once 
excess PBS was removed from slides, tissue sections were drawn around with 
hydrophobic barrier pen (ImmEdge Pen, Vector Laboratories) to create a 
waterproof barrier and slides placed into a humidity chamber. Peroxidase 
staining was then carried out using the appropriate antibody and Vectastain 
Elite ABC kit (Vector Laboratories), in the following stages. A 0.3% hydrogen 
peroxide solution (prepared using H2O2, Sigma Aldrich, UK) was pipetted onto 
each section and slides incubated at room temperature, for 30 minutes. This 
was carried out to remove endogenous peroxidase activity. Slides were then 
fully submerged in PBS for 15 minutes changing the PBS regularly.   
Sections were then incubated for 20 minutes with the appropriate 
blocking serum (Vector Laboratories, ABC Kit) (see Appendix) depending on 
which species the primary antibody was raised in, to prevent non-specific 
antibody binding. The excess blocking serum was removed, but not washed, 
and replaced with the primary antibody. Table 2.2 shows the primary antibodies 
used for immunoperoxidase staining. Slides with sections known to be positive 
or negative were used when staining with each antibody, to determined true 
staining versus false positives. The slides were washed in PBS for 15 minutes, 
regularly changing the PBS and incubated with the appropriate peroxidase-
linked anti-IgG secondary antibody for 30 minutes (Vector Laboratories, ABC 
Kit) (see Appendix).  
Slides were washed for 15 minutes with PBS. The sections were 
incubated with ABC Reagent (Vector Laboratories, ABC Kit) (see Appendix) for 
30 minutes. The slides were washed in PBS for 15 minutes. Each section was 
covered with Nova Red solution (Vector Laboratories) (see Appendix) until a 
colour change was detected. Slides were rinsed in running water for 3 minutes.  
Counter staining was carried out using Gill’s Haematoxylin (Vector 
Laboratories) for 60 seconds. Slides were rinsed in running water for 5 minutes 
to destain, then passed sequentially through increasing alcohol concentrations 
(60 seconds in each) to dehydrate the sections (50%, 70%, 90%, 100%, 100%) 
and placed in Xylene until mounting. Slides were mounted with coverslips 
(Scientific Laboratory Supplies Ltd) and Pertex mounting medium (CellPath, 
Newtown Powys, UK). 
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Table 2.2 Working concentrations of primary antibodies used for 
immunoperoxidase staining 
 
 
Antibody 
Working 
Conc. 
(µg/ml) 
Incubation 
Time Temperature 
Manufacturer and 
Catalogue Number 
Host 
Species Ref 
Arg1 5 60 minutes Room temperature Santa Cruz (sc-18354) Goat 1 
CD74 5 60 minutes Room temperature Pharmingen (555317) Rat 2 
Collagen 
I 5 60 minutes 
Room 
temperature Sigma Aldrich (C2456) Mouse 3 
ERα 5 o/n 4˚C Santa Cruz (sc-8002) Mouse 4 
ERβ† 10 o/n 4˚C Serotec (MCA1974) Mouse 5 
IL-6 5 o/n 4˚C R&D Systems (AF-406-NA) Goat 6 
Ly-6G 10 60 minutes Room temperature Pharmingen (550291) Rat 7 
Mac-3 10 60 minutes Room temperature Pharmingen (01781D) Rat 8 
MIF 5 60 minutes Room temperature 
R&D Systems 
(AF-289-PB) Goat 9 
MMP9 5 o/n 4˚C Santa Cruz (sc-6840) Goat 10 
TNF-α 20 60 minutes Room temperature 
R&D Systems 
(AF-410-NA) Goat 11 
 
The concentration of the antibodies and the incubation time were determined by pilot studies. 
Antigen retrieval was achieved using citrate buffer except †Low-temperature antigen retrieval. 
o/n = overnight for 16 hours. 
 
Ref = references for original description of antibody. [1] Diez, et al. Biol Chem Hoppe Seyler 1994. 375: 537-541 [2] 
Bertolino et al. Crit Rev Immunol 1996. 16: 359-379 [3] Rodriguez et al. J Cell Biochem 2000. 79: 557-565 [4] Norfleet et 
al. Endocrinology 1999. 140: 3805-3814 [5] Torlakovic et al. Hum Pathol 2002. 33: 646-651 [6] Novick et al. Hybridoma 
1989. 8: 561-567 [7] Brummer et al. J Leukoc Biol 1984. 36: 505-520 [8] Springer et al. J Biol Chem 1981. 536: 3833-
3839 [9] Burmeister et al. Immunobiology 1986. 171:461-474 [10] Matsubara et al. Dev Biol 1991. 147: 425-439 [11] 
Sheehan et al. J Immunol 1989. 142: 3884-3893. 
 
2.1.10     Low-temperature Antigen Retrieval 
 
Slides were dehydrated in decreasing concentrations of ethanol as usual 
and then placed in EDTA buffer (see Appendix) in a Pyrex flask. The EDTA 
buffer was heated to 60 ˚C (measured using a temperature probe) and 
continually stirred on a hot plate using a magnetic flea. The slides were 
incubated in the buffer for 1 hour and then placed in Tris Buffered Saline (TBS) 
(see Appendix) for 60 seconds (Pillai et al., 2003). The remaining protocol was 
performed as usual. 
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2.1.11     Image Analysis 
 
 A Nikon Eclipse E600 microscope with a SPOT camera and software 
(Image Solutions Inc, Preston, UK) was used to capture images from all stained 
sections. Images for wound measurements were taken at x4 magnification, 
whilst images for cell number quantification were taken at x20 magnification. 
The images were analysed and wound area measurements taken using Image 
Pro-Plus software (Media Cybernetics, Finchampstead, UK). 
 The wound area was considered as the area of the wound above the 
panniculus adiposus, to the margins of normal skin on either side of the wound, 
and under the epidermis and/or the clot as in Figure 2.3.  
 
    
 
 
 
 
 
 
The percentage of wound re-epithelialisation was calculated by dividing 
the sum of the lengths of the newly formed epidermis, measured from the point 
of hyperproliferative wound edge epidermis, (lines A and B, Figure 2.4) by the 
distance the epidermis would have to migrate under the clot to fully close the 
wound (line C, Figure 2.4). 
 
 
d 
d 
pa 
pa 
c 
Figure 2.3. Area of the wound determined by Image Pro Plus. The wound area is 
enclosed by the black line. A line was traced above the panniculus adiposus (pa), between 
the uninjured dermis (d) on either side of the wound and beneath the clot or fully reformed 
epidermis (c). The area enclosed by this line was calculated as the total wound area. 
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Scale bars were generated using the Nikon Eclipse E600 microscope 
with a SPOT camera and software (Image Solutions Inc, Preston, UK) for 
pictures at  x4 and x20 magnifications. 
Total stained cell numbers within the wound area were calculated using 
five representative areas of the wound, as shown in Figure 2.5. Slides were 
blinded and the total numbers of stained cells present were counted using 
Image Pro-Plus software and a colour threshold tool. The results of the cell 
counts were pooled in order to calculate the average cell density per mm2 in 
each wound.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A 
B C 
wm 
wm 
Figure 2.4. Example of a percentage re-epithelialisation measurement using Image 
Pro Plus software. The newly formed epidermis is measured from the wound margins 
(wm) of normal skin to the leading edge of the epidermis. Percentage re-epithelialisation is 
determined using the sum of the lengths of lines A and B and calculated by dividing by the 
length of line C. 
 
Figure 2.5. Example of total wound cell number measurements using Image Pro Plus 
software. The boxes represent the 5 areas of the wound where wound cell numbers per 
mm2 are measured. An average was worked out per wound from the 5 pictures. 
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2.2 In vitro analysis 
 
2.2.1 Dermal fibroblast isolation from skin 
 
Hair was removed from murine skin at the roots by waxing (Veet Warm 
Wax). A section of skin was cut and removed from the subcutaneous fat and 
rinsed several times in Hank’s Balanced Salt Solution (HBSS) (Invitrogen) in a 
Petri dish. The skin was cut into strips using a scalpel blade and placed in Petri 
dishes containing 0.25% trypsin (Cascade Biologics, Mansfield, UK) and 
incubated overnight at 4 ˚C. The following day the epidermis was detached from 
the dermis by separating the layers using forceps. The dermis was chopped up 
as finely as possible using a scalpel blade (Swann-Morton) and placed in a 
Falcon tube containing 0.3 % collagenase type I (Sigma Aldrich, UK), re-
suspended in NCTC 109 medium (Sigma Aldrich, UK), and incubated at 37 ˚C 
and 5% CO2 for 30 minutes, with rotation to agitate (Baxter et al., 2005). 
The collagenase solution was filtered through a mesh disc and 
centrifuged for 5 minutes at 9,000 G. The supernatant was discarded and the 
pellet re-suspended in 1 ml culture media (DMEM without phenol red (Lonza) + 
5% charcoal stripped calf serum (Pierce, Thermo Scientific, IL, USA) + L-
Glutamine (Invitrogen) (10 ml/500 ml) + 1% Penicillin-Streptomycin-
Amphotericin B (PSA) (Cascade Biologics) by gently pipetting up and down 
(Mansbridge, 2002). DMEM without phenol red was used as phenol red has 
estrogenic activity (Welshons et al., 1988) while serum was charcoal-stripped to 
remove estrogens (Berthois et al., 1986). 200 µl of the solution was added to a 
25 cm3 vented cap tissue culture flask (Fisher Scientific, Loughborough, UK) 
containing 6 ml of culture media and the flasks were gently shaken to evenly 
disperse the cells and incubated at 37 ˚C and 5% CO2. 
Every 2-3 days the media in the flasks was changed by gently pipetting 
out the old media and replacing with a similar volume of pre-warmed new 
media. The cells were visualised daily using an inverted light microscope and 
once they became 80-90% confluent on the bottom of the flask the cells were 
split into new flasks to allow the proliferation to continue, as fibroblasts exhibit 
contact inhibition of growth. If fibroblast cells are allowed to get to 100% 
confluence they may permanently lose their ability to proliferate. The media was 
removed from the flask by pipetting and discarded and the cells were rinsed by 
adding 10 ml of HBSS, swirling gently and the HBSS removed. 3 ml of trypsin 
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EDTA solution (Cascade Biologics) was added to the flask and incubated at 
room temperature for up to 4 minutes, visualising the cells at regular intervals 
under the microscope to determine when most cells had detached from the 
flask. 6 ml of trypsin neutraliser solution (Cascade Biologics) was added to 
quench the action of the trypsin. The cell suspension was removed from the 
flask by a pipette into a falcon tube and the flask was rinsed with a further 2 ml 
of Trypsin Neutraliser solution and this added to the original cell suspension. 
The tube was spun in a centrifuge at 9,000 G for 5 minutes, the supernatant 
discarded and the pellet re-suspended in new media. The cell suspension was 
pipetted into new flasks containing new media. One flask has adequate cells to 
split into 2 or 3 flasks depending on confluence of cells at splitting. 
Charcoal-stripped serum and phenol red free DMEM were used in all 
subsequent assays, unless stated otherwise, to remove any estrogenic 
compounds (Berthois et al., 1986; Welshons et al., 1988). 
 
2.2.2 Epidermal keratinocyte isolation from skin 
 
 The separated epidermis was placed with the basal layer facing down 
onto a 200 µl drop of TrypLE Select (Invitrogen) in a Petri dish and incubated for 
30 minutes at room temperature. The Petri dish was tilted and 2 ml of CnT-07 
medium (CellNTech, Switzerland) was added. The epidermis was gently rubbed 
on the base of the Petri dish to separate cells from the cell sheet. 2 ml of CnT-
07 medium was added to wash cells down to the bottom of the tilted dish and 
the cell solution was transferred to a 15 ml Falcon tube. The solution was spun 
at 160 G at room temperature for 5 minutes. The supernatant was discarded 
and the cell pellet resuspended in 2 ml CnT-07 media. The cells were counted 
using a haemocytometer and seeded in collagen IV (Sigma Aldrich, UK) coated 
plates (see Appendix) at a density of 5 x 104 cells/cm2 and cultured at 35°C and 
5% CO2.  
 The media was changed and replaced with pre-warmed media every 2-3 
days and the cells visualised using an inverse light microscope. Flasks with fully 
confluent cells were split using the following protocol. Media was aspirated and 
cells rinsed with PBS. 2 ml of TrypLE Select (Invitrogen) was added to the flask 
and incubated for 30 minutes at 35°C, regularly che cking for cell detachment 
under a microscope. The TrypLE Select was diluted with 2.5 times more CnT-
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07 medium and gently pipetted up and down to break up any cell aggregates. 
The solution was transferred to a 15 ml Falcon tube and spun at 160 G for 5 
minutes. The supernatant was discarded and the pellet resuspended in 5 ml 
CnT-07 medium. Cells were seeded at a density of 3 x 104 cells/cm2 and 
cultured at 35°C and 5% CO 2. Cells were transferred into CnT-02 medium 
(CellNTech) for functional assays. 
 
2.2.3 Passage of cells 
 
The Hayflick Limit dictates that dividing cells in cell culture can divide 
about 50 times before dying. As the cells approach this limit they show signs of 
ageing (Hayflick and Moorhead, 1961). Cells divide in 3 phases, where Phase I 
is the primary culture where the cells multiply to cover the surface of the culture 
flask. Phase II is where the cells multiply in culture. Once the cells have covered 
the surface they stop multiplying due to contact inhibition. For the multiplication 
to continue cells require sub-cultivation. The cells will reattach to the new flask 
surface and start diving again. The division of the cells eventually starts to slow, 
which indicates the start of Phase III. The cells eventually stop dividing and die 
(Hayflick, 1984). 
Primary cell lines were used for all in vitro assays. The cells were 
passaged 2 or 3 times before use to obtain adequate numbers of cells and to 
reduce any contaminating cells by using selective media. Cells were not 
passaged more than 4 times to avoid cells entering Phase III and becoming 
senescent. By using early passages, the cells did not require monitoring for 
signs of senescence. 
 
2.2.4 Fibroblast Proliferation Assay 
 
The proliferation assay was performed using a CellTiter96® AQueous kit 
(Promega, WI, USA), which is a colorimetric method for determining the number 
of viable cells in a proliferation assay. The assay is composed of 3-(4,5-
dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2- (4-sulfophenyl)-2H-
tetrazolium, inner salt (MTS), which, in the presence of phenazine 
methosulphate (PMS), an electron coupling reagent, gives a water-soluble 
formazan product that has an absorbance maximum at 490-500 nm in 
phosphate-buffered saline. The amount of coloured product that forms is 
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proportional to the number of cells and the time of incubation of the cells with 
MTS and PMS. The assay can be read directly from a 96-well plate without 
further processing (Cory et al., 1991).  
Fibroblasts were removed from flasks and harvested using the normal 
method and re-suspended in 1 ml of culture media (DMEM + 5% charcoal 
stripped calf serum + L-Glutamine(10 ml/500 ml) + 1%PSA). The cells were 
counted using a haemocytometer and diluted with DMEM to obtain a dilution of 
5000 cells per 100 µl. 100 µl of cell-media solution was pipetted into each well 
of a 96 well plate, with 6 wells per cell group. The experiment was performed in 
duplicate. Standard dilutions of 10000, 20000, 50000 and 100000 cells per 100 
µl were set up for each group to allow calibration curves to be made. The plate 
was incubated at 37˚C and 5% CO2 for 6 days and a further 3 days. 
After 6 days the CellTiter96® AQueous One Solution Reagent was thawed 
for 90 minutes at room temperature.  20 µl of CellTiter96® AQueous One Solution 
Reagent was added to 3 of the 6 wells for every group and to all the wells with 
standard dilutions in. 100 µl of culture media containing no cells and 20 µl of 
CellTiter96® AQueous One Solution Reagent was added to a free well as a blank. 
The plate was incubated at 37 ˚C and 5% CO2 for 3 hours and the absorbance 
at 490 nm read on the Revelation plate reader computer program (Dynex 
Technologies, West Sussex, UK). The plate was then returned to the incubator 
for a further 3 days and the same process undertaken with the remaining wells 
after 3 days. A calibration curve was produced and the numbers of cells in the 
unknown wells was determined using the calibration curve.  
 
2.2.5 Fibroblast Attachment Assay 
 
Fibroblasts were harvested using normal method and re-suspended in 
culture media (DMEM + 5% charcoal stripped calf serum + L-Glutamine(10 
ml/500 ml) (Cambrex) + 1% PSA (Cascade Biologics)). Cell attachment assays 
were performed in the wells of 6 well plates, which had been previously coated 
with collagen I (Vitrogen 100). 
2 ml of cell solution containing 2 million cells was pipetted into each well 
and the plates were incubated at 37 ˚C and 5% CO2 for 60 minutes (Aumailley 
et al., 1989). The media containing unattached cells was removed by pipetting 
and the wells were carefully washed with PBS (Lewandowska et al., 1987; Yang 
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et al., 2000). The adhered cells were stained using crystal violet. Glycerol was 
added to the wells and coverslipped and photographed using a Nikon Eclipse 
E600 microscope with a SPOT camera and software (Image Solutions Inc) and 
cells were counted using Image Pro-Plus software (Media Cybernetics). 
 
2.2.6 Fibroblast Contraction Assay 
 
A contraction assay modified from Vernon and Gooden, 2002a, was 
used to assess the contractile ability of fibroblasts in vitro. A solution of 10x 
DMEM solution, without phenol red (Cambrex), was prepared from stock. L-
Glutamine (10 ml/500 ml) and 1% PSA were added to the DMEM solution. A 
collagen matrix was prepared using 1 part 10x DMEM solution, 1 part NaHCO3 
(Invitrogen) and 8 parts of chilled Collagen Type I (Vitrogen 100) and the 
solution stored at 4 ˚C until required. 
Die-cut Teflon washers with an outer diameter of 20.6 mm and an inner 
diameter of 12.7 mm, with a thickness of 1.59 mm were purchased and the 
inner surfaces smoothed with sandpaper to remove irregularities. Circles of 
Teflon bakeware sheet of 20.6 mm diameter were cut using a scalpel blade. 
One circular Teflon liner and 0.5 ml of mineral oil (Sigma Aldrich, UK) was 
added to each well of a 12-well plate and one Teflon washer added and 
pressed firmly down into the well to expel air bubbles (Figure 2.6). The plates 
were tilted to ensure that all washers were immersed in oil and the plates 
incubated at 37 ˚C to heat the oil. Mineral oil and Teflon washers and liners 
were used to prevent the collagen discs from attaching to the components of 
the assay. 
Dermal fibroblasts were harvested using the usual method and re-
suspended in 1 ml culture media (DMEM + L-Glutamine (10 ml/500 ml) + 1% 
PSA). Cells were counted using a haemocytometer and diluted using the 
collagen matrix solution to obtain cells at a concentration of 3x105 per ml. 300 µl 
of the cell-collagen mixture was added to each well of a 12 well plate containing 
a washer, Teflon disc and mineral oil. The plate was incubated at 37 ˚C for 60 
minutes to allow gelation to occur. 0.5 ml of DMEM (+ L-Glutamine (10 ml/500 
ml) + 5% charcoal stripped calf serum+ 1% PSA)) solution was added to each 
well and the plates returned to the incubator at 37 ˚C and 5% CO2  (Vernon and 
Gooden, 2002a). After 24 hours the washers and Teflon discs were removed 
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and the collagen discs were visualised and photographed using a scanner. The 
sizes of the discs were measured using Image Pro-Plus every 24 hours to 
determine the amount of contraction occurring. 
 
 
 
 
 
 
2.2.7 2-Dimensional Fibroblast Migration Assay 
 
Fibroblasts were grown to approximately 80 % confluence in media 
(DMEM + L-Glutamine (10 ml/500 ml) + serum + 1% PSA) in 6 well plates at 37 
˚C and 5% CO2. The plates were visualised under an inverted light microscope 
to determine confluence. A cross scratch was made across the centre of each 
well using the narrow end of a sterile 1000 µl pipette tip and the plates returned 
to the incubator for 24 hours (Liang et al., 2007; Yarrow et al., 2004). The media 
was carefully removed from the wells using a pipette and the cells stained by 
adding 1 ml of crystal violet for 1 minute and then rinsing with PBS. The wells 
were visualised and photographed using a Nikon Eclipse E600 microscope with 
a SPOT camera and software (Image Solutions Inc). The images were analysed 
and measurements made using Image Pro-Plus software (Media Cybernetics). 
 
2.2.8 3-Dimensional Fibroblast Migration Assay 
 
A migration assay in 3-dimensions was modified from Vernon and 
Gooden, 2002b. 9 parts of Collagen Type 1 (Vitrogen 100) was mixed with 1 
part NaHCO3-saturated, 10x Medium 199 (Invitrogen). Then charcoal-stripped 
calf serum, 1xDMEM and a small volume of 1N NaOH were added to give a 
solution of 0.6 mg/ml collagen and 10% charcoal stripped calf serum at a pH of 
7.2-7.4. The solution was stored at 4 ˚C until required. A ring of Nitex nylon 
1 
2 
3 
Figure 2.6. The components for production of a contraction assay; (1) mineral oil, (2) 
well of tissue culture plate, (3) Teflon disc liner, (4) Teflon washer, (5) collagen disc with 
suspended cells (figure adapted from Vernon and Gooden, 2002a, drawn by the author 
[EE]). 
 
4 
5 
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mesh (12.5 mm outer diameter and 8 mm inner diameter) was placed on a 
Teflon disc (12.5 mm outer diameter and 0.38 mm thick, with a 1 mm bore in 
the centre).  
Cells were harvested as usual and re-suspended in a small amount of 
DMEM and a cell count performed. 0.8 µl of DMEM solution containing 5x103-
5x104 cells was pipetted into the central bore. A ring of nylon mesh was placed 
over the disc and 125 µl of collagen solution was pipetted over the Teflon 
support, the central bullseye and the mesh. The plates were then incubated at 
37 °C for 45 minutes to polymerise the gel. Once po lymerised forceps were 
used to peel the mesh and the completed disc away from the Teflon support 
and discs were inverted, flooded with a further 125 µl of collagen solution on 
their upper faces and placed back into the incubator for 45 minutes to 
polymerise, producing a double layer assay disc (Figure 2.7). The discs were 
then all placed into 1 ml of DMEM in a 24 well plate and incubated at 37 ˚C 
(Vernon and Gooden, 2002b). The discs were visualised on an inverted 
microscope with a camera attached. The area of cell migration was measured 
using Image Pro-Plus software. At the end of the assay the discs were stained 
with crystal violet (Sigma Aldrich, UK) for 1 minute and de-stained in dH2O. 
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Figure 2.7. The components for production of a 3D “bullseye” assay. A. A ring of Nitex 
nylon mesh (12.5 mm outer diameter and 8 mm inner diameter) [1] was placed on a Teflon 
disc (12.5 mm outer diameter and 0.38 mm thick) [2] with a 1 mm central bore hole [3]. B. 
Cells were pipetted into the bore hole [4]. C. The upper surface was flooded with cell-free 
collagen [5]. D. Once set the mesh and collagen were rotated through 180° and the 
underside flooded with cell-free collagen [5] to produce a cell “bullseye” enclosed in collagen 
(figure adapted from Vernon and Gooden, 2002b, drawn by the author [EE]). 
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2.2.9  2-Dimensional Keratinocyte Migration Assay 
 
Keratinocytes were grown to approximately 80 % confluence in CnT-07 
medium and then seeded in to 12 well plates in CnT-02 medium (CellNTech). A 
2D migration assay protocol was followed, as in 2.2.7. 
 
2.2.10  Macrophage Migration Assay 
 
Macrophages re-suspended in RPMI 1640 medium were plated into 24 
well plates containing 6.5 mm polycarbonate Transwell membranes with a 3.0 
µm pore size. 600 µl RPMI 1640 medium + 1% FCS was pipetted into the well 
of the culture plate and 50 ng / ml of MCP-1 (Calbiochem) added to each well 
as chemoattractant (Arefieva et al., 2005). 100 µl of RPMI 1640 medium 
containing 5x105 macrophages was added to the top of each insert. Wells were 
treated with estradiol (10-7 M) or MIF (10 ng) or remained untreated. Plates 
were incubated for 16 hours at 37 °C and 5% CO2   (Suelves et al., 2007). 
Cells on the upper surface of the membrane were scraped off and the 
membranes fixed in methanol and 5 % crystal violet. Cells in the medium in the 
lower chamber were photographed and counted (Suelves et al., 2007). 
 
2.3 Quantitative Real-Time Polymerase Chain Reaction 
 
2.3.1 RNA Isolation 
 
Total RNA was isolated from cultured fibroblasts using TRIzol® reagent 
(Invitrogen, Paisley, UK) using the following protocol:  
o Cultured fibroblasts were washed once with PBS and 1 ml of TRIzol®  
was added to each well and a cell scraper used to detach the cells 
o TRIzol® solution was transferred to an eppendorf tube using a pipette 
and samples homogenised for up to 1 minute 
o Samples were incubated at room temperature for 5 minutes and 
centrifuged at 500 G for 5 minutes to pellet debris 
o The supernatant was removed and transferred to a new tube 
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Total RNA was isolated from cultured macrophages using TRIzol® reagent 
(Invitrogen, Paisley, UK) using the following protocol:  
o Cultured macrophages were washed once with PBS and 1 ml of TRIzol® 
was added to each well and a cell scraper used to detach the cells 
o TRIzol® solution was transferred to an eppendorf tube using a pipette 
and the solution vortexed for 30 seconds 
o Samples were incubated at room temperature for 5 minutes and 
centrifuged at 500 G for 5 minutes to pellet debris 
o The supernatant was removed and transferred to a new tube 
RNA was extracted from frozen wound tissue using the following protocol: 
o Mouse wound tissue was allowed to thaw and was subsequently sliced 
up into small pieces under sterile conditions 
o Wound tissue was added to 1 ml of TRIzol® and mechanically 
homogenised for 2 minutes using an Ultra Turrax IKA-T1 homogeniser. 
o Homogenised samples were incubated at room temperature for 5 
minutes 
The following steps were performed for all, using a PureLink RNA MiniKit 
(Invitrogen), following the manufacturer’s instructions: 
o 100 µl of chloroform per 500 µl TRIzol® was added to each sample and 
the solution vigorously shaken for 15 seconds to mix and incubated at 
room temperature for 2 minutes 
o The solution was centrifuged at 12,500 G at 4 °C f or 15 minutes 
o The resulting upper aqueous phase was transferred to a 1.5 ml RNAse 
free tube 
o An equal volume of 70% ethanol was added to each tube and inverted to 
mix  
o The solution was pipetted into a spin column and centrifuged at 12,000 G 
at room temperature for 15 seconds. The flow-through was discarded 
o 700 µl Wash Buffer I was added to the spin cartridge and centrifuged at 
12,500 G at room temperature for 15 seconds. The flow-through and 
collection tube was discarded 
o The spin cartridge was inserted into a new collection tube and 500 µl 
Wash Buffer II with ethanol added to the column and centrifuged at 
12,500 G at room temperature for 15 seconds. The flow-through was 
discarded 
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o This step was then repeated 
o The spin cartridge and collection tube was centrifuged at 12,500 G at 
room temperature for 1 minute to dry the membrane 
o The spin cartridge was inserted into a recovery tube and 100 µl RNase-
free water added to the centre and incubated at room temperature for 1 
minute 
o The spin cartridge and recovery tube were centrifuged at 12,500 G at 
room temperature for 2 minutes 
o The flow-through was collected and stored at -80 °C until required. 
 
2.3.2 RNA Quality and Yield Assessment 
 
 RNA sample yields were determined by measuring the absorbance at 
260 nm of a 1:50 dilution of the original sample in RNase-free water using a 
UV1101 spectrophotometer (WPA, Cambridge, UK), an absorbance of 1.0 
corresponding to an RNA concentration of 2 µg/µl. The level of protein 
contamination was assessed by measuring the absorbance at 280 nm of the 
same 50-fold diluted sample and calculating a 260 nm/280 nm ratio. A ratio of 
1.8-2.0 indicated an acceptable level of protein contamination. RNA sample 
quality was determined by formaldehyde agarose (FA) gel electrophoresis. A 
1.2% FA gel was prepared by adding 1.2 g of agarose to a mixture of 90 ml 
RNase-free water and 10 ml 10x FA gel buffer (see Appendix) and heating for 2 
minutes. 5 µl of Safeview and 1.8 ml formaldehyde (BDH) was added per 100 
ml gel volume. The gel was applied to a gel block, allowed to set and immersed 
in 1x FA gel running buffer (see Appendix). 1-2 µg RNA samples were diluted 
out with RNase-free water to a volume of 8 µl and 2 µl of 5x RNA loading buffer 
(see Appendix) added and pipetted to mix. The resulting 10 µl RNA samples 
were heat-denatured at 65°C for five minutes and then loaded to the gel and 
electrophoresed at 70 V for 2 hours with DNA Hyperladder I (Bioline, London, 
UK). The gel was visualised and RNA sample integrity was indicated by the 
presence of strong bands for the 18S and 28S rRNAs and the absence of 
material at low molecular weights. 
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2.3.3 cDNA Synthesis 
 
cDNA was transcribed from 1 µg of RNA (cDNA Synthesis Kit, Bioline) 
following the manufacturer’s instructions. Per reaction 1 µg RNA, 1 µl Random 
Hexamer and 1 µl dNTP (10 mM) was added to an RNase-free tube and made 
up to 10 µl using DEPC-treated water. Samples were incubated at 65 °C for 10 
minutes and placed on ice for 2 minutes. Per reaction 4 µl 5x RT buffer, 1 µl 
RNase inhibitor and 0.25 µl Reverse Transcriptase (200 µg/µl) was added to a 
tube and made up to 10 µl using DEPC-treated water. 10 µl of the above mix 
was added to each RNA tube and samples were incubated at 42 °C for 45 
minutes, then the reaction terminated at 70 °C for 15 minutes and samples 
chilled on ice. The samples were stored at -20 °C u ntil required.  
 
2.3.4 Quantitative real-time PCR Analysis 
 
Quantitative real-time PCR was performed using the SBYR green I core 
kit (Eurogentec, Southampton, UK) and an Opticon qPCR thermal cycler (Bio-
Rad, UK). The components of each reaction are shown in table 2.6 (see 
Appendix). For each primer set an optimal dilution was determined and melting 
curves were used to determine amplification specificity. Each sample was 
serially diluted over three orders of magnitude and the samples analysed in a 
96-well plate. All primer sequences are listed in table 2.7 (see Appendix).  Gene 
expression was determined against a standard sample and normalised using a 
value derived from four separate control primer sets to 18s rRNA and the 
housekeeping genes Gapdh, Ywhaz and Hprt. 18s rRNA is often used as an 
internal control of total RNA (Burleigh, 2001; Klok et al., 2002). Gapdh is a good 
marker of genomic DNA and cDNA amplification products and Ywhaz and Hprt 
are both constitutively expressed genes and are used as a marker of 
expression stability and as reference genes. The conditions used in the PCR 
are listed in table 2.3. 
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Table 2.3 Thermal cycler conditions used during target amplification. 
Step Temperature (°C) 
Duration 
(minutes) Function 
1 95 10 Enzyme Activation 
2 95 0.25 Template Denaturation 
3 60(¤) 1 Primer Annealing and Elongation 
4 - - Plate Read 
5 As Steps 2-4 As Steps 2-4 Repeat Steps 2-4 a further 39 times 
6 60-90 - 
Melting Curve (increase temperature from 60 to 
90°C; plate read every 0.3°C; hold for 1 second 
between reads 
 
The final reaction volume was increased to 25 µl upon the addition of cDNA template, control 
genomic DNA or dH2O (no template control) (¤, annealing temperature varied to 58°C for Tnfα). 
 
2.4 Protein Analysis 
 
2.4.1 Protein Extraction  
 
 Total protein was extracted from homogenised mouse wound tissue by 
homogenising for 2 minutes in 500 µl sodium dodecyl sulphate (SDS) sample 
buffer (see Appendix) and followed by boiling for 5 minutes. The solution was 
centrifuged for 1 minute at 8,000 G and the supernatant withdrawn and 
transferred to a clean tube and stored at -20˚C. A BCA protein assay (Perbio, 
Pierce, UK) was performed in triplicate on all samples to determine 
concentrations. Briefly, 25 µl of a 1:100 dilution of each sample was pipetted 
into a well of a 96-well plate and 200 µl of assay buffer added to each well. The 
plate was incubated at 37 ˚C for 30 minutes and the absorbance measured at 
570nm using a plate reader (Dynex Technologies, MRX II). 
 
2.4.2 Western  Blot Analysis 
 
To determine the relative levels of particular proteins between total wound 
protein samples Western blotting was performed. The technique involves a 
standard protein separation by SDS PAGE and subsequent transfer of 
separated proteins to a nitrocellulose membrane. Incubations with primary and 
HRP-linked secondary antibodies are followed by target detection using a 
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peroxidise substrate which is metabolised in a chemiluminescent reaction. The 
light emitting product of this reaction reacts with photographic film. SDS-
polyacrylamide gel electrophoresis was carried out on 7, 10 or 12% gels (see 
Appendix) with the Bio-Rad Protein III system.  Wound protein samples were 
thawed on ice and 10 µl samples each containing 1 mg of protein were 
prepared through dilution with dH2O. 6 µl Laemmli Sample Buffer (Bio-Rad) 
containing 5% (v/v) 2-mercaptoethanol (Bio-Rad) was added to each sample 
and incubated at 100 °C for 5 minutes to denature and placed on ice. The 
following Western blotting protocol was the applied using the Bio-Rad Protein III 
system. 
 
1. A separating polyacrylamide gel was prepared (see Appendix) and 
covered with propan-2-ol (BDH) in order to create a smooth surface and 
allowed to set. The propan-2-ol was removed once set and the gel 
washed with dH2O. 
2. A stacking polyacrylamide gel was prepared (see Appendix) and was 
layered onto the separating gel. Combs were inserted into the top of the 
gel and allowed to set. 
3. The Mini-PROTEAN 3 electrophoresis apparatus (Bio-Rad) was 
assembled and the gels were immersed in 1 x running buffer (prepared 
by dilution of 10 x TGS buffer (Bio-Rad) in dH2O). 
4. Each 16 µl sample was loaded into a well of the gel with 5 µl 
Kaleidoscope Prestained Standards (Bio-Rad) and separated by SDS 
PAGE. The gel was run at 90 V for 2 hours. 
5. The Mini Trans-Blot Electrophoretic Transfer Cell apparatus (Bio-Rad) 
was assembled. The gel was removed from the electrophoretic 
apparatus and placed on a 0.2 µm nitrocellulose membrane, between 2 
sheets of blotting paper. The sandwich was then inserted into a gel 
cassette holder. 
6. The cassettes were inserted into the gel tank and the tank filled with 
transfer buffer (see Appendix). An ice cooling unit was inserted and the 
tank placed on a magnetic stirrer (Jenway) and protein transfer 
performed at 200 rpm with specific voltage and duration for the target 
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7. The cassettes were removed from the tank and the blots incubated 
overnight in 5% TBS-Tween milk (see Appendix) at 4 °C, to block non-
specific antibody binding sites. 
8. The TBS-Tween milk was discarded and the blots were washed in TBS-
Tween for 10 minutes. 
9. The blots were placed in plastic sleeves and 1 ml of primary antibody 
(Table 2.4), diluted in TBS-Tween milk (0.5% w/v) (see Appendix), 
added. The blots were incubated at room temperature for 1 hour, with 
shaking. 
10. The blots were placed in plastic sleeves and underwent four washes in 
TBS-Tween to remove any unbound antibody. 
11.  Dilutions of HRP-linked secondary antibodies (Table 2.4) were prepared 
in TBS-Tween (see Appendix). Blots were transferred to new plastic 
sleeves and incubated in 5 ml of secondary antibody at room 
temperature for 1hour with shaking. 
12. The blots were removed and underwent four washes in TBS-Tween to 
remove any unbound secondary antibody. 
13. Blots were developed using the SuperSignal West Pico kit (Pierce, 
Perbio, UK). 1 ml of SuperSignal West Stable Peroxide Solution and 1 ml 
of SuperSignal West Pico Lumino/Enhancer Solution were combined 
with 10 µl of SuperSignal West Femto Kit. Blots were placed in new 
plastic sleeves and incubated with 1 ml of the detection reagent for 5 
minutes at room temperature. 
14. Blots were removed from the plastic sleeves and covered in cling film 
and developed in the dark using autoradiography film (GRI, Braintree, 
UK). 
 
Protein intensity was quantified by densitometric analysis (Image Pro Plus 
software). 
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Table 2.4  Antibody working concentrations and transfer conditions used 
during Western Blotting 
 
 
Working antibody 
concentrations (µg/ml) Target 
Protein 
Manufacturer and 
catalogue number 
Host 
species 
Primary Secondary 
Transfer 
Conditions Ref 
αSMA Sigma Aldrich (A5228) Mouse 1 0.1 70V, 90 minutes 1 
β-actin Sigma Aldrich (A5441) Mouse 1 0.14 70V, 90 minutes 2 
CD163 BD Biosciences (556017) Mouse 1 0.14 70V, 90 minutes 3 
ERK1/2 Santa Cruz  (sc-135900) Rabbit 0.5 0.1 70V, 90 minutes 4 
MMP9 Chemicon (AB805) Rabbit 0.1 0.325 70V, 90 minutes 5 
pERK1/2 BD Biosciences (612358) Mouse 0.5 0.14 70V, 90 minutes 6 
TGFβ1 Santa Cruz  (sc-146) Rabbit 1 0.1 70V, 90 minutes 7 
TNFα Abcam (ab6671) Rabbit 0.1 0.325 55V, 75 minutes 8 
 
The antibody concentrations and transfer conditions were optimised for each target protein. 
 
Ref = references for original description of antibody. [1] Skalli et al. J Cell Biol 1986. 103: 2787-2796 [2] Liao et al. 
Biotechniques 2000. 28: 216-218 [3] Law et al. Eur J Immunol 1993. 23: 2320-2325 [4] Krutzik et al. Cytometry 2003. 
55: 61-70 [5] Matsubara et al. Dev Biol 1991. 147: 425-439 [6] Sivaraman et al. J Clin Invest 1997. 99: 1478-1483 [7] 
Lucas et al. J Immunol 1990. 145: 1415-1422 [8] Sheehan et al. J Immunol 1989. 142: 3884-3893. 
 
2.5 Protease activity analysis 
 
2.5.1 Protein Extraction and Preparation 
 
Protein samples were prepared in addition to those used for Western blot 
analysis, as follows: 
1. Frozen tissue was thawed and chopped finely with a scalpel blade. 
2. The chopped tissue was then transferred to a round-bottomed tube and 500µl 
of sample buffer added (see Appendix) 
3. Tissue was homogenised on ice for 5 minutes 
4. The samples were then transferred to 1.5 ml eppendorf tubes and centrifuged 
at 12,500 G and 4˚C for 5 minutes to pellet tissue debris 
5. Supernatants were transferred to fresh tubes and stored at -20˚C. 
 
Human MMP2 and MMP9 standard stocks, isolated from cultured human 
fibroblasts (Murphy et al., 1992), were kindly donated by Susan Atkinson, 
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Department of Oncology, Cancer Research UK Cambridge Research Institute, 
University of Cambridge. 
 
MMP standard solutions were prepared as follows: 
1. Stock MMP2 (250µg/ml) was diluted 1:100 in MMP dilution buffer (see 
Appendix). Stock MMP9 (900µg/ml) was diluted 1:1000 in MMP dilution buffer 
2. 1 µl of 24 mM p-aminophenyl mercuric acetate (APMA) (24mM) (see 
Appendix) was added to every 11 µl of diluted MMP. 
3. APMA treated MMP samples were incubated at 37 °C  in a heating block for 1 
hour to activate the gelatinase proforms (Mannello et al., 2003).  
4. 18 µl of dH2O and 15 µl of 5x gel loading buffer (see Appendix) was added to 
each 12 µl sample of APMA-activated MMP.  
 
Protein samples were prepared as follows: 
1. Frozen protein samples were thawed at 37 °C in a  heating block. 
2. Thawed protein samples were centrifuged at 9,000 G to pellet debris. 
3. Protein supernatants were diluted in sample buffer so all samples contained 
equal protein. 
4. Half the volume of sample of 5x gel loading buffer was added to each diluted 
protein sample. 
 
 2.5.2 Zymography 
 
A 7% lower polyacrylamide gel containing 0.5 mg/ml gelatin was 
prepared (see Appendix) and covered with propan-2-ol (BDH) in order to create 
a smooth surface and allowed to set. The propan-2-ol was removed once set 
and the gel washed with dH2O. A 7% upper polyacrylamide gel was prepared 
and was layered onto the separating gel. Combs were inserted into the top of 
the gel and allowed to set. Once the gel had set the Mini-PROTEAN 3 
electrophoresis apparatus (Bio-Rad) was assembled and the gels were 
immersed in gel running buffer (see Appendix) and 7 µl of Precision Plus ladder, 
8 µl of standards and 8µl of samples were loaded onto the gel. 
 The gel was run at 50 mA for 30-40 minutes at 4 °C . The gel was 
washed twice in 2.5% Triton X-100 (see Appendix) for 15 minutes each, then 
briefly rinsed in dH2O. The gel was incubated in assay buffer (see Appendix) for 
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16 hours at 37 °C and then stained with Coomassie s tain (see Appendix) for 20 
minutes. The gels were destained (see Appendix) until the upper gel was 
rendered colourless. Protein intensity was quantified by densitometric analysis 
(Image Pro Plus software). 
 
2.6 17β-estradiol Enzyme ImmunoAssay (EIA) 
 
 The 17β-estradiol Enzyme ImmunoAssay (EIA) test is based on the 
principle of competitive binding between 17β-estradiol (E2) in the test sample 
and E2-HRP conjugate. The assay plate consists of goat anti-rabbit IgG-coated 
wells and during incubation HRP-labelled E2 competes with the endogenous E2 
in the sample for the binding sites of the specific E2 antibody. Thus, the amount 
of E2-HRP that binds to the well progressively decreases as the concentration 
of E2 in the sample increases. After the addition of TMB reagent, which 
changes the solution in the wells to a blue colour, and the addition of HCl, which 
stops colour development, the intensity of the colour is measured. The intensity 
is inversely proportional to the amount of unlabelled E2 in the sample. 
A 17β-estradiol EIA (MP Biomedicals, Cambridge) was performed 
following the manufacturers instructions. Sera were prepared from mouse 
blood, centrifuged at 8,000 G for 5 minutes. All reagents were allowed to 
equilibrate to room temperature. 25 µl of standard sample, control sample or 
blood serum was pipetted into the appropriate coated well of the plate. 100 µl of 
E2-HRP Conjugate Reagent was pipetted into each well. 50 µl of rabbit anti-
Estradiol reagent was added to each well. The contents of the wells were mixed 
thoroughly using a plate vortex for 30 seconds. The plate was incubated at 
room temperature for 90 minutes. Following this the plate was rinsed and 
aspirated 5 times with dH2O. 100 µl of TMB Reagent was added to each well 
and the plate gently mixed for 10 seconds by rotating. The plate was incubated 
at room temperature for 20 minutes. Following this the reaction was stopped by 
adding 100µl of Stop Solution (HCl) to each well. The plate was gently mixed for 
30 seconds by rotating and the absorbance read on a platereader at a 
wavelength of 450 nm. 
A standard curve was prepared using the absorbance values of the 
standard samples and used to determine the corresponding concentration of 
estradiol (pg/ml) in each serum sample. 
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2.7 Uterotrophic Assay 
 
 The uteri were retained and inspected for signs of estrogen deprivation, 
which include a reduction in size and weight, as estrogen promotes endometrial 
cell proliferation (Garcia-Perez et al., 2006). An estrogen deprived uterus 
usually has a pale colouring instead of red/pink colour, consistent with a 
reduction in endometrial lining of the uterus due to low estrogen levels. The 
uteri were weighed using a balance (Mettler Toledo, Switzerland) and an 
average calculated for each group. 
 
2.8 Statistical Analysis 
 
Statistical analysis was carried out using Microsoft Excel (Microsoft 
Corporation, Washington, USA), SPSS (Chicago, USA) and SimFit (W. G. 
Bardsley, University of Manchester, UK). Normality tests were carried out using 
Shapiro-Wilks Normality test. If the data took the form of normal distribution a 
Student’s t-test or 1-way ANOVA (parametric data) was performed. If the 
ANOVA test signified data as significantly different, at p-value <0.05, a Tukey Q 
test was performed. This determined which pairs of means were significantly 
different from each other. For non-parametric data a Mann-Whitney U Test was 
performed. 
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2A MATERIALS AND METHODS APPENDIX 
 
2A1 Genotyping of ER knockout mice 
Table 2.5 Primers used for genotyping of estrogen receptor knockout 
(ER-/-) mice 
 
Gene Primer Sequences Products (bp) 
  
-/- -/+ +/+ ERα P1 5' ttgcccgataacaataacat 3' 
ERα P2 5' attgtctctttctgacac 3' P1+2 ---- 387 387 
ERα P3 5' ggcaattaccacttctcctgggagtct 3' 
ERα P4 5' tcgctttcctgaagacctttcatat 3' 
P3+4 255 255 815 
ERβ P1 5' tgaagaggaagcttggcggg 3' 
ERβ P2 5' cacaggaccagacaccgta 3' 
ERβ P3 5' tcatagcctgaagaacgaga 3' 
P1+2+3 317 317 & 256 256 
 
2A2 TAE buffer 
The TAE buffer was prepared as follows: 
1. 242 g TRIS base (Fisher Scientific, UK) 
2. 51.7 ml glacial acetic acid (BDH Laboratory Supplies, Poole, UK) 
3. 18.6 g EDTA (BDH Laboratory Supplies, Poole, UK) 
4. Up to 1000 ml with dH2O 
pH to 8.0 
 
2A3 Formalin Fixative 
The fixative was prepared as follows: 
1. 920 ml of dH2O 
2. 80 ml of formaldehyde (BDH Laboratory Supplies, Poole, UK) 
3. 9 g sodium chloride (Fisher Scientific, UK) 
4. 20 ml glacial acetic acid (BDH Laboratory Supplies, Poole, UK) 
5. 0.5 mg hexadecyl trimethyl-ammonium bromide (cetrimide) (Sigma 
Aldrich, UK) 
The above were all combined in a 1 litre bottle and mixed well 
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2A4 Vectabond coated slides 
Microscope slides were coated with Vectabond (Vector Laboratories, UK) as 
follows: 
1. Clean glass slides were placed in metal slide racks 
2. Slides were immersed in acetone (BDH Laboratory Supplies, Poole, UK) 
for 5 minutes 
3. Vectabond Reagent was prepared by adding all 7 ml of solution to 350 
ml acetone and stirring well 
4. The slides were removed from the acetone, tapped gently to drain and 
immediately placed into the Vectabond solution for 5 minutes 
5. The slides were removed from the Vectabond solution and tapped gently 
to drain 
6. Excess reagent was removed by dipping slides in dH2O, changing the 
water every 5 racks 
7. Slides were dried at 37˚C. 
 
2A5 Citrate Buffer Solution 
Citrate buffer was prepared as follows: 
1. 1800 ml of dH2O 
2. 3.8 g of citric acid (BDH Laboratory Supplies, Poole, UK) 
The above were combined in a 2 litre bottle and mixed well. The pH of the 
buffer was measured with a pH meter (Denver Instruments) and adjusted to pH 
6.0. The buffer solution was made up to 2000 ml with dH2O 
 
2A6 Phosphate Buffered Saline Solution 
Phosphate Buffered Saline (PBS) solution was prepared as follows: 
1. 2.5 litres PBS 1.0 M (Sigma Aldrich, UK) 
2. 150 g sodium chloride (Fisher Scientific, UK) 
3. 22.5 litres dH2O 
 
2A7 Vectastain Elite ABC Kit 
Vectastain Elite ABC Kit solutions (Vector Laboratories) were prepared as 
follows: 
1. 3 drops of the blocking (normal) serum was added to 10 ml of PBS and 
mixed to create the blocking solution 
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2. 2 drops of the biotinylated (anti-) secondary antibody was added to 10 ml 
of PBS and mixed to create secondary antibody solution 
3. 2 drops of Reagent A and 2 drops of  Reagent B was added to 5 ml of 
PBS and mixed to prepare ABC solution 
 
2A8 NovaRED Solution 
Vector NovaRED solution was prepared as follows: 
1. 3 drops of Reagent 1 was added to 5 ml of dH2O and mixed well 
2. 2 drops of Reagent 2 was added and mixed well 
3. 2 drops of Reagent 3 was added and mixed well 
4. 2 drops of Reagent 4 was added and mixed well 
The solution was used immediately. 
 
2A9 EDTA Buffer Solution 
EDTA buffer was prepared as follows: 
1. 2500 ml of dH2O 
2. 9.3 g of EDTA (BDH Laboratory Supplies, Poole, UK) 
3. 2.5ml of Tween 20 (Sigma-Aldrich, UK) 
The above were all combined in a 3 litre Pyrex beaker and mixed well. The pH 
of the buffer was measured and adjusted to 8.0. 
 
2A10 Tris Buffered Saline 
TBS was prepared as follows: 
1. 8 g NaCl (BDH Laboratory Supplies, Poole, UK) 
2. 0.2 g KCl (BDH Laboratory Supplies, Poole, UK) 
3. 3 g TRIS base (Fisher Scientific, UK) 
4. 800 ml dd H2O 
The above were combined and mixed well. The pH was measured and adjusted 
to 7.4. 
 
2A11 Collagen IV Coated Flasks 
Vial (Sigma Aldrich, UK) was defrosted slowly on ice 
Contents was diluted in 0.25% acetic acid to concentration of 0.5 mg/ml 
660 µl diluted solution was added to each 25 cm3 flask 
Flasks were incubated for 3 hours at room temperature 
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Remaining solution was aspirated and rinsed with PBS 
Flasks were stored at 4°C until required 
 
2A12 DEPC Water 
DEPC water was prepared as follows: 
A solution of 0.1% DEPC (Sigma Aldrich, UK) was made up using dH2O. 
The solution was allowed to mix overnight and then autoclaved. 
 
2A13 10x FA Gel Buffer      
1. 83.72 g 3-[N-morpholino]propanesulfonic acid (MOPS) (BDH Laboratory 
Supplies, Poole, UK) 
2. 13.6 g sodium acetate (BDH Laboratory Supplies, Poole, UK) 
3. 40 ml EDTA (0.5M) (BDH Laboratory Supplies, Poole, UK) 
4. Up to 2000 ml with DEPC water, pH adjusted to 7.0 
 
2A14 1x FA Gel Running Buffer   
1. 50 ml 10x FA gel buffer 
2. 10 ml 12.3 M formaldehyde (BDH Laboratory Supplies, Poole, UK) 
3. 440 ml RNase-free water 
 
2A15 5x RNA Loading Buffer    
1. 16 µl Saturated aqueous bromophenol blue solution 
2. 80 µl 500 mM EDTA, pH 8 (Sigma Aldrich, UK) 
3. 720 µl 12.3 M formaldehyde (BDH Laboratory Supplies, Poole, UK) 
4. 2 ml 100% glycerol (BDH Laboratory Supplies, Poole, UK) 
5. 3084 µl formamide (Sigma Aldrich, UK) 
6. 4 ml 10x FA gel buffer 
7. 0.1 ml RNase-free water 
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2A16 PCR MasterMix 
Table 2.6 Components of the quantitative qPCR master mix 
Mastermix Component Volume per Reaction 
10x Reaction Buffer 2.5 
MgCl2 (50 mM) 1.75 
dNTP Mix (5 nM) 1.0 
SYBR diluted 1:2000 in DMSO 0.5 
Hot GoldStar (5 U/µl) 0.125 
Rnase-free Water 8.675 
Left Primer (100 pM) 0.225 
Right Primer (100 pM) 0.225 
Total 15.0 
 
The final reaction volume was increased to 25 µl upon the addition of cDNA template, control 
genomic DNA or dH2O (no template control). 
 
2A17 qPCR Primers 
 Table 2.7 Primer sets used during quantitative real-time PCR analysis 
Primer Sequences 
Gene 
Left Right 
18s rRNA agtccctgcctttgtacaca gatccgagggcctcactaac 
GAPDH tgccactcagaagactgtgg ggatgcagggatgatgttct 
YWAZH ttgagcagaagacggaaggt gaagcattggggatcaagaa 
HPRT caggccagactttgttggat ccgctgtcttttaggctttg 
Mif agctcatgacttttagcggc aggccacacacagcagcttact 
Il-6 ccggagaggagacttcacag tccacgatttcccagagaac 
Tnfα ctcttcaagggccaaggctg ggtatgaagtggcaaatcgg 
ERα aatgaaatgggtgcttcagg aaggacaaggcagggctatt 
ERβ gagtagccggaagctgacac ctgctgctgggaagagattc 
 
Housekeeping genes are highlighted in green and wound-regulated target genes in purple.  
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2A18 1x Western blot (SDS) Sample Buffer 
1. 5 ml 0.5 M Tris (BDH Laboratory Supplies, Poole, UK) 
2. 4 ml Glycerol (BDH Laboratory Supplies, Poole, UK) 
3. 8 ml 10% SDS (Fisher Scientific, UK) 
4. Protease inhibitor cocktail, 1 mM (Sigma Aldrich, UK) 
5. Made up to 38 ml with H2O 
6. 2ml 2-mercaptoethanol (BioRad, UK) was added immediately prior to use 
 
2A19 Separating Polyacrylamide Gel 
The separating polyacrylamide gel is made as follows: 
1. 3.75 ml 4x Tris-HCl, pH 8.8 (BioRad, UK) 
2. 150 µl 10% SDS (Fisher Scientific, UK) 
3. 50µl 10% Ammonium Persulphate (Sigma Aldrich, UK) 
4. 10 µl TEMED (Sigma Aldrich, UK), added immediately prior to gel 
pouring 
5. Variable volumes of 30% acrylamide/0.8% bisacrylamide (BioRad, UK) 
and dH2O. See table 2.8 for detailed gel composition. 
 
Table 2.8 Composition of separating polyacrylamide gel 
 
Final Acrylamide Concentration (%) 
Stock Solution 
7 10 12 
30% acrylamide/0.8% bisacrlyamide 
(ml) 3.5 5 6 
4x Tris-HCl pH 8.8 (ml) 3.75 3.75 3.75 
dH2O 7.75 6.25 5.25 
10% Ammonium Persulphate (ml) 0.05 0.05 0.05 
TEMED (ml) 0.01 0.01 0.01 
10% SDS (ml) 0.15 0.15 0.15 
 
SDS = sodium dodecyl sulphate 
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2A20 Stacking Polyacrylamide Gel 
The stacking gel is prepared as follows: 
1. 0.6 ml 30% acrylamide/0.8% bisacrylamide (BioRad, UK) 
2. ml 4x Tris-HCl, pH 6.8  
3. 50 µl 10% SDS (Fisher Scientific, UK) 
4. 25 µl 10% Ammonium Persulphate (BioRad, UK) 
5. 3 ml dH2O 
6. 5 µl TEMED (Sigma Aldrich, UK), added immediately prior to gel pouring 
 
2A21 4x Tris-HCl, pH 6.8 
6.05 g of TRIS base (Fisher Scientific, UK) in 40 ml dH2O 
Adjust pH to 6.8 
Make to final volume of 100 ml 
 
2A22 4x Tris-HCl, pH 8.8 
91 g of TRIS base (Fisher Scientific, UK) in 300 ml dH2O 
Adjust pH to 8.8 
Make to final volume of 500 ml with dH2O 
 
2A23 Transfer Buffer 
1. 10 x TGS buffer, 10% v/v (BioRad, UK) 
2. Methanol, 20% v/v (BDH Laboratory Supplies, Poole, UK) 
3. dH2O, 70% v/v 
 
2A24 10 x TBS-Tween 
10 x TBS-Tween was prepared as follows: 
1. 6 g of TRIS base (Fisher Scientific, UK) 
2. 9 g of NaCl (BDH Laboratory Supplies, Poole, UK) 
3. 100 ml of Tween 20 (Sigma Aldrich, UK) 
4. Make to final volume of 1litre with dH2O 
 
2A25 1 x TBS-Tween 
100 ml 10 x TBS-Tween 
900 ml dH2O 
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2A26 TBS-Tween Milk (5% w/v) 
5g Non-fat dry milk 
Suspended in 100 ml 1 x TBS-Tween 
 
2A27 TBS-Tween Milk (0.5% w/v) 
TBS-Tween Milk (5% w/v) diluted 10-fold in 1 x TBS-Tween 
 
2A28 Zymography Sample Buffer 
The sample buffer was prepared as follows: 
1. 1.21 g TRIS base (Fisher Scientific, UK) 
2. 0.12 g NaCl (BDH Laboratory Supplies, Poole, UK) 
3. 10 g SDS (Fisher Scientific, UK)  
4. pH to 7.6 with HCl 
5. Add dH2O up to 100 ml 
 
2A29 MMP dilution buffer 
MMP dilution buffer was prepared as follows: 
1. 0.6 g TRIS base (Fisher Scientific, UK)  
2. g CaCl2.2H2O (BDH Laboratory Supplies, Poole, UK) 
3. 0.5 ml Brij 35 (Sigma Aldrich, UK) 
4. 0.02 g Sodium Azide (Sigma Aldrich, UK) 
5. pH to 7.6 with HCl 
 
2A30 APMA 
APMA (Sigma Aldrich, UK) was dissolved in DMSO to a stock concentration of 
24 mM and stored at -20 °C. 
 
2A31 5x gel loading buffer 
Gel loading buffer was prepared as follows: 
1. 0.08 g TRIS base (Fisher Scientific, UK)   
2. 0.2 g SDS (Fisher Scientific, UK)   
3. 200 µl 10% bromophenol blue  
4. 1 ml Glycerol (Sigma Aldrich, UK)   
5. pH to 6.6 with HCl, dH2O up to 10 ml 
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2A32 7% Polyacrylamide Gel - Lower 
1. 2.8 ml Acrylamide (30%) (BioRad, UK)    
2. ml Gelatin (2 mg/ml)   
3. ml Lower gel buffer (4x)    
4. ml dH2O      
5. 72 µl Ammonium persulphate (10%) (BioRad, UK) 
6. 14µl TEMED (Sigma Aldrich, UK)     
 
2A33 7% Polyacrylamide Gel – Upper 
1. 1.34 ml Acrylamide (30%) (BioRad, UK)    
2. 2.0 ml Upper gel buffer (4x)   
3. ml dH2O      
4. 120 µl Ammonium persulphate (10%) (BioRad, UK) 
5. 14µl TEMED (Sigma Aldrich, UK)    
 
2A34 Gelatin (2 mg/ml) 
Gelatin was prepared as follows: 
0.2 g Gelatin (Sigma Aldrich, UK)  
100 ml dH2O    
Warm to 65˚C (with agitation), filter (0.22 µm) and store at 4˚C 
 
2A35 Lower gel buffer 
90.75 g TRIS base (Fisher Scientific, UK)   
2 g SDS (Fisher Scientific, UK)   
pH to 8.8 with HCl, dH2O up to 500 ml 
 
2A36 Upper gel buffer 
30.25 g TRIS base (Fisher Scientific, UK)    
2 g SDS (Fisher Scientific, UK)   
pH to 6.8 with HCl, dH2O up to 500 ml 
 
2A37 10% bromophenol blue 
1 g of bromophenol blue (Sigma Aldrich) was dissolved in 10 ml of dH2O and 
the solution filtered. 
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2A38 Gel running buffer 
1. 3.03 g TRIS base (Fisher Scientific, UK)  
2. 14.4 g Glycine (Sigma Aldrich, UK) 
3. 1 g SDS (Fisher Scientific, UK)    
4. Made up to 1000 ml with dH2O, pH to 8.3 with HCl 
 
2A39 Triton X-100 
25 ml Triton X-100 (Sigma Aldrich, UK)  
Up to 1000 ml with dH2O    
 
2A40 Assay Buffer 
1. 12.12 g TRIS base (Fisher Scientific, UK) 
2. 6.58 g CaCl2 (BDH Laboratory Supplies, Poole, UK) 
3. 0.2 g Sodium Azide (Sigma Aldrich, UK) 
4. 0.5 ml Brij 35 (Sigma Aldrich, UK) 
5. Made up to 1000 ml with dH2O, pH to 7.9 with HCl 
 
2A41 Coomassie stain 
1. 1.25 g Coomassie Brilliant Blue G (Sigma Aldrich, UK)  
2. 250 ml Methanol (BDH Laboratory Supplies, Poole, UK)   
3. 50 ml Acetic Acid (VWR)    
 
2A42 Destain 
1. 300 ml Methanol (BDH Laboratory Supplies, Poole, UK)  
2. 10 ml Acetic Acid (VWR, Leicestershire, UK)  
3. 690 ml dH2O    
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3 THE ROLE OF ESTROGEN RECEPTORS IN 
WOUND HEALING 
 
 
 
 
The majority of the results presented in this chapter also appear in the following 
publication: 
 
Estrogen promotes cutaneous wound healing via estrogen receptor beta 
independent of it’s anti-inflammatory activities (2010). J Exp Med 207, 
1825-1833. 
 
Authors: Laura Campbell, Elaine Emmerson, Faith Davies, Stephen. C. Gilliver, 
Andre Krust, Pierre Chambon, Gillian. S. Ashcroft, and Matthew. J. Hardman. 
 
Author Contributions: In vivo and in vitro agonist experimental work was carried 
out by EE. Initial in vivo receptor ablation experimental work was carried out by 
EE and LC.  
 
Additional data appears in this publication, carried out by LC and FD.  
 
LC was involved in experimental design, surgical procedures, carried out 
experiments, analysed results and was involved in manuscript preparation. EE 
was involved in experimental design, surgical procedures, carried out 
experiments, analysed results and was involved in manuscript preparation. FD 
was involved in surgical procedures, carried out experiments and analysed 
results. SG carried out experiments. AK and PC provided receptor knockout 
mice. GA was involved in experimental design. MH was involved in 
experimental design, surgical procedures and manuscript preparation. 
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3.1 Introduction 
 
Age-related delayed healing is of considerable concern and has a huge 
impact on patient morbidity and mortality, while treatment results in large costs 
to the NHS (Bennett et al., 2004). While intrinsic ageing is a risk factor for 
delayed healing, estrogen decline, with age, is now thought to be the critical 
regulator of delayed healing in the elderly (Hardman and Ashcroft, 2008). In the 
absence of estrogen repair is significantly delayed, however, when estrogen is 
replaced, either exogenously or topically, this delay is reversed (Ashcroft et al., 
1997a; Ashcroft et al., 1999a).  
Estrogens, first discovered in the 1920s (Allen and Doisy, 1923) are 
active in target tissues of the human body, with the most noticeable effects in 
reproductive, breast and neuroendocrine tissues. Estrogen is vitally important in 
pregnancy, stimulating growth of the placenta, maintaining endometrium, 
promoting blood flow and maturing reproductive organs of the developing foetus 
whilst protecting it from the effects of maternal endocrine hormones (reviewed 
in Korach, 1994). Estrogen also plays a role post-pregnancy in the lactation 
process. During puberty estrogen stimulates breast development and pubic hair 
growth (Alonso and Rosenfield, 2003) and controls the menstrual cycle. 
Estrogen-signalling is also of importance in the male reproductive system 
(Gilliver and Ashcroft, 2007; Gilliver et al., 2008; Hess et al., 1997).  Estrogen 
plays a role in the development of peripheral tissues, by regulating bone density 
in foetus and adult life and the decline in estrogen post-menopause results in 
bone absorption by osteoclasts and bone loss (reviewed in Notelovitz, 1997). 
Estrogen replacement has a protective effect and reduces the incidence of 
osteoporotic fractures (Cenci et al., 2000). In the skin estrogen has a mitotic 
effect (Son et al., 2005; Verdier-Sevrain et al., 2004), increases collagen 
content (Brincat et al., 1985) and maintains cutaneous hydration (reviewed in 
Shah and Maibach, 2001). 
The majority of women residing in the developed world live for about one 
third of their lives with a deprivation of systemic estrogen (Barrett-Connor, 
1995), in the post-menopause years. Menopause is associated with increased 
incidence of osteoporosis (Melton et al., 1992), breast cancer (Rinaldi et al., 
2006) and heart disease (Colditz et al., 1987), while peri-menopause symptoms 
include hot flushes and mood swings (Bachmann, 1999). Hormone replacement 
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therapy (HRT) was designed as a treatment to reduce or eradicate these 
symptoms. However, studies such as the Women’s Health Initiative and the 
Million Women Study identified major risks associated with HRT, including an 
increased risk of breast cancer, stroke and heart disease (Anderson et al., 
2004; Beral et al., 2005b; Nabel, 2006). These studies highlight the urgent need 
to develop safer alternatives to estrogen.  
Estrogens, while able to act via genomic signalling, also elicit rapid 
cellular responses, providing compelling evidence that cell membrane estrogen 
receptors and co-activators exist (Jensen, 1962). It is now known that there are 
two estrogen receptors, ERα and ERβ (Kuiper et al., 1996; Walter et al., 1985). 
However, the understanding of estrogen signalling in the skin, and specifically in 
cutaneous wound repair is severely lacking. 
 
3.1.1 Estrogen Receptors 
 
The two estrogen receptors (ERs) are members of the nuclear receptor 
family and the steroid/retinoid receptor gene superfamily. ERs exhibit a 
structure that is characteristic of the nuclear receptor family, comprising 6 
domains (A-F) (Figure 3.1).  
 
 
 
The first human ER, now called ERα, was cloned in 1985 (Green et al., 
1986; Kumar et al., 1986; Walter et al., 1985). In 1996 a second human 
estrogen receptor was discovered from a prostate cDNA library, now named 
ERβ (Kuiper et al., 1996). Two years later a human ERβ species consisting of 
530 amino acids was described, now considered to be the full length protein 
C 
C 
E/F 
E/F 
530 aa 
30% 96% 30% 53% 
A/B 
A/B D 
D 
1 
1 
180 302 263 
149 248 214 
C-term
ERα 
N-term 
ERβ 
595 aa 
Figure 3.1. Structure of human ERα and ERβ showing schematic amino acid 
comparison and percentage homology (figure modified from Enmark and Gustafsson, 
1999, drawn by the author [EE]). The C region is also known as the DBD and the E/F 
region is also known as the LBD.  
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(Ogawa et al., 1998). The human ERs share a 96% homology in the DNA 
binding domain (DBD) region and just 53% homology in the ligand binding 
domain (LBD) region (Figure 3.1), while there is between 81.8% and 98.5% 
homology between the human and mouse estrogen receptor domains (Enmark 
and Gustafsson, 1999). The estrogen receptor proteins mediate the action of 
estrogen by activating or repressing gene transcription (Enmark and 
Gustafsson, 1999). 
ERα is predominantly found in reproductive tissues, such as 
endometrium (Zou and Ing, 1998), breast cancer tissue (Speirs et al., 1999), 
and ovaries (Kuiper et al., 1997). ERβ is more predominant in peripheral 
tissues, including kidney, brain, lung, bladder, (Kuiper et al., 1997), bone (Onoe 
et al., 1997), heart (Brandenberger et al., 1997) and hypothalamus (Couse et 
al., 1997), although it can be identified in normal breast tissue (Speirs et al., 
1999), testis and prostate (Kuiper et al., 1997). 
Sex steroid hormones are involved in the regulation of skin development 
and function, with both ERs expressed in skin. However, receptor distribution 
varies with body site: there are higher numbers in facial skin compared to tissue 
from the thigh or breast (Miller and Mac Neil, 1997). Some studies agree that 
ERβ is the predominant isoform in keratinocytes of human scalp skin 
(Mosselman et al., 1996; Thornton et al., 2003a, b), while in keratinocytes 
isolated from neonatal foreskin both ERα and ERβ protein is present, but in the 
case of ERα only with induction by estradiol (Verdier-Sevrain et al., 2004). 
Other studies report that epidermal keratinocytes and dermal fibroblasts 
express both isoforms and while ERα appears to be localised to the nucleus 
ERβ is expressed in both cytoplasm and nucleus (Haczynski et al., 2004; Merlo 
et al., 2009). Both isoforms are expressed in hair follicles and sebaceous glands 
(Mosselman et al., 1996; Thornton et al., 2006; Thornton et al., 2003a), while 
eccrine and apocrine glands express ERβ only (Beier et al., 2005; Mosselman 
et al., 1996; Thornton et al., 2003a). Ashworth (2005) identified both ERα and 
ERβ in the epidermis of young and old female human skin and both isoforms 
were present in epithelial cells of the hair follicles. Both ERα and ERβ are 
expressed in murine hair follicles at all stages of hair cycle (Ohnemus et al., 
2005) and while ERα and ERβ mRNA is expressed in normal (C57/BL6) female 
mouse skin only ERβ mRNA was identified in skin isolated from hairless 
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(Skh:hr-1) mice (Cho et al., 2008). Surprisingly, the differential distribution of the 
two ERs in murine skin has never been reported. 
 
3.1.2 Estrogen Signalling 
  
 The cellular signalling of estrogens is mediated through the two ERs, 
which are initially in an inactive state. With estrogen binding the receptors 
become activated and gene transcription is initiated. The DNA binding domain 
(DBD) of both receptors binds to a target site, now known as the estrogen 
responsive element (ERE) (Tremblay et al., 1997), with a similar affinity (Kuiper 
et al., 1997). In cells that express only one of the ER subtypes receptors will 
form homodimers of ERα or ERβ. In cells expressing both subtypes a 
heterodimer with one molecule of each of ERα and ERβ may also be formed. 
ERα/β heterodimers bind to DNA with a similar affinity to ERα homodimers, and 
with a higher affinity than ERβ homodimers. When bound to DNA heterodimers 
and homodimers can bind to the steroid receptor coactivator-1 and ultimately 
activate gene transcription (Cowley et al., 1997). 
 There are several downstream signalling pathways by which estrogens 
may act (Figure 3.2): 1) Ligand-dependant and ERE-dependent signalling, 
where ligand-bound ERs are able to bind directly to Estrogen Responsive 
Elements (ERE); 2) Ligand-dependent and ERE-independent signalling, where 
ligand-bound ERs can interact with other transcription factors, such as Fos or 
Jun. In this pathway gene regulation is affected by indirect DNA binding; 3) 
Non-genomic signalling, which involves a rapid physiological response without 
involving gene regulation. This pathway is poorly understood but has been 
found to act in many tissues; 4) Ligand-independent signalling involving 
activation through another signalling pathway, a good example of which is 
growth factor signalling (Figure 3.2) (Heldring et al., 2007). 
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Figure 3.2. Schematic representation of cellular estrogen signalling mechanisms. ER = 
estrogen receptor, ERE = estrogen responsive element, IGF = insulin-like growth factor, IGFR = 
IGF receptor, p = phosphorylation (figure drawn by the author [EE]). 
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3.1.3 Estrogen Receptor Knockout Mice 
 
Several mouse models are now available for the study of estrogen 
receptor function, including ERα knockouts (ERαKO), ERβ knockouts (ERβKO), 
ERα and ERβ double knockouts ERαβKO (Cicatiello et al., 1995; Dupont et al., 
2000; Korach, 1994; Krege et al., 1998; Lubahn et al., 1993; Shughrue et al., 
2002) and additionally aromatase knockouts (ArKO), where estrogen 
biosynthesis is disrupted (Fisher et al., 1998), conditional ER knockout mice 
utilising the Cre/LoxP system (Antal et al., 2008; Dupont et al., 2000) and mice 
where a point mutation in the DNA binding domain of the ER gene has been 
introduced (Jakacka et al., 2002; Jakacka et al., 2001; Swope et al., 2002).  
Krege et al. (1998) generated ERKO mice (now know as ERKOCH, 
generated in Chapel Hill, NC, USA), by targeting exon 3 of the ERα and ERβ 
genes. These mice were duplicated and moved to the Karolinksa Institute, 
Sweden (and renamed ERKOKI). These early strains of knockout mice 
demonstrated the importance of the role of the ERs with respect to all aspects 
of reproduction. Male and female ERαKOCH mice were found to be infertile 
(Korach, 1994), ERβKOCH females had reduced litter sizes, while ERβKOCH 
males were fertile (Krege et al., 1998), and in double ERKO (αβERKO) mice, 
both sexes were infertile (Couse et al., 1999). However, there was uncertainty 
over whether the ERαKOCH mice were true nulls as a truncated form of the ERα 
A/B domain was present in uterus of these mice (Couse et al., 1995; Kos et al., 
2002), while ERβKOCH and ERβKOKI mice, derived from the same mutant line, 
exhibited very different phenotypes. For this reason a new line of ERKO mice 
were generated in Strasbourg, France (ERKOST) (Dupont et al., 2000). These 
more recently generated strains (and those used in this study), [named 
ERαKOST and ERβKOST] exhibit similar phenotypes to the original strains: 
ERαKOST females are sterile and ERβKOST females are either infertile or 
subfertile. This is associated with a failure to ovulate, despite, in the case of 
ERαKOs, producing preovulatory follicles (Dupont et al., 2000). Both sexes of 
the floxed ERαST(L2/L2)  and ERβST(L2/L2) line are sterile but exhibit no other 
phenotype (Antal et al., 2008). Numerous studies have used these various 
knockout models to investigate ER-mediated signalling in peripheral tissues. 
When ERα is absent males suffer from decreased bone density and shorter 
bones while females exhibit aggressive behaviour, a reduction in sexual 
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behaviour, altered parental behaviour to new-born pups (Krege et al., 1998), 
decreased bone density and shorter bones (Walker and Korach, 2004). When 
ERβ is absent males exhibit more aggressive behaviour (Nomura et al., 2006), 
females show reduced social discrimination and increased bone density 
(Walker and Korach, 2004) and both sexes suffer from systolic and diastolic 
hypertension as they age (Otsuki et al., 2003). ERβKO mice are more prone to 
cardiac fibrosis and apoptosis than WT littermates, ultimately leading to heart 
failure (Fliegner et al., 2010). ERβKO mice exhibit defects in the alveoli of the 
lungs (Morani et al., 2006) and severe leukocyte infiltration to the lungs, 
consistent with myeloproliferative disease (Shim et al., 2003) and are assessed 
as deaf from 12 months old (Simonoska et al., 2009). Deletion of both ERs in 
αβERKO mice results in increased osteophytosis, a phenotype that was not, 
however, seen in single ERKO (Sniekers et al., 2009). In female aromatase 
knockout (ArKO) mice, where estrogen biosynthesis is disrupted, apoptosis of 
neurons of the frontal cortex of the brain is apparent (Hill et al., 2009). 
With reference to the skin, Moverare et al. (2002) identified that in 
castrated ERαKO male mice treatment with 17β-estradiol did not affect either 
hair growth or epidermal thickness, while in ERβKO male mice castration 
induced the anagen phase of hair growth, an effect that was inhibited by 17β-
estradiol. These results suggest that the effect of estrogen on hair follicle 
cycling is caused by ERα-mediated inhibition of telogen-anagen transition and 
the effect on epidermal thickness is caused by an ERα-mediated increase in 
proliferation of keratinocytes in the basal layer of the epidermis. Unfortunately, 
the authors did not investigate the effects of ER knockout in female mice in this 
study.  
 
Table 3.1 outlines the major effects on systems of the body with ER knockout. 
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Table 3.1 Effect of ER knockout in mice 
 
ERαKO ERβKO 
System ♂ ♀ ♂ ♀ 
Reproductive 
(Emmen 2003) 
(Krege 1998) 
(Dupont 2000) 
(Antal et al., 
2008) 
(Jakacka et al., 
2002) 
Infertile 
 
Infertile. Cysts on 
ovaries. No 
corpora lutea. 
Hypoplastic 
uterus. ERα 
knock-in mutant 
females are 
infertile 
Fertile. 
ERβST(L2/L2)  
infertile 
Subfertile. Few 
corpora lutea. 
Reduced 
induced 
ovulatory 
capacity. 
Smaller litters. 
ERβST(L2/L2)  
infertile 
Sexual 
Behaviour 
(Ogawa 2000) 
(Krege 1998) 
Reduced level 
of intromissions. 
No ejaculation. 
Mounting not 
affected 
Reduced sexual 
behaviour. 
Reduced parental 
behaviour to new 
born pups 
No difference 
compared to WT 
No difference 
compared to WT 
Cardiovascular 
(Otsuki 2003) 
(Fliegner et al., 
2010) 
No histological cardiovascular 
abnormalities 
Systolic and diastolic hypertension 
as mice age 
Acceleration of cardiac fibrosis, 
apoptosis and heart failure 
Brain 
(Hill et al., 2009) Apoptosis of neurons in the frontal cortex of ArKO mice 
Social 
Interaction 
(Choleris 2006) 
(Nomura 2006) 
(Ogawa 1998) 
(Tomihara et al., 
2009) 
- 
Impaired social 
discrimination 
Aggressive 
Increase in 
aggression in 
gonadally intact 
mice 
Reduced social 
discrimination. 
Anxiety in 
response to 
estradiol 
Bone 
(Korach 1994) 
(Walker 2004) 
Decreased 
bone density 
Shorter bones 
than WT 
Decreased bone 
density 
Shorter bones 
than WT. 
No difference 
compared to WT 
Increased bone 
density 
Lung 
(Morani et al., 
2006) (Shim et 
al., 2003) 
- - 
Alveoli defects 
and inflammation 
Alveoli defects 
and severe 
inflammation 
Skin  
(Moverare 2002) 
Estrogen 
treatment did 
not affect hair 
growth or 
epidermal 
thickness. 
- 
Estrogen 
treatment 
inhibited hair 
growth and 
increased 
epidermal 
thickness. 
- 
 
 
With the exception of hair cycling very little is known about the effect of 
estrogen receptor knockout on mouse skin and, in particular, wound healing. 
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3.1.4    Estrogen Receptor Agonists 
 
Estrogen receptor agonists are compounds capable of activating one or 
other ER to induce a full or partial pharmacological response (Frasor et al., 
2004). In recent years ERα- and ERβ-selective agonists have been developed 
as a pharmacological approach to evaluate the roles of the two estrogen 
receptors. Two commonly used estrogen receptor agonists are PPT and DPN 
(reviewed in Krom et al., 2006). Propyl pyrazole triol (PPT) is an ERα agonist 
(Figure 3.3. A) (Le Saux et al., 2006), displaying 410-fold binding selectivity for 
ERα over ERβ (Stauffer et al., 2000). PPT was developed by Katzenellenbogen 
and Katzenellenbogen in 1999, to distinguish the role of ERα in bone and 
uterus and other tissues (Harris et al., 2002; Stauffer et al., 2000; Sun et al., 
1999) and at present is used to investigate neonatal exposure to estrogens 
(Nakamura et al., 2008), trauma haemorrhage (Moeinpour et al., 2008), 
neuroendocrinology (Tiwari-Woodruff et al., 2007) and bone density (Harris et 
al., 2002). Diarylpropionitrile (DPN) is an ERβ agonist (Figure 3.3. B) (Le Saux 
et al., 2006), that displays 70-fold selectivity for ERβ over ERα (Krom et al., 
2006; Meyers et al., 2001). DPN was identified by Katzenellenbogen and 
Katzenellenbogen in 1999 in an aim to develop novel ligands with subtype 
selectivity for ERβ (Meyers et al., 2001; Sun et al., 2003) and at present is used 
to investigate colon cancer (Motylewska et al., 2009), neuroendocrinology 
(Tiwari-Woodruff et al., 2007) and cardiac protection by estrogen (Nikolic et al., 
2007). 
 
 
 
 
Figure 3.3. Structures of the ERα agonist, PPT (A), and the ERβ agonist, DPN (B) 
(figure drawn by the author [EE]) 
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OH 
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3.1.5 Current knowledge of ERs in wound healing 
 
There is currently very little known about the roles of the two ERs in 
wound healing. Both ER isoforms are expressed in fibroblasts (Haczynski et al., 
2002), keratinocytes [although ERβ is predominant] (Stevenson and Thornton, 
2007), macrophages (Ashcroft et al., 2003b), neutrophils (Yu et al., 2006) and 
hair follicles (Thornton et al., 2003a, b), which act as a source of adult stem 
cells critical to the repair process (Ito et al., 2005; Langton et al., 2008). Ovx 
rats treated with the ERα agonist PPT exhibit significantly reduced wound 
tensile strength compared to placebo-treated Ovx, while DPN treatment has no 
effect (Gal et al., 2010). Of crucial importance an allele of the ERβ dinucleotide 
CA repeat polymorphism is significantly associated with venous ulceration in the 
British Caucasian population (odds ratio of 2.8) (Ashworth et al., 2005, 2008). 
 
3.1.6 Aims of the Chapter 
 
Based on the limited data that exists surrounding ER-mediated action in 
skin and specifically in wound repair, the roles of the two isoforms, ERα and 
ERβ were assessed. The study utilised global ERKO mice, to determine the 
effects of complete deletion of one or other isoform, specifically investigating the 
effect of estrogen replacement in Ovx animals. Additionally, selective ER 
agonism in Ovx WT mice, by treatment with the ERα and β agonists PPT and 
DPN, was used to determine the effect of activation of one isoform alone on 
wound repair. 
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3.2 Materials and Methods 
 
3.2.1 Animal Experiments 
 
The initial study was performed to investigate the roles of ERα and ERβ, 
in wound healing, using the isoform specific ER agonists propyl pyrazole triol 
(PPT) and diarylpropionitrile (DPN). Secondly, experiments using ERαKO and 
ERβKO female mice, wounded in the presence and absence of estrogen were 
performed. 
Initially, 30 specific pathogen-free (SPF), female C57/BL6 mice, at 8 
weeks old, were used and split into 5 groups with 6 animals in each (Table 3.2). 
C57/BL6 mice were used as the strain has previously been very well 
characterised in wound healing studies and the mice display similar stages of 
wound healing to humans. Four of the groups (24 animals) were ovariectomised 
using the protocol described in chapter 2.1.4, and the remaining group (6 
animals) were left with intact ovaries. 
For the estrogen treated group a slow release (0.05 mg/21 day) 17β-
estradiol pellet (Innovative Research, USA) was inserted subcutaneously in the 
scapula region, using a trocar, on the day of wounding. DPN and PPT (Tocris, 
Bristol, UK, Catalogue numbers 1494 and 1426 respectively) were re-
suspended in DMSO (Sigma Aldrich, UK) initially and then corn oil (Sigma 
Aldrich) in the ratio of 5% DMSO to 95% corn oil. Stock solutions of 3.3 mg/ml 
DPN and 3.3 mg/ml PPT were prepared. Vehicle injections were comprised of 
5% DMSO and 95% corn oil. 100 µl per mouse per day was injected 
subcutaneously, on the day prior to wounding (day -1), day of wounding (day 0) 
and one day post-wounding (day +1). Table 3.2 shows the resulting doses 
given per mouse per day. The mice were treated subcutaneously (sc) to give a 
steady release of the compound, opposed to the fast and unpredictable release 
into the body that would occur from intra-peritoneal treatment.  
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Table 3.2 Experimental animals used and treatment groups 
 
Group Treatment 
Administration 
method and 
dosage 
Period of treatment 
Day of 
harvesting 
post-
wounding 
Number 
of mice 
1 Intact - - 3 6 
2 Ovx (+ vehicle) 100 µl sc vehicle injections 
Daily for 3 days 
starting 1 day before 
wounding 
3 6 
3 Ovx + estrogen 
sc pellet (21 day 
slow release) 
0.05mg 
Pellet inserted at time 
of wounding 3 6 
4 Ovx + DPN 100µl sc injections, 330µg/mouse/day 
Daily for 3 days 
starting 1 day before 
wounding 
3 6 
5 Ovx + PPT 100µl sc injections, 330µg/mouse/day 
Daily for 3 days 
starting 1 day before 
wounding 
3 6 
 
The first group (intact) were controls and were untreated (no intervention was carried out except 
wounding). Ovx = ovariectomised, sc = subcutaneous. 
 
 
 
The second part of the experiment utilised estrogen receptor knockout 
mice. ERαKOST and ERβKOST knockout mice (on a C57/BL6 background) were 
kindly donated by Pierre Chambon (Strasbourg) (Dupont et al., 2000). From this 
point knockouts will be referred to as ERα-/- and ERβ-/-. ERα-/- and ERβ-/- 
mice were bred from heterozygous mating pairs or triplets, earpunched at 5-6 
weeks old and genotyped using the protocol described in chapter 2.1.3. Female 
ERα-/- and ERβ-/- and female wild-type littermates were ovariectomised at 8 
weeks old, using the protocol described in chapter 2.1.4. Half the animals had a 
slow release (0.05 mg/21 day) 17β-estradiol pellet (Innovative Research, USA) 
inserted subcutaneously in the scapula region, using a trocar, on the day of 
wounding. The remaining animals were left untreated. Table 3.3 shows animal 
groups utilised. 
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Table 3.3 Experimental animals used and treatment groups 
 
Group Genotype Treatment 
Administration 
method and 
dosage 
Period of 
treatment 
Day of 
harvesting 
post-
wounding 
Number 
of mice 
1 ERα-/- Ovx - - 3 6 
2 ERα-/- Ovx + estrogen 
sc pellet (21 
day slow 
release) 
0.05mg 
Pellet 
inserted at 
time of 
wounding 
3 7 
3 ERβ-/- Ovx - - 3 4 
4 ERβ-/- Ovx + estrogen 
sc pellet (21 
day slow 
release) 
0.05mg 
Pellet 
inserted at 
time of 
wounding 
3 5 
5 Wild-type Ovx - - 3 11 
6 Wild-type Ovx + estrogen 
sc pellet (21 
day slow 
release) 
0.05mg 
Pellet 
inserted at 
time of 
wounding 
3 10 
 
The first, third and fifth groups (Ovx) were untreated (no intervention was carried out except 
ovariectomy and wounding). Ovx = ovariectomised, sc = subcutaneous. 
 
The mice were anaesthetised with isoflurane, oxygen and nitrous oxide 
inhalation and wounded following the protocol in section 2.1.5.1. The animals 
were given buprenorphine (0.1 mg/kg) as analgesia. 
 
3.2.2 Tissue harvest 
 
Blood, wound tissue, normal skin, peritoneal macrophages, liver for 
repeat genotyping (if required) and uterus was collected from each animal, as 
described in section 2.1.6.  
 
3.2.3 Wound processing and immunohistochemistry 
 
 Each wound was bisected and one half of each wound was placed in a 
formalin fixative solution while the other half was snap frozen in liquid nitrogen. 
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The fixed half of each wound was processed, embedded, sectioned and stained 
as described in section 2.1.8 and 2.1.9.  
 
3.2.4 Image Analysis 
 
 Images were captured from all stained sections and measurements 
taken at x4 and x20 magnification. The images were analysed and 
measurements taken using Image Pro-Plus software (Media Cybernetics, 
Finchampstead, UK) as described in section 2.1.11. 
 Statistical analysis was performed as described in section 2.8. 
 
3.2.5 Peritoneal Macrophage Culture 
 
Peritoneal macrophages were isolated from untreated C57/BL6 mice by 
intraperitoneal lavage with ice cold sterile PBS, as described in sections 2.1.6 
and 2.1.7, and pooled. Cell viability was determined by Trypan blue. 106 cells 
per ml in suspension in serum-free phenol-red free DMEM medium were treated 
with LPS (1 mg per ml) and consecutive 10-fold dilutions of 17β-estradiol 
(Sigma Aldrich), PPT or DPN (Tocris), reconstituted in ethanol (stock solutions) 
and subsequently diluted in PBS (Sigma Aldrich). Cells were washed, 0.5ml of 
Trizol (Invitrogen) added per well and stored at -80°C prior to RNA extraction.   
 
3.2.6 RNA Isolation and qPCR 
 
RNA was isolated from cultured macrophages and wound tissue as 
described in section 2.3. cDNA was transcribed and qPCR run using primers for 
Mif (see Table 2.7) 
 
3.2.7 Uterotrophic Assay 
 
Uteri were inspected for evidence of estrogen deprivation: a shrunken 
uterus indicates a lack of systemic estrogen (Garcia-Perez et al., 2006). The 
uteri were weighed and an average calculated for each group as described in 
section 2.7.  
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3.3 Results 
 
3.3.1 Estrogen Receptor distribution in murine skin 
 
 
Firstly, the expression of the two estrogen receptor isoforms, α and β, 
was investigated in normal skin and wound tissue from wild-type (WT) female 
mice with intact ovaries, as, surprisingly, tissue specific ER distribution in the 
skin has never been published. To detect cutaneous cells expressing ERα 6µm 
normal skin and wound tissue sections were stained using a mouse monoclonal 
ERα antibody, mapped at the C-terminus of human ERα (Santa Cruz, CA, 
USA). To detect cutaneous cells expressing ERβ normal skin and wound tissue 
sections were stained using a mouse anti-human monoclonal ERβ antibody 
(AbD Serotec, Kidlington, UK). 
ERα was expressed by keratinocytes in all layers of the epidermis, hair 
follicles, dermal fibroblasts and inflammatory cells in the granulation tissue of 
the wound. ERβ was expressed by keratinocytes in the basal layer of the 
epidermis but lacked expression in the upper layers (stratum corneum). ERβ 
was additionally expressed in cells of the hair follicles, dermal fibroblasts and 
inflammatory cells in the granulation tissue (Figure 3.4.). 
 
ER
β
 
ER
α
 
Figure 3.4. Cell-specific expression of ERα and ERβ in mouse skin. Both ERα and ERβ 
are expressed in epidermal keratinocytes (black arrows), hair follicles (green arrows), 
inflammatory cells (red arrows) and dermal fibroblasts (blue arrows). Scale bar = 50µm. 
Epidermis Dermis 
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3.3.2 The Effect of Estrogen Receptor Agonists on Wound Healing 
 
3.3.2.1 Wound Measurements 
 
Wound area and percentage re-epithelialisation was determined from 
Haematoxylin & Eosin (H&E) stained sections using Image Pro Plus software, 
as described in section 2.1.11 and Figure 2.3. In this study 8-week-old 
ovariectomised (Ovx) wild-type mice exhibited large delayed healing wounds at 
3 days post-wounding, compared to mice with intact ovaries (p<0.01), 
confirmed by quantification from H&E stained sections (Figure 3.5. A) as shown 
in Figure 3.5. B, and supporting results from previous studies (section 1.10) 
(Gilliver and Ashcroft, 2007; Hardman et al., 2005). When systemic estrogen 
was replaced, with the insertion of a subcutaneous 17β-estradiol pellet, the size 
of wounds was reduced to those of intact animals (p<0.01 compared to Ovx), 
confirming the beneficial effect of estradiol (Ashcroft et al., 1997a; Ashcroft et 
al., 1999a). Interestingly, systemic treatment with the ERβ agonist, DPN, 
reduced wound area to the same extent as 17β-estradiol (p<0.01 compared to 
Ovx), while systemic treatment with the ERα agonist, PPT, had no effect on 
healing, quantified by no reduction in wound area (Figure 3.5. A and B).  
Re-epithelialisation was also assessed by analysing H&E stained 
sections using Image Pro Plus software, as described in section 2.1.11 and 
Figure 2.4. Re-epithelialisation was retarded in the Ovx group compared to 
intact and estrogen treated groups (p<0.05) at day 3 (Figure 3.5. C), supporting 
findings from previous studies (Gilliver and Ashcroft, 2007; Hardman et al., 
2005). With the administration of DPN re-epithelialisation was significantly 
accelerated (p<0.05 compared to Ovx). In contrast, administration of PPT did 
not alter the percentage re-epithelialisation compared to Ovx (Figure 3.5. C). 
 
 
 
 
 
 140
 
0
20
40
60
80
100
0
0.5
1
1.5
2
2.5
Figure 3.5. The ERβ agonist, DPN, accelerates healing in Ovx mice, while the ERα 
agonist, PPT, has no effect. A. Representative Haemotoxylin and Eosin stained wax 
sections of incisional wounds taken at day 3 post-wounding. Arrows indicate the edges of 
the wounds. B. Mean areas of wounds taken at day 3 post-wounding. Wound area is 
significantly reduced in intact, +Estrogen and +DPN compared to Ovx. C. Mean percentage 
of re-epithelialisation of wounds taken at day 3 post-wounding. Re-epithelialisation is 
significantly accelerated in intact, +Estrogen and +DPN compared to Ovx. * indicates 
significance of p<0.05, ** p<0.01. Scale bar = 200µm. Results are presented as mean 
+SEM, n=6. Ovx = ovariectomised, +E = +Estrogen. 
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3.3.3 The Effect of Estrogen Receptor Agonists on Inflammatory Cell 
Infiltration 
 
3.3.3.1 Neutrophils 
 
Neutrophils arrive as the first stage of the inflammatory response and 
play an important role in the early phases of wound repair. Neutrophils enter the 
wound from the peripheral circulation in response to chemical signals and 
phagocytose bacteria, release elastase, collagenase, cytokines and reactive 
oxygen species (ROS) (James et al., 2003; Lee et al., 2003; Martin and Feng, 
2009; Roy et al., 2006). However, excessive neutrophil recruitment has been 
linked to impaired healing in both acute and chronic wounds, specifically 
relating to the release of matrix degrading elastase and excessive pro-
inflammatory cytokine production (Ashcroft et al., 1997e; Herrick et al., 1997; 
Moor et al., 2009). It has previously been shown that estrogen can reduce 
wound neutrophil influx (Ashcroft et al., 1999a; Ashcroft et al., 1997e). A purified 
rat anti-mouse monoclonal neutrophil antibody (Ly-6G, BD Biosciences 
Pharmingen) was used to detect and quantify neutrophil numbers. Ly-6G is a 
marker of mature granulocytes (Karimbakas et al., 1998). Cell numbers were 
quantified from tissue section immunolocalisation using Image Pro Plus 
software, as described in Section 2.1.11 and Figure 2.5. 
In this study there was a significant increase in neutrophils in wound 
tissue from Ovx mice compared to those with intact ovaries (p<0.05) supporting 
previous findings (Ashcroft et al., 2003b). With the replacement of systemic 
estrogen this was reversed and numbers of neutrophils recruited to the wound 
were significantly reduced (p<0.01) (Figure 3.6. A and B). Wounds from mice 
given systemic DPN treatment had reduced numbers of neutrophils compared 
to Ovx, suggesting efficient neutrophil resolution by day 3 post-wounding. 
Interestingly, however, wound tissue from mice treated with PPT also had 
reduced neutrophil infiltration (p<0.05) (Figure 3.6. A and B), despite a delay in 
healing (Figure 3.5). However, despite being significant, neither agonists at the 
doses administered were as effective as 17β-estradiol at reducing neutrophil 
recruitment.  
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3.3.3.2 Macrophages 
 
Macrophages play an essential role in the innate immune response, 
phagocytosing bacteria and foreign bodies within wounds, providing cytokines 
and growth factors, which orchestrate the inflammatory response and matrix 
remodelling. However, an excessive inflammatory response, as in chronic 
ulcers (Loots et al., 1998), can have negative effects on wound repair. Thus, 
careful regulation of wound macrophages is critical. To detect macrophages in 
the wound granulation tissue 6µm tissue sections were stained using a purified 
rat anti-mouse macrophage specific antibody (Mac-3, BD Biosciences 
Pharmingen). The Mac-3 antibody detects  the 92-110 kDa glycoprotein antigen 
on the surface of tissue macrophages (Ho and Springer, 1983; Nibbering et al., 
1987), but not on lymphocytes or monocytes (Ho and Springer, 1983). Sections 
were analysed and cell numbers quantified using Image Pro Plus software, as 
described in Section 2.1.11 and Figure 2.5.  
The presence of estrogen is a factor in regulating macrophage migration 
to the wound in response to injury (Ashcroft et al., 1997a). Supporting previous 
findings there was an increase in the number of macrophages in wound tissue 
from Ovx mice compared to those with intact ovaries (Ashcroft et al., 1997a; 
Ashcroft et al., 2003b), and this was reversed when Ovx mice were given 
systemic estrogen at the time of wounding (p<0.01) (Figure 3.7. A and B). 
Wounds from systemic DPN-treated mice had significantly reduced numbers of 
macrophages compared to Ovx (p<0.05). Interestingly, macrophages were 
significantly reduced in PPT treated mice (p<0.05 compared to Ovx), despite 
these animals having larger wounds, more reminiscent of those from Ovx 
animals (Figure 3.7. A and B). 
This combined novel data suggests a clear uncoupling of inflammation 
from overall healing. 
 
3.3.3 Alternatively Activated Macrophages 
 
 Macrophages are activated in one of two manners: classically or 
alternatively. Stein et al. (1992) described alternatively activated macrophages 
and how they had a specifically different phenotype to what are now known as 
classically activated macrophages. Classically activated macrophages exhibit a 
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Th1 response, promoting inflammation and matrix destruction while alternatively 
activated macrophages exhibit a Th2 response, promoting matrix generation, 
angiogenesis and cell proliferation. Classically activated macrophages are 
associated with chronic inflammation and tissue injury while alternatively 
activated macrophages act to resolve inflammation and promote wound healing 
and angiogenesis (Duffield, 2003; Gordon, 2003). Arginase I is a intracellular 
marker of alternatively activated macrophages, whilst Ym1 and Fizz1 are 
secreted markers of alternative activation (Tong et al., 2006). Delayed healing 
wounds are characterised by a scarcity of alternatively activated macrophages, 
associated with a reduction in Ym1 and Fizz1, a result that is reversed with 
estrogen replacement (Routley and Ashcroft, 2009). To further investigate the 
obvious differences in activity of PPT and DPN (both are anti-inflammatory 
while only DPN promotes healing) Arginase I immunohistochemical staining 
was performed to analyse macrophage activation, using an Arg1 antibody, 
raised in rabbit (Santa Cruz, CA, USA).  
The number of alternatively activated macrophages, was not significantly 
altered between intact, Ovx and estrogen treated wounds (Figure 3.8. A and B). 
However, when calculated as a percentage of the total number of wound 
macrophages there were significantly reduced numbers in the Ovx group (not 
shown). Interestingly, while both PPT and DPN exhibit similar anti-inflammatory 
properties, reducing neutrophil and macrophage influx (Figures 3.6 and 3.7) 
there were significantly fewer alternatively activated macrophages in PPT 
treated wounds than estrogen (p<0.05) or DPN (p<0.01) treated (Figure 3.8). 
This is one probable reason for the difference in healing between PPT and DPN 
treated wounds. 
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Figure 3.6. PPT and DPN reduce neutrophil recruitment to the wound. A. 
Representative neutrophil immunohistochemical localisation images from wounds at 3 days 
post-wounding. Arrows indicate positive cells (neutrophils). B. Total neutrophils within the 
granulation tissue. There is a significant reduction in neutrophils in intact, +Estrogen, +DPN 
and +PPT compared to Ovx. * indicates significance of p<0.05, ** p<0.01. Scale bar = 
50µm. Results are presented as mean +SEM, n=6.  
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Figure 3.7. PPT and DPN reduce macrophage recruitment to the wound. A. 
Representative macrophage immunohistochemical localisation images from wounds at 3 
days post-wounding. Arrows indicate positive cells (macrophages). B. Total macrophages 
within the granulation tissue. There is a significant reduction in macrophages in intact, 
+Estrogen, +DPN and +PPT compared to Ovx. * indicates significance of p<0.05, ** p<0.01. 
Scale bar = 50µm. Results are presented as mean +SEM, n=6. 
Ovx +Estrogen Intact +PPT 
A 
+DPN 
 145
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
B 
Figure 3.8. PPT and DPN differentially affect macrophage activation. A. Representative 
Arginase I immunohistochemical localisation images from wounds at 3 days post-wounding. 
Arrows indicate positive cells (alternatively activated macrophages). B. Total arginase 1-
positive cells within the granulation tissue. There is a significant reduction in arginase1-
positive cells in +PPT compared to +Estrogen and +DPN. * indicates significance of p<0.05, 
** p<0.01. Scale bar = 50µm. Results are presented as mean +SEM, n=6. 
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3.3.4 The Effect of Selective Estrogen Receptor Agonists on 
Inflammatory Cytokine Production 
 
3.3.4.1 Macrophage Migration Inhibitory Factor (MIF) 
 
 
The atypical pro-inflammatory cytokine MIF is produced by a variety of 
cell types, including monocytes, macrophages, and keratinocytes (Abe et al., 
2001; Calandra et al., 1994). MIF stimulates the production of other cytokines 
and growth factors, including TNF-α, IL-1 and IL-6 (Calandra and Bucala, 1995). 
Ashcroft et al. have previously demonstrated a link between MIF and healing 
and identify MIF as a candidate master regulator of estrogen’s positive effects 
on wound healing. In vivo MIF is upregulated in non-healing human wounds and 
delayed healing (Ovx) mouse wounds, while MIF is reduced in wound tissue 
from estrogen treated Ovx mice (Ashcroft et al., 2003b). In vitro estrogen 
directly inhibits MIF production by activated murine macrophages and human 
monocytes (Ashcroft et al., 2003b). Using an affinity-purified goat polyclonal 
antibody (R&D Systems, Oxford, UK) MIF was immunolocalised to inflammatory 
cells and fibroblasts in the wound granulation tissue (Figure 3.9. A) and 
epidermal keratinocytes. At 3 days post-wounding granulation tissue from Ovx 
mice had large numbers of MIF-positive cells, while wound tissue from intact 
and estrogen-treated Ovx mice displayed reduced MIF-positive cells (p<0.01) 
(Figure 3.9. A and B) as previously reported (Ashcroft et al., 2003b). Novel data 
presented here now indicate that DPN-treated Ovx mice also have significantly 
reduced numbers of wound tissue MIF-positive cells compared with Ovx 
(p<0.01). Ovx mice treated with PPT also exhibited reduced numbers of MIF-
positive cells (p<0.01) (Figure 3.9. A and B), suggesting that PPT is able to 
reduce cytokine levels despite having no effect on overall healing.  
Mif expression, assessed by qPCR, is increased in Ovx mice relative to 
intact animals (p<0.01). Furthermore, wound tissue from exogenous estrogen-, 
PPT- and DPN-treated Ovx mice displayed reduced expression of Mif (p<0.05) 
(Figure 3.9. C), supporting findings from histological analysis. Complimentary in 
vitro analysis reveals that both PPT and DPN (100 nm) reduced the relative 
expression of Mif by isolated peritoneal macrophages, to a comparable or 
greater extent than 17β-estradiol (Figure 3.9. D). 
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Figure 3.9. PPT and DPN reduce MIF expression in vivo and in vitro. A. Representative 
MIF immunohistochemical localisation images from wounds at 3 days post-wounding. 
Arrows indicate MIF-positive cells. B. Total MIF-positive cells within the granulation tissue. 
There is a significant reduction in MIF-positive cells in intact, +Estrogen, +DPN and +PPT 
compared to Ovx. C. Levels of expression of Mif in wound tissue, relative to intact. There is 
a significant reduction in Mif expression in intact, +Estrogen, +DPN and +PPT compared to 
Ovx. D. Levels of expression of Mif by isolated peritoneal macrophages in vitro, relative to 
untreated. There is a significant reduction in Mif expression in E (100nM), DPN (100nM) and 
PPT (100nM) compared to untreated (-). * indicates significance of p<0.05, ** p<0.01 
compared to Ovx or untreated. Scale bar = 50µm. Results are presented as mean +SEM, 
n=6 (B, C), n=3 (D). - = untreated, E = 17β-estradiol. 
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3.3.4.2 Interleukin-6 (IL-6) 
 
IL-6 plays a crucial role in inflammatory responses (Akira and Kishimoto, 
1992) and is expressed by macrophages, T cells, fibroblasts, keratinocytes and 
endothelial cells (Kishimoto et al., 1992). Healing is significantly delayed in IL-6 
knockout mice (Gallucci et al., 2000), while wild-type mice administered with 
neutralising anti-IL-6 monoclonal antibody exhibit significantly delayed wound 
closure (Lin et al., 2003). IL-6 expressing cells were identified in wound 
granulation tissue using an affinity purified IL-6 polyclonal antibody raised in 
goat (R&D Systems, Oxford, UK).  
IL-6 was primarily localised to inflammatory cells in all treatment groups 
(Figure 3.10.A). Despite no significant difference between intact and Ovx there 
was a significant reduction in IL-6 expressing cells with exogenous estrogen 
treatment (p<0.05) (Figure 3.10. A and B). Novel data presented here 
demonstrates that Ovx mice treated with either PPT or DPN also displayed 
significantly reduced IL-6-positive cells in wound tissue (p<0.01) (Figure 3.10. A 
and B).  
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Figure 3.10. PPT and DPN reduce IL-6 expression in vivo. A. Representative IL-6 
immunohistochemical localisation images from wounds at 3 days post-wounding. Arrows 
indicate IL-6-positive cells. B. Total IL-6-positive cells within the granulation tissue. There is a 
significant reduction in MIF-positive cells in +E, +DPN and +PPT compared to Ovx. * indicates 
significance of p<0.05, ** p<0.01. Scale bar = 50µm. Results are presented as mean +SEM, 
n=6. 
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3.3.5 The Effect of Estrogen Receptor Agonists on wound ERα and ERβ 
expression 
 
Much of the known effects of estrogen are mediated through its nuclear 
hormone receptors, ERα and ERβ, which are differentially expressed in cells 
and tissues throughout the body. As previously mentioned PPT is a potent ERα 
agonist, with 410-fold selectivity over ERβ (Stauffer et al., 2000), while DPN is 
and ERβ agonist, with 70-fold selectivity over ERα (Meyers et al., 2001). To 
determine the effect of PPT and DPN on ERα and ERβ expression in wound 
tissue ERα and ERβ immunohistochemistry was performed. 
 
3.3.5.1 Estrogen Receptor-Alpha (ERα) 
 
 
ERα has been identified in unwounded skin (Kuiper et al., 1997), 
neutrophils (Molero et al., 2002), fibroblasts (Malet et al., 1991), human and 
murine macrophages (Gulshan et al., 1990) and murine adipose tissue (Spong 
et al., 2000). However, the distribution of ERα in mouse skin and wound tissue 
has never been published. The number of cells expressing ERα in wound tissue 
was determined using a mouse monoclonal ERα antibody, mapped to the C-
terminus of human ERα (Santa Cruz, CA, USA).  
In wound tissue ERα was predominantly localised to inflammatory cells, 
fibroblasts and keratinocytes in all treatment groups (Figure 3.11. A and B). 
There was no change in either dermal (Figure 3.11. A) or epidermal (Figure 
3.11. B) levels of ERα in all groups compared to Ovx (Figure 3.11. C and D). 
 
 
3.3.5.2 Estrogen Receptor-Beta (ERβ) 
 
 ERβ has also been reported in human unwounded skin (Kuiper et al., 
1997), to a far greater extent than ERα (Pelletier and Ren, 2004; Thornton et 
al., 2003a). ERβ is highly expressed in human epidermal keratinocytes and all 
epidermal layers stain positively (Thornton et al., 2003a), and in sebaceous 
glands, sebocytes, and hair follicles (Thornton et al., 2003a, b). ERβ 
immunolocalises to human endothelial cells of blood vessels, muscle cells and 
fibroblasts in blood vessels, mostly in the nuclei, with some weak cytoplasmic 
staining (Thornton et al., 2003a). As with ERα, the distribution of ERβ in mouse 
skin and wound tissue has never been published. The number of cells 
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expressing ERβ in wound tissue was determined using a mouse anti-human 
monoclonal ERβ antibody (AbD Serotec, Kidlington, UK). 
 In wound tissue ERβ was localised to inflammatory cells, fibroblasts 
and basal keratinocytes (Figure 3.12. A and B). There was a significant 
increase in the number of ERβ-positive cells in wound granulation tissue from 
mice treated with estrogen compared to Ovx (p<0.01), while there was no 
difference in the number of ERβ-positive cells in granulation tissue from DPN or 
PPT treated mice (Figure 3.12. A and C). ERβ was also expressed in epidermal 
keratinocytes, particularly those at the leading edge of the newly formed 
epidermis. There were significantly more ER-β-positive keratinocytes in the 
epidermal leading edge in all treatment groups (+estrogen, +PPT, +DPN) and 
the intact group, compared to Ovx animals (p<0.05) (Figure 3.12. B and D). 
This exciting novel data clearly suggests that 1) ER ligands confer different 
effects on ER expression depending on the cell type, and 2) selective induction 
of ERβ, not ERα, makes it more likely that there exists a specific role for this 
isoform during healing. 
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Figure 3.11. ERα and ERβ specific agonists have no effect on ERα epidermal and 
dermal expression. A. Representative ERα immunohistochemical localisation images from 
wounds at 3 days post-wounding. Black arrows indicate positive inflammatory cells, green 
arrows indicate positive fibroblasts. B. Representative ERα immunohistochemical 
localisation images of epidermis at the wound edge from incisional wounds at 3 days post-
wounding. Red dashed line represents the epidermal-dermal junction. C. Total ERα-positive 
cells within the granulation tissue. D. Total ERα-positive cells in the epidermis. Statistical 
test result p>0.05 and therefore not significant. Scale bar = 50µm (A), 100µm (B). Results 
are presented as mean +SEM, n=6.  
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Figure 3.12. ERα and ERβ specific agonists have differential effects on ERβ epidermal 
and dermal expression. A. Representative ERβ immunohistochemical localisation images 
from wounds at 3 days post-wounding. Black arrows point to positive inflammatory cells, 
green arrows point to positive fibroblasts. B. Representative ERβ immunohistochemical 
localisation images of the leading edge of epidermis from incisional wounds at 3 days post-
wounding. Arrows indicate the leading epidermal front, red dashed line represents the 
epidermal-dermal junction. C. Total ERβ-positive cell numbers within the granulation tissue. 
There is a significant increase in ERβ-positive cells in +Estrogen compared to Ovx. D. Total 
ERβ-positive cells in the leading edge of the epidermis. There is a significant increase in 
ERβ-positive cells in intact, +Estrogen, +PPT and +DPN compared to Ovx. * indicates 
significance of p<0.05, ** p<0.01. Scale bar = 50µm (A), 100µm (B). Results are presented 
as mean +SEM, n=6. 
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3.3.6 The Role of Estrogen Receptor Agonists on Cell Migration in vitro 
 
 In vivo studies suggest the two ER agonists have very different effects on 
wound healing. While both are anti-inflammatory only DPN reverses delayed 
healing in the Ovx mouse model. However, interpretation of in vivo experimental 
data is complicated as multiple cell types are involved. To address this issue the 
effect of 17β-estradiol, PPT and DPN on cell migration was assessed in vitro in 
two of the crucial cell types involved in cutaneous wound repair: keratinocytes 
and fibroblasts. Firstly, 17β-estradiol accelerated 2-dimensional migration of 
both keratinocytes and fibroblasts across an artificial scratch (Figure 3.13. A 
and B, Figure 3.14. A and B), supporting findings that estradiol treated Ovx 
mice have smaller wounds which exhibit increased re-epithelialisation (Figure 
3.5).  In vivo PPT treated mice exhibit larger wounds with delayed re-
epithelialisation, while in vitro PPT did not significantly promote keratinocyte 
migration (Figure 3.13. A and B) or fibroblast migration (Figure 3.14. A and B). 
Interestingly, DPN accelerated migration of both keratinocytes (Figure 3.13. A 
and B) and fibroblasts (Figure 3.14. A and B), supporting in vivo results that 
DPN treatment reduces wound area and increases re-epithelialisation in Ovx 
mice, while PPT does not (Figure 3.5). Thus, there is strong correlation between 
in vivo data and in vitro experiments on fibroblasts and keratinocytes. This data 
suggests that both cell types are contributing to improved healing with 17β-
estradiol and DPN treatment.  
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Figure 3.13. Estrogen, DPN and PPT differentially affect keratinocyte migration in 
vitro. A. Representative photomicrographs of 2D keratinocyte scratch assay. B. 
Keratinocytes treated with estrogen or DPN display significantly increased migration in 2-
dimensions, compared to untreated (-), * indicates significance of p<0.05. Scale bar = 
500µm. Results are presented as mean +SEM, outcome of 3 individual experiments. - = 
untreated, +E = +estrogen.  
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Figure 3.14. Estrogen, DPN and PPT differentially affect fibroblast migration in vitro. 
A. Representative photomicrographs of 2D fibroblast scratch assay. B. Fibroblasts treated 
with estrogen or DPN display significantly increased migration in 2-dimensions, compared 
to untreated (-), * indicates significance of p<0.05.  Scale bar = 500µm. Results are 
presented as mean +SEM, outcome of 3 individual experiments. - = untreated, +E = 
+estrogen. 
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3.3.7 Estrogen replacement in Estrogen Receptor Knockout mice 
 
3.3.7.1 Wound Measurements 
 
To investigate the role of ERα- versus ERβ-mediated signalling female 
ERα-/- and ERβ-/- mice were wounded in the presence or absence of systemic 
estrogen (Ovx vs Ovx + estrogen). H&E stained sections were analysed to 
quantify wound area and percentage re-epithelialisation (as described in section 
2.1.11). In the absence of estrogen (Ovx) there was no significant difference in 
wound area between WT, ERα-/- and ERβ-/- groups (Figure 3.15. A and B). 
In Ovx WT mice systemic estrogen replacement increases the rate of 
healing, characterised by a reduction in wound area (Ashcroft et al., 1997a; 
Ashcroft et al., 1999a; Ashcroft et al., 2003b) (Figure 3.5. A and B). The 
replacement of systemic estrogen in ERα-/- female mice gives the same result, 
although the reduction is non-significant. This is likely to be due to group size, 
and with a larger number of mice it would be expected to be significant. Of 
importance, estrogen replacement in ERβ-/- mice actually resulted in an 
increase in wound area, a significant difference compared to WT +E (Figure 
3.15. A and B), clearly having the opposite effect to what is usually seen. 
 Systemic estrogen treatment is commonly accompanied by accelerated 
re-epithelialisation, with 17β-estradiol directly accelerating keratinocyte 
migration (Figure 3.13). Here, the replacement of estrogen in WT Ovx mice 
resulted in a significant increase in percentage re-epithelialisation (p<0.05), 
while estrogen replacement resulted in no difference in re-epithelialisation in 
Ovx ERα-/- or ERβ-/- (Figure 3.15. C). This is interesting considering that 
estrogen replacement has a detrimental effect on wound area in Ovx ERβ-/- 
(my primary measure of healing), while it has no such effect on re-
epithelialisation. This is fascinating in light of the result that the ERβ specific 
agonist DPN accelerates keratinocyte migration, while the ERα agonist PPT has 
less of an effect, and may reflect potential differences between systemic versus 
topical treatment in vivo. 
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Figure 3.15. Systemic estrogen replacement accelerates healing in WT and ERα-/- mice 
but delays healing in ERβ-/- mice. A. Representative Haemotoxylin and Eosin stained wax 
sections of incisional wounds taken at day 3 post-wounding. Arrows indicate the edges of the 
wounds. B. Mean areas of wounds taken at day 3 post-wounding. Wound area is significantly 
different between Ovx ERα-/- +E and Ovx ERβ-/- +E, Ovx ERβ-/- +E and Ovx WT +E, Ovx WT 
and Ovx WT +E. C. Mean percentage of re-epithelialisation of wounds taken at day 3 post-
wounding. Re-epithelialisation is significantly different between ERβ-/- +E and WT+E, WT Ovx 
and WT+E. * indicates significance of p<0.05, ** p<0.01. Results are presented as mean 
+SEM, n=4-11. Scale bar = 200µm. Ovx = ovariectomised, +E = estrogen treated. 
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3.3.7.2 Inflammatory Cell Infiltration 
 
As previously mentioned estrogen reduces wound neutrophil influx 
(Ashcroft et al., 1999a). Here, the replacement of estrogen in Ovx WT mice led 
to a significant reduction in wound neutrophil recruitment (Figure 3.16. A and B). 
Both ERα-/- and ERβ-/- mice responded differently to WT mice with respect to 
neutrophils: systemic estrogen replacement failed to dampen neutrophil 
numbers in Ovx ERα-/-, while it substantially increased neutrophil recruitment 
Ovx ERβ-/- (Figure 3.16. A and B). 
Estrogen is also a known regulatory factor in macrophage recruitment to 
injured tissue. In WT mice exogenous estrogen treatment reduces the number 
of macrophages in Ovx wound tissue (Ashcroft et al., 2003b) (Figure 3.5). In 
this study both Ovx WT and Ovx ERβ-/- mice responded to the replacement of 
estrogen with a reduction in wound macrophages (Figure 3.17. A and B). 
Interestingly, in ERα-/- mice estrogen replacement resulted in a non-significant 
increase in wound macrophages (Figure 3.17. A and B). However, Ovx ERα-/- 
wounds have significantly less wound macrophages than Ovx WT wounds, 
which could be an important observation in the noted differences in anti-
inflammatory activity of estrogen (Figure 3.17. A and B). 
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WT ERα-/- ERβ-/-
Figure 3.16. Systemic estrogen replacement has different effects on wound neutrophil 
recruitment in Ovx ERα-/- and ERβ-/- mice.  A. Representative neutrophil 
immunohistochemical localisation images from wounds at 3 days post-wounding. Arrows 
indicate positive cells (neutrophils). B. Total neutrophils within the granulation tissue. There 
is a significant difference in neutrophils between Ovx ERα-/- +E and Ovx ERβ-/- +E, Ovx 
ERβ-/- +E and Ovx WT +E, Ovx ERβ-/- and Ovx ERβ-/- +E, Ovx WT and Ovx WT +E. * 
indicates significance of p<0.05. Scale bar = 50µm. Results are presented as mean +SEM, 
n=4-11.   
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Figure 3.17. Systemic estrogen replacement has different effects on wound 
macrophage recruitment in Ovx ERα-/- and ERβ-/- mice. A. Representative macrophage 
immunohistochemical localisation images from wounds at 3 days post-wounding. Arrows 
indicate positive cells (macrophages). B. Total macrophages within the granulation tissue. 
There is a significant difference in macrophages between Ovx WT and Ovx WT +E. * 
indicates significance of p<0.05. Scale bar = 50µm. Results are presented as mean +SEM, 
n=4-11.  
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3.3.7.3 Pro-inflammatory cytokine production 
 
Estrogen directly down-regulates wound MIF, which appears to be a key 
mediator of estrogen’s beneficial effects on healing. In WT mice estrogen 
treatment dampens local MIF production, in line with reduced inflammation 
(Ashcroft et al., 2003b). In this study estrogen reduced wound MIF-positive cells 
in both WT and ERβ-/- mice. In contrast wound MIF-positive cells were 
unaltered in ERα-/- mice (Figure 3.18. A and B).  
The number of cells expressing the pro-inflammatory cytokine IL-6 
followed the same trend, although non-significantly (Figure 3.19. A and B). 
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Figure 3.18. Systemic estrogen replacement has different effects on wound MIF 
expression in Ovx ERα-/- and ERβ-/- mice.  A. Representative MIF immunohistochemical 
localisation images from wounds at 3 days post-wounding. Black arrows indicate MIF-
positive inflammatory cells, green arrows indicate MIF-positive fibroblasts. B. Total MIF-
positive cells in the granulation tissue. There is a significant difference in MIF-positive cells 
between Ovx ERα-/- and Ovx ERβ-/-, Ovx ERα-/- and Ovx WT, Ovx WT and Ovx WT +E, 
Ovx ERβ-/- and Ovx ERβ-/- +E. * indicates significance of p<0.05. Scale bar = 50µm. 
Results are presented as mean +SEM, n=4-11.   
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Figure 3.19. Systemic estrogen replacement has different effects on wound IL-6 
expression in Ovx ERα-/- and ERβ-/- mice.  A. Representative IL-6 immunohistochemical 
localisation images from wounds at 3 days post-wounding. Black arrows indicate IL-6-
positive inflammatory cells, green arrows indicate IL-6-positive fibroblasts. B. Total IL-6-
positive cells. There is a significant difference in IL-6-positive cells between Ovx WT +E and 
Ovx ERα-/- +E, Ovx WT and Ovx WT+E. * indicates significance of p<0.05. Scale bar = 
50µm. Results are presented as mean +SEM, n=4-11.  
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3.3.8 Estradiol Enzyme ImmunoAssay (EIA) 
  
 EIA was performed using whole blood serum, collected from mice at 
sacrifice, to confirm 1) successful ovariectomy and, 2) estrogen replacement. 
There was a significant increase in the concentration of 17β-estradiol in Ovx + 
estrogen animals, compared to untreated Ovx, in all groups (WT, ERα-/- and 
ERβ-/-) (Figure 3.20. A). Thus ovariectomy efficiently reduced systemic 
estrogen, an effect that was reversed by estrogen replacement. 
 
3.3.9 Uterotrophic Assay 
 
Estrogen is known to be uterotrophic (Huynh and Pollak, 1994) and uteri 
are therefore substantially decreased in weight following estrogen deprivation. 
Uteri were weighed as a complimentary technique to confirm EIA. Estrogen 
treatment increased uteri weights in all groups (WT, ERα-/- and ERβ-/-) (Figure 
3.20. B). This supports EIA data, confirming successful ovariectomy and 
estrogen replacement. 
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Figure 3.20. Confirmation of systemic estrogen manipulation. A. Mean estradiol 
concentration in serum from Ovx and Ovx + E mice. There is a significant increase in 
estradiol concentration in Ovx +E groups compared to Ovx, in all strains. B. Mean uterus 
weight from Ovx and Ovx + E mice. There is a significant increase in weight in Ovx +E 
groups compared to Ovx, in all strains. * indicates significance of p<0.05, ** p<0.01. 
Results are presented as mean +SEM, n=4-11. 
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3.4  Discussion                                                                                                                                                                                                                                                  
 
Estrogen has direct effects on the skin, increasing collagen content and 
enhancing overall thickness in humans (Brincat et al., 1985; Brincat et al., 1987) 
and rodents (Smith and Allison, 1966a, b) while modulating cutaneous wound 
healing in human and rodents (Ashcroft et al., 1997a; Ashcroft et al., 1999a; 
Ashcroft et al., 1997c; Ashcroft et al., 2003b; Gilliver and Ashcroft, 2007; 
Hardman and Ashcroft, 2008). Thus, unsurprisingly estrogen receptors (ERs) 
are present in human skin cells (Haczynski et al., 2002; Merlo et al., 2009; Miller 
and Mac Neil, 1997; Thornton et al., 2003a, b). Estrogens, in fact, signal 
through two nuclear hormone estrogen receptors (ERα and ERβ) with the 
majority of estrogen’s known effects thought to be mediated by ER ligand-
activated transcription factors, that activate or repress the transcription of 
specific genes (Enmark and Gustafsson, 1999). In cells that express only a 
single ER subtype receptors will exclusively form homodimers, while in cells 
expressing both subtypes ERα/β heterodimers can also form (Enmark and 
Gustafsson, 1999). ERα and ERβ have a yin yang relationship: ERβ inhibits 
ERα-mediated transcription, while ERβ can compensate for the absence of ERα 
(Lindberg et al., 2003). Cutaneous estrogenic effects have been reported in 
mouse (Azzi et al., 2005; Gendimenico et al., 2002), as has the presence of 
both ERα and ERβ mRNA (Cho et al., 2008). However, data presented in this 
thesis with respect to expression and distribution of the two ERs in murine skin 
is novel. In this study both ERα and ERβ were localised to murine dermal 
fibroblasts, inflammatory cells and hair follicles, and while ERα was present in 
all layers of the epidermis ERβ was localised to the basal layer only.   
The two human ER isoforms share a 96% homology in the DNA binding 
domain (DBD) region but just 53% homology in the ligand binding domain (LBD) 
region, which makes it possible to design synthetic estrogens that are specific 
for one of the two receptor isoforms. This has had exciting implications for 
clinical studies in tissues where the different isoforms have diverse roles. This 
study utilised two recently developed ER isoform selective agonists to 
determine the functional role of specific ER activation in wound healing. PPT is 
a potent ERα agonist with a 410-fold higher affinity for ERα over ERβ (Stauffer 
et al., 2000). In contrast DPN is a selective ERβ agonist which exhibits 
preferential binding (70-fold) for ERβ over ERα (Krom et al., 2006; Meyers et 
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al., 2001). Data presented in this chapter suggest that both ERs influence 
cutaneous healing but play very different roles: while ERα is involved in the 
control and regulation of inflammation, ERβ beneficially and globally modulates 
wound healing. Of great importance the initial results of this chapter indicate 
that selective agonism of ERβ (DPN) promotes healing in Ovx mice while 
agonism of ERα (PPT) has no effect. 
Despite specific activation of ERα with PPT failing to promote healing 
there was no evidence of an excessive inflammatory response usually seen in 
Ovx wounds. In this study both PPT and DPN exhibited anti-inflammatory 
potential, dampening neutrophil and macrophage influx and reducing the 
expression of the pro-inflammatory cytokines MIF and IL-6. Both agonists are 
known to have anti-inflammatory potential in astrocyte cultures, reducing levels 
of IL-1β (Lewis et al., 2008). Despite the similarity in anti-inflammatory activity, 
there were differences in the activation states of wound macrophages in this 
study: there were significantly fewer alternatively activated (Th2, healing 
promoting) macrophages in wounds from PPT treated mice than DPN treated 
mice, despite similar numbers of total wound macrophages. This suggests that 
while specific activation of ERα results in a reduction of inflammatory cell 
recruitment to the wound this alone is not sufficient to reverse delayed healing 
in Ovx mice and macrophage activation may play a critical role. 
The involvement of ERα in the regulation of inflammation and the 
immune response has previously been demonstrated in a number of studies. 
Estrogen is therapeutically effective in several inflammatory and 
neurodegenerative disorders, including multiple sclerosis (MS), Parkinson’s 
disease, cerebral ataxia, epilepsy and Alzheimer’s disease (reviewed in Vegeto 
et al., 2008). Moreover, the ERα agonist PPT is both neuroprotective and anti-
inflammatory while the ERβ agonist DPN is only neuroprotective  (Tiwari-
Woodruff et al., 2007) with a number of mechanisms suggested for the effects 
(Liu et al., 2003; Polanczyk et al., 2003; Vegeto et al., 2003). The protective 
effect of estrogen in experimental autoimmune encephalomyelitis is dependent 
upon ERα in the prototypic Th1-mediated model (Liu et al., 2003; Polanczyk et 
al., 2003), while the protective effect of estrogen in acute and chronic brain 
injuries and macrophage recruitment is mediated through ERα (Vegeto et al., 
2003). ERα is required to mediate the enhancement of primary antigen specific 
CD4+ T cell expansion and Th1 development in vivo in response to estradiol 
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(Maret et al., 2003). However, ERβ is implicated as the isoform responsible for 
down-regulation of inflammation in rat carotid injury and human acute and 
chronic cardiac allograft vasculopathy (Makela et al., 1999; Savolainen et al., 
2001). The results from PPT and DPN treatment are summarised in Table 3.4. 
 
Table 3.4  Summarised results of administration of estrogen or ER 
agonists on wound healing at day 3 
 
Effect of 
Wound Healing 
Parameter Ovx ¤ +Estrogen § +DPN (ERβ) § 
+PPT (ERα) 
§ 
Wound Area ↑ ↓ ↓ ↔ 
Re-epithelialisation ↓ ↑ ↑ ↔ 
Neutrophil numbers  ↑ ↓ ↓ ↓ 
Macrophage 
numbers  ↑ ↓ ↓ ↓ 
MIF cell numbers  ↑ ↓ ↓ ↓ 
IL-6 cell numbers  ↑ ↓ ↓ ↓ 
 
¤ compared to intact, § compared to Ovx. Black arrows represent a significant change, red 
arrows represent a non-significant trend. 
 
ER knockout mice have been used extensively to elucidate the roles of 
the ERs in numerous tissues, however, the effects of global ERα or ERβ 
ablation on wound healing have, until now, never been assessed. In a number 
of pathological states one ER isoform is often more strongly implicated than the 
other. ERα expression is associated with the differentiation of human breast 
cancer cells (Herynk and Fuqua, 2004) and a repeat polymorphism in the ERα 
gene (Esr1) has been associated with an increased risk of breast cancer in 
post-menopausal women (Cai et al., 2003). The effects of estradiol on 
endometrial cancer cells are mediated through ERα via PKCα (Yang et al., 
2008), while high levels of ERα in endometrial cancer cells inhibit malignant 
growth by modulating angiogenesis, therefore acting as a protective factor in 
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cancer progression (Yang et al., 2008). Interestingly, two single nucleotide 
polymorphisms (SNPs) in the human ERβ gene (Esr2) are also associated with 
increased breast cancer risk (Zheng et al., 2003). ERβ is the predominant 
isoform in normal and malignant colon tissue and is identified in several human 
colon cancer cell lines (Arai et al., 2000; Fiorelli et al., 1999; Foley et al., 2000; 
Qiu et al., 2002), although ERβ protein levels are lower in colon tumours 
compared to normal colon tissue (Foley et al., 2000) and the loss of ERβ is 
associated with tumour cell differentiation and advanced stages of colon cancer 
(Campbell-Thompson et al., 2001; Jassam et al., 2005; Konstantinopoulos et 
al., 2003) suggesting a protective role for ERβ in colon cancer progression. ERβ 
is more highly expressed than ERα in the prostate (Harkonen and Makela, 
2004) and ERβ expression is reduced in prostate tumours (Horvath et al., 2001; 
Leav et al., 2001). The effects of estradiol are mediated via ERα in brain (Dubal 
et al., 2001; Fugger et al., 2000), bone (Saika et al., 2001) and the 
cardiovascular system (Brouchet et al., 2001; Darblade et al., 2002), and in 
obesity (Cooke et al., 2001; Heine et al., 2000; Homma et al., 2000; Ohlsson et 
al., 2000).  
Far less is known about the roles the two ERs play in skin function and 
homeostasis. Moverare et al. (2002) investigated the roles of the ERs in 
modulating epidermal thickness and hair cycling, identifying ERα as the 
principle isoform, while Ohnemus et al. (2005) have determined the importance 
of ERα in regulating the hair cycle in mice. ERα was implicated as the principal 
receptor involved in mediating the actions of 17β-estradiol in a skin flap necrosis 
model (Toutain et al., 2009). Interestingly, Chang et al. (2010) identified ERβ as 
the crucial isoform in protecting against damage in the skin caused by UV 
exposure,  while an ERβ agonist successfully maintained tail skin temperature 
in Ovx rats, in a model of post-menopausal hot flush (Opas et al., 2009).  
From my results the removal of systemic hormones has the same effect 
in WT, ERα-/- and ERβ-/- mice, ie. increase in wound area compared to intact 
(data not shown). As Ovx removes all circulating estrogen we would expect it to 
cause delayed healing in all strains, as without estrogen signalling the lack of 
ERs becomes redundant. Minor, non-significant differences in parameters 
between Ovx WT, ERα-/- and ERβ-/- mice could be due to local estrogen 
production in the skin by aromatase conversion (reviewed in Nelson and Bulun, 
2001) or ligand-independent signalling, such as IGF-1 (Klotz et al., 2002). Of 
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novel importance in the absence of ERβ (ERβ-/- mouse) systemic estrogen 
replacement does not reverse delayed healing in Ovx, and in fact, further delays 
healing.  
Non-healing wounds in post-menopausal women and Ovx mice are 
associated with an excessive and inappropriate inflammatory response, while 
estrogen replacement reverses the effect and reduces the number of 
inflammatory cells recruited to the wound site (Ashcroft et al., 1999a; Ashcroft et 
al., 2003b). In the absence of ERα (ERα-/- mouse) estrogen replacement does 
not reduce inflammation in Ovx, failing to dampen macrophage recruitment and 
the expression of the pro-inflammatory cytokines MIF and IL-6. This result 
suggests that ERα is required for estrogen-regulated macrophage recruitment 
While ERα appears to be the regulating factor in the effects of estrogen on 
macrophage recruitment the opposite appears to be apparent as far as 
neutrophils are concerned. Estrogen replacement in ERα-/- mice had no effect 
on neutrophil recruitment, while in ERβ-/- mice wound neutrophils were 
increased. 
Estrogen is a known keratinocyte mitogen (Son et al., 2005; Verdier-
Sevrain et al., 2004), accelerating keratinocyte migration in vitro and re-
epithelialisation in vivo, and is therefore a key determinant in the delayed 
healing seen in mice and humans suffering from estrogen deficiency. My data 
suggests that while estrogen replacement in female ERβ-/- mice has a 
detrimental effect on wound healing as a whole, this is not due to reduced 
keratinocyte migration. Conversely, accelerated healing in ERα-/- is not due to 
accelerated re-epithelialisation. Thus, both receptors appear to be are required 
for the beneficial affects of estrogen on keratinocyte migration in vivo. Merlo et 
al. have reported accelerated migration of human keratinocytes in vitro following 
treatment with either 10 nM 17β-estradiol, PPT or DPN across an artificial 
scratch between 5 and 24 hours after wounding (Merlo et al., 2009). My data 
indicate that 17β-estradiol and DPN promote murine keratinocyte (and 
fibroblast) in vitro migration, while PPT had a non-significant effect. The differing 
species (human cell line vs murine primary cells) and treatment concentrations 
(100 nM (PPT), 1 nM (DPN) vs. 100 nM PPT and 100 nM DPN) may explain the 
difference in results. 
The results from the estrogen receptor knockout experiments are 
summarised in Table 3.5. 
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Table 3.5  Summarised results of administration of estrogen on wound 
healing in ERα-/- and ERβ-/- and wild-type (WT) littermates at day 3 
 
Effect of estrogen replacement in 
Wound Healing 
Parameter 
WT ¥ ERα-/- ¤ ERβ-/- § 
Wound Area ↓ ↓ ↑ 
Re-epithelialisation ↑ ↔ ↔ 
Neutrophil numbers  ↓ ↔ ↑ 
Macrophage numbers  ↓ ↑ ↓ 
MIF cell numbers ↓ ↑ ↓ 
IL-6 cell numbers  ↓ ↑ ↓ 
 
¥ compared to Ovx WT, ¤ compared to Ovx ERα-/-, § compared to Ovx ERβ-/-. Black arrows 
represent a significant change, red arrows represent a non-significant trend. 
 
In conclusion, in the absence of ERβ estrogen replacement severely 
delays healing, while in the absence of ERα, estrogen signalling through ERβ 
alone is beneficial to healing but has influences on inflammation. This suggests 
a clear uncoupling of inflammation and overall wound repair, and highlights the 
significance of other phases of repair. 
The results from this study are important in light of the Women’s Health 
Initiative (WHI) and the Million Women Study (MWS), which have emphasised 
the detrimental side-effects of estrogen treatment in post-menopausal women. 
ER isoform selective compounds (Selective Estrogen Receptor Modulators) are 
presently in clinical use for the treatment of some pathologies, such as breast 
cancer and osteoporosis. The potential of these SERMs in the context of wound 
healing will be discussed in the next chapter. Future pre-clinical studies may be 
able to utilise these results to activate one isoform over the other in the skin, to 
promote efficient healing. 
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4 THE THERAPEUTIC POTENTIAL OF SERMS 
IN WOUND HEALING 
 
 
 
 
The majority of the results presented in this chapter also appear in the following 
publications: 
 
Selective estrogen receptor modulators accelerate cutaneous wound 
healing in ovariectomized female mice (2008). Endocrinology 149, 551-7. 
 
Authors: Matthew. J. Hardman, Elaine Emmerson, Laura Campbell, and Gillian. 
S. Ashcroft. 
 
Author Contributions: MH was involved in experimental design, surgical 
procedures, carried out experiments, analysed results and was involved in 
manuscript preparation. EE was involved in experimental design, surgical 
procedures, carried out experiments, analysed results and was involved in 
manuscript preparation. LC was involved in surgical procedures. GA was 
involved in experimental design and manuscript preparation.  
 
The phytoestrogen genistein promotes wound healing by multiple 
independent mechanisms (2010). Mol Cell Endocrinol 321,184-193. 
 
Authors: Elaine Emmerson, Laura Campbell, Gillian. S. Ashcroft and Matthew. 
J. Hardman. 
 
Author Contributions: EE was involved in experimental design, surgical 
procedures, carried out experiments, analysed results and was involved in 
manuscript preparation. LC was involved in surgical procedures. GA was 
involved in experimental design and manuscript preparation. MH was involved 
in experimental design and manuscript preparation. 
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4.1 Introduction 
 
Cutaneous wound repair is a complex sequence of overlapping phases 
following injury, including haemostasis, inflammatory cell migration, 
angiogenesis, matrix deposition. The skin acts as a target for estrogenic action 
and estrogens play an important role in many, if not all, of these stages. In the 
absence of estrogen healing is significantly delayed and this can be reversed 
when estrogen is replaced, either exogenously or topically in animal models and 
humans (Ashcroft et al., 1997a; Ashcroft et al., 1999a). 
 There are three major naturally occurring estrogens in women: estriol, 
estradiol and estrone. All three possess a core aromatic ring, which facilitates 
binding to the ERs (Brzozowski et al., 1997). Estrogen is active in numerous 
target tissues, most noticeably those involved in reproduction (e.g. uterus, ovary 
and breast). Estrogen levels fall significantly during menopause and lead to a 
higher incidence of multiple pathologies involving non-reproductive tissues, 
such as osteoporosis or cardiovascular disease (Colditz et al., 1987; Melton et 
al., 1992). With increasing life expectancy the majority of women who live in the 
developed world now spend a significant portion of their lives in a state of 
systemic estrogen deprivation, post-menopause (Barrett-Connor, 1995). 
Hormone replacement therapy (HRT) was developed as a treatment for peri-
menopause symptoms (e.g. hot flushes) that also protects against the 
development of chronic pathology (e.g. osteoporosis). However, recent 
research has highlighted the risks associated with prolonged use of HRT, 
including breast cancer, stroke and heart disease (Anderson et al., 2004; Nabel, 
2006). Such studies emphasise the urgent need to develop safer alternatives to 
estrogen in physiological responses. 
The structural and functional skin changes that occur after the 
menopause are well characterised. Estrogen maintains skin thickness and 
collagen content (Brincat et al., 1987), homeostasis (reviewed in Verdier-
Sevrain et al., 2006) and regulates cutaneous wound healing (Ashcroft et al., 
1997a; Ashcroft et al., 1999a; Hardman and Ashcroft, 2008). Estrogen 
replacement accelerates healing by stimulating epithelialisation, reducing 
inflammation and enhancing matrix deposition (Ashcroft et al., 1997a; Ashcroft 
et al., 1999a).  
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As outlined in the previous chapter estrogen signals through two nuclear 
hormone receptors, estrogen receptors alpha and beta (ERα and ERβ) (Enmark 
and Gustafsson, 1999). Each ER has three functional domains: the 
transactivation function domain, DNA binding domain (DBD) and the ligand 
binding domain (LBD). The ligand binding cavity of the ERs is large, twice the 
volume of estradiol (Brzozowski et al., 1997). The aromatic rings of estriol, 
estradiol and estrone facilitate binding to the ERs, while steroids lacking an 
aromatic ring have a much lower binding affinity for ER (Delettre et al., 1980). In 
estradiol, the presence of two hydrogen bonds also assists in binding the 
structure to the ER by the means of non-polar hydrophobic interactions between 
the estradiol structure and the receptor (Nakai et al., 1999) making a high-
affinity bond.  
It has been proposed that tissue specific variations in the effects of 
estrogen are due to a) differential expression of each ER isoform, and b) 
differential expression of a range of co-factors and co-repressors (McKenna and 
O'Malley, 2001). Results from the previous chapter indicate very different roles 
for the two ERs in the context of wound healing. Supporting this, recent 
evidence indicates that a repeat polymorphism in the human ERβ gene is 
significantly associated with venous ulceration in the British Caucasian 
population and that a specific ERβ variant is associated with impaired healing in 
the elderly. Variation in the regulatory region of the ERβ gene may predispose 
those in the British Caucasian population to venous ulceration. Interestingly, 
variations in the ERα gene have no effect on wound repair (Ashworth et al., 
2005, 2008). The low degree of homology seen in the ligand binding domains of 
the two ER subtypes suggests that they are no more similar than receptor pairs 
with different ligands, such as the progesterone receptor and the glucocorticoid 
receptor (reviewed in Enmark and Gustafsson, 1999). This has very important 
clinical implications for targeting one specific ER pathway in treatment of 
disease. The differential expression of the two ER isoforms throughout tissues 
of the body is increasingly being exploited for therapeutic use: an excellent 
example of which is the use of Selective Estrogen Receptor Modulators 
(SERMs), which rely on ligands binding to the ERs and exhibiting selective 
tissue specific activity (Klotz et al., 2000).  
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4.1.1 Selective Estrogen Receptor Modulators 
 
SERMs are compounds that are able to bind to the ER and exploit 
natural estrogen signalling mechanisms to confer tissue specific estrogenic or 
anti-estrogenic effects. SERMs that are structurally similar to each other can 
display diverse functions in tissues with different co-activators and repressors 
(McKenna and O'Malley, 2001). SERMs have been developed to confer 
estrogen-like beneficial effects, to treat disorders such as osteoporosis, while 
this tissue specific approach should bypass systemic estrogen risks, including 
breast cancer (Matsumoto, 2006). Indeed, SERMs are distinguished from pure 
ER agonists and antagonists by their differing actions in various tissues. 
SERMs are a chemically diverse group of compounds that do not have the 
steroid structure of estrogens but instead possess a tertiary structure that allows 
them to bind to the ER LBD (Riggs and Hartmann, 2003), most notably an 
aromatic ring (Brzozowski et al., 1997). Arguably the two most well 
characterised and commonly used SERMs are tamoxifen and raloxifene. Both 
are considered ER antagonists in the breast, but have the potential to act as ER 
agonists in other tissues (Frasor et al., 2004). This ability is, in part, dependant 
on the cell and tissue specific profile of co-activator/repressors. For example, 
helix 12 of ERα cannot bind raloxifene to the hydrophobic pocket because the 
anti-estrogenic side chain interacts with ASP 351 which ultimately blocks co-
activator binding (Manni and Verderame, 2002). 
 The pharmacology of SERMs can be explained by three different 
mechanisms: 1) differential ER expression in the target tissue; 2) differential ER 
conformation after binding of the ligand; and 3) differential expression and 
binding of the co-regulator proteins to the ER. Firstly, target cells contain tissue-
specific levels of ERα or ERβ homodimers, and α/β heterodimers. The relative 
levels of expression of the two isoforms affects cellular responsiveness to 
estrogen and estrogenic compounds (Hall and McDonnell, 1999; Pettersson et 
al., 2000; Riggs and Hartmann, 2003). Secondly, it has been shown, by protein 
crystallography, that estradiol and SERMs cause ligand-specific conformational 
changes when bound to the ER (Paige et al., 1999; Riggs and Hartmann, 
2003). And finally, more than 20 co-regulator proteins that bind to ERs have 
been discovered (McKenna et al., 1999; Norris et al., 1999). In fact, the SERMs 
tamoxifen and raloxifene act in an antagonistic manner in some tissues by 
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sequestering a critical AF-2 helix 12, in an inhospitable conformation for steroid 
co-activator binding (Shiau et al., 1998). In addition, recent evidence now 
indicates that anti-estrogens may act not only by repressing co-activator 
binding, but also by promoting co-repressor binding which represses gene 
transcription (Nettles and Greene, 2005; Shiau et al., 1998; Torchia et al., 
1998). The activity of a SERM on the ER may be sensitive to the competing 
pool of co-activators and co-repressors in the tissue (McKenna et al., 1999). For 
example, conformational changes in ERα as the result of tamoxifen binding 
promotes interactions with the co-activator PGC-1β enabling co-operation with 
the ER co-activator SRC-1 and ultimately resulting in tamoxifen ER agonism 
(Kressler et al., 2007). It is thought that tamoxifen inhibits the transcription of 
genes regulated by the estrogen responsive element (ERE) but activates 
transcription of genes that are under the control of an AP1 promoter (Webb et 
al., 1995). A clearer understanding of the agonistic and antagonistic properties 
of SERMs will lead to the development of safer and tissue specific compounds.  
 
4.1.2 History of SERMs 
 
First generation SERMs include tamoxifen, droloxifene, toremifene and 
idoxifene and are collectively known as Triphenyethylenes (reviewed in Manni 
and Verderame, 2002). They were the first SERM compounds to be designed 
and produced, primarily as anti-estrogens. Droloxifene was tested in the 1990s 
for effectiveness at preventing bone loss in ovariectomised rodents (Ke et al., 
1995), toremifene was designed as a treatment for late stage metastatic breast 
cancer in the late 1980s (Kangas et al., 1985) and idoxifene was trialled as a 
breast cancer treatment in the early 1990s (Chander et al., 1991). However, use 
of droloxifene and idoxifene has stopped following evidence of side effects 
(Fleischer et al., 1999; Pickar et al., 2010). Second generation SERMs include 
raloxifene and LY 353381, collectively known as Benzothiophenes (reviewed in 
Manni and Verderame, 2002). Both were trialled in the late 1990s for their 
effectiveness at reducing weight increase and cholesterol, and preventing bone 
loss in post-menopausal women (Sato et al., 1998).  
Third generation SERMs include lasofoxifene, developed by Pfizer for 
the treatment of osteoporosis and vaginal atrophy in post-menopausal women. 
Lasofoxifene demonstrated a significant improvement in bone density in phase 
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II and III clinical trials (McClung et al., 2006) and Pfizer subsequently applied for 
approval from the Food and Drug Administration, USA (FDA) in 2004, but were 
denied in 2005 due to fears over higher death rates in treated women (Gennari, 
2005; Gennari et al., 2006). Ormeloxiphene, more commonly known as 
Centchroman, was developed to treat irregular uterine bleeding, but is now 
used as a contraceptive (Singh, 2001). Fourth generation SERMs include EM-
652 and EM-800 and are collectively known as Benzopyrans (Manni and 
Verderame, 2002). EM-652 was developed as a breast cancer treatment, with 
the view to minimal risks of endometrial cancer (Labrie et al., 2001) while EM-
800 was developed to treat tamoxifen-resistant breast cancers (Labrie et al., 
2004). In addition, EM-800 is the precursor to acolbifene, presently in phase II 
clinical trials for the prevention of breast cancer in pre-menopausal women (Al-
Dhaheri et al., 2006). New generation SERMs include ospemifene, which is 
being developed for the treatment of vaginal atrophy in post-menopausal 
women (Voipio et al., 2002). Hormos Medical (subsidiary of QuatRx, Finland) 
have successfully completed Phase III trials for ospemifene under the brand 
name Ophena™. 
 
4.1.2.1     Tamoxifen 
 
Tamoxifen, the first SERM to be developed, was approved by the FDA in 
1977. It contains one aromatic ring, like the estrogens, which allows binding to 
the ERs (Figure 4.1). The effect of tamoxifen depends on the cell type, ERE-
promoter context, and ER subtypes; tamoxifen binds to both mammalian ERα 
and ERβ (Ball et al., 2009; Watanabe et al., 1997).  
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Tamoxifen is administered orally for the prevention and treatment of early 
and advanced breast cancer in pre- and post-menopausal women (Riggs and 
Hartmann, 2003) due to its antagonistic activity in the breast (Jordan, 2003). 
Interestingly, tamoxifen has also been found to reduce the occurrence of bone 
fractures in women with a high risk of breast cancer (Gail et al., 1999). Studies 
have demonstrated maintained bone density in tamoxifen treated rats (Jordan 
et al., 1987), results which have since been supported in human studies (Fisher 
et al., 2005). Tamoxifen acts as an estrogen agonist in the uterus (McInerney 
and Katzenellenbogen, 1996) dependent on the presence of Steroid Receptor 
Co-activator-1 (SRC-1) (Shang and Brown, 2002). Unfortunately, this uterine 
agonistic activity means that treatment is associated with an increased risk of 
endometrial cancer, in addition to increasing other side effects such as the risk 
of deep-vein thrombosis and pulmonary embolism (Fisher et al., 2005).  
 
4.1.2.2      Raloxifene 
  
Raloxifene is also an oral SERM, first used for the prevention of 
osteoporosis in post-menopausal women. It was subsequently shown to be 
effective at preventing breast cancer without increasing the risk of endometrial 
cancer (Cummings et al., 1999), a major disadvantage of tamoxifen treatment. 
O 
N CH3 
CH3 
CH3 
Figure 4.1. Structure of the SERM tamoxifen (figure drawn by the author [EE]) 
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Raloxifene contains one aromatic ring, similar to estradiol and tamoxifen, which 
allows binding to the ERs (Figure 4.2).  
 
 
 
 
 
 
 
 
 
 
 
 
Raloxifene binds to both ERα and ERβ with high affinity, but appears to 
be more selective for ERβ (Ball et al., 2009; Kuiper et al., 1998). It has anti-
estrogenic effects on breast and endometrial tissue and estrogenic effects on 
bone, lipid metabolism, and blood clotting (reviewed in Riggs and Hartmann, 
2003). Raloxifene was approved for use by the FDA in 1998 for the treatment of 
osteoporosis. However, it is ineffective at treating many symptoms of the peri-
menopause, the period during the onset of menopause where most symptoms 
are experienced, and specifically worsens hot flushes  (Cohen and Lu, 2000). 
 
4.1.2.3     Genistein 
 
The high consumption of soy-rich foods by the Asian population has 
been linked to a reduced risk of chronic diseases in many epidemiological 
studies (reviewed in Setchell, 1998). This protective function has been 
attributed, at least in part, to isoflavones, such as genistein. Genistein is a 
SERM and a naturally occurring phytoestrogen, primarily found in soy products. 
The structure of phytoestrogens, the presence of one aromatic ring with a 
hydroxyl group able to bind two α-helices of both ERs means they can exhibit 
both ER-mediated agonistic effects (Kuiper et al., 1998) and anti-estrogenic 
antagonistic effects (Dang et al., 2003) (Figure 4.3).  
 
Figure 4.2. Structure of the SERM raloxifene (figure drawn by the author [EE]) 
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The binding affinity of genistein is 60-fold higher for ERβ than ERα 
(Nikov et al., 2000) yet is much lower than that of estrogen. Numerous studies 
suggest that genistein has beneficial effects on human diseases (Cassidy et al., 
2006; Goldwyn et al., 2000) including cancer, osteoporosis (Newton et al., 
2006) and cardiovascular disease in post-menopausal women (Atteritano et al., 
2007; Villa et al., 2009).  
 
4.1.3 The ERE-luciferase reporter mouse 
 
The ERE-luciferase reporter mouse model is a transgenic mouse that 
expresses a luciferase reporter gene when estrogen receptors are activated via 
the estrogen responsive element (ERE) (classical estrogen signalling) and is 
used to determine in vivo estrogen receptor activity. The construct consists of 
the reporter gene driven by a dimerised estrogen-responsive element (ERE) 
and a minimal promoter (TK) (Ciana et al., 2001) (Figure 4.4). 
 
 
 
 
 
 
 
 
 
Figure 4.3. Structure of the SERM genistein (figure drawn by the author [EE]) 
 
OH 
OH O HO 
O 
 180
 
 
 
 
 
 
 
 
 
 
Several other SERMs have previously been profiled in this mouse model 
(Rando et al., 2010), however, not in the context of skin and wound healing. 
SERM activity has been profiled in bone (Maru et al., 2009), endometrium 
(Singleton et al., 2003) and breast (Shaw et al., 2006) using the ERE-luc mouse 
in vivo, while effects have been investigated in MCF7 ERE-luc cells in vitro 
(Joung et al., 2003). 
The estrogen receptors (ERs) and luciferase activity colocalise in the 
ERE-luc mouse in vivo and bioluminescence is intensified with increasing 
estrogen concentration (Ciana et al., 2001). Ciana et al. (2003) established that 
there is estrogen receptor activity in both reproductive and non-reproductive 
tissues using the ERE-luc mouse and the peak transcriptional activity of 
estrogen receptors in reproductive tissues occurs at proestrus, whereas in bone 
and brain the peak occurs at diestrus. The ERE-luc mouse is an ideal model for 
visualising and determining real time ER activation in a live animal, in vivo. 
 
4.1.4 Aims of the Chapter 
 
The replacement of estradiol in estrogen-deprived post-menopausal 
women or Ovx mice significantly accelerates healing (Ashcroft et al., 1997a; 
Ashcroft et al., 1999a; Ashcroft et al., 2003b). However, systemic estrogen 
replacement in post-menopausal women has been linked to a substantial risk of 
breast cancer, stroke and coronary heart disease (Anderson et al., 2004; Nabel, 
2006). SERMs, such as tamoxifen and raloxifene, have been developed for 
their anti-estrogenic activity, specifically in the breast, yet also display 
estrogenic activity in a limited number of peripheral tissues. Both compounds 
MAR MAR ERE2X TK Luciferase 
+/- +/- 
Figure 4.4. pERE vector used for the generation of ERE-luc transfected cells (figure 
modified from Ciana et al., 2001, drawn by the author [EE]). The vector consists of the 
reporter gene (luciferase), a dimerised ERE element (ERE2X) and a minimal promoter (TK). 
 
 181
are currently in clinical use in post-menopausal women yet their activities in the 
skin and in cutaneous repair have never been assessed. Similarly, the effects of 
the phytoestrogen genistein on the skin are poorly understood and have never 
been assessed with respects to wound repair. 
Using a well characterised model of post-menopause, the Ovx mouse, 
the effect of these SERMs on in vivo wound healing and separate phases of 
wound repair was investigated, and compared to systemic estrogen 
replacement. 
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4.2 Materials and Methods 
 
4.2.1 Animal Experiments 
 
The second study was performed to investigate the effects of depletion of 
sex steroid hormones and replacement with the Selective Estrogen Receptor 
Modulators (SERMs) tamoxifen, raloxifene and genistein on the rate of wound 
healing. 
36 specific pathogen-free (SPF), female C57/BL6 mice, at 8 weeks old, 
were used and split into 6 groups with 6 animals in each (Table 4.1). Five of the 
groups (30 animals) were ovariectomised using the protocol described in 
section 2.1.4, and the remaining group (6 animals) were left with intact ovaries. 
For the estrogen treated group a slow release (0.05 mg/21 day) 17β-
estradiol pellet (Innovative Research, USA) was inserted subcutaneously in the 
scapula region, using a trocar, on the day of wounding. Tamoxifen citrate, 
raloxifene hydrochloride and genistein (Tocris, Bristol, UK, Catalogue numbers 
0999, 2280 and 1110 respectively) were re-suspended in DMSO (Sigma 
Aldrich, UK) initially and then corn oil (Sigma Aldrich, UK) in the ratio of 5% 
DMSO to 95% oil. Stock solutions of 5mg/ml tamoxifen, 2mg/ml raloxifene and 
15 mg/ml genistein were prepared. Vehicle injections were comprised of 5% 
DMSO and 95% corn oil.  Table 4.1 shows the resulting doses given per mouse 
per day. 100 µl per mouse per day was injected subcutaneously (sc), on the day 
prior to wounding (day -1), day of wounding (day 0) and one day post-wounding 
(day +1). The mice were given the treatment subcutaneously, in the scapula 
region, as this gives a steady release of the drug into the body. In addition, 
peritoneal macrophages were to be isolated from the mice post-sacrifice, for 
study, and therefore it was required that the treatments to not directly affect the 
peritoneal cavity.  
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Table 4.1 Experimental animals used and treatment groups 
 
Group Treatment Administration 
method and dosage 
Period of 
treatment 
Day of 
harvesting 
post-
wounding 
Number 
of mice 
1 Intact - - 3 6 
2 Ovx (+vehicle) 100 µl sc vehicle injections 
Daily for 3 days 
starting 1 day 
before wounding 
3 6 
3 Ovx + estrogen sc pellet (21 day slow 
release) 0.05mg 
Pellet inserted at 
time of wounding 3 6 
4 Ovx + tamoxifen 
100ul sc injections, 
500ug/mouse/day 
Daily for 3 days 
starting 1 day 
before wounding 
3 6 
5 Ovx + 
raloxifene 
100ul sc injections, 
200ug/mouse/day 
Daily for 3 days 
starting 1 day 
before wounding 
3 6 
6 Ovx + genistein 100ul sc injections, 1.5mg/mouse/day 
Daily for 3 days 
starting 1 day 
before wounding 
3 6 
 
The first group (Intact) were controls and were untreated (no intervention was carried out except 
wounding). Ovx = ovariectomised, sc = subcutaneous. 
 
 
The second half of this study was performed to investigate the effects of 
blocking the estrogen receptors (ERs) with ICI or blocking the Insulin-like 
Growth Factor-1 receptor (IGF-1R) with JB3 on the activity of genistein in 
wound repair. ICI 182780, is an ER antagonist that, due to its commonalities in 
structure with estradiol, binds to both ERs and inhibits binding by other 
estrogens (Wakeling et al., 1991). JB3 is a 12 amino acid peptide antagonist for 
the IGF-1R (Haylor et al., 2000). 
30 specific pathogen-free (SPF), female C57/BL6 mice, at 8 weeks old, 
were used and split into 6 groups with 5 animals in each (Table 4.2). All animals 
were ovariectomised using the protocol described in section 2.1.4. The estrogen 
and genistein treated groups were treated as before. ICI (Tocris, Catalogue 
number 1047) and JB3 (custom made, Invitrogen) (sequence from Haylor et al., 
2000) was re-suspended in DMSO and corn oil in the ratio of 95% to 5%. Table 
4.2 shows the resulting doses given per mouse per day. 100 µl of each 
compound was injected subcutaneously, on the day prior to wounding (-1), day 
of wounding (0) and one day post-wounding (+1) or, in the case of JB3, 50µl per 
wound injected locally at the wound site at days -1, 0, +1 and +2. 
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Table 4.2 Experimental animals used and treatment groups 
 
Group Treatment Administration method 
and dosage 
Period of 
treatment 
Day of 
harvesting 
post-
wounding 
Number 
of mice 
1 Ovx (+vehicle) 100 µl sc vehicle injections 
Daily for 3 days 
starting 1 day 
before 
wounding 
3 5 
2 Ovx + 
estrogen 
sc pellet (21 day slow 
release) 0.05mg 
Pellet inserted 
at time of 
wounding 
3 5 
3 Ovx + 
estrogen + ICI 
sc pellet (21 day slow 
release) 0.05mg and 
60ug/mouse/day ICI 
Pellet inserted 
at time of 
wounding. 
Daily ICI 
injections for 3 
days starting 1 
day before 
wounding 
3 5 
3 Ovx + genistein 
100ul sc injections, 
1.5mg/mouse/day 
Daily for 3 days 
starting 1 day 
before 
wounding 
3 5 
4 Ovx + genistein + ICI 
100ul sc injections, 
1.5mg/mouse/day 
genistein and 
60ug/mouse/day ICI 
Daily for 3 days 
starting 1 day 
before 
wounding 
3 5 
5 
Ovx + 
genistein + 
JB3 
100ul sc injections, 1.5 
mg/mouse/day 
genistein and 
0.9ug/mouse/day JB3 
Daily for 3/4 
days starting 1 
day before 
wounding 
3 5 
 
Ovx = ovariectomised, sc = subcutaneous. 
 
 
The mice were anaesthetised with isoflurane, oxygen and nitrous oxide 
inhalation and wounded following the protocol in chapter 2.1.5.1. The animals 
were given buprenorphine (0.1 mg/kg) as analgesia. 
 
4.2.2 Tissue harvest 
 
Blood, wound tissue, normal skin, peritoneal macrophages and uterus 
was collected from each animal, as described in section 2.1.6.  
 
4.2.3 Wound Processing and Immunohistochemistry 
 
 Each wound was bisected and one half of each wound was placed in a 
formalin fixative solution and the other snap frozen in liquid nitrogen. The fixed 
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half of each wound was processed, embedded, sectioned and stained as 
described in sections 2.1.8 and 2.1.9.  
 
4.2.4 Image Analysis 
 
 Images were captured from all stained sections and measurements 
taken at x4 and x20 magnification. The images were analysed and 
measurements taken using Image Pro-Plus software (Media Cybernetics, 
Finchampstead, UK) as described in section 2.1.11. 
 Statistical analysis was performed as described in section 2.8. 
 
4.2.5 Peritoneal Macrophage Culture 
 
Peritoneal macrophages were isolated from untreated C57/BL6 mice by 
intraperitoneal lavage with ice cold sterile PBS, as described in sections 2.1.6 
and 2.1.7, and pooled. Cell viability was determined by Trypan blue. 106 cells 
per ml in suspension in serum-free phenol-red free DMEM medium were treated 
with LPS (1 mg per ml) and consecutive 10-fold dilutions of 17β-estradiol 
(Sigma Aldrich), tamoxifen or raloxifene (Tocris), reconstituted in ethanol (stock 
solutions) and subsequently diluted in PBS (Sigma Aldrich). Cells were washed, 
0.5ml of Trizol (Invitrogen) added per well and stored at -80°C prior to RNA 
extraction.   
 
4.2.6 RNA Isolation and qPCR 
 
RNA was isolated from cultured macrophages and wound tissue as 
described in section 2.3. cDNA was transcribed and qPCR run using primers for 
Mif, Tnfα, Il-6, ERα and ERβ (see Table 2.7) 
 
4.2.7 Western Blot Analysis 
 
 Total protein was extracted from homogenised mouse wound tissue 
following the protocol described in section 2.4, and Western blot analysis was 
performed to determine the relative levels of ERK1 and pERK. 
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4.2.8 Zymography 
 
Protein samples were prepared in addition to those used for Western blot 
analysis. Zymography was performed using protein samples, as described in 
section 2.5, to assess the activity of MMP9 in tissue samples. 
 
4.2.9 Capture of luciferase activity in vivo in ERE-luc mice 
 
 ERE-luciferase mice were kindly donated by Adrianna Maggi, 
Pharmacology Department, Centre of Excellence on Neurodegenerative 
Diseases, University of Milan. The ERE-luc mice were imaged to detect 
bioluminescence from the luciferase activity, in presence of the substrate 
luciferin. The mice were anaesthetised and received an intra-peritoneal injection 
of 50 µl of an aqueous solution of luciferin (beetle luciferin potassium salt; 
Promega, 25 mg/kg) 15 minutes prior to image capture and bioluminescence 
quantification. The luciferin was given intra-peritoneally to result in a fast uptake 
into the body. The mice were placed in a lightproof chamber coupled to a Night 
Owl imaging unit (Berthold Technologies, Bad Wildbad, Germany) consisting of 
a Peltier cooled charge-coupled device (CCD) slow-scan camera, with a 25 
mmf/0.95 lens. A gray-scale image of the animals was initially taken with 
dimmed light, using a Night Owl LB981 image processor, and transferred via 
video cable to a peripheral component interconnect (PCI) frame grabber using 
WinLight software (Berthold Technologies). 
  An acquisition was then taken for 5 minutes to determine the 
bioluminescence. To colocalise the bioluminescent photon emission on the 
animal body, gray-scale and pseudocolour images were merged using 
WinLight32 imaging software (Berthold Technologies). Luminescence 
measurements were expressed as the integration of the average 
brightness/pixel unit visualised with the imaging unit. The images were 
generated by a Night Owl LB981 image processor and transferred via video 
cable to a PCI frame grabber using WinLight software (Berthold Technologies) 
(Ciana et al., 2005). 
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4.2.10  Analysis of luciferase activity in ERE-luc tissue 
 
The Promega luciferase assay used is a sensitive and rapid assay for the 
quantification of firefly luciferase. The cells which contain luciferase must be 
lysed before the addition of any reagents. The frozen tissue (wound, normal 
skin or liver [positive control]) was pulverised into a fine powder by hand 
grinding using a pestle and mortar with liquid nitrogen. Liver was used as a 
positive control, as it has been established by Rando et al. (2009) that liver 
gives a very strong signal in ERE-luc mice. 500 µl of Passive Lysis Buffer x1 
was added to the tissue and pipetted into a clean eppendorf tube and vortexed 
for 15 minutes at 4 ˚C. The tubes were flash frozen and thawed 3 times using 
alternating liquid nitrogen and a 37 ˚C heating block (Techne Dri-Block DB.20). 
Samples were centrifuged for 3 minutes at 5,500 G, the supernatant removed 
using a pipette and transferred to a new eppendorf tube (Wood, 1990). The 
extracts were stored at -80 ˚C 
20 µl of each sample was pipetted into a tube and using a luminometer 
(Berthold Technologies Lumat LB 9507) a luciferase assay was performed. The 
Lumat LB 9507 injected 100µl of Luciferase assay buffer (Promega) into each 
tube and the level of firefly luciferase was measured and quantified. 
 
4.2.11  Protein Assay 
 
 A protein assay was performed on all the supernatant samples to 
normalise tissue protein concentrations. The assay was performed using a 
Pierce BCA Protein assay kit (Perbio) in a 96 well plate. The BCA Protein Assay 
is a colourimetric assay that is able to detect and quantify total protein. The 
assay combines the reduction of Cu2+ to Cu1+ by protein, in an alkaline solution, 
with the selective colourimetric detection of the Cu1+ ions. A purple colour is 
produced by the chelation of 2 BCA molecules with 1 Cu1+ ion. The water 
soluble complex exhibits an absorbance at 562 nm, which is almost linear with 
increasing protein concentrations, from 20 to 2000 µg/ml (Smith et al., 1985). 
10 standard solutions with known protein concentrations were prepared 
from bovine albumen and analysed in duplicate to enable a calibration curve to 
be drawn. A trial was used with the standard solutions and a selection of 
samples to determine what dilution of the samples to use for the assay so that 
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the values would be in the range of the standard and the concentrations could 
be determined.  
25 µl of sample and 200 µl of Reagent A plus Reagent B (made up in a 
ratio of 1:50) was pipetted into each well. The plate was covered with film and 
incubated for 30 minutes at 37 ˚C. After incubation the plate was read at a 
wavelength of 570 nm, and a calibration curve drawn from the readings from the 
standard solutions. The concentrations of protein in each sample were recorded 
and the assay performed again for duplicate readings and an average 
calculated. 
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4.3 Results 
 
4.3.1 The effect of Selective Estrogen Receptor Modulators (SERMs) on 
wound repair 
 
4.3.1.1 Wound Measurements 
 
Wound area and percentage re-epithelialisation was determined from 
Haematoxylin & Eosin (H&E) stained sections using Image Pro Plus software, 
(as described in Section 2.1.11 and Figure 2.3). In this study (as previously 
reported) (Gilliver and Ashcroft, 2007; Hardman et al., 2005) (Chapter 3) 8-
week-old ovariectomised (Ovx) mice exhibited large delayed healing wounds at 
3 days post-wounding, compared to mice with intact ovaries (p<0.01), 
confirmed by quantification from H&E stained sections (Figure 4.5. A and B). 
When systemic estrogen was replaced, via subcutaneous 17β-estradiol pellet, 
wound size was reduced to that of intact animals (p<0.01 compared to Ovx), 
confirming the beneficial effect of estradiol (Ashcroft et al., 1997a; Ashcroft et 
al., 1999a). Of note, the SERMs tamoxifen, raloxifene and genistein all 
significantly accelerated wound repair in Ovx mice (p<0.05, p<0.05 and p<0.01, 
respectively compared to Ovx) (Figure 4.5. A and B). 
Re-epithelialisation (again assessed using Image Pro Plus software; 
Section 2.1.11 and Figure 2.4) was retarded in the Ovx group compared to 
intact and estrogen treated groups (p<0.05) at day 3 (Figure 4.5. C), supporting 
findings from previous studies (Gilliver and Ashcroft, 2007; Hardman et al., 
2005) (Chapter 3). With the administration of tamoxifen, raloxifene or genistein 
re-epithelialisation was also significantly accelerated (p<0.05, p<0.05 and 
p<0.01, respectively compared to Ovx) (Figure 4.5.C). 
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Figure 4.5. The SERMs tamoxifen, raloxifene and genistein accelerate healing in Ovx 
mice. A. Representative Haematoxylin and Eosin stained wax sections of incisional wounds 
taken at day 3 post-wounding. Arrows indicate the edges of the wounds. B. Mean areas of 
wounds taken at day 3 post-wounding.  Wound area is significantly reduced in intact, 
+Estrogen, +Tamoxifen, +Raloxifene and +Genistein compared to Ovx. C. Mean percentage 
of re-epithelialisation of wounds taken at day 3 post-wounding. Re-epithelialisation is 
significantly accelerated in intact, +Estrogen, +Tamoxifen, +Raloxifene and +Genistein 
compared to Ovx. * indicates a significance of p<0.05, ** p<0.01. Scale bar = 200µm. 
Results are presented as mean +SEM, n=6. Ovx = ovariectomised, +E = +Estrogen, +Tam 
= +Tamoxifen, +Ral = +Raloxifene, +Gen = +Genistein. 
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4.3.2 The effect of SERMs on Inflammatory Cell Infiltration 
 
4.3.2.1 Neutrophils 
 
As previously mentioned neutrophils arrive from the peripheral circulation 
as the first stage of the inflammatory response, phagocytose bacteria and 
release proteases and ROS (James et al., 2003; Lee et al., 2003; Roy et al., 
2006). Excessive and prolonged neutrophil influx is associated with impaired 
healing in the elderly, due to the release of elastase and the production of 
excessive pro-inflammatory cytokines (Ashcroft et al., 1999a; Ashcroft et al., 
1997e; Herrick et al., 1997; Moor et al., 2009). Estrogen promotes efficient 
inflammatory cell resolution in the skin, and also reduces neutrophil influx and 
subsequent tissue damage in the vasculature (Hay et al., 2001; Xing et al., 
2004) and the liver (Shimizu et al., 2008). A purified rat anti-mouse monoclonal 
neutrophil antibody (Ly-6G, BD Biosciences Pharmingen) was used to detect 
and quantify neutrophils from tissue sections using Image Pro Plus software (as 
described in Section 2.1.11 and Figure 2.5). 
There was a significant increase in neutrophil numbers in wound tissue 
from Ovx mice compared to those with intact ovaries (p<0.05) supporting 
previous findings (Ashcroft et al., 2003b) (Figure 4.6. A and B). With systemic 
estrogen replacement this was reversed and numbers of neutrophils recruited to 
the wound were significantly reduced (p<0.01) (Figure 4.6. A and B). Our novel 
data now indicate that mice treated with systemic genistein had reduced 
numbers of neutrophils compared to Ovx, indicating efficient neutrophil 
resolution by day 3 post-wounding (Figure 4.6. A and B). Surprisingly, tamoxifen 
and raloxifene treatment failed to significantly reduce neutrophil influx, despite 
accelerating healing (Figure 4.6. A and B). 
 
4.3.2.2 Macrophages 
 
Macrophages play an essential role in the innate immune response, 
phagocytosing bacteria and foreign bodies within wounds, providing cytokines 
and growth factors, which orchestrate the inflammatory response and matrix 
remodelling (Werner and Grose, 2003). However, excessive macrophage 
recruitment has negative effects on wound repair and chronic ulcers contain 
excessive macrophages (Loots et al., 1998). A rat anti-mouse antibody (Mac-3, 
 192
BD Biosciences Pharmingen) was used to detect macrophages in the wound 
granulation tissue and quantified using Image Pro Plus software. 
Estrogen regulates macrophage recruitment in diverse systems 
[including vasculature, brain and joints (Harkonen and Vaananen, 2006; Seli et 
al., 2002)], in addition to wound repair. Supporting previous findings there was 
an increase in the number of macrophages in wound tissue from Ovx mice 
compared to those with intact ovaries (Ashcroft et al., 1997a; Ashcroft et al., 
2003b), and this was reversed by systemic estrogen treatment at the time of 
wounding (p<0.01) (Figure 4.7. A and B). While tamoxifen and raloxifene failed 
to promote neutrophil resolution both significantly reduced macrophage 
recruitment (Figure 4.7. A and B). Conversely, genistein failed to significantly 
reduce macrophage recruitment, despite accelerating repair and dampening 
neutrophil influx (Figure 4.7. A and B). Thus, despite all three compounds 
promoting overall healing there are clear differences on the inflammatory 
response.  
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Figure 4.6. Genistein reduces wound neutrophil influx in Ovx mice. A. Representative 
neutrophil immunohistochemical localisation images from wounds at 3 days post-wounding. 
Arrows indicate positive cells (neutrophils). B. Total neutrophils within the granulation tissue. 
There is a significant reduction in neutrophils in intact, +Estrogen and +Genistein compared 
to Ovx, * indicates a significance of p<0.05, ** p<0.01. Scale bar = 50µm. Results are 
presented as mean +SEM, n=6. 
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Figure 4.7. Tamoxifen and raloxifene reduce wound macrophage recruitment in Ovx 
mice. A. Representative macrophage immunohistochemical localisation images from 
wounds at 3 days post-wounding. Arrows indicate positively stained cells (macrophages). B. 
Total macrophages within the granulation tissue. There is a significant reduction in 
macrophages in intact, +Estrogen, +Tamoxifen and +Raloxifene compared to Ovx, * 
indicates a significance of p<0.05, ** p<0.01. Scale bar = 50µm. Results are presented as 
mean +SEM, n=6. 
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4.3.3 The effect of SERMs on Inflammatory Cytokine Production 
 
4.3.3.1 Macrophage Migration Inhibitory Factor (MIF) 
 
The pro-inflammatory cytokine MIF, produced by various cells (Abe et al., 
2001; Calandra et al., 1994), stimulates the production of other cytokines and 
growth factors, including TNF-α, IL-1 and IL-6 (Calandra and Bucala, 1995). As 
previously mentioned Ashcroft et al. identify MIF as a candidate master 
regulator of estrogen’s positive effects on wound healing (Ashcroft et al., 2003b; 
Hardman et al., 2005). Of interest in vivo MIF is upregulated in non-healing 
human wounds (Emmerson et al., 2009; Gilliver et al., 2010) and Ovx mouse 
wounds (Ashcroft et al., 2003b; Hardman et al., 2005), while MIF is reduced in 
wound tissue in response to estrogen replacement (Ashcroft et al., 2003b). In 
vitro estrogen directly inhibits MIF production by activated murine macrophages 
and human monocytes (Ashcroft et al., 2003b; Hardman et al., 2005). 
Using an affinity-purified goat polyclonal antibody (R&D Systems, Oxford, 
UK) MIF was immunolocalised to inflammatory cells and fibroblasts in the 
wound granulation tissue (Figure 4.8.A) and epidermal keratinocytes. At 3 days 
post-wounding granulation tissue from Ovx mice had large numbers of MIF-
positive cells, while wound tissue from intact and estrogen-treated Ovx mice 
displayed reduced MIF-positive cells (p<0.01) (Figure 4.8. A and B) as 
previously reported (Ashcroft et al., 2003b; Hardman et al., 2005). Novel data 
presented provide evidence that tamoxifen, raloxifene or genistein reduce the 
expression of wound MIF-positive cells in Ovx mice (p<0.01) (Figure 4.8. A and 
B). To assess Mif expression in wound tissue qPCR was performed using 
primers designed to the mouse Mif gene (see Table 2.7). Mif expression was 
increased in Ovx mice relative to intact animals (p<0.01), while estrogen 
replacement significantly reduced Mif (p<0.01). In agreement with 
immunolocalisation data wound tissue from tamoxifen, raloxifene and genistein 
treated Ovx mice had significantly reduced Mif expression (p<0.01) (Figure 4.8. 
C). Additionally, both tamoxifen and raloxifene dose-dependently reduced the 
relative expression of Mif by isolated mouse peritoneal macrophages in vitro 
(p<0.01), more so than equimolar 17β-estradiol (E2) (p<0.05) (Figure 4.8. D). 
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4.3.3.2 CD74 
 
CD74 has been identified as a cell surface receptor for MIF (Leng et al., 
2003) and has been localised in human macrophages and fibroblasts (Koch et 
al., 1984) both of which play central roles in the healing process. CD74 in 
granulation tissue was localised to inflammatory cells and fibroblasts in all 
treatment groups. At 3 days post-wounding Ovx wounds had large numbers of 
cells expressing CD74, which were reduced by estrogen replacement (p<0.05) 
(Figure 4.9. A and B). While tamoxifen and raloxifene non-significantly reduced 
CD74 expression, in a similar trend to estrogen, genistein failed to reduce 
positive cells compared to Ovx. There was a significant increase in CD74-
positive cells in genistein treated wounds compared to raloxifene (Figure 4.9. A 
and B), an unexpected result considering both SERMs reduced MIF expression 
to a similar extent (Figure 4.8), which suggests that CD74 expression is 
unimportant for MIF activity and overall healing. 
 
4.3.3.3 Tumour Necrosis Factor alpha (TNF-α) 
 
TNF-α, a pro-inflammatory cytokine, produced by macrophages (Nedwin 
et al., 1985), neutrophils, keratinocytes, endothelial cells and mast cells, is a 
central regulator of inflammation (Bendtzen, 1988). TNF-α is important for 
wound repair, promoting granulation tissue formation (Rapala, 1996). However, 
tight regulation is critical as excessive TNF-α can inhibit granulation tissue 
formation (Rapala et al., 1991). TNF-α in granulation tissue was localised to 
inflammatory cells. At 3 days post-wounding granulation tissue from Ovx mice 
had large numbers of TNF-α-positive cells, while estrogen replacement reduced 
numbers (p<0.01) (Figure 4.10. A and B). Novel data now indicate that 
tamoxifen, raloxifene or genistein reduce the number of wound TNF-α-positive 
cells compared with Ovx (p<0.01) (Figure 4.10. A and B). To assess Tnfα 
expression in wound tissue qPCR was carried out using primers designed to the 
mouse Tnfα gene (see Table 2.7). There was an increase in Tnfα expression in 
Ovx mice relative to intact animals (p<0.05), while estrogen, tamoxifen, 
raloxifene and genistein treated Ovx mice had significantly reduced levels of 
Tnfα expression (p<0.05 or 0.01) (Figure 4.10. C), supporting results from 
histological analysis. Additionally, 17β-estradiol and raloxifene dose-
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dependently reduced the relative expression of Tnfα by isolated peritoneal 
macrophages in vitro (p<0.01) (Figure 4.10. D). 
  
4.3.3.4  Interleukin 6 (IL-6) 
 
As described in the previous chapter IL-6 plays a crucial role in 
cutaneous repair (Akira and Kishimoto, 1992) and is expressed by 
macrophages, T cells, fibroblasts, keratinocytes and endothelial cells (Kishimoto 
et al., 1992). Healing is significantly delayed in IL-6 knockout mice (Gallucci et 
al., 2000), while wild-type mice administered with neutralising anti-IL-6 
monoclonal antibody exhibit significantly delayed wound closure (Lin et al., 
2003). IL-6 expression is down-regulated by estrogen in osteoblasts and bone 
marrow stromal cells (Stein and Yang, 1995). In this study IL-6 was localised to 
fibroblasts and inflammatory cells in granulation tissue using an affinity purified 
polyclonal antibody (R&D Systems, Oxford, UK). At 3 days post-wounding 
granulation tissue from Ovx mice had large numbers of IL-6-positive cells, while 
estrogen replacement reduced numbers (p<0.05) (Figure 4.11. A and B). 
Tamoxifen, raloxifene or genistein treatment also reduced the number of wound 
IL-6-positive cells compared with Ovx (p <0.01), to a greater extent than 
estrogen (Figure 4.11. A and B). To assess Il-6 expression qPCR was carried 
out using primers designed to the mouse Il-6 gene (see Table 2.7). There was 
an increase in Il-6 expression in Ovx mice relative to intact (p<0.05), while 
estrogen replacement significantly reduced Il-6 (p<0.05); as did tamoxifen, 
raloxifene and genistein treatment (p<0.05, 0.01 and 0.01 respectively) (Figure 
4.11. C), supporting results from histological analysis. Additionally, tamoxifen 
and raloxifene dose-dependently reduced the relative expression of Il-6 by 
isolated peritoneal macrophages in vitro (p<0.01) as effectively as estrogen 
(Figure 4.11. D).  
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Figure 4.8. SERMs reduce wound MIF expression in vivo and in vitro. A. 
Representative MIF immunohistochemical localisation images from wounds at 3 days post-
wounding. Black arrows indicate positively stained macrophages, green arrows indicate 
positively stained fibroblasts. B. Total MIF-positive cells within the granulation tissue. There 
is a significant reduction in MIF-positive cells in intact, +Estrogen, +Tamoxifen, +Raloxifene 
and +Genistein compared to Ovx. C. Relative Mif expression in wound tissue. There is a 
significant reduction in expression of MIF in intact, +Estrogen, +Tamoxifen, +Raloxifene and 
+Genistein compared to Ovx. D. Relative expression of Mif by isolated peritoneal 
macrophages in vitro, relative to untreated. There is a significant reduction in Mif expression 
between untreated and E (100nM), Tam (100nM) and Ral (100nM). * indicates a 
significance of p<0.05, ** p<0.01, with respect to Ovx or untreated. Scale bar = 50µm. 
Results are presented as mean +SEM, n=6 (B, C), n=3 (D). - = untreated, E = 17β-estradiol. 
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Figure 4.9. Tamoxifen, raloxifene and genistein fail to reduce expression of the MIF 
receptor, CD74, in Ovx wound tissue. A. Representative CD74 immunohistochemical 
localisation images from wounds at 3 days post-wounding. Arrows indicate positively stained 
cells. B. Total CD74-positive cells within the granulation tissue. There is a significant 
reduction in CD74-positive cells in +Estrogen compared to Ovx and an increase in Genistein 
compared to +Estrogen or +Raloxifene, * indicates a significance of p<0.05. Scale bar = 
50µm. Results are presented as mean +SEM, n=6.  
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Figure 4.10. SERMs reduce TNF-α expression in vivo and in vitro. A. Representative 
TNF-α immunohistochemical localisation images from wounds at 3 days post-wounding. 
Arrows indicate positive cells. B. Total TNF-α-positive cells within the granulation tissue. 
There is a significant reduction of TNF-α-positive cells in +Estrogen, +Tamoxifen, 
+Raloxifene and +Genistein compared to Ovx. C. Relative expression of Tnfα in wound 
tissue. There is a significant reduction in expression of Tnfα in intact, +Estrogen, 
+Tamoxifen, +Raloxifene and +Genistein compared to Ovx. D. Relative expression of Tnfα 
by isolated peritoneal macrophages in vitro, relative to untreated. There is a significant 
reduction in Tnfα expression between untreated and E (100nM) and Ral (100nM). * 
indicates a significance of p<0.05, ** p<0.01, with respect to Ovx or untreated. Scale bar = 
50µm. Results are presented as mean +SEM, n=6 (B, C), n=3 (D). - = untreated, E = 17β-
estradiol.  
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Figure 4.11. SERMs reduce IL-6 expression in vivo and in vitro. A. Representative IL-6 
stained immunohistochemical localisation from wounds at 3 days post-wounding. Arrows 
indicate positive cells. B. Total IL-6-positive cells within the granulation tissue. There is a 
significant reduction in IL-6-positive cells in +Estrogen, +Tamoxifen, +Raloxifene and 
+Genistein compared to Ovx. C. Relative expression of Il-6 in wound tissue. There is a 
significant reduction in expression of Il-6 in intact, +Estrogen, +Tamoxifen, +Raloxifene and 
+Genistein compared to Ovx. D. Levels of expression of Il-6 by isolated peritoneal 
macrophages in vitro, relative to untreated. There is a significant reduction in Il-6 expression 
between untreated (-) and E (100nM), Tam (10nM and 100nM) and Ral (100nM). * indicates 
a significance of p<0.05, ** p<0.01, with respect to untreated or Ovx group. Scale bar = 
50µm. Results are presented as mean +SEM, n=6 (B, C), n=3 (D). - = untreated, E = 17β-
estradiol. 
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4.3.4 The effect of SERMs on wound ERα and ERβ expression 
 
Much of the known effects of estrogen are mediated through its nuclear 
hormone receptors, ERα and ERβ. Due to the differential expression of the ERs 
in cells and tissues throughout the body SERMs such as tamoxifen, raloxifene 
and genistein are agonistic in some tissues and antagonistic in others. However 
their action in the skin has, until now, not been assessed. Estrogen and SERMs 
act by binding to homo- and hetero-dimeric ERs to induce different 
conformations of the ER (Dutertre and Smith, 2000). 
 
4.3.4.1 Estrogen Receptor-Alpha (ERα) 
 
ERα expression has been reported in human unwounded skin (Kuiper et 
al., 1997), neutrophils (Molero et al., 2002), fibroblasts (Malet et al., 1991), 
human and murine macrophages (Gulshan et al., 1990) and murine adipose 
tissue (Spong et al., 2000). Data presented in this thesis (Chapter 3) revealed 
the presence of ERα in murine keratinocytes, fibroblasts, inflammatory cells and 
hair follicles. Here, the number of cells expressing ERα in wound tissue was 
determined using a mouse monoclonal ERα antibody, mapped to the C-
terminus of human ERα (Santa Cruz, CA, USA). There was no change in either 
dermal (Figure 4.12) or epidermal (Figure 4.13) levels of ERα protein as a result 
of SERM treatment. To assess ERα expression in wound tissue qPCR was 
carried out using primers designed to the mouse ERα gene (see Table 2.7). 
Again, no significant difference was observed in the wound tissue expression of 
ERα (Figure 4.12. C). 
 
4.3.4.2 Estrogen Receptor-Beta (ERβ) 
 
ERβ expression has been reported in human dermis (Kuiper et al., 
1997), epidermis (Thornton et al., 2003a), sebaceous glands, sebocytes, and 
hair follicles (Thornton et al., 2003a, b), endothelial cells (blood vessels), 
muscle cells and fibroblasts (Thornton et al., 2003a). The number of cells 
expressing ERβ in wound tissue was determined using a mouse anti-human 
monoclonal ERβ antibody (AbD Serotec, Kidlington, UK). As before (Chapter 3) 
ERβ was detected in murine keratinocytes (basal layer), fibroblasts, 
inflammatory cells and hair follicles. 
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There was a significant increase in the number of ERβ-positive cells in 
wounds from mice treated with estrogen compared to Ovx (p<0.01) (Figure 
4.14. A and B). Interestingly, tamoxifen and genistein also significantly 
increased ERβ-positive dermal expression in Ovx mice (p<0.01 and p<0.05, 
respectively) with a non-significant trend toward an increase with raloxifene 
(Figure 4.14. A and B). There were significantly more ERβ-positive cells in peri-
wound epidermis in intact and estrogen treated wounds, compared to Ovx. Of 
significance, tamoxifen, raloxifene and genistein all increased expression of 
epidermal ERβ compared to Ovx (Figure 4.15. A and B). 
To assess ERβ expression in wound tissue qPCR was carried out using 
primers designed to the mouse ERβ gene (see Table 2.7). Despite results from 
immunohistochemical analysis there was no significant difference in the 
expression of ERβ in wound tissue, but a trend toward an increase with 
estrogen, raloxifene and genistein treatment (Figure 4.14. C). Thus, estrogen 
and SERMs preferentially induced dermal and epidermal cellular expression of 
ERβ (Figure 4.14 vs 4.12). This is fascinating in light of the results from the 
previous chapter and the publication of studies demonstrating the importance of 
ERβ in healing (Ashworth et al., 2005, 2008).  
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Figure 4.12. Tamoxifen, raloxifene and genistein do not alter wound ERα expression 
A. Representative ERα immunohistochemical localisation images from wounds at 3 days 
post-wounding. Arrows indicate positive cells. B. Total ERα-positive cells within the 
granulation tissue. Statistical test result p>0.05 and therefore not significant. C. Relative 
expression of ERα in wound tissue. Statistical test result p>0.05 and therefore not 
significant. Scale bar = 50µm. Results are presented as mean +SEM, n=6.  
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Figure 4.13. Tamoxifen, raloxifene and genistein do not alter epidermal ERα 
expression A. Representative ERα immunohistochemical localisation images of epidermis 
at the wound edge. The dashed red line indicates the dermal-epidermal junction. B. Total 
ERα-positive cells. Statistical test result p>0.05 and therefore not significant. Scale bar = 
100µm.Results are presented as mean +SEM, n=6. E = epidermis, D= dermis. 
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Figure 4.14. Tamoxifen, raloxifene and genistein induce ERβ expression. A. 
Representative ERβ immunohistochemical localisation images from wounds at 3 days post-
wounding. Arrows indicate positive cells. B. Total ERβ-positive cells within the granulation 
tissue. There is a significant increase in ERβ-positive cells in +Estrogen, +Tamoxifen and 
+Genistein compared to Ovx, * indicates a significance of p<0.05 ** p<0.01. C. Relative 
expression of ERβ in wound. Statistical test result p>0.05 and therefore not significant. 
Scale bar = 50µm. Results are presented as mean +SEM, n=6.  
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Figure 4.15. Tamoxifen, raloxifene and genistein induce epidermal ERβ expression. A. 
Representative ERβ immunohistochemical localisation images of epidermis at the wound 
edge. The dashed red line indicates the dermal-epidermal junction. B. Total ERβ-positive 
cells. There is a significant increase in ERβ-positive cells in the epidermis of intact, 
+Estrogen, +Tamoxifen, +Raloxifene and +Genistein compared to Ovx. * indicates a 
significance of p<0.05, ** p<0.01. Scale bar = 100µm. Results are presented as mean 
+SEM, n=6. E = epidermis, D= dermis.  
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4.3.5 Genistein Activity 
 
Tamoxifen and raloxifene are currently in clinical use for the treatment of 
breast cancer and osteoporosis, respectively. In contrast, genistein, whilst being 
a SERM, is also a naturally occurring dietary phytoestrogen. Much is known 
about the effects of tamoxifen and raloxifene on specific tissues, but the mode 
of action of genistein is largely unknown. For this reason the estrogenic activity 
of genistein was investigated in more detail in the context of wound healing. 
 
4.3.5.1 Real-time ER activity in the ERE-luc mouse 
 
The ERE-luciferase reporter mouse expresses a luciferase reporter gene 
when estrogen receptors are activated via the ERE (classical estrogen 
signalling) and can used to determine real-time in vivo estrogen receptor 
activity. Bioluminescence was detected using a CCD camera and pseudocolour 
images created. 
 The replacement of systemic estrogen in wounded Ovx ERE-luciferase 
reporter mice specifically upregulated bioluminescence in the peri-wound area 
indicating active ERE-mediated signalling, while untreated Ovx mice lacked 
ERE induction and subsequently displayed less bioluminescence. Intriguingly 
the administration of genistein failed to induce ERE and generate a 
bioluminescent signal (Figure 4.16. A). This suggests the beneficial effects of 
genistein on wound healing are not mediated through a classical ligand-
dependant and ERE-dependant mechanism. When the bioluminescence was 
quantified (Night Owl LB981 image processor, WinLight32 imaging software, 
Berthold Technologies) the increase in estrogen treated Ovx animals was 
significant. However, bioluminescence quantification for genistein treated Ovx 
mice was unchanged from untreated Ovx (Figure 4.16. B). When tissue taken 
from sacrificed mice was assessed for luciferase activity using a firefly 
luciferase assay (Promega) there was increased activity in wound tissue 
derived from estrogen treated mice, compared to Ovx and genistein treated 
mice (Figure 4.16. C), and although this failed to reach statistical significance it 
supports bioluminescence quantification. 
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Figure 4.16. Estrogen induces peri-wound luciferase activity in Ovx ERE-luc mice 
while genistein fails to cause an induction. A. Visualisation of Ovx, estrogen-treated 
and genistein-treated ERE-luciferase mice. Bioluminescence was determined by photon 
emission and transformed to pseudocolour. The amount of bioluminescence is displayed 
as a colour threshold, with blue as the lowest level, pink, orange and yellow as the 
highest. Arrows indicate the position of the two incisional wounds. B. Quantification of 
bioluminescence in the peri-wound area of Ovx, estrogen-treated and genistein-treated 
ERE-luciferase mice. The bioluminescence was determined by photon emission captured 
over 5 minutes. There was a significant increase in bioluminescence in +Estrogen 
compared to Ovx and +Gensitein. * indicates a significance of p<0.05. C. Quantification of 
luciferase activity in wound tissue from Ovx, estrogen-treated and genistein-treated ERE-
luciferase mice. Statistical test result p>0.05 and therefore not significant. Results are 
presented as mean +SEM, n=4.  
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4.3.6  The effect of ICI on estrogen signalling in wound repair 
 
As ERE-luciferase mouse data suggested that genistein was promoting 
healing via a non-ERE-mediated mechanism the logical next question was 
whether the ERs were involved. The estrogen receptor antagonist, ICI 182780, 
blocks both ER isoforms, α and β (Howell et al., 2000). Mills et al. have 
previously used ICI to investigate the actions of the steroid precursor, DHEA in 
wound healing (DHEA accelerates healing in Ovx mice and ICI co-treatment 
completely reverses this). However, the authors failed to investigate the effect 
of ICI on estrogen-promoted wound repair (Mills et al., 2005). Thus, the 
effectiveness of ICI to block signalling via the ERs was assessed. 
Estrogen replacement in Ovx female mice significantly reduced wound 
area (Figure 4.17. A and B), as previously shown (Figure 4.5. A and B). Co-
treatment with the ER antagonist ICI completely reversed estrogen’s effects 
(wound area: p<0.01, +E vs +E+ICI) (Figure 4.17. A and B). Estrogen 
replacement in Ovx female mice significantly reduced macrophage influx 
(Figure 4.17. C), as previously shown (Figure 4.7), while ICI completely 
inhibited this anti-inflammatory activity, significantly increasing wound 
macrophage recruitment (p<0.05, +E vs +E+ICI) (Figure 4.17. C). 
While estrogen promotes the in vitro migration of isolated murine primary 
keratinocytes, fibroblasts and isolated peritoneal macrophages (p<0.01, 0.01 
and 0.05, respectively) (Figure 4.18. A, B and C), ICI significantly blocked this 
effect in all cell types (p<0.01, +E vs +E+ICI) (Figure 4.18. A, B and C). These 
data confirm ICI as a valid tool to block ER signalling in the context of wound 
healing, both in vivo and in vitro. 
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Figure 4.17. The ER antagonist ICI is a valid tool to block estrogen signalling through 
the ERs in in vivo wound healing. A. Representative Haematoxylin and Eosin stained wax 
sections of incisional wounds taken at day 3 post-wounding. Arrows indicate the edges of 
the wounds. B. Mean areas of wounds taken from mice at day 3 post-wounding. There is a 
significant reduction in area of +E compared to Ovx and +E+ICI. C. Total macrophage 
numbers within the wound area. There is a significant reduction in macrophages in +E 
compared to Ovx and +E+ICI. * indicates a significance of p<0.05, ** p<0.01. Scale bar = 
200µm. Results are presented as +SEM, n=5. Ovx = ovariectomised, +Estrogen = 
Ovx+17β-estradiol, +Estrogen+ICI = Ovx+17β-estradiol+ICI.   
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Figure 4.18. The ER antagonist ICI is a valid tool to block estrogen signalling through 
the ERs in vitro. A. Percentage closure of an artificial scratch in a keratinocyte monolayer, 
in vitro. Migration is significantly promoted in +E compared to - and +E+ICI. B. Percentage 
closure of an artificial scratch in a fibroblast monolayer, in vitro. Migration is significantly 
promoted in +E compared to - and +E+ICI. C. Number of isolated peritoneal macrophages 
migrated in a Transwell chamber. Migration is significantly promoted in +E compared to - 
and +E+ICI. Results are presented as mean +SEM, outcome of 3 individual experiments. * 
indicates a significance of p<0.05, ** p<0.01. – = untreated, +E = 10-7M 17β-estradiol, 
+E+ICI = 10-7M 17β-estradiol and 10-7M ICI. 
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4.3.7 The effect of ICI on genistein signalling in wound repair 
 
4.3.7.1 Wound Measurements 
 
Estrogen replacement or genistein treatment in Ovx female mice 
accelerated healing, significantly reducing wound area and promoting re-
epithelialisation (Figure 4.19. A, B and C), confirming previous results (Figure 
4.5. A, B and C). When estrogen receptor signalling was blocked by co-
treatment with the ER antagonist ICI, wound area was non-significantly 
increased compared to genistein treatment alone (Figure 4.19. A and B), while 
re-epithelialisation was significantly (p<0.05) but only partially delayed (Figure 
4.19. A and C). This is very relevant in light of the result that ICI completely 
reverses the beneficial effects of estrogen (ie. reducing wound area) (Figure 
4.17) and suggests that genistein is only partially signalling through the ERs to 
promote healing. 
 
4.3.7.2 Inflammatory Cell Infiltration 
 
Genistein is anti-inflammatory and is particularly efficient at resolving 
wound neutrophils (Figure 4.6. A and B). Interestingly, the anti-inflammatory 
properties of genistein were unaffected by co-treatment with ICI, with respect to 
both neutrophils (Ly6G antibody) (Figure 4.20. A and B) and macrophages 
(Mac3 antibody) (Figure 4.20. C and D), suggesting that the anti-inflammatory 
activity of genistein is mediated by an ER-independent mechanism. 
 
4.3.7.3 Matrix Metalloproteinases (MMPs) 
 
Up-regulation of MMPs (ECM degrading enzymes) has been associated 
with delayed healing (Ashcroft et al., 1997e; Lobmann et al., 2002; Madlener et 
al., 1998; Vaalamo et al., 1996). MMP9 is produced by epidermal keratinocytes 
and inflammatory cells (Parks, 1999). Although co-treatment with ICI had no 
effect on genistein’s anti-inflammatory activity ICI co-treatment entirely reversed 
the genistein-dependent decrease in wound MMP9.  
MMP9 immunohistochemical localisation was performed using an MMP9 
antibody, raised in goat, which is mapped to the C-terminus of MMP9 of human 
 212
origin, which is homologous to murine MMP9 (Santa Cruz, CA, USA). The 
antibody has no cross reactivity with any other MMP family members. MMP9-
positive cells in the granulation tissue of genistein + ICI treated mice were 
substantially elevated compared to those in the wounds of genistein or estrogen 
treated mice (p<0.05 compared to genistein alone), and unchanged from Ovx 
mice (Figure 4.21. A and B). Changes in protein level were also confirmed for 
activity measured by gelatin zymography. MMP9 activity was reduced in protein 
isolated from the wound tissue of estrogen or genistein treated mice and this 
was reversed with ICI co-treatment (Figure 4.21. C).  
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Figure 4.19. The ER antagonist ICI only partially reverses the beneficial effects of 
genistein. A. Representative Haematoxylin and Eosin stained wax sections of incisional 
wounds taken at day 3 post-wounding. Arrows indicate the edges of the wounds. B. Mean 
areas of wounds taken from mice at day 3 post-wounding. There is a significant reduction in 
area of +E, +Gen and +Gen+ICI compared to Ovx. C. Mean percentage of re-
epithelialisation of wounds taken at day 3 post-wounding. Re-epithelialisation is significantly 
promoted in +E, +Gen and +Gen+ICI compared to Ovx and in +Gen compared to +Gen+ICI. 
* indicates a significance of p<0.05, ** p<0.01.  Scale bar = 200µm. Results are presented 
as mean +SEM, n=5. Ovx = ovariectomised, +E = Ovx+17β-estradiol, +Gen = 
Ovx+genistein, +Gen+ICI = Ovx+genistein+ICI. 
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Figure 4.20. The ER antagonist ICI fails to alter the anti-inflammatory effect of 
genistein.  A. Representative neutrophil immunohistochemical localisation images from 
wounds at 3 days post-wounding. Arrows indicate positive cells (neutrophils). B. Total 
neutrophils within the granulation tissue. There is a significant reduction in neutrophils in +E, 
+Gen and +Gen+ICI compared to Ovx. C. Representative macrophage 
immunohistochemical localisation images from wounds at 3 days post-wounding. Arrows 
indicate positive cells (macrophages). D. Total macrophages within the granulation tissue. 
There is a significant reduction in macrophages in +E, compared to Ovx. * indicates a 
significance of p<0.05, ** p<0.01. Scale bar = 50µm. Results are presented as mean +SEM, 
n=5. Ovx = ovariectomised, +E = Ovx+17β-estradiol, +Gen = Ovx+genistein, +Gen+ICI = 
Ovx+genistein+ICI.   
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Figure 4.21. The ER antagonist ICI blocks genistein’s ability to dampen MMP9 
expression. A. Representative MMP9 immunohistochemical localisation images from 
wounds at 3 days post-wounding. Arrows indicate positive cells. B. Total MMP9-positive 
cells within the granulation tissue. There is a significant reduction in MMP9-positive cells in 
+Estrogen and +Genistein compared to Ovx, and an increase between +Genistein and 
+Genistein+ICI. C. Day 3 wound levels of Matrix Metalloproteinase 9 (MMP9), assessed by 
gelatin zymography. Bands visible at 105kDa (latent form) and 97kDa (active form). 
Numbers illustrate intensity of bands relative to Ovx. * indicates a significance of p<0.05, ** 
p<0.01.  Scale bar = 50µm. Results are presented as mean +SEM, n=5.  
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4.3.8 The effect of genistein on in vitro cell migration 
 
 Wild-type primary keratinocytes were isolated from female C57/BL6 mice 
(section 2.2.2) and plated in phenol red-free media containing charcoal stripped 
serum. Cells were cultured to confluency and subsequently scratched (in vitro 
scratch wound model). Keratinocytes treated with either 17β-estradiol (10-7 M) 
or genistein (10-6 M) at the time of “wounding” migrated significantly further into 
the denuded area than those that were untreated, indicating a specific role for 
estrogen and genistein in accelerating keratinocyte migration. However, when 
cells were co-treated with both genistein and ICI (10-7 M) this accelerated 
migration was significantly reversed (Figure 4.22. A). However, when the same 
experiment was performed using primary wild-type fibroblasts, isolated from 
female C57/BL6 mice (section 2.2.1), while 17β-estradiol (10-7 M) or genistein 
(10-6 M) accelerated the migration of fibroblasts into the denuded area of an 
artificial scratch, co-treatment with both genistein and ICI (10-7 M) did not 
reverse the beneficial effects of genistein alone (Figure 4.22. B). The same 
result was obtained in a macrophage migration assay, where 17β-estradiol (10-7 
M) and genistein (10-6 M) accelerated cell migration in a Boyden chamber 
assay, while co-treatment with genistein and ICI (10-7 M) did not alter migration 
(Figure 4.22. C). It is interesting to note that the results from in vitro keratinocyte 
migration experiments support the re-epithelialisation phenotype of in vivo 
wounds, where genistein + ICI partially retards re-epithelialisation compared to 
genistein alone (Figure 4.19. A and C). That in vitro and in vivo effects were not 
equivalent (i.e. full reversal in vitro [Figure 4.22. A] and only partial reversal in 
vivo [Figure 4.19. A and C]) is not unexpected and probably reflects other 
influencing factors in vivo. Similarly, this is true for inflammatory cells: ICI has 
no effect in vitro or in vivo. 
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Figure 4.22. Genistein promotes migration of keratinocytes, fibroblasts and 
macrophages, while ICI blocks migration in keratinocytes only. A. Percentage closure 
of an artificial scratch in a keratinocyte monolayer, in vitro. Migration is significantly 
promoted in +E and +Gen compared to -, and significantly impaired in +Gen+ICI compared 
to +Gen. B. Percentage closure of an artificial scratch in a fibroblast monolayer, in vitro. 
Migration is significantly promoted in +E, +Gen and +Gen+ICI compared to –. C. Number of 
isolated peritoneal macrophages migrated in a Transwell chamber. Migration is significantly 
promoted in +E, +Gen and +Gen+ICI compared to –. * indicates a significance of p<0.05, ** 
p<0.01. Results are presented as mean +SEM, outcome of 3 individual experiments. – = 
untreated, +E = 10-7M 17β-estradiol, +Gen = 10-6M genistein, +Gen+ICI = 10-6M genistein 
and 10-7M ICI.   
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4.3.9 IGF-1 receptor-mediated genistein signalling 
 
  There is a well established a cross-talk between the estrogen and IGF-1 
pathways (Klotz et al., 2002; Klotz et al., 2000). Indeed, genistein is able to act 
through the IGF-1 signalling pathway, independently up-regulating IGF-1 
receptor expression and enhancing IGF-1 signalling (Chen and Wong, 2004). 
Thus, genistein signalling via the IGF-1R was assessed in this study by 
exploiting the IGF-1 receptor antagonist JB3. 
 
4.3.9.1 Wound Measurements 
 
As previously reported genistein treatment in Ovx female mice 
accelerated healing, significantly reducing wound area and promoting re-
epithelialisation (Figure 4.23. A, B and C). When IGF-1R signalling was blocked 
(JB3 co-treatment) wound area was only non-significantly increased compared 
to genistein treatment alone (Figure 4.23. A and B), while re-epithelialisation 
was significantly (p<0.05) but only partially delayed (Figure 4.23. A and C). 
These results mirror co-treatment with ICI (partial reversal) and is supported by 
a significant reduction in migration of keratinocytes, in vitro, in response to JB3 
and genistein co-treatment compared to genistein alone (Figure 4.24). 
 
4.3.9.2 Inflammatory Cell Infiltration 
 
The anti-inflammatory properties of genistein were unaffected by the 
IGF-1R antagonist JB3. Neutrophils, identified by immunohistological 
localisation using a Ly-6G antibody, were unchanged in wounds taken from 
genistein+JB3 treated mice, compared to tissue from those treated with 
genistein alone (Figure 4.25. A) mirroring co-treatment with ICI. Macrophages, 
identified by immunohistological staining using a Mac-3 antibody, were actually 
further reduced in wounds taken from genistein+JB3 treated mice, compared to 
tissue from those treated with genistein alone (Figure 4.25. B). This suggests 
the anti-inflammatory activity of genistein is mediated through neither the ER or 
IGF-1R.  
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4.3.9.3 Matrix Metalloproteinases 
 
While co-treatment with genistein and ICI reversed the positive effect 
genistein has on protease levels (Figures 4.21) simultaneous treatment with 
genistein and JB3 did not (i.e. no difference in wound MMP9-positive cell 
numbers between genistein and genistein+JB3 groups) (Figure 4.26). Thus, 
blocking the estrogen receptors is sufficient to inhibit the actions of genistein on 
wound protease levels while blocking the IGF-1R is not. 
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Figure 4.23. The IGF1-R antagonist JB3 only partially reverses the beneficial effects 
of genistein. A. Representative Haematoxylin and Eosin stained wax sections of 
incisional wounds taken at day 3 post-wounding. Arrows indicate the edges of the 
wounds. B. Mean areas of wounds taken from mice at day 3 post-wounding. Wound area 
is significantly reduced in +E and +Gen compared to Ovx. C. Mean percentage of re-
epithelialisation of wounds taken at day 3 post-wounding. Re-epithelialisation is 
significantly improved in +E and +Gen compared to Ovx, while significantly impaired in 
+Gen+JB3 compared to +Gen. * indicates a significance of p<0.05.  Scale bar = 200µm. 
Results are presented as mean +SEM, n=5. Ovx = ovariectomised, +E = Ovx + 17β-
estradiol, +Gen = Ovx + genistein, +Gen+JB3 = Ovx + genistein + JB3. 
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Figure 4.24. The IGF-1R antagonist JB3 partially reverses the accelerated migration of 
genistein treated keratinocytes. Percentage closure of an artificial scratch in a 
keratinocyte monolayer, in vitro. Migration is significantly promoted in +E and +Gen 
compared to -, while significantly impaired in +Gen+JB3 compared to +Gen. Results are 
presented as mean +SEM, n=3. – = untreated, +E =10-7M 17β-estradiol, +Gen = 10-6M 
genistein, +Gen+JB3 = genistein + 10-9M JB3.   
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Figure 4.25. The IGF-1R antagonist JB3 fails to alter the anti-inflammatory effect of 
genistein. A. Total neutrophils within the granulation tissue. There is a significant reduction 
in neutrophils in +E, +Gen and +Gen+JB3 compared to Ovx. B. Total macrophages within 
the granulation tissue. There is a significant reduction in macrophages in +E and +Gen+JB3 
compared to Ovx and in Gen+JB3 compared to +Gen. * indicates a significance of p<0.05, 
** p<0.01. Results are presented as mean +SEM, n=5.  
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Figure 4.26. The IGF-1R antagonist JB3 fails to alter the effect of genistein on 
wound protease activity. Total MMP9-positive cells within the granulation tissue. There 
is a significant reduction in MMP9-positive cells in +E, +Gen and +Gen+JB3 compared to 
Ovx. ** indicates a significance of p<0.01. Results are presented as mean +SEM, n=5.  
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4.3.10  Anti-inflammatory activity of genistein 
 
While genistein is potently anti-inflammatory in estrogen deprived (Ovx) 
mice co-treatment with either ICI or JB3 failed to alter this anti-inflammatory 
potential, suggesting that genistein is anti-inflammatory in a wound via a 
mechanism independent of the ERs or IGF-1R. Genistein displays anti-
inflammatory activity in a number of other body systems (Asmis et al., 2006; 
Sadowska-Krowicka et al., 1998; Seibel et al., 2009). It is inextricably linked to 
the mitogen-activated protein kinase (MAPK) pathway (Borras et al., 2006; Li et 
al., 2008) and has been shown to be anti-inflammatory via MAPK and tyrosine 
kinase (TK) pathways (Bian et al., 2003; Dahle et al., 2004; Gutierrez-Venegas 
et al., 2007). Genistein is also a known TK inhibitor (Akiyama et al., 1987). In 
this study genistein treatment of peritoneal-derived macrophages increased 
phosphorylated ERK1/2 (pERK) protein in vitro, compared to untreated, while 
ERK1/2 levels remained unchanged. Moreover, MAPK inhibition with the MEK 
inhibitor U0126 reduced pERK levels (Figure 4.27). Furthermore, treatment of 
peritoneal-derived macrophages with genistein dampened LPS-induced 
expression of the pro-inflammatory cytokines Mif, Tnfα and Il-6, assessed by 
qPCR, an effect that was partially (Tnfα/Il-6) or fully (Mif) reversed by U0126 co-
treatment (Figure 4.28. A, B and C). This provides evidence that the anti-
inflammatory activity of genistein is mediated through the MAPK pathway. 
 
 
 
 
 
 
 
ERK 
pERK 
β-actin 
1.0            0.98           0.82 
1.0            1.88            0.8 
1.0           0.92            1.11 
Untreated   +Gen    +Gen+U0126 
Figure 4.27. Genistein induces phospho-ERK, while the MEK inhibitor U0126 blocks 
production. Levels of phosphorylated ERK1/2 (pERK) and ERK1/2 protein produced by 
untreated, genistein-treated and genistein- and U0126-treated isolated peritoneal 
macrophages, in vitro. β-actin used as loading control. Numbers illustrate expression 
relative to untreated. 
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Untreated +Gen +Gen+U0126
Untreated +Gen +Gen+U0126
A 
B 
C 
* * 
* * 
* 
Figure 4.28. The MEK inhibitor U0126 reverses the in vitro anti-inflammatory effects of 
genistein. A. The relative expression of Mif by untreated, genistein-treated and 
genistein+U0126-treated macrophages, in vitro. There was a significant increase in Mif 
expression in +Gen+U0126 compared to +Gen. B. The relative expression of Tnfα by 
untreated, genistein-treated and genistein+U0126-treated macrophages, in vitro. There was 
a significant reduction in Tnfα expression in +Gen compared to untreated and increase in 
+Gen+U0126 compared to +Gen. C. The relative expression of Il-6 by untreated, genistein-
treated and genistein+U0126-treated macrophages, in vitro. There was a significant 
reduction in Il-6 expression in +Gen compared to untreated and increase in +Gen+U0126 
compared to +Gen. * indicates a significance of p<0.05. Results are presented as mean 
+SEM, n=3. 
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4.4 Discussion 
 
As the two human ER isoforms (ERα and ERβ) share just 53% homology 
in the ligand binding domain (LBD) (Enmark and Gustafsson, 1999) it has 
enabled the design of synthetic estrogenic compounds that are ER isoform 
specific. SERMs are compounds that, due to the differential distribution of the 
ERs, can confer tissue specific estrogen receptor agonistic or antagonistic 
effects (reviewed in Pickar et al., 2010). 
The skin is a complex, multi-layered organ composed of numerous 
different cell types. Each cell type contains different ratios of the two ER 
isoforms and for this reason our knowledge of the role of SERMs in the skin as 
a whole organ is severely lacking. Of interest, raloxifene significantly increases 
skin elasticity in post-menopausal women (Sumino et al., 2009) and stimulates 
collagen synthesis, while the oral administration of two raloxifene analogues, 
LY139481 and LY353381, to female BALB/c mice results in decreased dermal 
thickness (Zeitlin et al., 2003). While there is no data on the effects of tamoxifen 
on normal skin topical treatment improves the appearance of keloid scars in 
acute burns patients, by inhibiting fibroblast proliferation and collagen synthesis 
(Gragnani et al., 2009; Mousavi et al., 2010). Both tamoxifen and raloxifene 
stimulate fibroblast proliferation in vitro, but fail to promote fibroblast migration 
(Stevenson et al., 2009) and raloxifene stimulates in vitro collagen biosynthesis 
by fibroblasts (Surazynski et al., 2003). Human fibroblasts treated with estrogen 
or tamoxifen in vitro expressed both ER isoforms, while raloxifene selectively 
induced only ERβ (Haczynski et al., 2004).  
Knowledge in other organs, such as bone is more complete: raloxifene 
and tamoxifen regulate very different genes in the human osteosarcoma cell 
lines U2OSERα and U2OSERβ, regulating only 27% of the same genes (Kian 
Tee et al., 2004), indicating that most genes regulated by ERα are distinct from 
those regulated by ERβ, in response to estrogen or SERMs. Crucially, the 
effects of SERMs on wound healing in vivo have been, until now, unknown. 
Data presented in this chapter provided evidence that both tamoxifen 
and raloxifene have strong agonistic effects in the skin. These findings are 
interesting based on the fact that the two compounds have very different 
properties in some organs. Tamoxifen is an ER agonist in normal uterine tissue 
(Harper and Walpole, 1967; Terenius, 1971) while raloxifene is an ER 
antagonist in the uterus (Bryant et al., 1996). However, both compounds are 
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antagonistic in the breast, whilst having agonistic properties in the bone 
(Kauffman and Bryant, 1995). 
Using a well characterised murine model of post-menopause, the Ovx 
mouse, this study has clearly demonstrated the beneficial effects of short-term 
systemic administration of tamoxifen and raloxifene on the inflammatory 
response and wound healing, indicating the therapeutic potential of the 
compounds to aid wound healing. This has important implications for human 
age-associated delayed healing and is of major clinical relevance. Excessive 
and inappropriate inflammation is associated with delayed healing in the elderly 
(Ashcroft et al., 1998), while estrogen replacement in post-menopausal women 
has potent cutaneous anti-inflammatory effects (Ashcroft et al., 1997a; Ashcroft 
et al., 1999a). Tamoxifen and raloxifene were considerably anti-inflammatory in 
vivo and in vitro, particularly with respect to macrophages. However, while 
neither treatment was as effective as estrogen in reducing neutrophil numbers, 
overall healing, i.e. wound area and re-epithelialisation, was significantly 
accelerated. This again, as discussed in the previous chapter, suggests an 
uncoupling of inflammation and healing. The anti-inflammatory action of 
tamoxifen and raloxifene is further evidenced by reduced levels of pro-
inflammatory cytokines, including MIF. Tamoxifen treatment is also beneficial in 
a mouse model of systemic lupus erythematosus (SLE), an autoimmune 
disorder associated with excessive inflammation and tissue damage (Sthoeger 
et al., 2003). Tamoxifen is anti-inflammatory and protective after stroke and 
spinal chord injury (Tian et al., 2009), while both tamoxifen and raloxifene have 
anti-inflammatory effects on astrocyte and microglial cultures, dampening LPS-
induced in vitro production of cytokines (Cerciat et al., 2010; Tapia-Gonzalez et 
al., 2008). The anti-inflammatory activity of tamoxifen and raloxifene is one 
probable reason for the healing-promoting effects seen in vivo. 
As found in vitro by Haczynski et al., (2004) it was interesting to find that 
while estrogen-treated mice exhibited both ERα and ERβ induction, tamoxifen 
induced wound ERα and ERβ expression (qPCR), while raloxifene preferentially 
induced ERβ expression over ERα. SERMs are able to induce different 
conformations of the ER (Dutertre and Smith, 2000; Manni and Verderame, 
2002) and in doing so the two ERs are differentially regulated at the level of 
transcription. It is interesting that both tamoxifen and raloxifene dramatically 
increased the proportion of epidermal keratinocytes expressing ERβ protein. 
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This change in the receptor profile may be an important contributing factor in 
the accelerated re-epithelialisation seen in tamoxifen and raloxifene treated 
mice, and could be further investigated by treating primary epidermal 
keratinocytes with SERMs and examining migration in vitro. 
Genistein, a phytoestrogen and a SERM, is known to have estrogenic 
properties in many peripheral tissues, including bone and the cardiovascular 
system (Atteritano et al., 2007; Newton et al., 2006) and while able to bind to 
both ERs has a significantly higher affinity for ERβ (Kuiper et al., 1998). 
Genistein consumption is thought to have beneficial effects on human health, 
for example, the high consumption of soy-rich foods in Asia has been linked to 
lowered incidence of a number of chronic diseases, including cancers, 
cardiovascular disease and osteoporosis (reviewed in Goldwyn et al., 2000). 
While having a protective effect over many tissues the effect of genistein in the 
skin is poorly understood. Topical and systemic genistein protects against 
cutaneous damage and inflammation after UV exposure (Brand and 
Jendrzejewski, 2008; Shyong et al., 2002; Widyarini et al., 2001) and topical 
genistein improves dermal vascularisation and increases epidermal thickness in 
post-menopausal women (Moraes et al., 2009). 
Again, using the Ovx mouse, data presented in this chapter clearly 
demonstrates the effects of systemic administration of genistein on wound 
healing, accelerating wound closure and dampening inflammation. Whilst 
tamoxifen and raloxifene are both clinically relevant compounds, in use in post-
menopausal women, genistein has only recently been identified as a SERM and 
little is known about its mechanism of action. However, in recent years it has 
become a focus of many studies. This study identified that not only was 
genistein also able to significantly accelerate wound repair, it was also potently 
anti-inflammatory. While tamoxifen and raloxifene significantly reduced 
macrophage numbers and healing was accelerated, genistein reduced 
neutrophil numbers and not macrophages, but healing was still accelerated. 
Again this suggests that inflammatory cell numbers alone do not directly affect 
measures of successful healing, i.e. wound area and re-epithelialisation, and is 
further evidence of an uncoupling of inflammation and overall healing (see 
Chapter 3). Results from SERMs treatment are summarised in Table 4.3. 
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Table 4.3  Summarised results of administration of estrogen or SERMs on 
wound healing at day 3 
 
Effect of Wound Healing 
Parameter Ovx ¤ +Estrogen § 
+Tamoxifen 
§ 
+Raloxifene 
§ 
+Genistein 
§ 
Wound Area ↑ ↓ ↓ ↓ ↓ 
Re-
epithelialisation ↓ ↑ ↑ ↑ ↑ 
Macrophage 
numbers  ↑ ↓ ↓ ↓ ↓ 
Neutrophil 
numbers  ↑ ↓ ↓ ↓ ↓ 
MIF cell 
numbers  ↑ ↓ ↓ ↓ ↓ 
 
¤ compared to intact, § compared to Ovx. Black arrows represent a significant change, red 
arrows represent a non-significant trend. 
 
 
17β-estradiol contains an aromatic phenolic A-ring which allows it to bind 
to the estrogen receptors. Tamoxifen, raloxifene and genistein all contain an 
equivalent region, an ‘A-ring mimic’, which enables all compounds to bind to the 
transcriptional activation function (AF)-1 region of the estrogen receptor. 17β-
estradiol, raloxifene and genistein also contain a hydroxyl group, but tamoxifen 
does not. While genistein has a very similar structure to that of 17β-estradiol, 
tamoxifen and raloxifene contain an extended side chain which is able to 
additionally bind to the (AF)-2 region of the estrogen receptor (Pike, 2006; Pike 
et al., 1999). This binding affects the agonistic/antagonistic potential of the 
compound. Figure 4.29. outlines the differences in structure of 17β-estradiol, 
tamoxifen, raloxifene and genistein. 
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Despite their very different structures this study suggests that tamoxifen, 
raloxifene and genistein all act in an agonistic manner in the skin, i.e., have an 
estrogenic effect. This is most likely due to co-factor/co-repressor profiles in the 
skin. However, due to the selective nature of SERMs, this varies in other 
tissues. For example, while tamoxifen and raloxifene are both antagonistic in 
the breast, and for this reason are used in the treatment of breast cancer in 
humans (Cole et al., 1971; Cummings et al., 1999), genistein appears to have 
some agonistic properties and leads to the proliferation of ER-dependent breast 
cancer cells (Maggiolini et al., 2001). Tamoxifen is associated with an increased 
risk of uterine cancer because of its agonistic activity in the uterus (Bergman et 
al., 2000; Ismail, 1996; Jordan and Morrow, 1999), while raloxifene is 
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Figure 4.29. The differing structures of 17β-estradiol (A), tamoxifen (B), raloxifene (C) 
and genistein (D). While estradiol contains a phenolic A-ring (highlighted in red), tamoxifen, 
raloxifene and genistein contain an A-ring mimic, which allows binding to both estrogen 
receptor isoforms (highlighted in red), while only 17β-estradiol, raloxifene and genistein 
contain an adjacent hydroxyl group (highlighted in blue) (figure drawn by the author [EE]). 
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antagonistic in the uterus (Bryant et al., 1996). Less is known about the action 
of genistein: some studies suggest that it exhibits agonistic properties in the 
rodent uterus (Diel et al., 2001; Santell et al., 1997) while others find genistein 
has antagonistic activity in mouse uterus (Erlandsson et al., 2005), but this may 
be due to differing animal species/strains used. Raloxifene is an estrogen 
agonist in the bone and is used as treatment for bone loss and osteoporosis in 
post-menopausal women (Heaney and Draper, 1997). Genistein also exhibits 
estrogenic effects in bone (Ishimi et al., 1999) while tamoxifen prevents bone 
loss in post-menopausal, but not pre-menopausal women (Powles et al., 1996). 
All three compounds act as estrogen agonists in the cardiovascular system 
(Guetta et al., 1995; McCarty, 2006; Muchmore, 2000) and tamoxifen and 
genistein are agonistic in the ovaries (Jefferson et al., 2006; Kedar et al., 1994) 
while raloxifene has indirect estrogenic effects on the ovary (Neven et al., 
2002). These findings are summarised in Figure 4.30. 
 
 
 
While estrogen, tamoxifen and raloxifene accelerate healing via a 
suspected estrogen receptor-dependent pathway, genistein appears to act via 
both ER and non-ER mediated pathways. The effect of genistein on healing 
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Raloxifene 
Genistein 
UTERUS 
Tamoxifen 
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Raloxifene 
Genistein 
SKIN 
Tamoxifen 
Raloxifene 
Genistein 
Figure 4.30. Outline of the activity profiles of tamoxifen, raloxifene and genistein in 
different tissue systems of the body. Those listed in green have an agonistic (estrogenic) 
effect in the particular tissue, while those in red have an antagonistic (anti-estrogenic) effect. 
The activity of those listed in orange is controversial (main body of the figure modified from 
Raymond, 2006). 
Key 
Agonist 
Antagonist 
Controversial 
VASCULATURE 
Tamoxifen 
Raloxifene 
Genistein 
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was largely unaltered when the ERs were blocked by an antagonist (ICI). 
Blocking the action of genistein via the estrogen receptors did, however, 
partially reverse the accelerated keratinocyte migration and subsequent re-
epithelialisation seen with genistein treatment and also prevented the reduction 
of MMPs. Additionally, IGF-1R antagonism also partially reversed the 
accelerated migration of keratinocytes in vitro and in vivo in response to 
genistein. Interestingly, neither ER or IGF-1R antagonism affected the anti-
inflammatory activity of genistein. In other body systems genistein is potently 
anti-inflammatory, reducing inflammation in a rodent model of TNBS-induced 
chronic colitis (Seibel et al., 2009) and reducing  nitric oxide and granulocyte 
infiltration in a guinea pig model of chronic ileitis (Sadowska-Krowicka et al., 
1998). Genistein inhibits TNF-α production in brain microvascular endothelial 
cells (Lu et al., 2009) and modulates pro-inflammatory cytokines in an 
experimental model of multiple sclerosis (MS) (De Paula et al., 2008). 
Additionally, genistein is anti-inflammatory with respect to granulocytes, 
monocytes and lymphocytes in a mouse model of arthritis (Verdrengh et al., 
2003). This study demonstrates that genistein potently inhibits the production of 
the cytokines Mif, Tnfα and Il-6 by macrophages, in vitro, while significantly 
dampening neutrophil influx to the wound.  
Genistein is able to act via alternative non-ER pathways: protecting 
against oxidation via MAPK activation and induction of the NF-kB signalling 
pathway (Mahn et al., 2005). This study demonstrates that genistein is able to 
signal via MAPK activation to reduce wound pro-inflammatory cytokines by 
macrophages, an effect that is reversed by MEK inhibition with the compound 
U0126. Thus, genistein accelerates healing through a number of mechanisms, 
accelerating keratinocyte migration and subsequent re-epithelialisation through 
both ER-dependent and IGF-1R-dependent pathways, down-regulating MMPs 
through an ER pathway and reducing inflammation via a MAPK or tyrosine 
kinase pathway. These results are summarised in Figure 4.31. 
 Since the publication of this data (Emmerson et al., 2010) another 
research group have corroborated the initial findings, demonstrating accelerated 
healing in Ovx rats in response to genistein aglycone (Marini et al., 2010). 
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The side effects of tamoxifen and raloxifene, including hot flushes, 
nausea, headaches and thrombosis, are well documented (Boehm et al., 2009; 
Goldstein et al., 2008), but effects of genistein are less well known.  Soymilk-
based infant formula is becoming increasingly popular, in the US especially, 
accounting for approximately 25% of formula fed infants, which equates to 
about 15% of all infants in the US (Strom et al., 2001; Yellayi et al., 2002). 
Infants fed on a soy-based formula consume between 6.0 and 11.0 mg of 
isoflavones per kg of weight per day (Setchell et al., 1997, 1998). Mice injected 
with 8 mg/kg per day of genistein produced serum genistein levels comparable 
with those reported in soy-fed infants (Yellayi et al., 2002). Thymic and immune 
abnormalities have been identified in mice injected with this dose of genistein 
and infants fed on a soy-based formula diet. While this should be taken into 
Figure 4.31. Proposed mechanisms by which genistein accelerates wound healing 
(this figure also appears in Emmerson et al., 2010, drawn by the author [EE]). Genistein 
signals through two ER-independent pathways to accelerate cutaneous wound healing. 
While genistein reduces wound protease levels and accelerates re-epithelialisation through 
classical estrogen receptor (ER)- signalling it also accelerates keratinocyte migration and re-
epithelialisation via the IGF-1 receptor. The anti-inflammatory activity of genistein seen in in 
vivo healing is attributed to the action of genistein via the MAPK pathway. 
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consideration for future translational studies in the aforementioned study mice 
were treated with a high-dose (50 mg/kg) acute treatment for three days only. 
However, with all therapeutic compounds intended for human use the 
benefits must outweigh the side-effects. The advantages of SERMs in post-
menopausal women has been discussed at length (reviewed in Johnson et al., 
2001; Pickar et al., 2010). There are understandable advantages of prescribing 
SERMs in topical, rather than oral form, for cutaneous treatment. In addition, 
short acute treatments are of benefit to both health professionals and the 
patient. Next generation SERMs such as Ophena™ (Hormos, Finland) are now 
being designed to have tissue specific estrogen actions that can separate the 
positive biological effects from the undesirable ones (e.g. hot flushes, increased 
risk of breast cancer and uterine cancer). An ideal, but yet to be discovered, 
SERM would have entirely beneficial effects without causing cancer or other 
side-effects. 
In conclusion, the SERMs tamoxifen, raloxifene and genistein promote 
healing in hormonally deprived (Ovx) female mice, emphasising the clear 
therapeutic potential for use to treat delayed healing in post-menopausal 
women. While, all compounds were comparably beneficial to overall healing 
there were significant differences in the anti-inflammatory activities between the 
clinically relevant SERMs tamoxifen and raloxifene and the phytoestrogen 
genistein. However, despite differences in neutrophil/macrophage profiles all 
compounds dampen the expression of the pro-inflammatory cytokine MIF. The 
relevance of MIF and estrogen in healing in vivo and in vitro will be discussed at 
length in the next chapter. An interesting prospective study would be to evaluate 
healing in post-menopausal women currently prescribed tamoxifen or 
raloxifene. The SERMs tamoxifen, raloxifene and genistein represent excellent 
therapeutic candidates to treat pathological healing. 
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5 THE ROLES OF ESTROGEN AND 
MACROPHAGE MIGRATION INHIBITORY 
FACTOR IN WOUND HEALING 
 
 
 
 
The majority of the results presented in this chapter also appear in the following 
publication:  
 
Unique and synergistic roles for 17beta-estradiol and macrophage 
migration inhibitory factor during cutaneous wound closure are cell type 
specific (2010). Endocrinology 150, 2749-2757. 
 
Authors: Elaine Emmerson, Laura Campbell, Gillian. S. Ashcroft and Matthew. 
J. Hardman. 
 
Author Contributions: EE was involved in experimental design, surgical 
procedures, carried out experiments, analysed results and was involved in 
manuscript preparation. LC was involved in surgical procedures. GA was 
involved in experimental design and manuscript preparation. MH was involved 
in experimental design, surgical procedures and manuscript preparation. 
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5.1 Introduction 
 
The pro-inflammatory cytokine Macrophage Migration Inhibitory Factor 
(MIF) has been implicated as a candidate master regulator of estrogen’s 
positive effects on wound healing (Hardman et al., 2005).  In a state of estrogen 
deprivation MIF expression is upregulated, while with estrogen replacement MIF 
is reduced (Ashcroft et al., 2003b). MIF is a small, 12.5 kDa, pro-inflammatory 
cytokine (Calandra and Roger, 2003) which is expressed in a number of 
tissues, including the immune system, pituitary, brain (Bernhagen et al., 1993; 
Calandra et al., 1994), bowel (de Jong et al., 2001) and lung (Bargagli et al., 
2009). MIF is a trimer of identical subunits (Figure 5.1) (Suzuki et al., 1996), a 
structure which is unique among cytokines (Sun et al., 1996). 
 
 
 
MIF, discovered over 40 years ago during investigation into the cause of 
delayed contact hypersensitivity, was originally thought to be a molecule that 
inhibited the migration of macrophages, hence the name (Bloom and Bennett, 
1966; David, 1966). Until MIF was successfully cloned (in 1989) (Weiser et al., 
1989) the biological activities were poorly understood. In 1991 MIF was 
“rediscovered” as a molecule released by the cells of the anterior pituitary 
gland, in a mechanism similar to that of a hormone. Thus, MIF has emerged as 
a mediator between endocrine and immune systems (Calandra and Roger, 
2003), re-evaluated as both a pro-inflammatory cytokine and pituitary-derived 
hormone (reviewed in Donn and Ray, 2004). MIF has been implicated in septic 
Figure 5.1. The structure of a trimer of the pro-inflammatory cytokine Macrophage 
Migration Inhibitory Factor (MIF). The inside of the trimer is comprised of three 5-
stranded β-sheets (green arrows) (taken from Suzuki et al., 1996). 
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shock (Bernhagen et al., 1993), rheumatoid arthritis (RA) (Onodera et al., 
1999), multiple sclerosis (Niino et al., 2000), atherosclerosis (Burger-Kentischer 
et al., 2002) and systemic lupus erythematosus (SLE) (Foote et al., 2004) and 
animal models of asthma (Magalhaes et al., 2007) and inflammatory bowel 
disease (IBD) (de Jong et al., 2001).  
The human MIF gene is located on chromosome 22 (22q11.2) with some 
syntenic conservation with the part of mouse chromosome 10 that contains the 
Mif gene. A number of polymorphisms of the human MIF gene have been linked 
to pathologies, including systemic-onset juvenile arthritis (Donn et al., 2002; 
Donn et al., 2004a), rheumatoid arthritis (RA) (Baugh et al., 2002; Radstake et 
al., 2005), SLE (Sanchez et al., 2006), psoriasis (Donn et al., 2004b) and 
gastric cancer (Tahara et al., 2010). A single MIF mRNA species of 
approximately 0.8kb is found in humans, mice and rats (Kozak et al., 1995; 
Paralkar and Wistow, 1994), encoding a 114-amino-acid protein (reviewed in 
Calandra and Roger, 2003), which has no significant sequence homology to 
any other protein (Baugh and Bucala, 2002). All mammalian MIFs have about 
90 percent homology (Mitchell et al., 1995), a degree of conservation across 
species that indicates important biological functions.  
 
5.1.1 MIF function 
 
MIF is a multi-functional molecule: while acting as a pituitary-derived 
protein secreted in response to endotoxic challenge (Bernhagen et al., 1993; 
Calandra and Roger, 2003), it also acts as a tautomerase (Rosengren et al., 
1997; Rosengren et al., 1996), although this function is now controversial 
(Fingerle-Rowson et al., 2009), a pro-inflammatory cytokine (Calandra et al., 
2003; Santos and Morand, 2009), and is involved in glucocorticoid production 
(Calandra and Bucala, 1995; Fingerle-Rowson et al., 2003). MIF signals via 
CD74, CD44 and CXCR complexes (Bernhagen et al., 2007; Leng et al., 2003; 
Shi et al., 2006) and CSN5 (Jab1) (Kleemann et al., 2000; Lue et al., 2007) and 
activates MAPK pathway (Mitchell et al., 1999; Santos et al., 2004) (Figure 5.2). 
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5.1.2 MIF and inflammation  
 
Evidence supports the theory that MIF is an integral component of the 
host inflammatory response. Using MIF-deficient cells, MIF-specific antibodies 
or recombinant MIF researchers have shown that MIF directly or indirectly 
promotes the production or expression of many pro-inflammatory molecules, 
including TNF-α, interleukins and IFNγ, nitric oxide, MMPs and their inhibitors 
(reviewed in Calandra and Roger, 2003). MIF also plays an important role in 
regulating both the set-point and the direction of the inflammatory response by 
counter-regulating the anti-inflammatory and immunosuppressive effects of 
glucocorticoids (Baugh and Bucala, 2002; Calandra and Bucala, 1995).  
Initially, it was thought that T cells were the main cellular source of MIF in 
the immune system. However, monocytes, macrophages, blood dendritic cells, 
B cells, neutrophils, eosinophils, mast cells and basophils have since been 
shown to express MIF. In addition to the immune system MIF has broad tissue 
distribution, and is especially expressed by cells and tissues that have direct 
contact with the natural environment, such as the lung, the epithelial lining of 
the skin, and the gastrointestinal and genitourinary tracts (Baumann et al., 
MIF 
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Tautomerase 
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Glucocorticoid 
signalling 
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Figure 5.2. MIF is a multi-functional molecule (a modified version of this figure also 
appears in Gilliver et al., 2010, drawn by the author [EE]). MIF acts as a cytokine, a 
tautomerase and a pituitary hormone. MIF can signal via CD74/CD44, CXCR and CSN5 
(Jab1) and can induce glucocorticoid production. 
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2003; Fingerle-Rowson et al., 2003; Morand et al., 2002; Popa et al., 2006; 
Shimizu et al., 1996). MIF expression is high in tissues of the endocrine system, 
especially those involved in the stress responses, such as the hypothalamus 
and the pituitary and adrenal glands (reviewed in Calandra and Roger, 2003). 
Cytokines play important roles in the homeostasis of normal skin (Shimizu et al., 
1996) and MIF is expressed in the skin by keratinocytes, sebaceous glands, 
hair follicles, endothelial cells and fibroblasts (Abe et al., 2000; Emmerson et al., 
2009; Shimizu et al., 1996) (Figure 5.3).  
 
 
 
 
 
 
 
 
 
 
 
The fact that MIF has been shown to be produced by a variety of cell types 
suggests multifunctional physiological effects.  
  
5.1.3 MIF and pathology 
 
As previously mentioned, MIF plays a crucial role in the response to 
endotoxemia and septic shock (Bernhagen et al., 1993) and MIF production is 
linked to inflammatory diseases including atherosclerosis (Bernhagen et al., 
2007; Burger-Kentischer et al., 2002), rheumatoid arthritis (Onodera et al., 
1999) and SLE (Foote et al., 2004). Human melanoma cells produce MIF, which 
inhibits the ability of natural killer cells to lyse them (Repp et al., 2000) and 
increased MIF mRNA has been detected in prostate, colon and liver cancer 
cells (Legendre et al., 2003; Meyer-Siegler et al., 1998; Ren et al., 2003) and 
adenoma of the lung (Kamimura et al., 2000). High expression of  MIF is found 
in animal models of colitis (Houdeau et al., 2007), irritable bowel disease (IBD) 
(de Jong et al., 2001), osteoporosis (Oshima et al., 2006), lung trauma damage 
Figure 5.3. MIF is expressed by human epidermal keratinoctyes (A), dermal 
fibroblasts (B) and in venous ulcer tissue (C) (this figure also appears in Emmerson et 
al., 2009). 
A B C 
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(Hsieh et al., 2007) and kidney disease (Lan et al., 1997). A common factor in 
the majority of these pathologies involves the infiltration of inflammatory cells at 
the site of injury.  
MIF is also important in skin pathogenesis with increased local MIF 
expression a feature of many skin diseases, including dermatitis (Malorny et al., 
1988; Shimizu et al., 1997), eczema (Gomez et al., 1990), psoriasis (Shimizu et 
al., 2001; Steinhoff et al., 1999) and urticaria (Czarnetzki et al., 1989). MIF is 
differentially expressed in keratinocytes of atopic dermatitis (AD) sufferers: in 
normal skin MIF is more intense in the basal layer, while in skin lesions from 
patients with AD MIF is distributed throughout the entire epidermal layer 
(Shimizu et al., 1997; Shimizu et al., 1996). As the clinical features of AD 
improve serum levels of MIF decrease (Shimizu et al., 1996), while levels of 
MIF in blood serum are increased in human psoriasis vulgaris sufferers 
(Shimizu et al., 2001). MIF expression and protein is significantly increased in 
response to UVA (Watanabe et al., 2004) and UVB irradiation (Shimizu et al., 
1999) in human dermal fibroblasts and epidermal keratinocytes, and MIF is 
present in melanoma (Miracco et al., 2006) and non-melanoma skin cancers 
(Martin et al., 2009). Serum MIF is elevated in patients following skin flap 
surgery (Gilliver et al., 2010) while MIF expression is markedly elevated in 
venous ulcer tissue (Emmerson et al., 2009). 
MIF expression is reported to change with age: levels in heart, liver and 
skeletal muscle decline in aged rats (Rohrbach et al., 2008). However, there is 
much controversy concerning age-related changes in serum MIF levels in 
humans: one study reports that serum MIF is essentially invariant with age in 
healthy individuals (Mizue et al., 2000), while another report identifies a decline 
with age in males (but not females) (Aloisi et al., 2005).  
 
5.1.4 MIF and hormones 
 
Several studies have connected MIF and steroid sex hormones: serum 
MIF is negatively correlated with estradiol in human females and MIF is 
increased in post-menopausal women, an effect that is reversed by HRT 
(Hardman et al., 2005), while in males, testosterone is positively correlated with 
MIF (Aloisi et al., 2005; Mizue et al., 2000). Expression of MIF and the MIF 
receptor CSN5 (Jab1) is significantly increased in Ovx female mice (Ashcroft et 
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al., 2003b; Gilliver et al., 2008). Estrogen strongly down-regulates MIF in vitro 
and in vivo (Hardman et al., 2005) while the steroid precursor DHEA reduces 
wound MIF expression after its conversion to estrogens (Mills et al., 2005). 
Healing is normally impaired in Ovx mice as a consequence of estrogen 
deprivation (Ashcroft et al., 1997a; Ashcroft et al., 1999a). In contrast, healing in 
Mif knockout (Mif KO) mice is not affected by ovariectomy (Ashcroft et al., 
2003b; Hardman et al., 2005). Additionally, healing is improved in Ovx WT mice 
by administration of neutralising anti-MIF antibody, while healing is retarded in 
Mif KO mice in response to local administration of recombinant MIF (Ashcroft et 
al., 2003b). Crucially, systemic estrogen replacement fails to improve healing in 
Ovx mice treated with MIF (Gilliver et al., 2008).  
Gender hormones differentially alter healing: MIF clearly contributes to 
the estrogenic regulation of skin repair in female animals (Ashcroft et al., 2003b) 
(Hardman et al., 2005) and MIF delays healing during estrogen deprivation 
(Gilliver et al., 2008). In contrast in castrated (CSX) male mice healing was 
impaired with simultaneous treatment of testosterone and MIF, but not MIF 
alone, suggesting that in males MIF does not posses the same inhibitory 
properties as in females (Gilliver et al., 2008). 
 
5.1.5 Aims of the Chapter 
 
 Estrogen’s beneficial effects on cutaneous repair are due, at least in part, 
to estrogen’s ability to down-regulate MIF expression. Existing data indicates 
that MIF is critically involved in cutaneous pathology and inflammation (Ashcroft 
et al., 2003b; Hardman et al., 2005). The aim of this chapter is to further 
investigate the role of estrogen and MIF in detail, a) in vivo, at different stages 
of the wound repair process, using the Mif KO mouse, and b) in vitro, exploring 
cell-specific interactions between 17β-estradiol and MIF on three of the primary 
cell types involved in cutaneous repair: keratinocytes, fibroblasts and 
macrophages. 
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5.2 Materials and Methods 
 
5.2.1 Animal Experiments 
 
5.2.1.1  The roles of MIF and estrogen in wound repair 
 
5.2.1.1.1 Incisional model 
 
 An extensive initial wound study was performed to investigate in detail 
the interaction between the steroid hormone estrogen and the pro-inflammatory 
cytokine macrophage migration inhibitory factor (MIF) in vivo during wound 
healing (Table 5.1). This study builds upon findings from previous studies 
(Ashcroft et al., 2003b; Hardman et al., 2005). 
Mif KO mice (on a BALB/c background) (Honma et al., 2000), were kindly 
donated by Toshinori Nakayama (Chiba University, Japan). It is important to 
note that there has been more than one strain of Mif KO mouse generated 
(Bozza et al., 1999; Honma et al., 2000; Nishihira et al., 1995). 30 specific 
pathogen-free (SPF) female BALB/c mice at 8 weeks old, and 30 female Mif KO 
mice at 8 weeks old, were used. In addition fifteen of the BALB/c and fifteen of 
the Mif KO mice were ovariectomised (Ovx) following the protocol in section 
2.1.4 (Table 5.1).  
The mice were anaesthetised with isoflurane, oxygen and nitrous oxide 
inhalation and wounded following the protocol in section 2.1.5.1. The animals 
were given buprenorphine (0.1 mg/kg) as analgesia. 
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Table 5.1 Experimental animals used in the incisional wound study 
 
Group Strain Surgery 
Day of 
harvesting post-
wounding 
Number of 
mice 
1 Mif KO Intact 3 5 
2 Mif KO Ovariectomised 3 5 
3 WT (BALB/c) Intact 3 5 
4 WT (BALB/c) Ovariectomised 3 5 
5 Mif KO Intact 7 5 
6 Mif KO Ovariectomised 7 5 
7 WT (BALB/c) Intact 7 5 
8 WT (BALB/c) Ovariectomised 7 5 
9 Mif KO Intact 14 5 
10 Mif KO Ovariectomised 14 5 
11 WT (BALB/c) Intact 14 5 
12 WT (BALB/c) Ovariectomised 14 5 
 
The first, third, fifth, seventh, ninth and eleventh groups (intact) were controls and were 
untreated (no intervention was carried out except wounding). The second, fourth, sixth, eighth, 
tenth and twelfth groups underwent ovariectomy one moth prior to wounding. WT=Wild-type, 
KO = knockout. 
 
 
5.2.1.1.2 Excisional model 
 
An excisional wound experiment was set up in parallel to the incisional 
experiment (Table 5.2). 8 specific pathogen-free (SPF), female BALB/c mice at 
8 weeks old, and 8 female Mif KO mice at 8 weeks old, were used in this study. 
Four of the BALB/c and four of the Mif KO mice were ovariectomised. The 
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protocol was as for previous study (5.2.1.1), with the exception of 6 mm 
excisional, not incisional wounds (section 2.1.5.2). 
 
Table 5.2 Experimental animals used in the excisional wound study 
 
Group Strain Treatment 
Day of 
harvesting post-
wounding 
Number of 
mice 
1 Mif KO Intact 7 4 
2 Mif KO Ovariectomised 7 4 
3 WT (BALB/c) Intact 7 4 
4 WT (BALB/c) Ovariectomised 7 4 
 
 
The first and third groups (intact) were controls and were untreated (no intervention was carried 
out except wounding). The second and fourth groups underwent ovariectomy one month prior to 
wounding. WT=Wild-type. 
 
 
5.2.1.2 The interaction between the estrogen receptors and MIF in 
wound healing 
 
The third study was performed to investigate the interaction between the 
2 estrogen receptors, ERα and ERβ, and MIF in wound healing, and to 
determine if the effects of estrogen on MIF downregulation are ERα- or ERβ-
dependent. 15 specific pathogen-free (SPF), female BALB/c mice at 8 weeks 
old, and 15 female Mif KO mice at 8 weeks old, were used in this study. All 
animals were ovariectomised, and 10 animals (5 BALB/c and 5 Mif KO) were 
treated with the ERα agonist Propyl pyrazole triol (PPT), 10 animals were 
treated with the ERβ agonist Diarylpropionitrile (DPN) and the remaining 10 
were treated with vehicle alone (Table 5.3). DPN and PPT (Tocris, Bristol, UK, 
Catalogue numbers 1494 and 1426 respectively) were re-suspended in DMSO 
(Sigma-Aldrich, UK) initially and then corn oil (Sigma-Aldrich, UK) in the ratio of 
5% DMSO to 95% corn oil. Stock solutions of 3.3 mg/ml DPN and 3.3 mg/ml 
PPT were prepared. Vehicle injections were comprised of 5% DMSO and 95% 
corn oil. Table 5.3 shows the resulting doses given per mouse per day. 100 µl 
per mouse per day was injected subcutaneously, on the day prior to wounding 
(-1), day of wounding (0) and one day post-wounding (+1).  
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Table 5.3 Experimental animals used and treatment groups 
 
Group Strain Treatment Administration 
method and dosage 
Period of 
treatment 
Day of 
harvesting 
post-
wounding 
Number 
of mice 
1 WT (BALB/c) Ovx (+vehicle) 
100 µl sc vehicle 
injections 
Daily for 3 
days starting 
1 day before 
wounding 
3 5 
2 Mif KO Ovx (+vehicle) 100 µl sc vehicle injections 
Daily for 3 
days starting 
1 day before 
wounding 
3 5 
3 WT (BALB/c) Ovx +PPT 
100µl SC injections, 
330µg/mouse/day 
Daily for 3 
days starting 
1 day before 
wounding 
3 5 
4 Mif KO Ovx +PPT 100µl SC injections, 330µg/mouse/day 
Daily for 3 
days starting 
1 day before 
wounding 
3 5 
5 WT (BALB/c) Ovx +DPN 
100µl SC injections, 
330µg/mouse/day 
Daily for 3 
days starting 
1 day before 
wounding 
3 5 
6 Mif KO Ovx +DPN 100µl SC injections, 330µg/mouse/day 
Daily for 3 
days starting 
1 day before 
wounding 
3 5 
 
Ovx = ovariectomised, sc = subcutaneous. 
 
 
5.2.2 Tissue harvest 
 
Blood, wound tissue, normal skin, peritoneal macrophages and uterus 
was collected from each animal, as described in section 2.1.6.  
 
5.2.3 Wound Processing and Immunohistochemistry 
 
 Each wound was bisected and one half of each wound was placed in a 
formalin fixative solution and the other snap frozen in liquid nitrogen. The fixed 
half of each wound was processed, embedded, sectioned and stained as 
described in sections 2.1.8 and 2.1.9.  
 
5.2.4 Image Analysis 
 
 Images were captured from all stained sections and measurements 
taken at x4 and x20 magnification. The images were analysed and 
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measurements taken using Image Pro-Plus software (Media Cybernetics, 
Finchampstead, UK) as described in section 2.1.11. Collagen I was quantified 
by histological grading for staining intensity. Slides were blinded and scored by 
2 independent persons. Results are represented as an average score. 
 Statistical analysis was performed as described in section 2.8. 
 
5.2.5 The role of MIF and estrogen in cell specific functions in vitro 
 
Dermal fibroblasts and epidermal keratinocytes were isolated from 
normal skin (BALB/c or Mif KO) as described in the protocol in chapter 2.2.1 
and 2.2.2. Proliferation assays, attachment assays, 2D and 3D migration 
assays and contraction assays were performed with WT and Mif KO fibroblasts 
as described in sections 2.2.4, 2.2.5, 2.2.6, 2.2.7 and 2.2.8. A 2D migration 
assay was performed with WT and Mif KO keratinocytes and a modified Boyden 
chamber assay was performed with macrophages derived from WT and Mif KO 
female mice, as described in sections 2.2.9 and 2.2.10. Statistical analysis was 
performed as described in section 2.8. 
 
5.2.5.1 Estrogen, MIF and agonist treatments 
 
 In the 2D and 3D fibroblast migration assays, the fibroblast contraction 
assay, 2D keratinocyte assay and the macrophage migration assay the effect of 
exogenous estrogen or MIF was investigated. In these assays either 17β-
estradiol (10-7 M) (Sigma Aldrich) or rhMIF (10 ng) (R&D Systems) was added 
to the media at the time of assay preparation. If the media was changed during 
the protocol estradiol or MIF was replaced with the new media. In 2D fibroblast 
migration assays the effect of PPT or DPN was also assessed. In these assays 
either PPT (10-7M) or DPN (10-7M) was added to the media in the wells at the 
time of preparation. 
 
5.2.6 RNA Isolation and qPCR 
 
Cultured fibroblasts were treated with consecutive 10-fold dilutions of 
17β-estradiol (Sigma Aldrich). Cells were washed, 0.5ml of Trizol (Invitrogen) 
added per well and stored at -80°C prior to RNA ext raction. cDNA was 
transcribed from 1 µg of RNA (Promega RT kit) and qPCR was performed using 
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primers for Mif (see Table 2.7), the SBYR green I core kit (Eurogentec, 
Southampton, UK) and an opticon qPCR thermal cycler (Bio-Rad, UK) as 
described in section 2.3.  
 
5.2.7 Western Blot Analysis 
 
 Total protein was extracted from homogenised mouse wound tissue or 
cultured fibroblasts following the protocol described in section 2.4. Western blot 
analysis was performed to determine the relative levels of CD163, TNF-α, 
TGFβ, MMP9 and αSMA following the protocol described in section 2.4.2. 
 
5.2.8 Zymography 
 
Protein samples were prepared in addition to those used for Western blot 
analysis. Zymography was performed using protein samples as described in 
section 2.5 to assess the activity of MMP9 in tissue samples. 
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5.3 Results 
 
5.3.1 The roles of MIF and estrogen in wound repair 
 
5.3.1.1 Wound Measurements 
 
Wound area and percentage re-epithelialisation were determined from 
Haematoxylin & Eosin (H&E) stained sections using Image Pro Plus software, 
as described in Section 2.1.11 and Figure 2.3. In this study 8-week-old 
ovariectomised (Ovx) wild-type mice exhibited large delayed healing wounds at 
3 days post-wounding, compared to mice with intact ovaries (p<0.05), 
confirmed by quantification from H&E stained sections  (Figure 5.4. A) as shown 
in Figure 5.4. B, and supporting results from previous studies (Gilliver and 
Ashcroft, 2007; Hardman et al., 2005) and previous chapters (Chapter 3 and 4), 
despite mice being on a different genetic background. Crucially, Ovx did not 
delay healing in Mif KO mice (p<0.05 compared to Ovx WT) (Figure 5.4. B), 
supporting results from previous studies (Ashcroft et al., 2003b; Hardman et al., 
2005). By day 7 there was a trend toward delayed in healing in the Ovx group, 
however this was no longer significant (Figure 5.5. A and B). By day 14 post-
wounding all differences had been resolved (Figure 5.6. A and B).  
In 2005 Zhao et al. reported that healing was significantly delayed in Mif 
KO mice compared to WT mice. Mif KO mice underwent four 5 mm excisional 
wounds and wound diameter was measured every day until each wound was 
completely healed. This was ascertained by studying the wounds daily and 
determining the day when all four wounds displayed 100% re-epithelialisation. 
In some, but not all, of the mice, wounds were harvested and fixed for 
histological analysis. From this assessment it was reported that Mif KO mice 
had significantly less granulation tissue than WT mice. These findings disagree 
with previous and present incisional healing studies from our research group 
[using the same targeted disruption of the Mif gene (Honma et al., 2000)] thus a 
similar experiment was performed here in Manchester with WT and Mif KO 
mice, two 6 mm excisional wounds, photographed daily for 7 days, followed by 
full histological and biochemical analysis at day 7. Initial macroscopic analysis 
revealed that Ovx WT and intact WT mice had much larger wounds after 7 days 
than the Ovx Mif KO and intact Mif KO mice (Figure 5.7. A.). H&E staining and 
wound area measurements confirmed these findings (Figures 5.7. B and C), 
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with a significant difference in wound area between WT and Mif KO groups. 
Thus, in an excisional model I again observed delayed healing in Ovx WT mice, 
but also unequivocally demonstrate dramatically accelerated healing in Mif KO 
mice, irrespective of systemic estrogen (Figure 5.7.).  
 
5.3.2 Re-epithelialisation and keratinocyte function 
 
Re-epithelialisation and keratinocyte proliferation and migration is an 
essential part of the wound repair process to restore the epidermal barrier. This 
is essential to protect the wound from invasion of pathogens and foreign bodies. 
Additionally, keratinocytes release cytokines crucial to the healing process, 
including IL-6 (Kishimoto et al., 1992), pro-angiogenic factors (Santoro and 
Gaudino, 2005; Singer and Clark, 1999) and matrix metalloproteinases (MMPs) 
(Ravanti and Kahari, 2000). At 3 days post-wounding re-epithelialisation was 
retarded in the intact WT group compared to intact Mif KO (p<0.05) and there 
was a non-significant trend toward delayed re-epithelialisation in the Ovx WT 
group (Figure 5.4. D). By day 7 a non-significant trend toward delayed re-
epithelialisation in the Ovx WT group was apparent (Figure 5.5. C) and by day 
14 all wounds in all groups were fully re-epithelialised (Figure 5.6. C). While re-
epithelialisation of excisional wounds was retarded in Ovx WT mice compared 
to intact and Mif KO, it was not further accelerated in Mif KO (Figure 5.7. D).  
In vivo results indicate that retarded re-epithelialisation in response to 
estrogen deprivation is confined to WT mice only, and estrogen has little effect 
on re-epithelialisation in Mif KO mice (Figures 5.4., 5.5., 5.6. and 5.7). While a 
trend toward accelerated re-epithelialisation in Mif KO mice in incisional wounds 
at day 3 is apparent (Figure 5.4. D), this is lost in the excisional model (Figure 
5.7. D). Interestingly, keratinocytes isolated from Mif KO mice displayed 
significantly reduced migration in vitro, compared to WT keratinocytes (p<0.05), 
however, this reduction, whilst statistically significant is not substantial (76% vs. 
67%) (Figure 5.8. A). 17β-estradiol promoted WT and Mif KO keratinocyte 
migration in vitro, independent of MIF, while exogenous MIF had no effect 
(Figure 5.8. B and C). 
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Figure 5.4. In the early-stage of wound repair estrogen deprivation delays healing 
only in the presence of macrophage migration inhibitory factor. A. Representative 
macroscopic photos of incisional wounds from BALB/c and Mif KO female mice at day 3 
post-wounding. B. Representative Haemotoxylin and Eosin stained wax sections of 
incisional wounds taken at day 3 post-wounding. Arrows indicate the edges of the wounds. 
C. Mean areas of incisional wounds taken at day 3 post-wounding. Wound area is 
significantly reduced in Ovx Mif KO, intact WT and intact Mif KO compared to Ovx WT. D. 
Mean percentage of re-epithelialisation of incisional wounds taken at day 3 post-wounding. 
Re-epithelialisation is significantly improved in intact Mif KO compared to intact WT. * 
indicates a significance of p<0.05. Scale bar = 4mm (A), 200µm (B). Results are presented 
as mean +SEM, n=5. Ovx = ovariectomised, WT =wild-type, KO = knockout.  
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Figure 5.5. In the mid-stage of wound repair there remains a trend toward delayed 
healing due to estrogen deprivation only in the presence of macrophage migration 
inhibitory factor. A. Representative Haemotoxylin and Eosin stained wax sections of 
incisional wounds taken at day 7 post-wounding. Arrows indicate the edges of the 
wounds. B. Mean areas of incisional wounds taken at day 7 post-wounding. Statistical test 
result p>0.05 and therefore not significant. C. Mean percentage of re-epithelialisation of 
incisional wounds taken at day 7 post-wounding. Statistical test result p>0.05 and 
therefore not significant. Scale bar = 200µm. Results are presented as mean +SEM, n=5. 
Ovx = ovariectomised, WT =wild-type, KO = knockout. 
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Figure 5.6. In the late-stage of wound repair estrogen deprivation-related delayed 
healing is resolved. A. Representative Haemotoxylin and Eosin stained wax sections of 
incisional wounds taken at day 14 post-wounding. Arrows indicate the edges of the wounds. 
B. Mean areas of incisional wounds taken at day 14 post-wounding. Statistical test result 
p>0.05 and therefore not significant. C. Mean percentage of re-epithelialisation of incisional 
wounds taken at day 14 post-wounding. Scale bar = 200µm. Results are presented as mean 
+SEM, n=5. Ovx = ovariectomised, WT =wild-type, KO = knockout. 
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Figure 5.7. In an excisional model healing is clearly accelerated in Mif KO mice. A. 
Representative macroscopic photos of excisional wounds from BALB/c and Mif KO female 
mice at day 7 post-wounding. B. Representative Haemotoxylin and Eosin stained wax 
sections of excisional wounds taken at day 7 post-wounding. Arrows indicate the edges of the 
wounds. C. Mean areas of excisional wounds taken at day 7 post-wounding. Wound area is 
significantly reduced in Ovx Mif KO, intact WT and intact Mif KO compared to Ovx WT, and 
intact Mif KO compared to intact WT. D. Mean percentage of re-epithelialisation of excisional 
wounds taken at day 7 post-wounding. Re-epithelialisation is significantly improved in Ovx Mif 
KO, intact WT and intact Mif KO compared to Ovx WT. * indicates a significance of p<0.05, ** 
p<0.01. Scale bar = 4mm (A), 200µm (B). Results are presented as mean +SEM, n=4. Ovx = 
ovariectomised, WT =wild-type, KO = knockout. 
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Figure 5.8. Estrogen and MIF differentially effect keratinocyte migration in vitro. A. 
Keratinocyte migration across a 2D scratch in vitro. Migration is significantly impaired in Mif 
KO fibroblasts compared to WT. B. WT keratinocyte migration across a 2D scratch in vitro. 
Migration is significantly improved with estrogen compared to untreated and significantly 
reduced with MIF compared to estrogen. C. Mif KO keratinocyte migration across a 2D 
scratch in vitro. Migration is significantly improved with estrogen compared to untreated. * 
represents a significance of p<0.05. Results are presented as mean +SEM, outcome of 3 
individual experiments. WT- = untreated WT, WT+E = 17β-estradiol treated WT, WT+M = 
MIF treated WT, KO- = untreated Mif KO, KO+E = 17β-estradiol treated Mif KO, KO+M = 
MIF treated Mif KO. 
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5.3.3  The effect of MIF on inflammation 
 
5.3.3.1 Neutrophils 
 
As previously mentioned neutrophils arrive from the peripheral circulation 
as the first stage of the inflammatory response, and phagocytose bacteria, 
release elastase (James et al., 2003; Lee et al., 2003; Roy et al., 2006). 
However, excessive and prolonged neutrophil influx can lead to delayed or 
impaired healing, primarily due to the release of elastase and the production of 
excessive pro-inflammatory cytokines (Ashcroft et al., 1997e; Herrick et al., 
1997; Moor et al., 2009). Estrogen replacement reduces neutrophil influx and 
subsequent tissue damage in the vasculature (Hay et al., 2001; Xing et al., 
2004) and the liver (Shimizu et al., 2008) as well as the skin (Ashcroft et al., 
1999a) (Chapters 3 and 4). A purified rat anti-mouse monoclonal neutrophil 
antibody (Ly-6G, BD Biosciences Pharmingen) was used to detect and quantify 
neutrophils.  
Excisional wounds from Mif KO mice were characterised by a 
pronounced scarcity of neutrophils, with a significant reduction in both Ovx Mif 
KO (p<0.05) and intact Mif KO (p<0.01) (Figure 5.9. A and B). In comparison, 
there was no difference in WT animals between intact and Ovx in this particular 
model. Collectively, these data suggests that regardless of prevailing estrogen 
level MIF promotes neutrophil recruitment.  
 
5.3.3.2 Macrophages 
 
Macrophages play an essential role in the innate immune response, 
phagocytosing invading bacteria and foreign bodies and producing cytokines 
and growth factors, which co-ordinate the inflammatory response and matrix 
remodelling. Macrophages phagocytose apoptotic neutrophils and therefore 
potentially accelerate the resolution of inflammation to allow the wound to 
progress to later stages of the repair process (Meszaros et al., 1999, 2000). 
While macrophage depletion severely impairs repair (Lucas et al., 2010; Mirza 
et al., 2009) excessive macrophage recruitment has negative effects on wound 
repair and chronic ulcers contain large numbers of macrophages (Loots et al., 
1998). A rat anti-mouse macrophage specific antibody (Mac-3, BD Biosciences 
Pharmingen) was used to detect macrophages in the wound granulation tissue. 
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Excisional wounds exhibit a non-significant trend toward reduced 
macrophages in Mif KO mice and increased numbers in WT mice, particularly 
Ovx. This interesting result mirrors the profile seen for wound area (the primary 
measure of healing) in the excisional model. These results suggest that in WT 
mice there is indeed a role for estrogen in modulating excessive macrophage 
recruitment to wounds (Figure 5.9. C and D), as previously described (Chapter 
3 and 4) and that in the absence of MIF macrophage resolution is efficient even 
in the absence of estrogen.  
 
5.3.3.3 Alternatively Activated Macrophages 
 
 Macrophages are activated towards either a classical, Th1-type, 
inflammatory response or an alternative, Th2-type wound healing response 
(Duffield, 2003; Gordon, 2003; Stein et al., 1992). Arginase-1 is a intracellular 
marker of alternatively activated murine macrophages (Raes et al., 2005). 
Delayed healing wounds are characterised by a relative absence of  
alternatively activated macrophages (Routley and Ashcroft, 2009) (Chapter 3, 
Figure 3.8) and often exhibit a delay in the switch from early classical activation 
to healing-promoting alternative activation (Albina et al., 1990; Deonarine et al., 
2007). Immunohistochemical staining was performed to analyse macrophage 
activation, using an Arginase 1 antibody, raised in rabbit (Santa Cruz, CA, 
USA). In excisional wounds from Ovx WT mice there was a reduction in 
alternatively activated macrophages, compared to intact WT (p<0.05), in 
accordance with findings from Routley and Ashcroft, and in Ovx Mif KO 
(p<0.05) (Figure 5.10. A and B), However, in Mif KO mice the presence or 
absence of estrogen (intact vs Ovx) had no effect on Arginase 1-positive cells 
(Figure 5.10. A and B). Surprisingly, there was no difference in Arginase-1-
positive cell numbers between intact WT and Mif KO groups, suggesting that 
the accelerated healing apparent in Mif KO is independent of alterative 
macrophage activation. 
 
5.3.3.4 In vitro macrophage function 
 
An appropriate inflammatory response is essential to overall wound 
repair, however an excessive inflammatory response has been associated with 
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chronic non-healing wounds in the elderly and in Ovx mice (Ashcroft et al., 
1999a; Hardman et al., 2005). Macrophage disruption at the early and mid 
stages of the repair process has a significant effect on overall repair (Goren et 
al., 2009; Lucas et al., 2010; Mirza et al., 2009). Macrophages clean the wound 
and phagacytose bacteria, while also playing a role in cytokine production, 
including regulation of TNF-α, IL-1 and IL-6, and new tissue formation (Shaw et 
al., 1990; Shiratsuch and Basson, 2005). Taking the extensive role of 
macrophages in wound repair (Goren et al., 2009; Lucas et al., 2010; Mirza et 
al., 2009) into account the difference in migration of isolated macrophages from 
Mif KO mice compared to those from WT mice was compared. Using a 
transwell migration assay system a significant increase (p<0.01) in macrophage 
migration was noted in cells derived from Mif KO mice compared to those from 
WT animals (Figure 5.11. A), a result that contrasts with assays in 
keratinocytes, where the lack of MIF (Mif KO) inhibits migration (Figures 5.8). 
Interestingly, MIF treatment significantly retarded the migration of WT 
macrophages (p<0.01) (Figure 5.11. B). Surprisingly, exogenous MIF no longer 
influenced macrophage migration in a MIF deficient background (Mif KO) 
(Figure 5.11. C), while 17β-estradiol accelerated migration of Mif KO, but not 
WT, macrophages (p<0.05) (Figure 5.11. B and C). This suggests that in the 
absence of both endogenous or exogenous MIF macrophage migration is 
promoted. Of particular interest, in the absence of MIF (Mif KO), where 
macrophage migration is promoted, estrogen further promotes migration (Figure 
5.11. C). 
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Figure 5.9. Neutrophil and macrophage recruitment is reduced in the absence of MIF 
in an excisional wound model. A. Representative neutrophil immunohistochemical 
localisation images from wounds at 7 days post-wounding. Arrows point to positive cells 
(neutrophils). B. Total neutrophils within the granulation tissue. There is a significant 
reduction in neutrophils in Ovx Mif KO compared to Ovx WT and in intact Mif KO compared 
to intact WT. * indicates a significance of p<0.05, ** p<0.01 C. Representative macrophage 
immunohistochemical localisation images from wounds at 7 days post-wounding. Arrows 
point to positive cells (macrophages). D. Total macrophages within the granulation tissue. 
Statistical test result p>0.05 and therefore not significant. Scale bar = 50µm. Results are 
presented as mean +SEM, n=4. 
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Figure 5.10. Ovx WT wounds contain fewer alternatively activated macrophages. A. 
Representative arginase-1 immunohistochemical localisation images from wounds at 7 days 
post-wounding. Arrows point to positively stained cells. B. Total arginase-1-positive cells 
within the granulation tissue. There are significantly more arginase-1-positive cells in Ovx 
Mif KO, intact WT and intact Mif KO compared to Ovx WT. * indicates a significance of 
p<0.05. Scale bar = 50µm. Results are presented as mean +SEM, n=4. 
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Figure 5.11. Estrogen and MIF differentially regulate macrophage migration in vitro.  
A. Macrophage migration in a Boyden chamber assay in vitro. There is a significant increase 
in cell migration in Mif KO compared to WT. B. WT macrophage migration in a Boyden 
chamber assay in vitro. Migration is significantly reduced with MIF compared to untreated. 
C. Mif KO macrophage migration in a Boyden chamber assay in vitro. Migration is 
significantly improved with estrogen compared to untreated and significantly reduced with 
MIF compared to estrogen. Results are presented as mean +SEM, outcome of 3 individual 
experiments. * represents a significance of p<0.05, ** p<0.01. WT- = untreated WT, WT+E = 
17β-estradiol treated WT, WT+M = MIF treated WT, KO- = untreated Mif KO, KO+E = 17β-
estradiol treated Mif KO, KO+M = MIF treated Mif KO. 
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5.3.4        The effect of MIF on inflammatory cytokine production 
 
Expression of the pro-inflammatory cytokine MIF is upregulated in non-
healing human wounds and Ovx mouse wounds, and reduced following 
estrogen replacement (Ashcroft et al., 2003b) (Chapters 3 and 4). Using an 
affinity-purified goat polyclonal antibody (R&D Systems, Oxford, UK) MIF was 
immunolocalised to inflammatory cells and fibroblasts in the wound granulation 
tissue (Figure 5.12. A). The absence of MIF staining in Mif KO mice confirms 
their null status (p<0.01, Mif KO vs WT). There was a trend toward more MIF 
expression in Ovx WT than intact WT, confirming the role of MIF in delayed 
healing wounds, however the difference was non-significant (Figure 5.12. A and 
B). 
CD74 is a cell surface binding protein for MIF (Leng et al., 2003), 
expressed by human macrophages, keratinocytes (Koch et al., 1984) and 
fibroblasts (Henne et al., 1995; Koch and Harris, 1984). Wound tissue CD74 
was localised to inflammatory cells and fibroblasts in all treatment groups 
(Figure 5.12. C). There was a significant reduction in CD74-positive cells in Ovx 
Mif KO compared to Ovx WT (p<0.05) and intact Mif KO (p<0.05) (Figure 5.12. 
D), which suggests that CD74 requires MIF and/or estrogen, as in the absence 
of both (Mif KO Ovx group) CD74-positive cells are significantly reduced.  
TNF-α is a pro-inflammatory cytokine, predominantly produced by 
macrophages (Nedwin et al., 1985), but also by neutrophils, keratinocytes, 
endothelial cells and mast cells, and plays a role in regulating inflammation 
(reviewed in Bendtzen, 1988). However, excessive TNF-α can delay healing by 
inhibiting granulation tissue formation during the early stages of repair (Rapala, 
1996). A TNF-α antibody produced in goat (R&D Systems, Oxford, UK) was 
used to localise wound TNF-α to inflammatory cells (Figure 5.13. A). In 
excisional wounds TNF-α expression was non-significantly reduced in Mif KO 
mice (Figure 5.13. A and B), a profile mirrored by macrophages (Figure 5.9. C 
and D) and wound area (Figure 5.7), confirming the association between 
excessive TNF-α and delayed healing in WT Ovx mice. 
To further investigate Western blot analysis was performed using whole 
wound tissue samples. TNF-α protein was elevated in wound tissue from Ovx 
WT compared to intact WT, while low levels were detectable in both Mif KO 
groups (Figure 5.14. A and B). Crucially, this pattern of in vivo expression was 
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maintained at the protein level for the macrophage-specific haemoglobin 
scavenger receptor, CD163 (Figure 5.14. A and B), which is upregulated during 
the resolution of inflammation during healing (Zwadlo et al., 1987) and the 
cytokine TGFβ-1 (Figure 5.14. A and B), which is inextricably linked to the 
healing process, despite controversy surrounding its exact role (reviewed in Tan 
et al., 2005).  
Additionally, the gelatinase, MMP9 is increased in Ovx WT wounds, and 
both the latent and active forms (bands at 105 kDa and 97 kDa, respectively) 
are reduced in Mif KO wound tissue (Figure 5.15. A and B). Confirming this, 
gelatin zymography was performed to investigate specific MMP9 activity: both 
forms, specifically latent, are reduced in Mif KO wound tissue versus WT, in 
particular Ovx WT (Figure 5.15. C). 
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Figure 5.12. MIF expression is absent in Mif KO excisional wounds while the receptor 
CD74 is reduced in response to both estrogen and MIF deficiency. A. Representative 
MIF immunohistochemical localisation images from wounds at 7 days post-wounding. 
Arrows point to positive cells. B. Total MIF-positive cells within the granulation tissue at day 
7 post-wounding. There is a significant reduction in MIF-positive cells in Ovx Mif KO and 
intact Mif KO compared to Ovx WT and intact WT. C. Representative CD74 
immunohistochemical localisation images from wounds at 7 days post-wounding. Arrows 
point to positive cells. D. Total CD74-positive cells within the granulation tissue at day 7 
post-wounding. There is a significant reduction in CD74-positive cells in Ovx Mif KO 
compared to Ovx WT and intact Mif KO. * indicates a significance of p<0.05, ** p<0.01. 
Scale bar = 50µm. Results are presented as mean +SEM, n=4. 
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Figure 5.13. A. TNFα expression is reduced in Mif KO excisional wounds. A. 
Representative TNFα immunohistochemical localisation images from wounds at 7 days 
post-wounding. Arrows point to positive cells. B. Total TNFα-positive cells within the 
granulation tissue at day 7 post-wounding. Statistical test result p>0.05 and therefore not 
significant. Scale bar = 50µm. Results are presented as mean +SEM, n=4. 
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Figure 5.14. Pro-inflammatory cytokine production is reduced in Mif KO wounds. 
A. TNFα, CD163 and TGFβ1 protein levels assessed by Western blot are reduced in 
Mif KO wound tissue. β-actin used as a loading control. B. Densitometric quantification 
of TNFα, CD163 and TGFβ1 protein, relative to Ovx Mif KO.   
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Figure 5.15. MMP9 expression and activity is reduced in Mif KO wounds. A. MMP9 
protein levels assessed by Western blot are reduced in Mif KO wound tissue. β-actin 
used as a loading control. B. Densitometric quantification of pro- (105kDa) and active 
(97kDa) MMP9 protein relative to Ovx Mif KO.  C. Wound activity of MMP9 assessed by 
gelatin zymography. Bands visible at 105 kDa (pro- form) and 97 kDa (active form). 
Numbers illustrate intensity of bands relative to Ovx Mif KO. 
B 
Ovx Mif KO   Ovx WT     Int WT    Int Mif KO Ovx Mif KO Ovx WT    Int WT   Int Mif KO 
Ovx Mif KO       Ovx WT         Int WT           Int Mif KO 
 267
5.3.5        The effect of MIF on matrix remodelling and fibroblast function 
 
 MMP9 is a proteolytic enzyme that degrades much of the wound matrix, 
including collagen, elastin, basement membrane, fibrillins and fibronectin. 
Abundant MMP9 in Ovx WT wounds translated into substantially reduced 
collagen I deposition in wound tissue (Figure 5.16. A and B). In contrast, in Ovx 
Mif KO mice, where MMP9 activity was low there was abundant collagen I 
expression (Figure 5.16. A and B). 
Fibroblasts proliferate and migrate to repair the dermis (Martin, 1997; 
Shaw and Martin, 2009), differentiating into myofibroblasts, which then play a 
role in wound contraction (Werner et al., 2007), producing cytokines and 
depositing matrix (Werner and Grose, 2003). Fibroblast proliferation, migration 
and contraction are all critical for efficient repair (Beanes et al., 2003; Darby and 
Hewitson, 2007). Proliferation of cells within a wound is essential for repair and 
regeneration of new tissue as more cells leads to increased functional capacity. 
To assess fibroblast proliferation a validated colourimetric (CellTiter96® 
AQueous) assay was used. Surprisingly, based on in vivo data, dermal fibroblasts 
isolated from Mif KO mice had substantially reduced proliferative capacity 
compared to those isolated from WT mice (p<0.01) (Figure 5.17. A). Thus, in 
vivo fibroblasts in a WT mouse wound would be expected to proliferate at a 
greater rate than those in a Mif KO mouse wound, which would likely lead to 
accelerated healing in WT mice.  
Inappropriately excessive cell-cell and cell-matrix adhesion would be 
expected to have a negative impact on healing. Beurden et al. (2006) 
determined that highly migratory fibroblasts derived from the healing palatal 
wounds of rats had a weak capacity to adhere, whereas those from unwounded 
tissue with low migratory ability displayed a strong capability to adhere. To 
determine the relative cell-matrix properties of adherence of Mif KO fibroblasts 
versus WT fibroblasts in vitro, cells were incubated in collagen I coated flasks 
for 30 minutes. Significantly more Mif KO fibroblasts attached to the collagen 
surface, than WT fibroblasts (p<0.01) (Figure 5.17. B), suggesting that 
fibroblasts in Mif KO wounds are hyperadhesive, which would again be 
expected to delay healing.  
 The migration of fibroblasts is essential in the wound repair process. 
Foetal and neo- natal wounds have been found to heal without scarring, in part 
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because the migration of fetal dermal fibroblasts is faster than that of adult 
fibroblasts (Son et al., 2005). Initially, a 2-Dimensional (2D) migration “scratch” 
assay was used to analyse the in vitro migratory ability of fibroblasts isolated 
from WT and Mif KO mice. WT fibroblasts had migrated further than Mif KO 
fibroblasts after both 4 hours (data not shown) and 24 hours (Figure 5.17. D), 
indicating that WT fibroblasts have significantly improved 2D migratory ability 
than Mif KO fibroblasts (p<0.01) (Figure 5.17. C and D). This is contradictory to 
the results obtained from in vivo experimental work, as one would expect that 
as Mif KO mice exhibit faster healing than WT mice in vivo Mif KO fibroblasts 
would have greater migratory ability. The results suggest the cells act differently 
in vitro to in vivo, or that 2D migration is not a good in vitro measure of fibroblast 
migration. 
A “bullseye” assay to study the extent of migration in a 3D matrix  
(modified from Vernon and Gooden, 2002b) was also used as a more faithful 
model of wound tissue.  While the 2D “scratch” assay indicated that WT cells 
posses more in vitro migratory ability than Mif KO cells, the 3D migration assay 
showed no difference in migration between WT and Mif KO fibroblasts (Figure 
5.18. A and B). This result is of particular interest as it may be more indicative of 
how the cells behave in an in vivo wound, ie. there is no defect in migration in 
Mif KO fibroblasts. 
Contraction and remodelling of a wound are essential for tissue repair, 
and fibroblasts and myofibroblasts play a central role in this process (Werner et 
al., 2007). To investigate underlying differences in the contractile ability of 
fibroblasts derived from Mif KO mice compared to WT mice a contraction assay 
(modified from Vernon and Gooden, 2002a) was performed. Circular discs of 
collagen containing either WT or Mif KO fibroblasts were allowed to contract 
and measured. There was no difference in contraction between Mif KO and WT 
fibroblasts after 5 days incubation (Figure 5.19. A and B). 
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Figure 5.16. Collagen I expression is reduced in wounds from Ovx WT mice. A. 
Representative collagen I immunohistochemical localisation images from wounds at 7 days 
post-wounding. B. Semi-quantitative immunohistochemical scoring of collagen I staining. 
There is a significant increase in collagen I expression in Ovx Mif KO, intact WT and intact 
Mif KO compared to Ovx WT. * indicates a significance of p<0.05. Scale bar = 50µm. 
Results are presented as mean +SEM, n=4. 
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Figure 5.17. Mif KO fibroblasts exhibit reduced proliferation, increased attachment 
and reduced 2D migration in vitro. A. Fibroblast proliferation assay. There is a 
significant reduction in proliferation of Mif KO fibroblasts compared to WT, after 9 days 
incubation. B. Attachment assay. There is a significant increase in attachment of Mif KO 
fibroblasts compared to WT. C. Representative photomicrographs of 2D scratch assay at 
0, 4 and 24 hours. D. 2D scratch migration assay. There is a significant delay in 2D 
migration in Mif KO fibroblasts compared to WT at 24 hours. ** indicates a significance of 
p<0.01. Scale bar = 1000µm. Results are presented as mean +SEM, outcome of 3 
individual experiments.  
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Figure 5.18. Mif KO fibroblasts exhibit no difference to WT in 3D migration in vitro. A. 
Representative photomicrographs of a crystal violet stained ‘bullseye’ 3D migration assay 
after 5 days incubation. B. Area of migration of fibroblasts in a “bullseye” assay. Statistical 
test performed by Student’s t-test, p>0.05 and therefore not significant. Scale bar = 1000µm. 
Results are presented as mean +SEM, outcome of 3 individual experiments. 
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Figure 5.19. Mif KO fibroblasts exhibit no difference to WT in contraction in vitro.  A. 
Representative photomicrographs of contraction assay after 4 days incubation. B. 
Percentage contraction of collagen gels, relative to WT. Statistical test performed by 
Student’s t-test, p>0.05 and therefore not significant. Scale bar = 2 mm. Results are 
presented as mean +SEM, outcome of 3 individual experiments. 
  
WT                       Mif KO 
A 
WT Mif KO 
120
100
%
 
co
n
tra
ct
io
n 
o
f d
isc
s 
 273
5.3.6       The effect of exogenous estradiol and MIF on fibroblast function 
 
 The effect of 17β-estradiol (10-7M) or MIF (10 ng) in fibroblast migration 
and contraction was next assessed. 2D scratch assays were performed as 
previously described following treatment with 17β-estradiol (10-7 M) or MIF (10 
ng) (added directly to the culture medium), at the time of wounding (hour 0). 
There was a non-significant trend toward increased migration with 17β-estradiol 
in WT fibroblasts. In contrast, MIF significantly reduced fibroblast migration 
(p<0.05) (Figure 5.20. A). Interestingly, in Mif KO fibroblasts, where 2D 
migration was already significantly impaired (Figure 5.17) exogenous 17β-
estradiol or MIF had no effect on migration (data not shown). 
A 3D bullseye assay was performed with cells treated with 17β-estradiol 
or MIF into the culture medium, from hour 0. 17β-estradiol resulted in a trend 
toward increased 3D fibroblast migration of both WT and Mif KO fibroblasts 
(Figure 5.20. B and C). Interestingly, MIF reduced 3D migration of Mif KO 
fibroblasts (p<0.05) (Figure 5.20. C), while having no effect on 3D migration of 
WT fibroblasts (Figure 5.20. B). This data suggests that exogenous MIF has a 
very different effect on in vitro 3D migration depending on the initial presence or 
absence of cellular MIF.  
Contraction assays were performed as previously described following 
treatment with 17β-estradiol or MIF (in the culture medium, at hour 0). 17β-
estradiol inhibited contraction of both WT and Mif KO fibroblasts (WT p<0.05, 
Mif KO p<0.01), while treatment with MIF non-significantly increased contraction 
of both WT and Mif KO fibroblasts, with a greater trend in Mif KO fibroblasts 
(Figure 5.21. A, B and C). These results suggest that the effects of exogenous 
17β-estradiol and MIF on contraction are similarly mediated in WT and Mif KO 
fibroblasts. Interestingly, exogenous MIF (10 ng) increased the contraction-
associated protein αSMA in cultured WT and Mif KO fibroblasts (Figure 5.21. 
D). 
It has previously been demonstrated that estrogen directly inhibits MIF 
production by resting and activated human monocytes in a dose-dependent 
manner (Hardman et al., 2005). However, fibroblast function has not been 
assessed. Cultured fibroblasts, treated with varying concentrations of 17β-
estradiol (10-8, 10-9, 10-10 M), were used for RNA analysis. Estradiol dose-
dependently down-regulated fibroblast MIF production, significantly at a 
concentration of 10-8 M (p<0.01) (Figure 5.22). 
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Figure 5.20. Estrogen promotes fibroblast migration, while MIF impairs it. A. WT 
fibroblast migration across a 2D scratch in vitro, relative to WT-. There is a significant 
reduction in migration with MIF compared to untreated. B. WT fibroblast migration in a 3D 
migration assay in vitro. Statistical test result p>0.05 and therefore not significant. C. Mif KO 
fibroblast migration in a 3D migration assay in vitro. There is a significant reduction in 
migration with MIF compared to untreated. * indicates a significance of p<0.05.  Results are 
presented as mean +SEM, outcome of 3 individual experiments. WT- = untreated WT, 
WT+E = 17β-estradiol treated WT, WT+MIF = MIF treated WT, KO- = untreated Mif KO, 
KO+E = 17β-estradiol treated Mif KO, KO+MIF = MIF treated Mif KO.  
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Figure 5.21. Estrogen impairs fibroblast contraction in vitro while MIF promotes it. A. 
Representative photomicrographs of contraction assay after 4 days incubation. B. 
Percentage contraction of collagen gels containing WT fibroblasts, relative to untreated. 
There is a significant reduction in contraction with estrogen compared to untreated. C. 
Percentage contraction of collagen gels containing Mif KO fibroblasts, relative to untreated. 
There is a significant reduction in contraction with estrogen compared to untreated. D. α 
smooth muscle actin (αSMA) protein levels in WT and Mif KO fibroblasts treated with MIF. * 
indicates a significance of p<0.05, ** p<0.01. Scale bar = 2 mm. Results are presented as 
mean +SEM, outcome of 3 individual experiments. WT- = untreated WT, WT+E = 17β-
estradiol treated WT, WT+M = MIF treated WT, KO- = untreated Mif KO, KO+E = 17β-
estradiol treated Mif KO, KO+M = MIF treated Mif KO. 
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Figure 5.22. Estrogen dose-dependently inhibits in vitro fibroblast expression of Mif. 
Fold-change in expression of Mif, relative to untreated. There is a significant increase in 
expression with estradiol 10-8M relative to untreated. Results are presented as mean +/- 
SEM, outcome of 3 individual experiments. ** indicates a significance of p<0.01. E-8, E-9, E-10 
= 17β-estradiol concentrations of 10-8, 10-9 and 10-10 M, respectively. 
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5.3.7 The interaction between MIF and the estrogen receptors 
 
Estrogen modulates MIF expression and production by inflammatory 
cells, and as both estrogen receptor isoforms, ERα and ERβ are expressed by 
human monocytes, it can be postulated that both ERs act as potential mediators 
of the effects of estrogen on inflammatory cells. However, estrogen treatment 
fails to reduce MIF production by macrophages isolated from ERα knockout 
mice, in vitro, in response to LPS (Ashcroft et al., 2003b).  
Both the ERα agonist, PPT, and the ERβ agonist, DPN, efficiently 
reduced the number of MIF-positive cells, assessed by immunohistochemistry 
(Chapter 3, Figure 3.9. A and B), and Mif expression, in wound tissue and by 
treated macrophages, assessed by qPCR (Figure 3.9. C and D). While in WT 
Ovx and ERβ-/- Ovx mice systemic estrogen replacement reduced MIF 
expression, estrogen had no effect on MIF expression in ERα-/- mice (Chapter 
3, Figure 3.18). This implicates ERα as the primary receptor involved in the 
regulation of MIF by estrogen. 
Mif KO mice do not suffer from the delayed healing phenotype 
associated with estrogen deprivation that WT mice do (Figures 5.4, 5.5, 5.6 and 
5.7). Whilst in Ovx WT mice the ERα agonist, PPT, has no effect on healing the 
ERβ agonist, DPN, significantly accelerates healing (Chapter 3, Figure 3.5) 
However, neither PPT or DPN affect healing in Ovx Mif KO mice (wound area or 
re-epithelialisation) (Figure 5.23. A, B and C). This suggests that 1) MIF 
mediates the beneficial effects of estrogen signalling through both ERα and 
ERβ, or 2) as healing is not significantly delayed in Ovx Mif KO mice neither 
PPT or DPN have any further effect, whereas in the WT model the difference 
between PPT and DPN is pronounced due to delayed healing in Ovx.  
While PPT did not accelerate healing in Ovx WT mice it was anti-
inflammatory, reducing the recruitment of wound neutrophils and macrophages 
(Chapter 3, Figure 3.6 and 3.7). Ovx Mif KO mice do not suffer from the 
excessive inflammation that Ovx WT mice do, and numbers of neutrophils are 
remained unchanged in response to both PPT and DPN (Figure 5.24. A and B). 
Similarly, macrophage numbers remained unchanged in response to both PPT 
and DPN in Mif KO mice (Figure 5.25. A and B). 
In an in vitro environment PPT is less effective than DPN and 17β-
estradiol at promoting 2D migration of WT fibroblasts (Chapter 3, Figure 3.14), 
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complimenting in vivo studies where 17β-estradiol and DPN both accelerate 
healing while PPT has no effect (Chapter 3, Figure 3.5). However, when Mif KO 
fibroblasts were scratch wounded in vitro 17β-estradiol, PPT and DPN were 
equally effective at promoting migration compared to those that were untreated 
(Figure 5.26. A and B). This suggests that 1) in the absence of MIF ER 
expression is altered in fibroblasts, 2) that MIF is not important in fibroblasts 
(although data presented in this chapter suggest that it is), or 3) that in Mif KO 
fibroblasts the ER selective agonism of PPT and DPN is lost. 
Interestingly, the ER antagonist ICI 182780 blocked the beneficial effects 
of 17β-estradiol in Mif KO fibroblasts (Figure 5.26. A and B), mirroring results in 
WT fibroblasts (Figure 4.18), and suggesting that the effect of 17β-estradiol on 
migration in Mif KO fibroblasts is mediated through the ERs. 
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Figure 5.23. ERα and ERβ agonists have no effect on healing in the Ovx Mif KO 
mouse. A. Representative Haemotoxylin and Eosin stained wax sections of incisional 
wounds taken at day 3 post-wounding. Arrows indicate the edges of the wounds. B. Mean 
areas of incisional wounds taken at day 3 post-wounding. Wound area is significantly 
reduced in Ovx Mif KO compared to Ovx WT and Ovx WT +DPN compared to Ovx WT. C. 
Mean percentage of re-epithelialisation of wounds taken from mice with incisional wounds at 
day 3 post-wounding. Re-epithelialisation is significantly promoted in Ovx Mif KO compared 
to Ovx WT and Ovx WT +DPN compared to Ovx WT. Scale bar = 200µm. Results are 
presented as mean +SEM, n=5. * represents a significance of p<0.05, ** p<0.01. Ovx = 
ovariectomised, WT =wild-type, KO = knockout. 
 
 
* 
* 
* 
* 
WT 
Mif KO 
WT 
Mif KO 
C 
                  Ovx+PPT            Ovx +DPN                  Ovx+ PT            Ovx +DPN 
3 
2.5 
2 
1.  
 
0.  
 
Ar
ea
 
(m
m
2 ) 
100 
80 
60 
 
 
 
%
 
re
-
ep
 
 280
 
 
 
 
 
0
200
400
600
800
1000
Ovx +PPT +DPN
Figure 5.24. PPT and DPN do not effect wound neutrophil recruitment in Mif KO mice. 
A. Representative neutrophil immunohistochemical localisation images from incisional 
wounds at 3 days post-wounding. Arrows point to positively stained cells. B. Total 
neutrophils within the wound area at day 3 post-wounding. There is a significant reduction in 
neutrophils in Ovx Mif KO compared to Ovx WT. * indicates a significance of p<0.05. Scale 
bar = 50µm. Results are presented as mean +SEM, n=5. Ovx = ovariectomised, WT =wild-
type, KO = knockout. 
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Figure 5.25. PPT and DPN do not effect wound macrophage recruitment in Mif KO 
mice. A. Representative macrophage immunohistochemical localisation images from 
incisional wounds at 3 days post-wounding. Arrows point to positively stained cells. B. Total 
macrophages within the wound area at day 3 post-wounding. There is a significant reduction 
in macrophages in Ovx WT +PPT and Ovx WT +DPN compared to Ovx WT. * indicates a 
significance of p<0.05. Scale bar = 50µm. Results are presented as mean +SEM, n=5. Ovx 
= ovariectomised, WT =wild-type, KO = knockout. 
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Figure 5.26. PPT and DPN both accelerate migration of Mif KO fibroblasts.  A. 
Representative photomicrographs of 2D scratch assay. B. Fibroblasts treated with estrogen, 
PPT or DPN display significantly increased migration in 2-dimensions, compared to 
untreated (-). Fibroblasts co-treated with estrogen and ICI display no difference in 2D 
migration compared to untreated and significantly reduced migration compared to estradiol 
alone. * indicates significance of p<0.05.  Scale bar = 500µm. Results are presented as 
mean +SEM, outcome of 3 individual experiments. - = untreated. 
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5.5 Discussion 
 
Hormonal deprivation in post-menopausal women and Ovx mice leads to 
delayed cutaneous wound repair, a change that can be reversed by estrogen 
replacement (Ashcroft et al., 1997a; Ashcroft et al., 1999a). Delayed healing in 
Ovx mice is accompanied by an increase in Macrophage Migration Inhibitory 
Factor (MIF) (Ashcroft et al., 2003b; Hardman et al., 2005). MIF has been 
implicated as a necessary intermediate, and master downstream mediator, of 
the beneficial effects estrogen has on wound repair (Ashcroft et al., 2003b) and 
there is extensive interaction between estrogen and MIF at the level of gene 
expression regulation during the repair process (Hardman et al., 2005). MIF has 
also been associated with other age-associated pathologies, including 
atherosclerosis (Bernhagen et al., 2007), osteoporosis (Oshima et al., 2006) 
and rheumatoid arthritis (Mikulowska et al., 1997), and pathology linked to 
excessive inflammation, such as SLE (Hoi et al., 2006), colitis (Houdeau et al., 
2007), atopic dermatitis (Shimizu et al., 1997) psoriasis (Shimizu et al., 2002; 
Shimizu et al., 2001) and eczema (Gomez et al., 1990). 
Zhao et al. (2005) have reported delayed healing in Mif KO mice and that 
the local exogenous MIF treatment promoted healing in C57/BL6 mice and 
diabetic (db/db) mice. Curiously, these finding are at odds with the wider 
understanding of MIF’s involvement in inflammatory conditions (Bernhagen et 
al., 2007; Hoi et al., 2006; Morand et al., 2006) and previously published 
incisional wound studies from our group (Ashcroft et al., 2003b; Hardman et al., 
2005). To address this apparent discrepancy I investigated healing of both 
incisional and excisional cutaneous wounds in Mif KO mice. Interestingly, using 
an excisional wound model I observed accelerated healing in Mif KO mice, a 
phenotype that was not apparent in published incisional studies (Ashcroft et al., 
2003b; Hardman et al., 2005).  In this thesis I have also investigated later 
stages of repair (days 7 and 14) demonstrating that the delay in healing in WT 
Ovx at day 3 is eventually resolved. It is unclear why Zhao et al. report delayed 
healing in Mif KO mice, yet my data clearly indicate accelerated healing [using 
the same targeted disruption of the Mif gene, but on a different background 
(Honma et al., 2000)], but the methods used to quantify healing may be a key 
contributing factor. Zhao et al. monitored macroscopic wound closure on a daily 
basis, with an end-point of the day post-wounding at which closure was 
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complete. This method gives an estimation of re-epithelialisation and is a 
somewhat subjective stand-alone method for quantifying healing. I have used 
extensive macroscopic and histological analysis, which gives a far more reliable 
assessment of healing. 
The inflammatory response is an important aspect of the wound healing 
process and is required to clean the wound and remove foreign bodies at the 
site of injury, however, excessive inflammation has been associated with 
impaired healing and chronic wounds (Ashcroft et al., 1997c; Loots et al., 1998).  
In this study, macrophages isolated from Mif KO mice displayed significantly 
improved migration in vitro, while exogenous MIF treatment impaired migration 
of both WT and Mif KO macrophages. In vivo, wounds from Mif KO mice were 
characterised by a scarcity of inflammatory cells, particularly neutrophils, which 
may be a contributing factor to the accelerated healing phenotype. Of interest, 
Ovx Mif KO wounds contained abundant alternatively activated macrophages, 
those associated with resolving inflammation and promoting wound healing 
(Duffield, 2003; Gordon, 2003), which were lacking in Ovx WT wounds. MIF 
acts directly, or indirectly, to promote the production or expression of many pro-
inflammatory cytokines, including TNF-α and interleukins (reviewed in Calandra 
and Roger, 2003) and in this study wounds from Mif KO mice had substantially 
reduced levels of several pro-inflammatory cytokines. Taken together these 
results suggest that one major way in which MIF impairs healing is by reducing 
macrophage migration, leading to delayed resolution of inflammation and 
increased cytokine production (Figure 5.27). These results are interesting in 
light of the fact that Mif KO mice exhibit less severe reactions in models of 
inflammatory diseases than WT mice, including asthma (Mizue et al., 2005), 
allergic rhinitis (Nakamaru et al., 2005), colitis (de Jong et al., 2001; Ohkawara 
et al., 2008) and arthritis (Santos et al., 2008). 
Excessive protease production during wound remodelling can have a 
detrimental effect on healing (Ashcroft et al., 1997e; Rayment et al., 2008). 
Wounds from Ovx mice contain high protease activity, contributing to the 
delayed healing noted. Interestingly, wounds from Mif KO mice contained 
reduced protease activity, which in turn translated into improved matrix 
deposition (Figure 5.27). This data is supported by findings that MIF promotes 
MMP9 production in vivo and in vitro (Kong et al., 2005; Yu et al., 2007).  
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During remodelling fibroblasts must migrate into the wound granulation 
tissue, and differentiate, to be able to efficiently contract and close the wound 
(Werner and Grose, 2003; Werner et al., 2007), which in turn requires adequate 
matrix scaffold to attach to. Based upon my in vivo studies I expected Mif KO 
fibroblasts to exhibit improved proliferative ability, an increase in migration and 
better contraction (in vitro) than WT fibroblasts. Paradoxically, my data indicate 
that the absence of MIF (Mif KO) resulted in significantly less proliferative ability 
and a lower migratory ability in a 2D assay. MIF promotes tumorigenesis, 
regulating the balance between proliferation and apoptosis (Mitchell, 2004; 
Mitchell et al., 1999) and is able to induce the phosphorylation of ERK/MAPK, 
stimulating proliferation of quiescent cells. Thus, it is not unexpected that cells 
lacking MIF would exhibit reduced proliferation. While in vitro studies indicated 
migratory defects in Mif KO fibroblasts there was a notable difference between 
2D and 3D assays. Defects in Mif KO fibroblasts in the 2D ‘scratch’ assay that 
were noted in this project and in studies by Zhao et al. are most likely to be due 
to the increased adhesion of Mif KO fibroblasts to collagen matrix or the culture 
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Figure 5.27. Proposed mechanism by how MIF impairs cutaneous healing. 1. MIF 
reduces macrophage migration, impairing resolution of inflammation and promotes pro-
inflammatory cytokine production. 2. MIF increases MMP production, intensifying wound 
proteolysis and reducing matrix remodelling. 3. MIF reduces dermal fibroblast proliferation 
and migration. Together these consequences have a detrimental effect on cutaneous repair 
(figure drawn by author [EE]). 
2 
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vessel. I have optimised a 3D assay that is a more realistic representation of the 
in vivo situation. In this 3D assay a near equivalent migration by WT and Mif KO 
fibroblasts suggests no physiological difference in fibroblast migration function. 
Additionally, no difference in contraction between WT and Mif KO fibroblasts 
was noted. Further complexity is indicated by data showing exogenous MIF 
impairs fibroblast migration in both 2D and 3D (Figure 5.27). That I identify 
different responses to endogenous and exogenous MIF most likely reflects 
cellular defects in the absence of MIF. 
17β-estradiol and MIF clearly have opposing effects on wound repair 
(17β-estradiol accelerates while MIF inhibits), generally thought to be due to 
17β-estradiol directly down-regulating MIF. Indeed, 17β-estradiol dose 
dependently inhibits MIF production by fibroblasts (Figure 5.22) and 
macrophages (Hardman et al., 2005). Table 5.4 summarises the primary 
differences of Mif KO mice in vivo which contribute to accelerated healing. 
 
Table 5.4 Summarised results of excisional wound healing experiment in 
Mif KO female mice 
 
Wound healing 
parameter Ovx WT ¤ Ovx Mif KO ¤ Intact Mif KO ¤ 
Wound area ↑ ↓ ↓ 
Re-epithelialisation ↓ ↔ ↔ 
Neutrophils ↔ ↓ ↓ 
Macrophages ↑ ↔ ↓ 
MIF ↑ - - 
Pro-inflammatory 
cytokines ↑ ↓ ↓ 
Proteases ↑ ↓ ↓ 
Matrix ↓ ↔ ↔ 
 
¤ compared to intact WT. Black arrows represent a significant change, red arrows represent a 
non-significant trend. 
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CD74 has been identified as the cell surface binding receptor for MIF 
(Leng et al., 2003), which, in conjunction with CD44, forms a cell surface MIF 
signal transduction complex (Shi et al., 2006). In this study wound CD74-
positive cells displayed correlation with the presence of both estradiol and MIF. 
In the absence of both (Ovx Mif KO) expression was significantly reduced. Only 
2% to 5% of cellular CD74 is actually expressed on the cell surface (Sant et al., 
1985; Wraight et al., 1990), thus it is acceptable that MIF and CD74 are not 
necessarily always co-expressed in wound tissue. While CD74 alone is able to 
facilitate MIF binding cellular signalling also requires the receptor CD44, for 
example, MIF-induced ERK1 and ERK2 phosphorylation (Shi et al., 2006). 
Additionally, MIF signal transduction via alternative signalling pathways, with 
regulators such as CSN5 (Jab1) (Kleemann et al., 2000), implies that MIF is 
able to signal via pathways other than the CD74/CD44 complex. In future 
studies it would be advantageous to assess the expression of the alternative 
MIF receptors, CD44 and CSN5 (Jab1) in intact and Ovx Mif KO animals. 
Collectively my data suggest that improved healing in Mif KO mice is 
most likely due to: 1) accelerated resolution of inflammation and dampening of 
inflammatory cytokine production; 2) increased fibroblast migration, and; 3) 
reduced protease activity leading to matrix deposition and more efficient 
remodelling (Figure 5.27). 
It is unclear whether estrogen regulation of MIF in wound healing is 
mediated through one, both or neither of the estrogen receptors (ERα or ERβ). 
Both ERα and ERβ are expressed by human monocytes (Ashcroft et al., 2003b) 
and both the ERα agonist, PPT, and the ERβ agonist, DPN, successfully reduce 
MIF expression in this cell type (Chapter 3). However, estrogen treatment fails 
to down-regulate MIF production in ERα-null monocytes (Ashcroft et al., 2003b), 
and while estrogen replacement in ERβ-/- mice dampens MIF expression in 
ERα-/- mice expression is increased, implicating ERα as an integral component 
required for the down-regulation of MIF by estrogen. When investigating this in 
more detail using the ER agonists PPT and DPN in Ovx Mif KO mice receptor 
specific differences were unclear, primarily due to the already accelerated 
healing seen in Ovx Mif KO mice. It is possible that both PPT and DPN can 
signal through the ERs to down-regulate MIF or that Mif KO mice are non-
responsive to the ER specific effects of PPT and DPN.  
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 In my opinion the major findings of this study has been unambiguous 
demonstration of accelerated of healing in Mif KO mice, accompanied by 
investigation of the causative changes that lead to this phenotype using a 
comprehensive selection of in vitro assays. MIF acts as a master mediator of 
wound repair, regulating the function of a range of cell types, but the tissue/cell 
specific functions of MIF appear to be even more complicated than initially 
thought. The 17β-estradiol- and MIF-mediated changes in healing observed in 
vivo are the result of altered wound inflammatory profile. In wounds from WT 
Ovx mice increased proteolysis and MMP activity leads to reduced matrix 
deposition which in turn results in a delay in healing. In contrast female Mif KO 
Ovx mice exhibit accelerated healing, associated with reduced inflammation, 
reduced MMP activity and increased matrix deposition. That MIF and 17β-
estradiol play such diverse roles in different wound cell types is intriguing in light 
of the heterogeneous nature of estrogen receptor isoform expression within a 
wound. The relationship between MIF and the estrogen receptors is fascinating 
but complex, and requires further investigation to be fully understood. However, 
tissue MIF reduction could be a valuable biomarker for the treatment of chronic, 
non-healing wounds and it is intriguing that the selective compounds reported to 
have therapeutic potential in the previous chapter are all able to down-regulate 
MIF in wound tissue, despite their structural differences.  
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6 DISCUSSION AND FUTURE WORK 
 
With increasing life expectancy the elderly population is expanding at an 
alarming rate. With this comes an escalating incidence of age-related 
pathologies, such as dementia, osteoporosis, stroke, and a risk of delayed 
healing which in turn leads to a higher incidence of chronic wounds. 
Additionally, the increasing prevalence of obesity and diabetes, particularly in 
the Western world, has lead to a substantial rise in those developing lower limb 
ulcers, a pathology that can ultimately lead to amputation or even death. 
Treatment of chronic wounds in the elderly and immobile is estimated to cost 
the National Health Service over £2 billion per year (Bennett et al., 2004) and 
has an enormous effect on patient morbidity and mortality. The current “gold 
standard” of wound management comprises regular assessment for infection 
and risk factors, and frequent debridement of necrotic tissue. Current 
treatments focus on secondary complications, such as reducing infection, using 
silver-impregnated dressings (reviewed in White and McIntosh, 2008) or 
maggot debridement therapy (Bowling et al., 2007; Sherman, 2003); or are 
extremely basic, eg. compression dressings for venous ulcers (Blair et al., 1988; 
Enoch et al., 2006) and offloading therapy for diabetic ulcers (Edmonds, 2006). 
Understanding of the molecular and cellular basis of non-healing wounds is 
severely lacking. While there are differences between the underlying causes of 
each type of chronic wound there are a number of common factors, for 
example, prolonged and excessive inflammation and ineffective re-
epithelialisation (reviewed in Hardman and Ashcroft, 2005).  
A growing body of evidence has implicated age-associated changes in 
circulating sex steroid hormones as a principal causative factor for delayed 
healing in the elderly (Gilliver et al., 2008; Hardman and Ashcroft, 2008). 
Estrogen replacement improves the appearance of post-menopausal skin 
(Pierard-Franchimont et al., 1995; Schmidt et al., 1996a; Shah and Maibach, 
2001) and improves the rate of healing in post-menopausal women (Ashcroft et 
al., 1999a). In the developed world most women now live for at least a third of 
their lives in a state of systemic estrogen deprivation, post-menopause (Barrett-
Connor, 1995), with substantial effects on health, increasing the risk of heart 
disease, osteoporosis and breast cancer, in addition to delayed wound repair. 
Furthermore, elderly males also suffer from altered local levels of estrogens, in 
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addition to high levels of the androgen testosterone and reduced conversion of 
steroid precursors to estrogens via aromatisation (reviewed in Ashcroft and 
Ashworth, 2003). 
It is currently believed that one of the main reasons chronic non-healing 
wounds develop in the elderly is a prolonged and excessive inflammatory 
response, which leads to exaggerated tissue proteolysis and breakdown. Some 
studies have found that the inflammatory response is altered in the elderly, with 
reduced neutrophil burst activity, impaired chemotaxis and phagocytosis 
(Butcher et al., 2001; Lipschitz and Udupa, 1986) and a delay in T lymphocyte 
recruitment (Swift et al., 2001). Collectively, these defects lead to increased 
inflammatory cell influx in wounds of aged mice and elderly humans (Ashcroft et 
al., 1997a; Ashcroft et al., 1997c, 1998), particularly in the very early stages of 
repair. Estrogen is potently anti-inflammatory and reduces the influx of 
inflammatory cells in cutaneous repair (Ashcroft et al., 1997a; Ashcroft et al., 
1999a), bone pathology (Josefsson et al., 1992) and brain injury (Akabori et al., 
2010; Suzuki et al., 2006). 
Additionally, retarded re-epithelialisation in the elderly impacts upon 
wound closure, leading to a prolonged open wound at significantly increased 
risk from infection. Keratinocytes exhibit age-related decline in response to 
growth factors, such as epidermal growth factor (EGF), during wound closure 
(reviewed in Rattan and Derventzi, 1991), while becoming increasingly sensitive 
to negative growth factors, such as Interferon (IFN) (Peacocke et al., 1989). Re-
epithelialisation is retarded in elderly humans and aged mice (Ashcroft et al., 
1997d; Holt et al., 1992) with expression of EGF and its receptor, EGFR, 
reduced in murine epidermal keratinocytes at the wound edge in aged mice 
(Ashcroft et al., 1997d). Estrogen is a keratinocyte mitogen (Son et al., 2005; 
Verdier-Sevrain et al., 2004) and hormone replacement accelerates re-
epithelialisation in post-menopausal women (Ashcroft et al., 1997a). 
Estrogen replacement in post-menopausal women has significant 
beneficial effects in numerous tissues, eg. bone (reviewed in Upton, 1984); 
however, recent studies have highlighted the substantial risks of Hormone 
Replacement Therapy (HRT). The Women’s Health Initiative (WHI),  a US-led 
study initiated in 1991, investigating the causes of morbidity and mortality in 
post-menopausal women, found that conjugated estrogen and progesterone 
HRT was associated with an increased risk of breast cancer, stroke and 
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coronary heart disease (Anderson et al., 2004; Nabel, 2006). The Million 
Women Study (MWS), a UK study initiated in 1996, confirmed findings from the 
WHI, while also identifying increased risks of ovarian cancer and of uterine 
cancer in those taking estrogen-only HRT (Banks et al., 2004; Beral et al., 2007; 
Beral et al., 2005a; Beral et al., 2005b). In the ensuing years there has been 
much controversy surrounding the long-term risks of HRT use (Rossouw et al., 
2007). What is indisputable, however, is that since the publication of such 
studies the prescription of HRT has dropped by more than 50% (Figure 6.1) 
(Faber et al., 2005; Menes et al., 2009; Parente et al., 2008; Udell et al., 2006). 
 
 
 
The implications of this are immense. For example, while HRT use has 
decreased in the past ten years, the prescription of anti-depressants has 
increased proportionally (Figure 6.2). Estrogen has pronounced effects on 
neuronal function (Chakravorty and Halbreich, 1997; Kendall et al., 1982; 
McEwen et al., 1997) and depression is prolific in menopausal women, 
particularly those in the peri-menopause period (Burt et al., 1998). 
 
Figure 6.1.  The rate of HRT use has dropped substantially since 2001 in conjunction 
with the Women’s Health Initiative and the Million Women Study (modified from Menes 
et al., 2009). HRT = Hormone Replacement Therapy. 
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These data highlight the urgent need for alternatives to estrogen replacement 
for a variety of post-menopausal conditions. Estrogen clearly accelerates 
cutaneous healing in estrogen deprived humans and mice (Ashcroft et al., 
1997a; Ashcroft et al., 1999a). While treatment to aid wound repair would 
require a very short term regime, in comparison to treatment for post-
menopausal symptoms, and can be applied locally to the wound area, the use 
of steroidal estrogen therapy is now actively avoided, since the publication of 
estradiol as a human carcinogen by the National Institutes for Health (NIH, 
2002). A key aim of this study was to further identify the cellular and molecular 
effects of estrogen in cutaneous healing, focussing on receptor-specific 
signalling and downstream mediators with a view to developing alternative 
treatments to accelerate wound repair in the elderly. 
In order to expand our understanding of estrogen signalling during 
cutaneous wound healing the role of the two estrogen receptors (ERs) was 
assessed using ER knockout (ER-/-) mice and ER specific agonists. Estrogen 
deprivation (Ovx or menopause) normally results in a delay in healing which can 
be reversed by exogenous estrogen replacement (Ashcroft et al., 1997a; 
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Figure 6.2.  As the rate of HRT use has declined the prescription of serotonergic anti-
depressants has increased (modified from McIntyre et al., 2005). Linear regression 
models of the number of prescriptions against time. There was a statistically significant 
decrease in HRT prescription and increase in anti-depressant prescription between 
September 2002 and July 2003, p<0.001. HRT = Hormone Replacement Therapy.  
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Ashcroft et al., 1999a). This study repeated these groundbreaking experiments 
and then substantially advanced by exploring ERα vs ERβ signalling. Important 
new findings indicate that by signalling through ERβ alone (in ERα-/- mice) 
promotes healing. However, signalling through ERα alone (in ERβ-/- mice) 
actually further retarded healing. Further validating this, treatment with the 
selective ERβ agonist, DPN, accelerates healing in Ovx mice, comparable with 
estrogen replacement. This implicates ERβ as an important mediator of the 
beneficial effects of estrogen on cutaneous healing. This is fascinating in light 
of: 1) studies identifying ERβ as the predominant ER isoform present in human 
skin (Mosselman et al., 1996; Thornton et al., 2003a, b); 2) recent studies 
linking polymorphisms in the human ERβ gene with an increased risk of venous 
ulceration in the UK Caucasian population (Ashworth et al., 2005, 2008).  
Interestingly, the selective ERα agonist, PPT, failed to promote wound 
healing in Ovx mice, but was potently anti-inflammatory, reducing the 
recruitment of neutrophils and macrophages to the wound. This suggests a 
clear uncoupling of inflammation and overall healing. One major difference 
between the anti-inflammatory properties of PPT and DPN was the presence of 
large numbers of alternatively activated macrophages following DPN treatment, 
those associated with resolving inflammation and promoting wound healing 
(Duffield, 2003; Gordon, 2003). By contrast alternatively activated macrophages 
were noticeably lacking in wounds from Ovx and PPT treated mice. Additionally, 
while estrogen replacement in ERα-/- mice did accelerate healing, reducing 
wound area, it didn’t dampen inflammation. Conversely, while estrogen 
replacement delayed healing in ERβ-/- mice it did have an anti-inflammatory 
effect, reducing macrophage recruitment. Collectively, this suggests that while 
all my data point to ERβ being the critical receptor in mediating the healing 
promoting effects of estrogen, the anti-inflammatory benefits of estrogen may 
be, at least in part, also mediated via ERα. Of note, estrogen is anti-
inflammatory via ERα in a number of other body systems, including brain (Liu et 
al., 2003; Polanczyk et al., 2003; Vegeto et al., 2003).  
 These findings strongly highlight the differences in the two ERs in wound 
repair and suggest that selective manipulation of ER-mediated signalling could 
be a very real therapeutic approach for the treatment of chronic wounds in 
elderly post-menopausal women and men. However, changes in skin ER 
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expression and distribution with age or menopause in humans are still largely 
unknown. This should be addressed in the near future. 
Additionally, through the use of conditional knockout mouse models it will 
be possible to investigate the effect of each ER in specific skin cells. By 
crossing ERαSTL2/L2  (Dupont et al., 2000) and ERβSTL2/L2  (Antal et al., 2008) 
mice with the well characterised K14-Cre line (Li et al., 2001) epidermal-specific 
knockouts can be created. Similarly, by crossing ERαSTL2/L2 and ERβSTL2/L2 mice 
with the LysM-Cre line (Clausen et al., 1999) inflammatory cell-specific 
knockouts can be created. Work using these exciting conditional knockout 
models within our laboratory is ongoing. 
Differential ER function led me to explore Selective Estrogen Receptor 
Modulators (SERMs). Several SERMs (tamoxifen, raloxifene and genistein), but 
notably not all that were tested, were able to promote wound healing in the Ovx 
model, despite their diverse activities in other tissues. Tamoxifen and raloxifene 
are both antagonists in the breast (Black et al., 1994; Love et al., 1992), hence 
their use in breast cancer chemotherapy (Cole et al., 1971; Cummings et al., 
1999). In contrast, both are ER agonists in bone (Black et al., 1994; Love et al., 
1992), with raloxifene in particular used for osteoporosis treatment (Heaney and 
Draper, 1997). In other tissues their activity diverges, eg. tamoxifen is an 
agonist in uterus (Kedar et al., 1994), while raloxifene is an antagonist (Black et 
al., 1994). Genistein is an agonist in bone (Ishimi et al., 1999) but its activity in 
other tissues is contentious (Diel et al., 2001; Santell et al., 1997). Of note, the 
agonistic/antagonistic activity of these SERMs has not previously been fully 
determined in skin. Also, in light of my finding with respect to ERβ and wound 
healing it is interesting that genistein has a reportedly higher affinity for ERβ 
than ERα (Kuiper et al., 1998) and while estradiol has equal relative binding 
affinities for ERα and ERβ, tamoxifen and raloxifene are both also reported to 
be more selective for ERβ than ERα (tamoxifen; 1.2:1, raloxifene; 2.2:1) 
(Weatherman et al., 2001). 
It is interesting to note anti-inflammatory differences between synthetic 
SERMs tamoxifen and raloxifene, and the dietary phytoestrogen genistein. 
Although all 3 promote repair tamoxifen and raloxifene specifically dampen 
wound macrophage recruitment, whilst genistein dampens neutrophil influx, with 
less effect on macrophages. This is particularly fascinating in light of the 
expression of ERβ, but not ERα, in bovine neutrophils during the parturition 
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period (Lamote et al., 2006) and the ERβ selectivity of genistein (Nikov et al., 
2000). In a trauma haemorrhage model it has recently been reported that only 
an ERβ agonist, and not an ERα agonist prevents neutrophil activation (Doucet 
et al., 2010) However, circulating neutrophils isolated from post-menopausal 
women express both ERα and ERβ, with the expression of both increased 
following estradiol treatment (Molero et al., 2002).  
 Whilst tamoxifen and raloxifene now represent promising therapeutic 
candidates to treat delayed healing in ageing humans there are still significant 
side-effects associated with their prolonged use. One major disadvantage of 
tamoxifen is its agonistic activity in uterus leading to a substantially increased 
risk of uterine cancer (DeMichele et al., 2008; Fisher et al., 2005), while 
raloxifene substantially worsens hot flushes (Cohen and Lu, 2000). However, 
tamoxifen and raloxifene are first and second generation SERMs, respectively. 
Many advances have been made in the field since their generation, and next 
generation SERMs are now being designed and tested. An ideal SERM would 
have beneficial effects in tissues including bone and skin, without having any 
cancer causing activity in reproductive tissues such as breast and uterus. 
SERMs such as ospemifene (Ophena, Hormos, Finland), HMR3339 and 
RAD1901 are presently being tested for efficacy and safety in clinical trials. It 
has been reported that RAD1901 has bone-protective effects without 
stimulating breast or uterine cancer (Radius, 2009). In summary, as the 
aforementioned SERMs appear to preferentially activate ERβ, the predominant 
isoform in human skin (Mosselman et al., 1996; Thornton et al., 2003a, b), and 
studies described in this thesis provide clear evidence that ERβ is the crucial 
receptor involved in mediating the beneficial effects of estrogen in cutaneous 
healing, it follows that a SERM with beneficial effects in bone may have similar 
effects in skin. 
 SERMs are also becoming increasingly popular for the treatment of age-
associated pathologies in men, meaning the benefits of these studies will not be 
confined to women only. Raloxifene has been shown to be beneficial at 
reducing bone resorption in elderly men (Doran et al., 2001; Uebelhart et al., 
2004), while in men undergoing treatment for prostate cancer, and 
subsequently at an increased risk of hip fracture, raloxifene and toremifene 
have shown clinical potential to reduce this risk (Smith et al., 2004; Smith et al., 
2008). Additionally, toremifene has shown potential to reduce the risk of 
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prostate cancer in a subset of men, without any reports of side-effects (Price et 
al., 2006).  
Ashcroft et al. (1999a) have demonstrated the effectiveness of topical 
estrogen treatment on promoting healing, in both female and male individuals, 
while others have shown that topical estrogen treatment can prevent skin 
ageing in post-menopausal females (Schmidt et al., 1996a). Topical tamoxifen 
treatment improves the appearance of keloid scars (Gragnani et al., 2009; 
Mousavi et al., 2010) while topical genistein protects against UV damage 
(Brand and Jendrzejewski, 2008; Shyong et al., 2002) and improves dermal 
vascularisation in post-menopausal women (Moraes et al., 2009). In the future it 
would be interesting to evaluate the effect of the SERMs tamoxifen, raloxifene 
and genistein on human cell function in vitro, using keratinocytes, fibroblasts 
and inflammatory cells. This data is the crucial first step to confirm cross-
species conservation. It would then be possible to evaluate the effect of topical 
SERMs on human wound healing.  
It should not be ignored that non-estrogenic ligands are also known to 
activate the estrogen receptor. A relationship between Insulin-like Growth 
Factor (IGF-1) and estrogen has been identified in the hypothalamus (Duenas 
et al., 1996), bone (Kudo et al., 1996), breast (van der Burg et al., 1988) and 
uterus (Klotz et al., 2002). In the uterus IGF-1 signalling can be initiated by 
estradiol and estradiol-independent ER activity can be induced by IGF-1 
signalling (Klotz et al., 2002). IGF-1 is structurally similar to insulin and plays a 
role in growth in childhood and continues to have an anabolic effect in 
adulthood. Its action is primarily mediated by binding to specific IGF receptors 
(Delafontaine et al., 2004), but a cross-talk with estrogen receptors is becoming 
increasingly apparent (Klotz et al., 2002; Klotz et al., 2000). There is also a 
strong link between IGF-1 and ageing and IGF-1 prevents loss of function with 
age in numerous tissues (reviewed in Anversa, 2005). The focus of future 
studies will be to investigate the therapeutic potential of IGF-1 in cutaneous 
repair in Ovx WT and ERE-luc mice. 
Whilst it is now widely appreciated that estrogen accelerates healing in a 
hormonal-deprived situation the cellular basis of estrogen’s beneficial effects 
has been until now, largely unknown. Data presented in this thesis reveal 
estrogen is a global regulator of healing, influencing numerous cell types 
involved in the repair process. Estrogen dampens inflammation in vivo and 
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reduces the expression of pro-inflammatory cytokines by isolated murine 
macrophages in vitro. Estrogen is a keratinocyte mitogen (Son et al., 2005; 
Verdier-Sevrain et al., 2004), and so, unsurprisingly, promotes proliferation and 
migration of primary murine epidermal keratinocytes in vitro, which in turn 
translates to accelerated wound re-epithelialisation in vivo. Estrogen also 
promotes migration of dermal fibroblasts, in 2D in a simple scratch assay model 
and in a 3D collagen matrix.  
A key aspect of the healing promoting effects of estrogen is the potent 
down-regulation of the pro-inflammatory cytokine macrophage migration 
inhibitory factor (MIF) in wound tissue. What is particularly interesting is that this 
study reports novel accelerated healing in mice that lack MIF (Mif KO). In vitro, 
the roles of exogenous estrogen and MIF appear to be diametrically opposed. 
While estrogen promotes keratinocyte and fibroblast migration, MIF impairs it, 
data which contributes toward explaining the accelerated healing in Mif KO 
mice. What is fascinating is the interaction between the ER agonists, SERMs 
and MIF. PPT, DPN, tamoxifen, raloxifene and genistein significantly reduce 
wound MIF expression in vivo and expression by isolated macrophages in vitro. 
Ovx Mif KO mice are protected from osteoporosis (Oshima et al., 2006), a 
pathology that occurs with estrogen deprivation (Edwards et al., 1992b; Most et 
al., 1995). MIF is often over-expressed in breast cancer tissue (Bando et al., 
2002), where high ERα expression is often noted (Ali and Coombes, 2000), and 
MIF is expressed at the early stages of pregnancy (Ietta et al., 2010; Ietta et al., 
2007) when ERα regulation is crucial (Bukovsky et al., 2003).  
In summary, my data strongly infers that estrogen promotes healing by 
improving epidermal keratinocyte and dermal fibroblast function and by down-
regulating expression of MIF, in turn dampening inflammation. Interestingly, 
data presented in this thesis implicate ERβ as the principal receptor mediating 
the beneficial effects of estrogen, while ERα is primarily responsible for the 
regulation of MIF and inflammation in cutaneous healing (Figure 6.3). Of 
interest, ERα is strongly associated with cancer progression (Ali and Coombes, 
2000), while selective ERβ agonists are becoming increasingly popular for 
treatment of post-menopausal pathologies, such as osteoporosis (Weaver and 
Legette, 2010). These exciting novel findings have wider implications for future 
therapeutics for the treatment of post-menopausal and age-associated 
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pathology in women and men and prospective therapies would target ERβ to 
treat chronic wounds and age-related delayed cutaneous healing. 
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Figure 6.3. Proposed mechanism of cutaneous estrogen signalling. Estrogen, 
tamoxifen, raloxifene and genistein signal primarily through ERβ to promote wound healing, 
while also signalling through ERα to down-regulate MIF expression and dampen cutaneous 
inflammation. Genistein also promotes healing via non-ER-dependant mechanisms, 
including the IGF-1R and MAPK pathway (figure drawn by author [EE]). 
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